

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 March 2002 (21.03.2002)

PCT

(10) International Publication Number
WO 02/22802 A1

(51) International Patent Classification⁷: C12N 15/00,
15/12, C07K 14/435

Drive, Lafayette Hill, PA 19444 (US). STRUM, Jay, C.
[US/US]; Five Moore Drive, Research Triangle Park, NC
27709 (US). XIE, Qing [CN/US]; 310 Sawmill Lane,
Horsham, PA 19044 (US).

(21) International Application Number: PCT/US01/28462

(74) Agents: FEDON, Jason, C. et al.; SmithKline Beecham
Corporation, Corporate Intellectual Property, UW2220,
709 Swedeland Road, P.O. Box 1539, King of Prussia, PA
19406-0939 (US).

(22) International Filing Date:
13 September 2001 (13.09.2001)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
60/232,463 13 September 2000 (13.09.2000) US
60/232,455 13 September 2000 (13.09.2000) US
60/237,293 2 October 2000 (02.10.2000) US
60/246,269 7 November 2000 (07.11.2000) US
60/252,049 20 November 2000 (20.11.2000) US


(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

(71) Applicants (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19103 (US). SMITHKLINE BEECHAM P.L.C. [GB/GB]; New Horizons Court, Great West Road, Brentford, Middlesex TW8 9EP (GB). GLAXO GROUP LIMITED [GB/GB]; Glaxo House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



A1

WO 02/22802

(54) Title: NOVEL COMPOUNDS

(57) Abstract: Polypeptides and polynucleotides of the genes set forth in Table I and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing polypeptides and polynucleotides of the genes set forth in Table I in diagnostic assays.

Novel Compounds

Field of Invention

This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in diagnosis and in identifying compounds that may be agonists, antagonists that are potentially useful in therapy, and to production of such polypeptides and polynucleotides. The polynucleotides and polypeptides of the present invention also relate to proteins with signal sequences which allow them to be secreted extracellularly or membrane-associated (hereinafter often referred collectively as secreted proteins or secreted polypeptides).

Background of the Invention

The drug discovery process is currently undergoing a fundamental revolution as it embraces "functional genomics", that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superseding earlier approaches based on "positional cloning". A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.

Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.

Proteins and polypeptides that are naturally secreted into blood, lymph and other body fluids, or secreted into the cellular membrane are of primary interest for pharmaceutical research and development. The reason for this interest is the relative ease to target protein therapeutics into their place of action (body fluids or the cellular membrane). The natural pathway for protein secretion into extracellular space is the endoplasmic reticulum in eukaryotes and the inner membrane in prokaryotes (Palade, 1975, *Science*, 189, 347; Milstein, Brownlee, Harrison, and Mathews, 1972, *Nature New Biol.*, 239, 117; Blobel, and Dobberstein, 1975, *J. Cell. Biol.*, 67, 835). On the other hand, there is no known natural pathway for exporting a protein from the exterior of the cells into the cytosol (with the exception of pinocytosis, a mechanism of snake venom toxin intrusion into cells). Therefore targeting protein therapeutics into cells poses extreme difficulties.

The secreted and membrane-associated proteins include but are not limited

to all peptide hormones and their receptors (including but not limited to insulin, growth hormones, chemokines, cytokines, neuropeptides, integrins, kallikreins, lamins, melanins, natriuretic hormones, neropsin, neurotropins, pituitary hormones, pleiotropins, prostaglandins, secretogranins, selectins, thromboglobulins, 5 thymosins), the breast and colon cancer gene products, leptin, the obesity gene protein and its receptors, serum albumin, superoxide dismutase, spliceosome proteins, 7TM (transmembrane) proteins also called as G-protein coupled receptors, immunoglobulins, several families of serine proteinases (including but not limited to proteins of the blood coagulation cascade, digestive enzymes), deoxyribonuclease 10 I, etc.

Therapeutics based on secreted or membrane-associated proteins approved by FDA or foreign agencies include but are not limited to insulin, glucagon, growth hormone, chorionic gonadotropin, follicle stimulating hormone, luteinizing hormone, calcitonin, adrenocorticotrophic hormone (ACTH), vasopressin, 15 interleukines, interferones, immunoglobulins, lactoferrin (diverse products marketed by several companies), tissue-type plasminogen activator (Alteplase by Genentech), hyaluronidase (Wydase by Wyeth-Ayerst), dornase alpha (Pulmozyme by Genentech), Chymodictin (chymopapain by Knoll), alglucerase (Ceredase by Genzyme), streptokinase (Kabikinase by Pharmacia) (Streptase by Astra), etc. This 20 indicates that secreted and membrane-associated proteins have an established, proven history as therapeutic targets. Clearly, there is a need for identification and characterization of further secreted and membrane-associated proteins which can play a role in preventing, ameliorating or correcting dysfunction or disease, including but not limited to diabetes, breast-, prostate-, colon cancer and other 25 malignant tumors, hyper- and hypotension, obesity, bulimia, anorexia, growth abnormalities, asthma, manic depression, dementia, delirium, mental retardation, Huntington's disease, Tourette's syndrome, schizophrenia, growth, mental or sexual development disorders, and dysfunctions of the blood cascade system including those leading to stroke. The proteins of the present invention which include the signal 30 sequences are also useful to further elucidate the mechanism of protein transport which at present is not entirely understood, and thus can be used as research tools.

Summary of the Invention

The present invention relates to particular polypeptides and polynucleotides of the 35 genes set forth in Table I, including recombinant materials and methods for their production. Such polypeptides and polynucleotides are of interest in relation to methods of treatment of

certain diseases, including, but not limited to, the diseases set forth in Tables III and V, hereinafter referred to as "diseases of the invention". In a further aspect, the invention relates to methods for identifying agonists and antagonists (e.g., inhibitors) using the materials provided by the invention, and treating conditions associated with imbalance of

5 polypeptides and/or polynucleotides of the genes set forth in Table I with the identified compounds. In still a further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate activity or levels the genes set forth in Table I. Another aspect of the invention concerns a polynucleotide comprising any of the nucleotide sequences set forth in the Sequence Listing and a polypeptide comprising a polypeptide

10 encoded by the nucleotide sequence. In another aspect, the invention relates to a polypeptide comprising any of the polypeptide sequences set forth in the Sequence Listing and recombinant materials and methods for their production. Another aspect of the invention relates to methods for using such polypeptides and polynucleotides. Such uses include the treatment of diseases, abnormalities and disorders (hereinafter simply referred to as diseases)

15 caused by abnormal expression, production, function and or metabolism of the genes of this invention, and such diseases are readily apparent by those skilled in the art from the homology to other proteins disclosed for each attached sequence. In still another aspect, the invention relates to methods to identify agonists and antagonists using the materials provided by the invention, and treating conditions associated with the imbalance with the identified

20 compounds. Yet another aspect of the invention relates to diagnostic assays for detecting diseases associated with inappropriate activity or levels of the secreted proteins of the present invention.

Description of the Invention

25 In a first aspect, the present invention relates to polypeptides the genes set forth in Table I. Such polypeptides include:

(a) an isolated polypeptide encoded by a polynucleotide comprising a sequence set forth in the Sequence Listing, herein when referring to polynucleotides or polypeptides of the Sequence Listing, a reference is also made to the Sequence Listing referred to in the

30 Sequence Listing;

(b) an isolated polypeptide comprising a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;

(c) an isolated polypeptide comprising a polypeptide sequence set forth in the Sequence Listing;

- (d) an isolated polypeptide having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;
- (e) a polypeptide sequence set forth in the Sequence Listing; and
- (f) an isolated polypeptide having or comprising a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to a polypeptide sequence set forth in the Sequence Listing;
- (g) fragments and variants of such polypeptides in (a) to (f).

Polypeptides of the present invention are believed to be members of the gene families set forth in Table II. They are therefore of therapeutic and diagnostic interest for the reasons set forth in Tables III and V. The biological properties of the polypeptides and polynucleotides of the genes set forth in Table I are hereinafter referred to as "the biological activity" of polypeptides and polynucleotides of the genes set forth in Table I. Preferably, a polypeptide of the present invention exhibits at least one biological activity of the genes set forth in Table I.

15 Polypeptides of the present invention also include variants of the aforementioned polypeptides, including all allelic forms and splice variants. Such polypeptides vary from the reference polypeptide by insertions, deletions, and substitutions that may be conservative or non-conservative, or any combination thereof. Particularly preferred variants are those in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, 20 from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acids are inserted, substituted, or deleted, in any combination.

Preferred fragments of polypeptides of the present invention include an isolated polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids from an amino acid sequence set forth in the Sequence Listing, or an isolated polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids truncated or deleted from an amino acid sequence set forth in the Sequence Listing. Preferred fragments are biologically active fragments that mediate the biological activity of polypeptides and polynucleotides of the genes set forth in Table I, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also preferred are those fragments that are antigenic or immunogenic in an animal, especially in a human.

30 Fragments of a polypeptide of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these variants may be employed as intermediates for producing the full-length polypeptides of the invention. A 35 polypeptide of the present invention may be in the form of the "mature" protein or may be a

part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence that contains secretory or leader sequences, pro-sequences, sequences that aid in purification, for instance multiple histidine residues, or an additional sequence for stability during recombinant production.

5 Polypeptides of the present invention can be prepared in any suitable manner, for instance by isolation from naturally occurring sources, from genetically engineered host cells comprising expression systems (*vide infra*) or by chemical synthesis, using for instance automated peptide synthesizers, or a combination of such methods. Means for preparing such polypeptides are well understood in the art.

10 In a further aspect, the present invention relates to polynucleotides of the genes set forth in Table I. Such polynucleotides include:

- (a) an isolated polynucleotide comprising a polynucleotide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polynucleotide sequence set forth in the Sequence Listing;
- (b) an isolated polynucleotide comprising a polynucleotide set forth in the Sequence Listing;
- (c) an isolated polynucleotide having at least 95%, 96%, 97%, 98%, or 99% identity to a polynucleotide set forth in the Sequence Listing;
- (d) an isolated polynucleotide set forth in the Sequence Listing;
- 15 (e) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;
- (f) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide set forth in the Sequence Listing;
- 20 (g) an isolated polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;
- (h) an isolated polynucleotide encoding a polypeptide set forth in the Sequence Listing;
- (i) an isolated polynucleotide having or comprising a polynucleotide sequence that has an

25 Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to a polynucleotide sequence set forth in the Sequence Listing;

- (j) an isolated polynucleotide having or comprising a polynucleotide sequence encoding a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to a polypeptide sequence set forth in the Sequence Listing; and

polynucleotides that are fragments and variants of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

Preferred fragments of polynucleotides of the present invention include an isolated polynucleotide comprising an nucleotide sequence having at least 15, 30, 50 or 100

5 contiguous nucleotides from a sequence set forth in the Sequence Listing, or an isolated polynucleotide comprising a sequence having at least 30, 50 or 100 contiguous nucleotides truncated or deleted from a sequence set forth in the Sequence Listing.

Preferred variants of polynucleotides of the present invention include splice variants, allelic variants, and polymorphisms, including polynucleotides having one or more 10 single nucleotide polymorphisms (SNPs).

Polynucleotides of the present invention also include polynucleotides encoding polypeptide variants that comprise an amino acid sequence set forth in the Sequence Listing and in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acid residues are substituted, deleted or 15 added, in any combination.

In a further aspect, the present invention provides polynucleotides that are RNA transcripts of the DNA sequences of the present invention. Accordingly, there is provided an RNA polynucleotide that:

(a) comprises an RNA transcript of the DNA sequence encoding a polypeptide set 20 forth in the Sequence Listing;

(b) is a RNA transcript of a DNA sequence encoding a polypeptide set forth in the Sequence Listing;

(c) comprises an RNA transcript of a DNA sequence set forth in the Sequence Listing; or

25 (d) is a RNA transcript of a DNA sequence set forth in the Sequence Listing; and RNA polynucleotides that are complementary thereto.

The polynucleotide sequences set forth in the Sequence Listing show homology with the polynucleotide sequences set forth in Table II. A polynucleotide sequence set forth in the Sequence Listing is a cDNA sequence that encodes a polypeptide set forth in the 30 Sequence Listing. A polynucleotide sequence encoding a polypeptide set forth in the Sequence Listing may be identical to a polypeptide encoding a sequence set forth in the Sequence Listing or it may be a sequence other than a sequence set forth in the Sequence Listing, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes a polypeptide set forth in the Sequence Listing. A polypeptide of a sequence set forth in the 35 Sequence Listing is related to other proteins of the gene families set forth in Table II, having

homology and/or structural similarity with the polypeptides set forth in Table II. Preferred polypeptides and polynucleotides of the present invention are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one activity of the genes set forth in Table I.

5 Polynucleotides of the present invention may be obtained using standard cloning and screening techniques from a cDNA library derived from mRNA from the tissues set forth in Table IV (see for instance, Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)).

10 Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

15 When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the polynucleotide may include the coding sequence for the mature polypeptide, by itself, or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. A polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

20 25 Polynucleotides that are identical, or have sufficient identity to a polynucleotide sequence set forth in the Sequence Listing, may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification reaction (for instance, PCR). Such probes and primers may be used to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes (including genes encoding paralogs from human sources and orthologs and paralogs from other species) that have a high sequence similarity to sequences set forth in the Sequence Listing, typically at least 95% identity. Preferred probes and primers will generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50, if not at least 100 nucleotides. Particularly preferred probes will have between

30 and 50 nucleotides. Particularly preferred primers will have between 20 and 25 nucleotides.

A polynucleotide encoding a polypeptide of the present invention, including homologs from other species, may be obtained by a process comprising the steps of

5 screening a library under stringent hybridization conditions with a labeled probe having a sequence set forth in the Sequence Listing or a fragment thereof, preferably of at least 15 nucleotides; and isolating full-length cDNA and genomic clones containing the polynucleotide sequence set forth in the Sequence Listing. Such hybridization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include

10 overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in 0.1x SSC at about 65°C. Thus the present invention also includes isolated polynucleotides, preferably with a nucleotide sequence of at least 100,

15 obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence set forth in the Sequence Listing or a fragment thereof, preferably of at least 15 nucleotides.

The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide does not extend all the way

20 through to the 5' terminus. This is a consequence of reverse transcriptase, an enzyme with inherently low "processivity" (a measure of the ability of the enzyme to remain attached to the template during the polymerisation reaction), failing to complete a DNA copy of the mRNA template during first strand cDNA synthesis.

There are several methods available and well known to those skilled in the art to

25 obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., Proc Nat Acad Sci USA 85, 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon (trade mark) technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon (trade mark)

30 technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the "missing" 5' end of the cDNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using 'nested' primers, that is, primers designed to anneal within the amplified product (typically an

35 adapter specific primer that anneals further 3' in the adaptor sequence and a gene specific

primer that anneals further 5' in the known gene sequence). The products of this reaction can then be analyzed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.

5. Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems comprising a polynucleotide or polynucleotides of the present invention, to host cells which 10 are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

15 For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention.

Polynucleotides may be introduced into host cells by methods described in many standard laboratory manuals, such as Davis et al., *Basic Methods in Molecular Biology* (1986) and Sambrook et al. (*ibid*). Preferred methods of introducing polynucleotides into host cells include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, 20 transvection, micro-injection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

25 Representative examples of appropriate hosts include bacterial cells, such as *Streptococci*, *Staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila S2* and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

30 A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, 35 vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector that is able to maintain, propagate or express a polynucleotide to produce a

polypeptide in a host may be used. The appropriate polynucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, (*ibid*). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the 5 translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. 10 In this event, the cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

Polypeptides of the present invention can be recovered and purified from 15 recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques 20 for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and/or purification.

Polynucleotides of the present invention may be used as diagnostic reagents, through detecting mutations in the associated gene. Detection of a mutated form of a gene is characterized by the polynucleotides set forth in the Sequence Listing in the cDNA or 25 genomic sequence and which is associated with a dysfunction. Will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques well known in the art.

30 Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or it may be amplified enzymatically by using PCR, preferably RT-PCR, or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the 35 amplified product in comparison to the normal genotype. Point mutations can be identified

by hybridizing amplified DNA to labeled nucleotide sequences of the genes set forth in Table I. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence difference may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, 5 with or without denaturing agents, or by direct DNA sequencing (see, for instance, Myers *et al.*, *Science* (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, *Proc Natl Acad Sci USA* (1985) 85: 4397-4401).

An array of oligonucleotides probes comprising polynucleotide sequences or 10 fragments thereof of the genes set forth in Table I can be constructed to conduct efficient screening of *e.g.*, genetic mutations. Such arrays are preferably high density arrays or grids. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability, see, for example, M. Chee *et al.*, *Science*, 274, 610-613 15 (1996) and other references cited therein.

Detection of abnormally decreased or increased levels of polypeptide or mRNA expression may also be used for diagnosing or determining susceptibility of a subject to a disease of the invention. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for 20 example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radio-immunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

25 Thus in another aspect, the present invention relates to a diagnostic kit comprising:
(a) a polynucleotide of the present invention, preferably the nucleotide sequence set forth in the Sequence Listing, or a fragment or an RNA transcript thereof;
(b) a nucleotide sequence complementary to that of (a);
(c) a polypeptide of the present invention, preferably the polypeptide set forth in the 30 Sequence Listing or a fragment thereof; or
(d) an antibody to a polypeptide of the present invention, preferably to the polypeptide set forth in the Sequence Listing.

35 It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly diseases of the invention, amongst others.

The polynucleotide sequences of the present invention are valuable for chromosome localisation studies. The sequences set forth in the Sequence Listing are specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available online through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (co-inheritance of physically adjacent genes). Precise human chromosomal localisations for a genomic sequence (gene fragment etc.) can be determined using Radiation Hybrid (RH) Mapping (Walter, M., Spillett, D., Thomas, P., Weissenbach, J., and Goodfellow, P., (1994) A method for constructing radiation hybrid maps of whole genomes, *Nature Genetics* 7, 22-28). A number of RH panels are available from Research Genetics (Huntsville, AL, USA) e.g. the GeneBridge4 RH panel (Hum Mol Genet 1996 Mar;5(3):339-46 A radiation hybrid map of the human genome. Gyapay G, Schmitt K, Fizames C, Jones H, Vega-Czarny N, Spillett D, Muselet D, Prud'Homme JF, Dib C, Auffray C, Morissette J, Weissenbach J, Goodfellow PN). To determine the chromosomal location of a gene using this panel, 93 PCRs are performed using primers designed from the gene of interest on RH DNAs. Each of these DNAs contains random human genomic fragments maintained in a hamster background (human / hamster hybrid cell lines). These PCRs result in 93 scores indicating the presence or absence of the PCR product of the gene of interest. These scores are compared with scores created using PCR products from genomic sequences of known location. This comparison is conducted at <http://www.genome.wi.mit.edu/>.

The polynucleotide sequences of the present invention are also valuable tools for tissue expression studies. Such studies allow the determination of expression patterns of polynucleotides of the present invention which may give an indication as to the expression patterns of the encoded polypeptides in tissues, by detecting the mRNAs that encode them. The techniques used are well known in the art and include *in situ* hybridization techniques to clones arrayed on a grid, such as cDNA microarray hybridization (Schena *et al*, *Science*, 270, 467-470, 1995 and Shalon *et al*, *Genome Res*, 6, 639-645, 1996) and nucleotide amplification techniques such as PCR. A preferred method uses the TAQMAN (Trade mark) technology available from Perkin Elmer. Results from these studies can provide an

indication of the normal function of the polypeptide in the organism. In addition, comparative studies of the normal expression pattern of mRNAs with that of mRNAs encoded by an alternative form of the same gene (for example, one having an alteration in polypeptide coding potential or a regulatory mutation) can provide valuable insights into the 5 role of the polypeptides of the present invention, or that of inappropriate expression thereof in disease. Such inappropriate expression may be of a temporal, spatial or simply quantitative nature.

A further aspect of the present invention relates to antibodies. The polypeptides of the invention or their fragments, or cells expressing them, can be used as immunogens to 10 produce antibodies that are immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against polypeptides of the present invention may be obtained 15 by administering the polypeptides or epitope-bearing fragments, or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., *Nature* (1975) 256:495-497), the trioma technique, the human B-cell hybridoma 20 technique (Kozbor *et al.*, *Immunology Today* (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies, such as those described in 25 U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography. Antibodies against polypeptides of the present invention may also be employed to treat 30 diseases of the invention, amongst others.

Polypeptides and polynucleotides of the present invention may also be used as vaccines. Accordingly, in a further aspect, the present invention relates to a method for inducing an immunological response in a mammal that comprises inoculating the mammal with a polypeptide of the present invention, adequate to produce antibody and/or T cell 35 immune response, including, for example, cytokine-producing T cells or cytotoxic T cells.

to protect said animal from disease, whether that disease is already established within the individual or not. An immunological response in a mammal may also be induced by a method comprises delivering a polypeptide of the present invention *via* a vector directing expression of the polynucleotide and coding for the polypeptide *in vivo* in order to induce 5 such an immunological response to produce antibody to protect said animal from diseases of the invention. One way of administering the vector is by accelerating it into the desired cells as a coating on particles or otherwise. Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid. For use a vaccine, a polypeptide or a nucleic acid vector will be normally provided as a vaccine formulation (composition). The 10 formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intra-muscular, intravenous, or intra-dermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions that may contain anti-oxidants, buffers, bacteriostats and solutes that render the formulation isotonic with the 15 blood of the recipient; and aqueous and non-aqueous sterile suspensions that may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the 20 immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Polypeptides of the present invention have one or more biological functions that are of relevance in one or more disease states, in particular the diseases of the invention 25 hereinbefore mentioned. It is therefore useful to identify compounds that stimulate or inhibit the function or level of the polypeptide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those that stimulate or inhibit the function or level of the polypeptide. Such methods identify agonists or antagonists that may be employed for therapeutic and prophylactic purposes for such 30 diseases of the invention as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, collections of chemical compounds, and natural product mixtures. Such agonists or antagonists so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide; a structural or functional mimetic thereof (see Coligan *et* 35 *al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)) or a small molecule. Such

small molecules preferably have a molecular weight below 2,000 daltons, more preferably between 300 and 1,000 daltons, and most preferably between 400 and 700 daltons. It is preferred that these small molecules are organic molecules.

The screening method may simply measure the binding of a candidate compound to 5 the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof, by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve measuring or detecting (qualitatively or 10 quantitatively) the competitive binding of a candidate compound to the polypeptide against a labeled competitor (*e.g.* agonist or antagonist). Further, these screening methods may test 15 whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Further, the screening methods may simply comprise the steps of mixing a candidate 20 compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring an activity of the genes set forth in Table I in the mixture, and comparing activity of the mixture of the genes set forth in Table I to a control mixture which contains no candidate compound.

Polypeptides of the present invention may be employed in conventional low 25 capacity screening methods and also in high-throughput screening (HTS) formats. Such HTS formats include not only the well-established use of 96- and, more recently, 384-well micotiter plates but also emerging methods such as the nanowell method described by Schullek *et al.*, *Anal Biochem.*, 246, 20-29, (1997).

Fusion proteins, such as those made from Fc portion and polypeptide of the genes set forth 25 in Table I, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett *et al.*, *J Mol Recognition*, 8:52-58 (1995); and K. Johanson *et al.*, *J Biol Chem*, 270(16):9459-9471 (1995)).

The polynucleotides, polypeptides and antibodies to the polypeptide of the present 30 invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents that may inhibit or enhance the production of polypeptide 35 (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

A polypeptide of the present invention may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance, ^{125}I), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide that compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

10 Examples of antagonists of polypeptides of the present invention include antibodies or, in some cases, oligonucleotides or proteins that are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the polypeptide, *e.g.*, a fragment 15 of the ligands, substrates, receptors, enzymes, etc.; or a small molecule that bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

15 Screening methods may also involve the use of transgenic technology and the genes set forth in Table I. The art of constructing transgenic animals is well established. For 20 example, the genes set forth in Table I may be introduced through microinjection into the male pronucleus of fertilized oocytes, retroviral transfer into pre- or post-implantation embryos, or injection of genetically modified, such as by electroporation, embryonic stem cells into host blastocysts. Particularly useful transgenic animals are so-called "knock-in" 25 animals in which an animal gene is replaced by the human equivalent within the genome of that animal. Knock-in transgenic animals are useful in the drug discovery process, for target validation, where the compound is specific for the human target. Other useful transgenic animals are so-called "knock-out" animals in which the expression of the animal ortholog of a polypeptide of the present invention and encoded by an endogenous DNA sequence in a cell is partially or completely annulled. The gene knock-out may be targeted to specific 30 cells or tissues, may occur only in certain cells or tissues as a consequence of the limitations of the technology, or may occur in all, or substantially all, cells in the animal. Transgenic animal technology also offers a whole animal expression-cloning system in which introduced genes are expressed to give large amounts of polypeptides of the present invention

Screening kits for use in the above described methods form a further aspect of the present invention. Such screening kits comprise:

- (a) a polypeptide of the present invention;
- (b) a recombinant cell expressing a polypeptide of the present invention;
- 5 (c) a cell membrane expressing a polypeptide of the present invention; or
- (d) an antibody to a polypeptide of the present invention;

which polypeptide is preferably that set forth in the Sequence Listing.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

10

Glossary

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

"Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, 15 single chain, and humanized antibodies, as well as Fab fragments, including the products of an

Fab or other immunoglobulin expression library.

"Isolated" means altered "by the hand of man" from its natural state, *i.e.*, if it occurs in nature, it has been changed or removed from its original environment, or both. For 20 example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Moreover, a polynucleotide or polypeptide that is introduced into an organism by transformation, genetic manipulation or by any other recombinant method is "isolated" even if it is still present in 25 said organism, which organism may be living or non-living.

"Secreted protein activity or secreted polypeptide activity" or "biological activity of the secreted protein or secreted polypeptide" refers to the metabolic or physiologic function of said secreted protein including similar activities or improved activities or these activities with decreased undesirable side-effects. Also included are antigenic and immunogenic 30 activities of said secreted protein.

"Secreted protein gene" refers to a polynucleotide comprising any of the attached nucleotide sequences or allelic variants thereof and/or their complements.

"Polynucleotide" generally refers to any polyribonucleotide (RNA) or polydeoxyribonucleotide (DNA), which may be unmodified or modified RNA or DNA. 35 "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that

is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-
5 stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, "polynucleotide" embraces chemically,
10 enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

"Polypeptide" refers to any polypeptide comprising two or more amino acids joined
15 to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as post-translational
20 processing, or by chemical modification techniques that are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the
25 same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-
30 ribosylation, amidation, biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation,
35 glycosylation, GPI anchor formation, hydroxylation, iodination, methylation,

myristylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for instance, Proteins - Structure and Molecular Properties, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., Post-translational Protein Modifications: Perspectives and Prospects, 1-12, in Post-translational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", Meth Enzymol, 182, 626-646, 1990, and Rattan *et al.*, "Protein Synthesis: Post-translational Modifications and Aging", Ann NY Acad Sci, 663, 48-62, 1992).

10 "Fragment" of a polypeptide sequence refers to a polypeptide sequence that is shorter than the reference sequence but that retains essentially the same biological function or activity as the reference polypeptide. "Fragment" of a polynucleotide sequence refers to a polynucleotide sequence that is shorter than the reference sequence set forth in the Sequence Listing.

15 "Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains the essential properties thereof. A typical variant of a polynucleotide differs in nucleotide sequence from the reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes 20 may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from the reference polypeptide. Generally, alterations are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide 25 may differ in amino acid sequence by one or more substitutions, insertions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. Typical conservative substitutions include Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe and Tyr. A variant of a polynucleotide or polypeptide may be naturally occurring such as an allele, or it may be a variant that is not 30 known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis. Also included as variants are polypeptides having one or more post-translational modifications, for instance glycosylation, phosphorylation, methylation, ADP ribosylation and the like. Embodiments include methylation of the N-terminal amino acid, phosphorylations of 35 serines and threonines and modification of C-terminal glycines.

"Allele" refers to one of two or more alternative forms of a gene occurring at a given locus in the genome.

"Polymorphism" refers to a variation in nucleotide sequence (and encoded polypeptide sequence, if relevant) at a given position in the genome within a population.

5 "Single Nucleotide Polymorphism" (SNP) refers to the occurrence of nucleotide variability at a single nucleotide position in the genome, within a population. An SNP may occur within a gene or within intergenic regions of the genome. SNPs can be assayed using Allele Specific Amplification (ASA). For the process at least 3 primers are required. A common primer is used in reverse complement to the polymorphism being assayed. This
10 common primer can be between 50 and 1500 bps from the polymorphic base. The other two (or more) primers are identical to each other except that the final 3' base wobbles to match one of the two (or more) alleles that make up the polymorphism. Two (or more) PCR reactions are then conducted on sample DNA, each using the common primer and one of the Allele Specific Primers.

15 "Splice Variant" as used herein refers to cDNA molecules produced from RNA molecules initially transcribed from the same genomic DNA sequence but which have undergone alternative RNA splicing. Alternative RNA splicing occurs when a primary RNA transcript undergoes splicing, generally for the removal of introns, which results in the production of more than one mRNA molecule each of that may encode different amino acid
20 sequences. The term splice variant also refers to the proteins encoded by the above cDNA molecules.

25 "Identity" reflects a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, determined by comparing the sequences. In general, identity refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of the two polynucleotide or two polypeptide sequences, respectively, over the length of the sequences being compared.

30 "% Identity" - For sequences where there is not an exact correspondence, a "% identity" may be determined. In general, the two sequences to be compared are aligned to give a maximum correlation between the sequences. This may include inserting "gaps" in either one or both sequences, to enhance the degree of alignment. A % identity may be determined over the whole length of each of the sequences being compared (so-called global alignment), that is particularly suitable for sequences of the same or very similar length, or over shorter, defined lengths (so-called local alignment), that is more suitable for sequences of unequal length.

"Similarity" is a further, more sophisticated measure of the relationship between two polypeptide sequences. In general, "similarity" means a comparison between the amino acids of two polypeptide chains, on a residue by residue basis, taking into account not only exact correspondences between a between pairs of residues, one from each of the sequences 5 being compared (as for identity) but also, where there is not an exact correspondence, whether, on an evolutionary basis, one residue is a likely substitute for the other. This likelihood has an associated "score" from which the "% similarity" of the two sequences can then be determined.

Methods for comparing the identity and similarity of two or more sequences are 10 well known in the art. Thus for instance, programs available in the Wisconsin Sequence Analysis Package, version 9.1 (Devereux J et al, Nucleic Acids Res, 12, 387-395, 1984, available from Genetics Computer Group, Madison, Wisconsin, USA), for example the programs BESTFIT and GAP, may be used to determine the % identity between two polynucleotides and the % identity and the % similarity between two polypeptide sequences. 15 BESTFIT uses the "local homology" algorithm of Smith and Waterman (J Mol Biol, 147, 195-197, 1981, Advances in Applied Mathematics, 2, 482-489, 1981) and finds the best single region of similarity between two sequences. BESTFIT is more suited to comparing two polynucleotide or two polypeptide sequences that are dissimilar in length, the program assuming that the shorter sequence represents a portion of the longer. In comparison, GAP 20 aligns two sequences, finding a "maximum similarity", according to the algorithm of Neddleman and Wunsch (J Mol Biol, 48, 443-453, 1970). GAP is more suited to comparing sequences that are approximately the same length and an alignment is expected over the entire length. Preferably, the parameters "Gap Weight" and "Length Weight" used in each program are 50 and 3, for polynucleotide sequences and 12 and 4 for polypeptide sequences, 25 respectively. Preferably, % identities and similarities are determined when the two sequences being compared are optimally aligned.

Other programs for determining identity and/or similarity between sequences are 30 also known in the art, for instance the BLAST family of programs (Altschul S F et al, J Mol Biol, 215, 403-410, 1990, Altschul S F et al, Nucleic Acids Res., 25:389-3402, 1997, available from the National Center for Biotechnology Information (NCBI), Bethesda, Maryland, USA and accessible through the home page of the NCBI at www.ncbi.nlm.nih.gov) and FASTA (Pearson W R, Methods in Enzymology, 183, 63-99, 1990; Pearson W R and Lipman D J, Proc Nat Acad Sci USA, 85, 2444-2448, 1988, available as part of the Wisconsin Sequence Analysis Package).

Preferably, the BLOSUM62 amino acid substitution matrix (Henikoff S and Henikoff J G, Proc. Nat. Acad Sci. USA, 89, 10915-10919, 1992) is used in polypeptide sequence comparisons including where nucleotide sequences are first translated into amino acid sequences before comparison.

5 Preferably, the program BESTFIT is used to determine the % identity of a query polynucleotide or a polypeptide sequence with respect to a reference polynucleotide or a polypeptide sequence, the query and the reference sequence being optimally aligned and the parameters of the program set at the default value, as hereinbefore described.

"Identity Index" is a measure of sequence relatedness which may be used to
10 compare a candidate sequence (polynucleotide or polypeptide) and a reference sequence. Thus, for instance, a candidate polynucleotide sequence having, for example, an Identity Index of 0.95 compared to a reference polynucleotide sequence is identical to the reference sequence except that the candidate polynucleotide sequence may include on average up to five differences per each 100 nucleotides of the reference sequence. Such differences are
15 selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion. These differences may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between these terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to
20 obtain a polynucleotide sequence having an Identity Index of 0.95 compared to a reference polynucleotide sequence, an average of up to 5 in every 100 of the nucleotides of the in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

25 Similarly, for a polypeptide, a candidate polypeptide sequence having, for example, an Identity Index of 0.95 compared to a reference polypeptide sequence is identical to the reference sequence except that the polypeptide sequence may include an average of up to five differences per each 100 amino acids of the reference sequence. Such differences are selected from the group consisting of at least one amino acid deletion, substitution,
30 including conservative and non-conservative substitution, or insertion. These differences may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between these terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a polypeptide sequence having an
35 Identity Index of 0.95 compared to a reference polypeptide sequence, an average of up to 5

in every 100 of the amino acids in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

5 The relationship between the number of nucleotide or amino acid differences and the Identity Index may be expressed in the following equation:

$$n_a \leq x_a - (x_a \bullet I),$$

in which:

n_a is the number of nucleotide or amino acid differences,

10 x_a is the total number of nucleotides or amino acids in a sequence set forth in the Sequence Listing;

I is the Identity Index,

• is the symbol for the multiplication operator, and

in which any non-integer product of x_a and I is rounded down to the nearest integer prior to subtracting it from x_a .

15 "Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a reference sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the two sequences as hereinbefore defined. Falling within this generic term are the terms "ortholog", and "paralog". "Ortholog" refers to a polynucleotide or 20 polypeptide that is the functional equivalent of the polynucleotide or polypeptide in another species. "Paralog" refers to a polynucleotide or polypeptide that within the same species which is functionally similar.

25 "Fusion protein" refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 533-A discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, e.g., EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion 30 protein has been expressed, detected and purified.

All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which

this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and references.

Table I.

Gene Name	GSK Gene ID	Nucleic Acid SEQ ID NO's	Corresponding Protein SEQ ID NO's
sbg960509cbrecpt	960509	SEQ ID NO:1	SEQ ID NO:45
sbg614126complifH	614126	SEQ ID NO:2 SEQ ID NO:3	SEQ ID NO:46 SEQ ID NO:47
sbg120703RNase	120703	SEQ ID NO:4	SEQ ID NO:48
sbg98530TS	98530	SEQ ID NO:5 SEQ ID NO:6	SEQ ID NO:49 SEQ ID NO:50
sbg563917RDP	63917	SEQ ID NO:7 SEQ ID NO:8	SEQ ID NO:51 SEQ ID NO:52
sbg618069LRR	618069	SEQ ID NO:9 SEQ ID NO:10	SEQ ID NO:53 SEQ ID NO:54
sbg934114Relaxin	934114	SEQ ID NO:11	SEQ ID NO:55
sbg99174LOX-like	99174	SEQ ID NO:12	SEQ ID NO:56
sbg995002PIGR	995002	SEQ ID NO:13	SEQ ID NO:57
sbg1033026C1q	1033026	SEQ ID NO:14 SEQ ID NO:15	SEQ ID NO:58 SEQ ID NO:59
sbg1003675RNase	1003675	SEQ ID NO:16	SEQ ID NO:60
sbg1015258PLM	1015258	SEQ ID NO:17	SEQ ID NO:61
sbg1003328IG	1003328	SEQ ID NO:18 SEQ ID NO:19	SEQ ID NO:62 SEQ ID NO:63
sbg1020829SGLT	1020829	SEQ ID NO:20	SEQ ID NO:64
sbg1005450UDPGT	1005450	SEQ ID NO:21 SEQ ID NO:22	SEQ ID NO:65 SEQ ID NO:66
sbg1002620T1a	1002620	SEQ ID NO:23 SEQ ID NO:24	SEQ ID NO:67 SEQ ID NO:68
sbg1002620T1b	1002620	SEQ ID NO:25	SEQ ID NO:69
sbg102200MCTa	102200	SEQ ID NO:26 SEQ ID NO:27	SEQ ID NO:70 SEQ ID NO:71
sbg102200MCTb	102200	SEQ ID NO:28	SEQ ID NO:72
sbg1020380LYG	1020380	SEQ ID NO:29 SEQ ID NO:30	SEQ ID NO:73 SEQ ID NO:74
sbg1007026SGLT	1007026	SEQ ID NO:31	SEQ ID NO:75
sbg1012732GLUT	1012732	SEQ ID NO:32 SEQ ID NO:33	SEQ ID NO:76 SEQ ID NO:77
sbg1012732GLUTb	1012732	SEQ ID NO:34	SEQ ID NO:78
sbg1018172CSP	1018172	SEQ ID NO:35 SEQ ID NO:36	SEQ ID NO:79 SEQ ID NO:80
sbg1004570ERGIC	1004570	SEQ ID NO:37 SEQ ID NO:38	SEQ ID NO:81 SEQ ID NO:82
sbg1016995IGBrecpt	1016995	SEQ ID NO:39 SEQ ID NO:40	SEQ ID NO:83 SEQ ID NO:84
sbg1151bSREC	1151	SEQ ID NO:41 SEQ ID NO:42	SEQ ID NO:85 SEQ ID NO:86
sbg1399854ANK	1399854	SEQ ID NO:43 SEQ ID NO:44	SEQ ID NO:87 SEQ ID NO:88

Table II

Gene Name	Gene Family	Closest Polynucleotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg960509 cbrecept	Carbohydrate-binding receptor	GB:AC007395 Direct submitted (25-APR-1999) Genome Sequencing Center, Washington University School of Medicine, 4444 Forest Park Parkway, St. Louis, MO 63108, USA	Mouse Kupffer cell c-type lectin receptor, gi: 7949066 Submitted (25-OCT-1996) to the DDBJ/EMBL/GenBank databases.	Membrane-bound
sbg614126 complfH	Complement factor H	SC:AL353809 Submitted (20-JAN-2001) by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Human H-factor like 1, gi:11321587 Estaller,C., Koistinen,V., Schwaeble,W., Dierich,M.P., and Weiss,E.H. <i>J. Immunol.</i> 146, 3190-3196 (1991)	Secreted
sbg120703 RNase	RNase	GB:AL157687 Direct Submitted (24-MAY-2000) to the EMBL/GenBank/DDBJ databases by Genoscope.	Human keratinocyte-derived RNase-like protein, geneseqp: Y44192 Submitted by INNOGENETICS NV Application number and publication date: EP-943679-A1, 22-SEP-99	Secreted
sbg98530T S	Thrombospordin type I	GB:AC027307 Submitted (30-MAR-2000) Production Sequencing Facility, DOE Joint Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA	Mouse RIKEN cDNA 2010109H09 gene, gi:13385092 The RIKEN Genome Exploration Research Group Phase II Team and FANTOM Consortium. <i>Nature</i> 409, 685-690 (2001)	Secreted
sbg563917 RDP	Renal dipeptidase	GB:AC009077 Directly submitted (03-AUG-1999) by Production Sequencing Facility, DOE Joint Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA	Human putative metallopeptidase (family M19) gi:11641273 Chen,J.M., Fortunato,M. and Barrett, A.J. Submitted (02-NOV-2000) Chen J.M., MRC Molecular Enzymology Laboratory, The Babraham Institute, Babraham, Cambridge, CB2 4AT, UK	Secreted

Table II (cont.).

Gene Name	Gene Family	Closest Polynucleotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg618069 LRR	Leucine-rich repeat	GB:AL589765 Submitted (16-MAR-2001) by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Macaca fascicularis brain protein, gi: 9651088 Submitted (28-JUL-2000) to the DDBJ/EMBL/GenBank databases. Katsuyuki Hashimoto, National Institute of Infectious Diseases, Division of Genetic Resources; 23-1, Toyama 1-chome, Shinjuku-ku, Tokyo 162-8640, Japan	Membrane-bound
sbg934114 Relaxin	Insulin	JGI:CIT978SKB_55O6 Found at Joint Genome Institute DoE/LLNL/LBNL/LANL.	Mouse insulin-like peptide (relaxin/insulin-like protein), gi:7387805 Conklin D, Lofton-Day CE, Haldeman BA, Ching A, Whitmore TE, Lok S, Jaspers S. 1999. Genomics 60:50-56.	Secreted
sbg99174L OX-like	C-type lectin	GB:AL137062 Direct submitted (09-AUG-2000) Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Mouse putative protein, gi: 12855891 The RIKEN Genome Exploration Research Group Phase II Team and FANTOM Consortium. Nature 409, 685-690 (2001)	Membrane-bound
sbg995002 PIGR	Polymeric immunoglobulin receptor (PIGR)	GB:AC027192 Direct submitted (28-MAR-2000) Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA.	Human TANGO 354 protein, geneseqp: B66271 Submitted by (MILL-) MILLENNIUM PHARM INC Application number and publication date: WO200100673-A1, 04-JAN-01	Membrane-bound
sbg103302 6C1q	C1q	GB:AL359736 Direct submitted (22-AUG-2000) Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Human adipocyte-specific secretory protein, gi: 4757760 Maeda,K., Okubo,K., Shimomura,I., Funahashi,T., Matsuzawa,Y. and Matsubara,K. Biochem. Biophys. Res. Commun. 221 (2), 286-289 (1996)	Secreted

Table II (cont.).

Gene Name	Gene Family	Closest Polynucleotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg100367 5RNase	RNase	EMBL:CNS01RIH Found at European Molecular Biology Laboratory.	Chinchilla brevicaudata pancreatic ribonuclease, gi:133205 Van Den Berg A, Van Den Hende-Timmer L, Beintema JJ. 1976. Biochim Biophys Acta 453:400-9.	Secreted
sbg101525 8PLM	Phosphole mman (PLM)	GB:AL022345 Direct submitted (10-DEC-1999) by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Human phospholemman-like protein, geneseqp:W51104 Submitted by (HUMA-) HUMAN GENOME SCI INC Application number and publication date: WO9839448-A2, 11-SEP-98	Membrane-bound
sbg100332 8IG	Immunogl obulin	EMBL:HSBA536C5 Found at European Molecular Biology Laboratory.	Human immune system molecule, geneseqp:B15536 Submitted by (INCY-) INCYTE PHARM INC Application number and publication date: WO200060080-A2, 12-OCT-00	Membrane-bound
sbg102082 9SGLT	Na+/gluco se cotranspor ter	GB:AJ009617 Directly submitted (17-JUL-1998) by MPIMG, Abt.Lehrach, Max Planck Institut fuer Molekulare Genetik, Ihnestrasse 73, Berlin, 14195, Germany.	Oryctolagus cuniculus Na/glucose cotransporters, gi:520469 Pajor,A.M. 1994 Biochim. Biophys. Acta 1194 (2), 349-51.	Membrane-bound
sbg100545 0UDPGT	UDP- glucuronos yltransfера ^r (UDPGT)	GB:AC016612 Submitted (04-DEC-1999) Production Sequencing Facility, DOE Joint Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA	Human PRO1780 protein , geneseqp: B24025 Submitted by GENENTECH INC Application number and publication date: WO200053750-A1, 14-SEP-00	Membrane-bound
sbg100262 0T1a	Cysteine- rich secretory protein (CRISP) trypsin inhibitor	GB:AC025280 Submitted (08-MAR-2000) by Production Sequencing Facility, DOE Joint Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA	Human hypothetical protein DKFZp434B044, gi: 13899332 Wiemann,S., Weil,B. et al. Genome Res. 11 (3), 422-435 (2001)	Secreted

Table II (cont.).

Gene Name	Gene Family	Closest Polynucleotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg100262 0T1b	Cysteine-rich secretory protein (CRISP) trypsin inhibitor	GB:AC025280 Submitted (08-MAR-2000) by Production Sequencing Facility, DOE Joint Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA	Rat late gestation lung protein 1 , gi:4324682 Kaplan,F., Ledoux,P., Kassamali,F.Q., Gagnon,S., Post,M., Koehler,D., Deimling,J. and Sweezey,N.B. Am. J. Physiol. 276 (6), L1027-L1036 (1999)	Secreted
sbg102200 MCTa	Monocarb oxylate cotransporter (MCT1)	GB: AC015918 Directly submitted (17-NOV-1999) by Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA.	Mouse unnamed protein product, gi:7670446 Submitted (12-APR-2000) to the DDBJ/EMBL/GenBank databases by Katsuyuki Hashimoto, National Institute of Infectious Diseases, Division of Genetic Resources; 23-1, Toyama 1-chome, Shinjuku-ku, Tokyo 162-8640, Japan	Membrane-bound
sbg102200 MCTb	Monocarb oxylate cotransporter (MCT1)	GB: AC015918 Directly submitted (17-NOV-1999) by Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA.	Human solute carrier 16 (monocarboxylic acid transporters), member 8, gi:13655082 Submitted (17-APR-2001) by National Center for Biotechnology Information, NIH, Bethesda, MD 20894, USA	Membrane-bound
sbg102038 0LYG	Goose-type lysozyme G	GB:AC023965 Directly submitted (20-FEB-2000) by Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA	Lysozyme G (1,4-beta-N-acetylmuramidas E) (Goose-type lysozyme). gi:126634 Schoentgen, F., Jolles,J. and Jolles, P. Eur. J. Biochem. 123 (3), 489-497 (1982)	Secreted
sbg100702 6SGLT	Sodium-glucose cotransporter	GB:AC046167 Direct submitted (13-APR-2000) Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141.	Human transport protein TPPT-13, genesep: B60093 Submitted by INCYTE GENOMICS INC Application number and publication date: WO200078953-A2, 28-DEC-00	Membrane-bound

Table II (cont.).

Gene Name	Gene Family	Closest Polynucleotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg101273 2GLUT	Glucose transporter	GB:AP000350 Direct submitted (10-JUN-1999) to the DDBJ/EMBL/GenBank databases. Nobuyoshi Shimizu, Keio university, school of medicine, Molecular Biology; 35 Shinanomachi, Shinjuku-ku, Tokyo 160-0016, Japan.	Human glucose transporter GLUT10, gi:13540598 Submitted (10-FEB-2000) Joost H.G., Institute of Pharmacology and Toxicology, Medical Faculty, Technical University of Aachen, Wendlingweg 2, Aachen, D-52057, GERMANY	Membrane-bound
sbg101273 2GLUTb	Glucose transporter	GB:AP000350 Direct submitted (10-JUN-1999) to the DDBJ/EMBL/GenBank databases. Nobuyoshi Shimizu, Keio university, school of medicine, Molecular Biology; 35 Shinanomachi, Shinjuku-ku, Tokyo 160-0016, Japan.	Human glucose transporter GLUT10, gi:13540598 Submitted (10-FEB-2000) Joost H.G., Institute of Pharmacology and Toxicology, Medical Faculty, Technical University of Aachen, Wendlingweg 2, Aachen, D-52057, GERMANY	Membrane-bound
sbg101817 2CSP	Chondroitin sulfate proteoglycan	EMBL:AL354819, and SC:AL590007. Submitted (30-APR-2001 and 04-MAY-2001) by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK. EMBL:AC017111, Submitted (09-DEC-1999) Genome Sequencing Center, Washington University School of Medicine, 4444 Forest Park Parkway, St. Louis, MO 63108, USA	Lytechinus variegatus embryonic blastocoelar extracellular matrix protein , gi:9837426 Submitted (14-JUL-2000) Biological Sciences, Carnegie Mellon University, 4400 Fifth Ave, Pittsburgh, PA 15213, USA	Secreted
sbg100457 0ERGIC	ER-Golgi intermediate compartment protein	GB:AC020705 Submitted (08-JAN-2000) Genome Sequencing Center, Washington University School of Medicine, 4444 Forest Park Parkway, St. Louis, MO 63108, USA	Human ERGL protein, gi:11141891 Submitted (06-SEP-2000) Laboratory of Molecular Biology, NCI, NIH, 37 Convent Dr., Bldg. 37, Rm. 4B20, Bethesda, MD 20892, USA	Membrane-bound

Table II (cont.).

Gene Name	Gene Family	Closest Polynucleotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg101699 5IGBrecpt	Immunoglobulin receptor	GB:AL353721 Submitted (07-JUL-2001) Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Human immunoglobulin superfamily receptor translocation associated 1, gi:14550416 Hatzivassiliou,G., Miller,I.J., Takizawa,J., et al. <i>Immunity</i> 14 (3), 277-289 (2001)	Membrane-bound
sbg1151bs REC	EGF-like LDL receptor protein	GB:AC005500 Chen,F., D,L., Do,T., Dumanski,J.P. and Roe,B.A. Direct submission (31-MAY-01) Department Of Chemistry and Biochemistry, The University Of Oklahoma, 620 Parrington Oval, Room 208, Norman, OK 73019, USA	Human nurse cell receptor B6TNC#10b, geneseqp: B60395 Submitted by (SHIO) SHIONOGI & CO LTD Application number and publication date: JP2000308492-A, 07-NOV-00	Membrane-bound
sbg139985 4ANK	The ankyrin repeat family	GB: AC020658 Direct submitted (08-JAN-2000) Multimegaparsec Sequencing Center, University of Washington, PO BOX 357730, Seattle, WA 98195, USA	Human KIAA1223 protein, gi:6330617 Nagase T, Ishikawa K, Kikuno R, Hirosawa M, Nomura N, and Ohara O; 1999 <i>DNA Res</i> 6:337-45.	Cytosolic

Table III

Gene Name	Uses	Associated Diseases
sbg960509 cbrecept	<p>An embodiment of the invention is the use of sbg960509cbrecept in the treatment or diagnosis of cancer. A close homologue of sbg960509cbrecept is Langerin. Langerin was a type II Ca2+-dependent lectin, an endocytic receptor and expressed by Langerhans cells (LC). Transfection of Langerin cDNA into fibroblasts created a compact network of membrane structures with typical features of Birbeck granules(BG). It was proposed that induction of BG was a consequence of the antigen-capture function of Langerin, allowing routing into these organelles and providing access to a nonclassical antigen-processing pathway (Valladeau J, Ravel O, Dezutter-Dambuyant C, Moore K, Kleijmeer M, Liu Y, Duvert-Frances V, Vincent C, Schmitt D, Davoust J, Caux C, Lebecque S, Saeland S. 2000. <i>Immunity</i> Jan;12(1):71-81). A striking incongruity was found between variably spliced transcripts for the second asialoglycoprotein receptor polypeptide, H2, in normal and transformed human liver cells (Paietta E, Stockert RJ, Racevskis J. 1992. <i>Hepatology</i> Mar;15(3):395-402). Human macrophage cell surface C-type lectin was demonstrated to recognize Tn Ag, a well-known human carcinoma-associated epitope (Suzuki N, Yamamoto K, Toyoshima S, Osawa T, Irimura T. 1996. <i>J Immunol</i> Jan 1;156(1):128-35).</p>	Autoimmune disorder and cancer
sbg614126 complfH	<p>An embodiment of the invention is the use of sbg614126complfH in the diagnosis or treatment of cancer, Alzheimer disease, and/or tumor cell evasion. A close homologue of sbg614126complfH is Human complement factor H. Human complement factor H was detected by the AM34 antibody in the cerebrospinal fluid from an Alzheimer's disease patient. It was recently found that AM34 was capable of staining senile plaques positively and factor H was associated with senile plaques in the human brain (Honda S, Itoh F, Yoshimoto M, Ohno S, Hinoda Y, Imai K. 2000. <i>J Gerontol A Biol Sci Med Sci</i> May;55(5):M265-9). It was also suggested that exceptional resistance of human H2 glioblastoma cells to complement-mediated killing was due to the production and binding of factor H and factor H-like protein 1 (Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF, Meri S. 2000. <i>J Immunol</i> Jun 1;164(11):6075-81). Moreover, factor H was shown to bind to bone sialoprotein and osteopontin and enable tumor cell evasion of complement-mediated attack (Fedarko NS, Fohr B, Robey PG, Young MF, Fisher LW. 2000. <i>J Biol Chem</i> Jun 2;275(22):16666-72). Finally, complement factor H gene mutation was associated with autosomal recessive atypical hemolytic uremic syndrome (Ying L, Katz Y, Schlesinger M, Carmi R, Shalev H, Haider N, Beck G, Sheffield VC, Landau D. 1999. <i>Am J Hum Genet</i> Dec;65(6):1538-46).</p>	Alzheimer's disease, cancer, tumor metastasis and autosomal recessive atypical hemolytic uremic syndrome

Table III (cont.).

Gene Name	Uses	Associated Diseases
sbg120703 RNase	An embodiment of the invention is the use of sbg120703RNase as a tool for anticancer therapy, and treating apoptosis-related disorders. It has been shown that a genetically engineered pancreatic RNase has cytotoxic action on mouse and human tumor cells, but lacks any appreciable toxicity on human and mouse normal cells. This variant of human pancreatic RNase selectively sensitizes cells derived from a human thyroid tumor to apoptotic death. Because of its selectivity for tumor cells, and because of its human origin, this protein is thought to represent a promising tool for anticancer therapy (Piccoli R, Di Gaetano S, De Lorenzo C, Grauso M, Monaco C, Spalletti-Cernia D, Laccetti P, Cinatl J, Matousek J, D'Alessio G. 1999. Proc Natl Acad Sci U S A 96:7768-73). In addition, RNase itself can be used to treat an RNA viral infection, and its antagonist may be useful in treating apoptosis-related disorders.	Cancer and infection
sbg98530TS	An embodiment of the invention is the use of sbg98530TS in the wound healing processes, development of the nervous system, and affecting cell migration, survival, or angiogenesis. Close homologues of sbg98530TS are thrombospondins. The thrombospondins are a family of proteins found widely in the embryonic extracellular matrix, and the expression patterns and in vitro properties of many thrombospondins suggest potential roles in the guidance of cell and growth cone migration, especially during the development of the nervous system (Adams JC, 2000. Tucker RP Dev Dyn 218:280-99). Cell interactions with extracellular matrices are important to pathological changes that occur during cell transformation and tumorigenesis. The thrombospondin-1 has been suggested to modulate tumor phenotype by affecting cell migration, survival, or angiogenesis (Liaw L, Crawford HC. 1999. Braz J Med Biol Res 32:805-12). In addition, thrombospondin-1 is also a transient component of extracellular matrix in developing and repairing tissues (Adams JC. 1997. Int J Biochem Cell Biol 29:861-5).	Cancer, wound healing disorders
sbg563917RDP	An embodiment of the invention is the use of sbg563917RDP in treatment or diagnosis of chronic renal failure and aged eye lenses and cataracts. Close homologues of sbg563917RDP are renal and lens dipeptidases. It has been reported that the renal dipeptidase activity was significantly lower in the chronic renal failure group (Fukumura Y, Kera Y, Oshitani S, Ushijima Y, Kobayashi I, LiuZ, Watanabe T, Yamada R, Kikuchi H, Kawazu S and Yabuuchi M. 1999 Ann Clin Biochem Mar;36 (Pt 2):221-5). In contrast, increased lens dipeptidase activity was detected in aging and cataracts (Sulochana KN, Ramakrishnan S and Punitham R. 1999 Br J Ophthalmol Jul;83(7):885).	Renal diseases, aging, cataract, cancer, and Alzheimer disease

Table III (cont.).

Gene Name	Uses	Associated Diseases
sb618069 LRR	An embodiment of the invention is the use of sb618069LRR in treatment or diagnosis of neural development and the adult nervous system disorders. Close homologues of sb618069LRR are Leucine-rich repeat proteins. Leucine-rich repeat protein, the spineless-aristapedia, has been shown to interact with tango bHLH-PAS proteins for controlling antennal and tarsal development in <i>Drosophila</i> (Emmons RB, Duncan D, Estes PA, Kiefel P, Mosher JT, Sonnenfeld M, Ward MP, Duncan I and Crews ST. 1999. <i>Development</i> Sep;126(17):3937-45). In mouse, neuronal Leucine-Rich Repeat NLRR-1 and NLRR-2 mRNAs were expressed primarily in the central nervous system and may play significant but distinct roles in neural development and in the adult nervous system (Taguchi A, Wanaka A, Mori T, Matsumoto K, Imai Y, Tagaki T and Tohyama M. 1996. <i>Brain Res Mol Brain Res</i> Jan;35(1-2):31-40). Furthermore, a new member of the leucine-rich repeat superfamily GAC1 was amplified and overexpressed in malignant gliomas (Almeida A, Zhu XX, Vogt N, Tyagi R, Muleris M, Dutrillaux AM, Dutrillaux B, Ross D, Malfoy B and Hanash S. 1998. <i>Oncogene</i> Jun 11;16(23):2997-3002).	Tango-associated diseases, disorders associated with the preservation and maintenance of gastrointestinal mucosa and the repair of acute and chronic mucosal lesions, Parkinson's disease, Alzheimer's disease, ALS, neuropathies, cancer, wound healing and tissue repair
sb934114 Relaxin	An embodiment of the invention is the use of sb934114Relaxin in treatment or diagnosis of collagen remodeling, breast cancer, and uterine contractile disorders. A close homologue of sb934114Relaxin is Relaxin. Relaxin has various biologic activities, including the induction of collagen remodeling and consequent softening of the tissues of the birth canal during delivery, the inhibition of uterine contractile activity, and the stimulation of growth and differentiation of the mammary gland (Bani D. 1997. <i>Gen Pharmacol</i> 28:13-22). Relaxin belongs to the insulin superfamily, and is produced primarily by the corpus luteum in both pregnant and nonpregnant females. In males, relaxin is synthesized in the prostate and released in the seminal fluid (Goldsmith LT, Weiss G, Steinert BG. 1995. <i>Endocrinol Metab Clin North Am</i> 24:171-86). It has been further demonstrated that relaxin regulates growth and differentiation of breast cancer cells in culture, promotes dilation of blood vessels in several organs, including the uterus, the mammary gland, the lung and the heart, has a chronotropic action on the heart, inhibits the release of histamine by mast cells, depresses aggregation of platelets and their release by megakaryocytes, and influences the secretion of hormones by the pituitary gland (Bani D. 1997. <i>Gen Pharmacol</i> 28:13-22). In addition, some reports have shown that relaxin is effective in decreasing skin involvement in systemic sclerosis (Furst DE. 1998. <i>Curr Opin Rheumatol</i> 10:123-8).	Cancer, rheumatic diseases, heart diseases, systemic sclerosis (scleroderma), and preterm birth

Table III (cont.).

Gene Name	Uses	Associated Diseases
sbg99174L OX-like	An embodiment of the invention is the use of sbg99174LOX-like in treatment or diagnosis of endothelial function or atherosclerosis. A close homologue of sbg99174LOX-like is oxidized low-density lipoprotein receptor 1. sbg99174LOX-like as well as oxidized low-density lipoprotein receptor 1, contain a C-type lectin domain (CTL) (Colonna M, Samardis J, Angman L. 2000. Eur J Immunol 30:697-704). Evidence suggests that oxidized low-density lipoprotein (OxLDL) plays a critical role in the changes in endothelial function. Lectin-like OxLDL receptor-1 (LOX-1) is the major endothelial OxLDL receptor. Functional changes of endothelial cells are implicated in the earliest stage of the pathogenesis of atherosclerosis (Aoyama T, Sawamura T, Furutani Y, Matsuoka R, Yoshida MC, Fujiwara H, Masaki T. Biochem J. 1999 339 (Pt 1):177-84).	Cardiovascular disorders (e.g. atherosclerosis, hypertension, stroke),
sbg995002 PIGR	An embodiment of the invention is the use of sbg995002PIGR to actively transport IgA and IgM to the apical surface of epithelia. A close homologue of sbg995002PIGR is polymeric-immunoglobulin receptor. The polymeric-immunoglobulin receptor binds polymeric IgA and IgM at the basolateral surface of epithelial cells. PIGR knockout mice completely lack active external IgA and IgM translocation, but remain normal and fertile (Johansen FE, Pekna M, Norderhaug JN, Haneberg B, Hietala MA, Krajci P, Betsholtz C, Brandtzaeg P. 1999. J Exp Med 190:915-22). In addition, it has been reported that PIGR can be upregulated by tumor necrosis factor (TNF)-alpha (Takenouchi-Ohkubo N, Takahashi T, Tsuchiya M, Mestecky J, Moldoveanu Z, Moro I; 2000. Immunogenetics 51:289-95).	Infection and inflammation such as inflammatory bowel disease, gluten-sensitive enteropathy, and urinary tract infection)
sbg103302 6C1q	An embodiment of the invention is the use of sbg1033026C1q to regulate central nervous system functions. A close homologue of sbg1033026C1q is C1q-related factor. C1q is a subunit of the C1 enzyme complex that activates the serum complement system. It has been shown that human C1q-related factor (CRF) transcript is expressed at highest levels in the brain, particularly in the brainstem. Similarly, in mouse brain CRF transcripts are most abundant in areas of the nervous system involved in motor function (Berube NG, Swanson XH, Bertram MJ, Kittle JD, Didenko V, Baskin DS, Smith JR, and Pereira-Smith OM., 1999, Brain Res. Mol. Brain Res. 63:233-240). Moreover, ACRP30 is structurally similar to complement factor C1q, and it forms large homooligomers that undergo a series of post-translational modifications. ACRP30 proteins may be a factor that participates in the complex balanced system of energy homeostasis involving food intake, carbohydrate catabolism, and lipid catabolism (Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF; 1995; J Biol Chem 270:26746-9).	Central nervous system disorder
sbg100367 5RNase	An embodiment of the invention is the use of sbg1003675RNase as a promising tool for anticancer therapy, and apoptosis-related disorders. A close homologue of sbg1003675RNase is RNase. It has been shown that a genetic-engineered pancreatic RNase has cytotoxic action on mouse and human tumor cells, but lacks any appreciable	Viral infection, and tumor

	<p>toxicity on human and mouse normal cells. This variant of human pancreatic RNase selectively sensitized cells derived from a human thyroid tumor to apoptotic death. Because of its selectivity for tumor cells, and because of its human origin, this protein was thought to represent a promising tool for anticancer therapy (Piccoli R, Di Gaetano S, De Lorenzo C, Grauso M, Monaco C, Spalletti-Cernia D, Laccetti P, Cinatl J, Matousek J, D'Alessio G. 1999. Proc Natl Acad Sci U S A 96:7768-73). Moreover, RNase itself can be used to treat an RNA viral infection, and its antagonist of this RNase may be useful in treating apoptosis-related disorders.</p>	
sbg101525 8PLM	<p>An embodiment of the invention is the use of sbg101525PLM to regulate skeletal and cardiac muscle disorders. A close homologue of sbg101525PLM is phospholemmann. The phospholemmann (PLM) is enriched in skeletal muscle and the heart, and is a major substrate phosphorylated in response to insulin and adrenergic stimulation. All phospholemmann proteins are small and have a single transmembrane domain (Chen LS, Lo CF, Numann R, Cuddy M. 1997. Genomics 41:435-4). Phospholemmann can be phosphorylated by protein kinases A and C to induce a hyperpolarization-activated chloride current, and therefore may play a role in muscle contraction. Recently phospholemmann was shown to be a substrate for myotonic dystrophy protein kinase, and therefore is associated with the disease, an autosomal dominant-inherited disorder with prominent effects on skeletal and cardiac muscle (Mounsey JP, John JE 3rd, Helmke SM, Bush EW, Gilbert J, Roses AD, Perryman MB, Jones LR, Moorman JR. 2000. J Biol Chem ;275:23362-7).</p>	Myotonic muscular dystrophy
sbg100332 8IG	<p>An embodiment of the invention is the use of sbg1003328IG to generate immunosuppressants to suppress immune responses. A close homologue of sbg1003328IG is V7, a human leukocyte surface protein (Stockinger H, Gadd SJ, Eher R, Majdic O, Schreiber W, Kasinrerk W, Strass B, Schnabl E, Knapp W. 1990. J Immunol 145:3889-97). sbg1003328IG is an immunoglobulin (Ig)-like membrane protein containing three potential Ig domains, and it has an overall strong sequence similarity to V7.</p>	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, and inflammation
sbg102082 9SGLT	<p>An embodiment of the invention is the use of sbg1020829SGLT to regulate Na(+) -dependent glucose transport. A close homologue of sbg1020829SGLT is Na+/glucose cotransporters. The human intestinal Na+/glucose cotransporter (SGLT1) was cloned and sequenced. Close homology was observed between the human and rabbit intestinal Na+/glucose cotransporters, and a significant homology was found between these and the <i>Escherichia coli</i> Na+/proline cotransporter (putP) indicating that the mammalian Na+/glucose and prokaryote Na+/proline cotransporters sharing a common ancestral gene (Hediger MA, Turk E, Wright EM. 1989 Proc Natl Acad Sci U S A Aug;86(15):5748-52). In addition, study of intestinal biopsies of glucose/galactose malabsorption (GCM) patients has revealed a specific defect in Na(+) -dependent absorption of glucose in the brush border. A single missense mutation was found in SGLT1 amplified from the genomic DNA derived from members of a family affected with GGM. This mutated SGLT1 cosegregated with the GGM</p>	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, inflammation and glucose/galactose malabsorption

	phenotype and resulted in a complete loss of Na(+) -dependent glucose transport in <i>Xenopus</i> oocytes injected with this complementary RNA (Turk E, Zabel B, Mundlos S, Dyer J, Wright EM. 1991 <i>Nature</i> Mar 28;350(6316):354-6).	
sbg100545 0UDPGT	An embodiment of the invention is the use of sbg1005450UDPGT to regulate estrogen and androgen catabolism in peripheral steroid target tissues. A close homologue of sbg1005450UDPGT is UDP-glucuronosyltransferase (UDPGT) gene. Mutations had been found in the promoter and coding regions of UDP-glucuronosyltransferase (UDPGT) gene in seven patients with Crigler-Najjar syndrome type II caused by reduction in hepatic bilirubin UDPGT activity (Yamamoto K, Soeda Y, Kamisako T, Hosaka H, Fukano M, Sato H, Fujiyama Y, Adachi Y, Satoh Y, Bamba T. 1998. <i>J Hum Genet</i> 43(2):111-4). A case of Gilbert syndrome caused by a homozygous missense mutation of the bilirubin UDPGT gene was also reported (Maruo Y, Sato H, Yamano T, Doida Y, Shimada M. 1998. <i>J Pediatr Jun</i> ;132(6):1045-7). In addition, monkey UDPGT UGT1A9 had been cloned and the mRNA was expressed in extrahepatic estrogen-responsive tissues indicating its potential role in estrogen metabolism (Albert C, Vallee M, Beaudry G, Belanger A, Hum DW. 1999. <i>Endocrinology Jul</i> ;140(7):3292-302). Human UDPGT UGT2B23 transcript was also expressed in extrahepatic tissues including prostate, mammary gland, epididymis, testis, and ovary. The activity of UGT2B23 was tested with 62 potential endogenous substrates and was demonstrated to be active on 6 steroids and the bile acid, hyodeoxycholic acid suggesting that UGT2B23 might play an important role in estrogen and androgen catabolism in peripheral steroid target tissues (Barbier O, Levesque E, Belanger A, Hum DW. 1999. <i>Endocrinology Dec</i> ;140(12):5538-48).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, inflammation Gilbert syndrome, Crigler-Najjar syndrome (CN) type II, and steroid hormone catabolism malfunction
sbg100262 0TIa	An embodiment of the invention is the use of sbg1002620TIa to regulate human tumor cells. A close homologue of sbg1002620TIa is human hypothetical protein DKFZp434B044. This gene is also similar to trypsin inhibitor which contains Sc7 family of extracellular domains at its N-terminal region (Genome Res. 11 (3), 422-435 (2001)). Trypsin inhibitor P25TI sequence had similarity to CRISP family proteins including insect venom allergens, mammalian testis-specific proteins and plant pathogenesis-related proteins. mRNA encoding P25TI and another two glioma pathogenesis-related protein GliPR and RTVP-1, which were also shown to be structurally similar to CRISP family proteins was frequently expressed in human tumor tissues but not detected in normal human tissue cell lines (Yamakawa T, Miyata S, Ogawa N, Koshikawa N, Yasumitsu H, Kanamori T, Miyazaki K. 1998. <i>Biochim Biophys Acta Jan</i> 21; 1395(2):202-8., Murphy EV, Zhang Y, Zhu W, Biggs J. 1995. <i>Gene Jun</i> 14;159(1):131-5., Rich T, Chen P, Furman F, Huynh N, Israel MA.1996. <i>Gene Nov</i> 21;180(1-2):125-30).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, inflammation, blood coagulation disorders, cellular adhesion disorders, pancreatitis, shock, multi-organ failure, and gastrointestinal ulceration
sbg100262 0TIb	An embodiment of the invention is the use of sbg1002620TIb as a marker for some nervous system tumors, and to regulate expression of human neuroblastoma and glioblastoma. A close homologue of sbg1002620TIb is late-gestation lung 1 (LGL1) protein. Late-gestation lung 1 (LGL1) protein showed 81% homology to P25TI, the trypsin	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders,

	<p>inhibitor purified from the culture medium of human glioblastoma cells (Kaplan F, Ledoux P, Kassamali FQ, Gagnon S, Post M, Koehler D, Deimling J, Sweezy NB. 1999. Am J Physiol Jun;276(6 Pt 1):L1027-36; Koshikawa N, Nakamura T, Tsuchiya N, Isaji M, Yasumitsu H, Umeda M, Miyazaki K. 1996. J Biochem (Tokyo) Feb;119(2):334-9). The cDNA encoding P25TI was isolated and the sequence had similarity to CRISP family proteins including insect venom allergens, mammalian testis-specific proteins and plant pathogenesis-related proteins. P25TI mRNA was frequently expressed in human neuroblastoma and glioblastoma but not detected in normal human tissues cell lines (Yamakawa T, Miyata S, Ogawa N, Koshikawa N, Yasumitsu H, Kanamori T, Miyazaki K. 1998. Biochim Biophys Acta Jan 21; 1395(2):202-8). Another two glioma pathogenesis-related protein GliPR and RTVP-1 were also shown to be structurally similar to CRISP family proteins. The GLIPR gene was highly expressed in the human brain tumor, glioblastoma multiforme/astrocytoma, but neither in normal fetal or adult brain tissue, nor in other nervous system tumors (Murphy EV, Zhang Y, Zhu W, Biggs J. 1995. Gene Jun 14;159(1):131-5). Multiple RTVP-1 mRNA species were highly expressed in a panel of cell lines from nervous system tumors arising from glia, in contrast, the expression of these RNAs was low or absent in nonglia-derived nervous system tumor cell lines (Rich T, Chen P, Furman F, Huynh N, Israel MA. 1996. Gene Nov 21;180(1-2):125-30).</p>	inflammation, blood coagulation disorders, cellular adhesion disorders, pancreatitis, shock, multi-organ failure, and gastrointestinal ulceration
sbg102200 MCTa	<p>An embodiment of the invention is the use of sbg102200MCTa in regulating cancer cells, including the hematopoietic lineages, Burkitt's lymphoma, and solid tumor cells. A close homologue of sbg102200MCTa is MCT1 from Chinese hamster and mouse. Mouse H+-monocarboxylate cotransporter (MCT1) was cloned and sequenced from Ehrlich Lettre tumour cells, the sequence of MCT1 is 93% and 87% homologous to MCT1 from Chinese hamster and human, respectively. N-glycanase-F treatment and an in vitro translation experiments demonstrated that glycosylation was not required for MCT1 function (Carpenter L, Poole RC, Halestrap AP. 1996. Biochim Biophys Acta Mar 13;1279(2):157-63). Chick monocarboxylate transporter MCT3 cloned from retinal pigment epithelium (RPE) cDNA library was found only expressed in RPE cells. A rat thyroid epithelial cell line FRTL transfected with pCl-neo/MCT3 showed enhanced pyruvate uptake suggesting that MCT3 may regulate lactate levels in the interphotoreceptor space (Yoon H, Fanelli A, Grollman EF, Philip NJ. 1997. Biochem Biophys Res Commun May 8;234(1):90-4). In human, MCT2 had been implicated as a primary pyruvate transporter in man. The mRNAs of MCT1 and MCT2 were found co-expressed in various human cancer cell lines, including the hematopoietic lineages HL60, K562, MOLT-4, Burkitt's lymphoma Raji, and solid tumor cells such as SW480, A549, and G361. These findings suggested that human MCT1 and MCT2 may have distinct biological roles (Lin RY, Vera JC, Chaganti RS, Golde DW. 1998. J Biol Chem Oct 30;273(44):28959-65).</p>	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, and inflammation
sbg102200 MCTb	<p>An embodiment of the invention is the use of sbg102200MCTb in regulating cancer cells, including the hematopoietic lineages, Burkitt's lymphoma, and solid tumor</p>	Cancer, infection, autoimmune disorder,

	<p>cells. A close homologue of sbg102200MCTb is MCT1 from Chinese hamster and mouse. Mouse H⁺-monocarboxylate cotransporter (MCT1) was cloned and sequenced from Ehrlich Lettre tumour cells, the sequence of MCT1 is 93% and 87% homologous to MCT1 from Chinese hamster and human, respectively. N-glycanase-F treatment and an in vitro translation experiments demonstrated that glycosylation was not required for MCT1 function (Carpenter L, Poole RC, Halestrap AP. 1996. <i>Biochim Biophys Acta</i> Mar 13;1279(2):157-63). Chick monocarboxylate transporter MCT3 cloned from retinal pigment epithelium (RPE) cDNA library was found only expressed in RPE cells. A rat thyroid epithelial cell line FRTL transfected with pCl-neo/MCT3 showed enhanced pyruvate uptake suggesting that MCT3 may regulate lactate levels in the interphotoreceptor space (Yoon H, Fanelli A, Grollman EF, Philp NJ. 1997. <i>Biochem Biophys Res Commun</i> May 8;234(1):90-4). In human, MCT2 had been implicated as a primary pyruvate transporter in man. The mRNAs of MCT1 and MCT2 were found co-expressed in various human cancer cell lines, including the hematopoietic lineages HL60, K562, MOLT-4, Burkitt's lymphoma Raji, and solid tumor cells such as SW480, A549, and G361. These findings suggested that human MCT1 and MCT2 may have distinct biological roles (Lin RY, Vera JC, Chaganti RS, Golde DW. 1998. <i>J Biol Chem</i> Oct 30;273(44):28959-65).</p>	hematopoietic disorder, wound healing disorders, and inflammation
sbg102038 OLYG	<p>An embodiment of the invention is the use of sbg102038OLYG in the immune system and enhance the activity of immunoagents and may serve as biomarkers of periodontal disease activity. Close homologues of sbg102038OLYG are lysozymes. Lysozymes are bacteriolytic defensive agents and have been adapted to serve a digestive function (Qasba PK, Kumar S, 1997, <i>Crit Rev Biochem Mol Biol</i> 32:255-306). Those in tissue and body fluids are involved in the immune system and enhance the activity of immunoagents. Lysozymes may serve as biomarkers of periodontal disease activity from inflammatory cell origin (Eley BM, and Cox SW, 1998, <i>Br Dent J</i> 184:323-8).</p>	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, and inflammation
sbg100702 6SGLT	<p>An embodiment of the invention is the use of sbg1007026SGLT, a human sodium-glucose cotransporter, in regulation of Glucose/galactose malabsorption (GGM), familial renal glycosuria, and diabetic renal disorders. Close homologues of sbg1007026SGLT are other sodium-glucose cotransporters from humans and rabbits. Human sodium-glucose cotransporters are responsible for the active accumulation of glucose in cells (Hediger MA, Turk E, Wright EM. 1989. <i>Proc Natl Acad Sci U S A</i> 86:5748-52). The renal sodium-glucose cotransporter may be related to the pathophysiology of renal diseases such as familial renal glycosuria and diabetic renal disorders (Kanai Y, Lee WS, You G, Brown D, Hediger MA. 1994. <i>J Clin Invest</i> 93:397-404). In addition, study of glucose/galactose malabsorption (GGM) patients has revealed a specific defect in sodium-dependent absorption of glucose in the brush border, and the consequent severe diarrhea and dehydration caused by glucose/galactose malabsorption are usually lethal unless these sugars are eliminated from the diet (Turk E, Zabel B, Mundlos S, Dyer J, Wright EM. 1991 <i>Nature</i> 350:354-6).</p>	Glucose/galactose malabsorption (GGM), familial renal glycosuria, and diabetic renal disorders

sbg101273 2GLUT	<p>An embodiment of the invention is the use of sbg101273GLUT, in the maintenance of cellular homeostasis and metabolism. Close homologues of sbg101273GLUT are transmembrane glucose transporters (gluts). Glucose uptake is achieved by transmembrane glucose transporters (gluts), and the transport of glucose across plasma membranes is important for the maintenance of cellular homeostasis and metabolism. Glucose is taken up by cells and then phosphorylated to glucose-6-phosphate, and glucose utilization by cancer cells is greatly enhanced when compared with that by normal tissue. Tumor tissue is frequently associated with the abnormal and/or over-expression of glucose transporters, especially glut1 (Smith TA. 1999. Br J Biomed Sci 56:285-92). Increased utilization of glucose in glomerular cells cause the increased expression and activity of aldose reductase, protein kinase C and TGF-beta, which have been implicated in excessive extracellular matrix accumulation in diabetic nephropathy (Z Katedry i Zakladu Patofizjologii, Akaemii Medycznej w Poznaniu. 1999. Przegl Lek 56:793-9). Changes in endothelial glucose transport and GLUT1 abundance in the barriers of the brain and retina may severely affect glucose delivery to these tissues and major implications in the development of two major diabetic complications, insulin-induced hypoglycemia and diabetic retinopathy (Kumagai AK. 1999. Diabetes Metab Res Rev 15:261-73).</p>	Tumor, diabetic nephropathy, and insulin-induced hypoglycemia
sbg101273 2GLUTb	<p>An embodiment of the invention is the use of sbg101273GLUTb, in the maintenance of cellular homeostasis and metabolism. Close homologues of sbg101273GLUTb are transmembrane glucose transporters (gluts). Glucose uptake is achieved by transmembrane glucose transporters (gluts), and the transport of glucose across plasma membranes is important for the maintenance of cellular homeostasis and metabolism. Glucose is taken up by cells and then phosphorylated to glucose-6-phosphate, and glucose utilization by cancer cells is greatly enhanced when compared with that by normal tissue. Tumor tissue is frequently associated with the abnormal and/or over-expression of glucose transporters, especially glut1 (Smith TA. 1999. Br J Biomed Sci 56:285-92). Increased utilization of glucose in glomerular cells cause the increased expression and activity of aldose reductase, protein kinase C and TGF-beta, which have been implicated in excessive extracellular matrix accumulation in diabetic nephropathy (Z Katedry i Zakladu Patofizjologii, Akaemii Medycznej w Poznaniu. 1999. Przegl Lek 56:793-9). Changes in endothelial glucose transport and GLUT1 abundance in the barriers of the brain and retina may severely affect glucose delivery to these tissues and major implications in the development of two major diabetic complications, insulin-induced hypoglycemia and diabetic retinopathy (Kumagai AK. 1999. Diabetes Metab Res Rev 15:261-73).</p>	Tumor, diabetic nephropathy, and insulin-induced hypoglycemia
sbg101817 2CSP	<p>An embodiment of the invention is the use of sbg1018172CSP in regulation of melanoma, autoimmune disorders, hematopoietic disorder, wound healing, and inflammation. A close homologue of sbg1018172CSP is melanoma-associated chondroitin sulfate proteoglycan</p>	Melanoma, infection, autoimmune disorder, hematopoietic

	(MCSP) core protein NG2. The MCSP core protein NG2 can act as a coreceptor for spreading and focal contact formation in association with alpha 4 beta 1 integrin in melanoma cells (Iida J, Meijne AM, Spiro RC, Roos E, Furcht LT, McCarthy JB. 1995. <i>Cancer Res</i> Mar 15;55(10):2177-85). Cloning of MCSP recognized by mAb 9.2.27 showed that the core protein contained an open reading frame of 2322 AAs, encompassing a large extracellular domain, a hydrophobic transmembrane region, and a relatively short cytoplasmic tail. MCSP RNA was detected in human melanoma cell lines and in biopsies prepared from melanoma skin metastases but not in other human cancer cells or a variety of human fetal and adult tissues (Pluschke G, Vanek M, Evans A, Dittmar T, Schmid P, Itin P, Filardo EJ, Reisfeld RA. 1996. <i>Proc Natl Acad Sci U S A</i> Sep 3;93(18):9710-5).	disorder, wound healing, and inflammation
sbg100457 0ERGIC	An embodiment of the invention is the use of sbg1004570ERGIC as a probe for studying protein trafficking in the secretory pathway which is crucial for the elucidation and treatment of many inherited and acquired diseases, such as cystic fibrosis, Alzheimer's disease and viral infections in regulation of melanoma, autoimmune disorders, hematopoietic disorder, wound healing, and inflammation. A close homologue of sbg1004570ERGIC is ERGIC-53, an ER-Golgi intermediate compartment (ERGIC) protein. A ERGIC protein was elevated more than two fold in HT-29 colon adenocarcinoma cells resistant to the the antitumor drug KRN5500. Together with other information, the cellular secretory pathway was suggested a primary determinant of sensitivity to KRN550 (Kamishohara M, Kenney S, Domergue R, Vistica DT, Sausville EA. 2000 <i>Exp Cell Res</i> May 1;256(2):468-79). Mutations in ERGIC-53 was shown to cause combined deficiency of coagulation factors V and VIII and it was suggested that ERGIC-53 might function as a molecular chaperone for the transport from ER to Golgi of a specific subset of secreted proteins, including coagulation factors V and VII (Nichols WC, Seligsohn U, Zivelin A, Terry VH, Hertel CE, Wheatley MA, Moussalli MJ, Hauri HP, Ciavarella N, Kaufman RJ, Ginsburg D. 1998. <i>Cell</i> Apr 3;93(1):61-70). In addition, ERGIC-53 was reviewed as an attractive probe for studying numerous aspects of protein trafficking in the secretory pathway which is crucial for the elucidation and treatment of many inherited and acquired diseases, such as cystic fibrosis, Alzheimer's disease and viral infections (Hauri HP, Kappeler F, Andersson H, Appenzeller C. 2000 <i>J Cell Sci</i> Feb;113 (Pt 4):587-96).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, inflammation, and Alzheimer's disease
sbg101699 SIGBrecpt	An embodiment of the invention is the use of sbg1016995IGBrecpt in the clearance of circulating autoantibodies and immune complexes. A close homologue of sbg1016995IGBrecpt is guinea pig Fc receptor for immunoglobulin (Tominaga M, Sakata A, Ohmura T, Yamashita T, Koyama J, Onoue K, 1990. <i>Biochem Biophys Res Commun</i> Apr 30;168(2):683-9). IgG Fc-receptor polymorphisms have been reported recently in patients with guillain-Barre syndrome indicating the role of IgG Fc-receptor in the clearance of circulating autoantibodies and immune complexes (Vedeler CA, Raknes G, Myhr KM, Nyland H. 2000 <i>Neurology</i> Sep 12;55(5):705-7).	Auto-immune diseases, allergy, and guillain-Barre syndrom

sbg1151bS REC	<p>An embodiment of the invention is the use of sbg1151bSREC, a scavenger receptor, in the regulation of pathogenesis in atherosclerosis and the formation of foam cells in atherosclerotic lesions. A close homologue of sbg1151bSREC is scavenger receptor class A type I and type II. Most of the scavenger receptors interacted with several structurally different ligands such as oxidized low density lipoprotein (Ox-LDL) and acetyl LDL. Several studies showed Ox-LDL was involved in the pathogenesis of atherosclerosis (Steinbrecher UP. 1999 <i>Biochim Biophys Acta</i> Jan 4;1436(3):279-98). In macrophages scattered in aortic walls without atherosclerotic lesions, scavenger receptor class A type I and type II (SRA) was detected weakly but consistently. In contrast, in atherosclerotic lesions, macrophages around the core region showed a strong immunoreactivity to SRA indicating the involvement of SRA in the formation of foam cells in atherosclerotic lesions (Nakata A, Nakagawa Y, Nishida M, Nozaki S, Miyagawa J, Nakagawa T, Tamura R, Matsumoto K, Kameda-Takemura K, Yamashita S and Matsuzawa Y. <i>Arterioscler Thromb Vasc Biol</i> 1999 May;19(5):1333-9).</p>	Atherosclerosis disease
sbg139985 4ANK	<p>An embodiment of the invention is the use of sbg1399854ANK in protein-protein interactions and it may act by inhibiting protein of cyclin dependent kinase. The present invention contains both death domain and ankyrin repeat region. The death domain is involved in cell death signaling (Cleveland J. and Ihle J.N. 1995. <i>Cell</i> 81:479-482). Ankyrin repeats (ANK) are tandem repeat modules of about 33 amino acids. Many ankyrin repeat regions are known to be involved in protein-protein interaction (Svetlana Gorina and Nikola P. Pavletich; 1996 <i>Science</i> 274:1001-1005).</p>	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, and inflammation

Table IV. Quantitative, Tissue-specific mRNA expression detected using SybrMan

Quantitative, tissue-specific, mRNA expression patterns of the genes were measured using SYBR-Green Quantitative PCR (Applied Biosystems, Foster City, CA; see Schmittgen T.D. et al., Analytical Biochemistry 285:194-204, 2000) and human cDNAs prepared from various human

5 tissues. Gene-specific PCR primers were designed using the first nucleic acid sequence listed in the Sequence List for each gene. The threshold cycle (C_t) is defined as the fractional cycle number at which the reporter fluorescence generated by cleavage of the probe reaches a threshold defined as 10 times the background. In cases sequence detection system software predicted more than one PCR product, Taqman was used for the specific PCR amplification as indicated under the specific genes.

10 In each gene's first subset table, two replicate measurements of gene of identification (GOI) mRNA were measured from various human tissues (column 3 and 4). The average GOI mRNA copies of the two replicates were made from each tissue RNA (column 5). The average amount of 18S rRNA from each tissue RNA was measured (column 6) and used for normalization. To make each tissue with the 15 same amount of 50 ng of 18S rRNA, the normalization factor (column 7) was calculated by dividing 50 ng with the amount of 18S rRNA measured from each tissue (column 6). The mRNA copies per 50 ng of total RNA were obtained by multiplying each GOI normalization factor and the average mRNA copies (column 8).

20 Fold changes shown in each gene's second subset table were only calculated for disease tissues which have a normal counterpart. There are blanks in the fold change column for all samples that do not have counterparts. In addition, the fold change calculations are the fold change in the disease sample as compared to the normal sample. Accordingly, there will not be a fold change calculation next to any of the normal samples. For patient matched cancer pairs (colon, lung, and breast), each tumor is compared to its specific normal counterpart. When patient-matched 25 normal/disease pairs do not exist, each disease sample was compared back to the average of all the normal samples of that same tissue type. For example, normal brain from the same patient that provided Alzheimer's brain is not applicable. Three normal brain samples and 4 Alzheimer's brain samples are used in the fold change. Three normal samples were averaged, and each of the Alzheimer's samples was compared back to that average.

30

Abbreviations

ALZ Alzheimer's Disease

CT CLONTECH (1020 East Meadow Circle Palo Alto, CA 94303-4230, USA)

KC Sample prepared by GSK investigator

35

COPD chronic obstructive pulmonary disease

endo endothelial

VEGF vascular endothelial growth factor

bFGF basic fibroblast growth factor

40

BM bone marrow

osteo osteoblast

OA osteoarthritis

RA rheumatoid arthritis

PBL peripheral blood lymphocytes

PBMNC peripheral blood mononuclear cells

45

HIV human immunodeficiency virus

HSV Herpes simplex virus

HPV human papilloma virus

Gene Name sbg960509cbrecept

Lowest overall expression in normal and disease samples. Highest normal expression in the whole brain, fetal liver, and uterus. Highest disease expression in 2 of the lung tumor samples, one of the breast tumor samples, and one of the normal breast samples. Downregulation in 1 of 4 colon tumors implies an involvement in cancer of the colon. Downregulation in 2 of 4 AD brain samples as well as high expression in whole brain suggests an involvement in Alzheimer's disease. Downregulation in 3 of 3 COPD lung samples and downregulation in 4 of 4 asthmatic lung samples implicates this gene in COPD and asthma. Upregulation in 2 of 3 heart samples proposes roles in non-obstructive and obstructive DCM. Patterns difficult to interpret due to Cts > 35. Moderate to low expression in immune cells. Moderate expression in OA and RA synovium.

Sample sbg960509cbrecept	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Averag e GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detecte d/50 ng total RNA
Subcutaneous Adipocytes Zenbio	40, 40	0	0	0.00	3.06	16.34	0.00
Subcutaneous Adipose Zenbio	40, 40	0	0	0.00	0.96	52.36	0.00
Adrenal Gland Clontech	40, 40	0	0	0.00	0.61	81.97	0.00
Whole Brain Clontech	33.26, 32.07	24.63	48.4	36.52	7.24	6.91	252.18
Fetal Brain Clontech	40, 40	0	0	0.00	0.48	103.95	0.00
Cerebellum Clontech	40, 40	0	0	0.00	2.17	23.04	0.00
Cervix	40, 40	0	0	0.00	2.42	20.66	0.00
Colon	40, 40	0	0	0.00	2.71	18.45	0.00
Endometrium	40, 40	0.81	0	0.41	0.73	68.21	27.63
Esophagus	40, 40	0	0	0.00	1.37	36.50	0.00
Heart Clontech	40, 40	0	0	0.00	1.32	37.88	0.00
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	40, 40	0	0	0.00	2.58	19.38	0.00
Jejunum	35.56, 34.42	6.66	12.71	9.69	6.60	7.58	73.37
Kidney	40, 40	0	0	0.00	2.12	23.58	0.00
Liver	40, 40	0	0	0.00	1.50	33.33	0.00
Fetal Liver Clontech	33.46, 34.83	14.95	27.51	21.23	10.40	4.81	102.07
Lung	40, 40	0	0	0.00	2.57	19.46	0.00
Mammary Gland Clontech	40, 40	21.94	10.06	16.00	13.00	3.85	61.54
Myometrium	40, 40	0	0	0.00	2.34	21.37	0.00
Omentum	40, 40	0	0	0.00	3.94	12.69	0.00
Ovary	40, 40	0	0	0.00	4.34	11.52	0.00
Pancreas	40, 40	0	0	0.00	0.81	61.80	0.00
Head of Pancreas	40, 40	0	0	0.00	1.57	31.85	0.00
Parotid Gland	40, 40	0	0	0.00	5.48	9.12	0.00
Placenta Clontech	40, 40	0.39	0	0.20	5.26	9.51	1.85
Prostate	40, 40	0	0	0.00	3.00	16.67	0.00
Rectum	40, 40	0	0	0.00	1.23	40.65	0.00
Salivary Gland	34.79, 40	10.31	0	5.16	7.31	6.84	35.26

Clontech							
Skeletal Muscle Clontech	40, 40	0	0	0.00	1.26	39.68	0.00
Skin	40, 40	0	0	0.00	1.21	41.32	0.00
Small Intestine Clontech	40, 40	0	0	0.00	0.98	51.07	0.00
Spleen	40, 40	0	0	0.00	4.92	10.16	0.00
Stomach	35.8, 38.29	5.82	1.41	3.62	2.73	18.32	66.21
Testis Clontech	40, 40	0	0	0.00	0.57	87.87	0.00
Thymus Clontech	35.13, 35.08	8.48	8.75	8.62	9.89	5.06	43.55
Thyroid	40, 40	0	0	0.00	2.77	18.05	0.00
Trachea Clontech	35.26, ND	7.9	ND	7.90	9.71	5.15	40.68
Urinary Bladder	40, ND	0	ND	0.00	5.47	9.14	0.00
Uterus	35.09, 33.87	8.67	17.4	13.04	5.34	9.36	122.05
genomic	26.62	1067.33					
b-actin	27.44	670.43					
1.00E+05	19.22	100000					
1.00E+05	19.38	100000					
1.00E+04	22.78	10000					
1.00E+04	20.52	10000					
1.00E+03	26.45	1000					
1.00E+03	27.03	1000					
1.00E+02	30.99	100					
1.00E+02	31.26	100					
1.00E+01	40	0					
1.00E+01	40	0					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg960509cbrectp	Reg number (GSK identifier)	Ct	Mean GOI copies	copies of mRNA detecte d/50 ng total RNA	Sample	Fold Change in Disease Populat ion
colon normal GW98-167	21941	29.42		332.32	colon normal	
colon tumor GW98-166	21940	30.95	66.31	132.62	colon tumor	-2.51
colon normal GW98-178	22080	31.32	53.01	106.02	colon normal	
colon tumor GW98-177	22060	30.57	83.1	166.20	colon tumor	1.57
colon normal GW98-561	23514	31.44	49.16	98.32	colon normal	
colon tumor GW98-560	23513	31.81	39.47	78.94	colon tumor	-1.25
colon normal GW98-894	24691	29.44	164.69	329.38	colon normal	
colon tumor GW98-893	24690	34.42	8.18	16.36	colon tumor	-20.13
lung normal GW98-3	20742	28.04	383.11	766.22	lung normal	

lung tumor GW98-2	20741	34.22	9.19	18.38	lung tumor	-41.69
lung normal GW97-179	20677	30.93	66.74	133.48	lung normal	
lung tumor GW97-178	20676	27.11	667.61	1335.22	lung tumor	10.00
lung normal GW98-165	21922	28.31	323.99	647.98	lung normal	
lung tumor GW98-164	21921	30.92	67.22	134.44	lung tumor	-4.82
lung normal GW98-282	22584	31.76	40.67	81.34	lung normal	
lung tumor GW98-281	22583	29.61	148.67	297.34	lung tumor	3.66
breast normal GW00-392	28750	27.64	487.44	487.44	breast normal	
breast tumor GW00-391	28746	27.47	539.99	1079.98	breast tumor	2.22
breast normal GW00-413	28798	33.36	15.44	15.44	breast normal	
breast tumor GW00-412	28797	30.88	68.84	137.68	breast tumor	8.92
breast normal GW00-235:238	27592-95	34.74	6.73	6.73	breast normal	
breast tumor GW00-231:234	27588-91	33.73	12.41	12.41	breast tumor	1.84
breast normal GW98-621	23656	27.7	469.27	938.54	breast normal	
breast tumor GW98-620	23655	33.1	18.13	36.26	breast tumor	-25.88
brain normal BB99-542	25507	31.46	48.61	97.22	brain normal	
brain normal BB99-406	25509	34.17	9.52	19.04	brain normal	
brain normal BB99-904	25546	35.69	3.79	7.58	brain normal	
brain stage 5 ALZ BB99-874	25502	40	0	0.00	brain stage 5 ALZ	-41.28
brain stage 5 ALZ BB99-887	25503	34.96	5.91	11.82	brain stage 5 ALZ	-3.49
brain stage 5 ALZ BB99-862	25504	33.13	17.82	35.64	brain stage 5 ALZ	-1.16
brain stage 5 ALZ BB99-927	25542	40	0	0.00	brain stage 5 ALZ	-41.28
CT lung KC	normal	29.53	155.88	311.76	CT lung	
lung 26 KC	normal				lung 26	
lung 27 KC	normal	39.2	0.46	0.46	lung 27	
lung 24 KC	COPD	40	0	0.00	lung 24	-104.07
lung 28 KC	COPD	40	0	0.00	lung 28	-104.07
lung 23 KC	COPD	34.81	6.44	6.44	lung 23	-16.16
lung 25 KC	normal	40	0	0.00	lung 25	
asthmatic lung ODO3112	29321	38.99	0.52	0.52	asthmatic lung	-200.14
asthmatic lung ODO3433	29323	33.69	12.65	25.30	asthmatic lung	-4.11
asthmatic lung ODO3397	29322	33.53	13.98	27.96	asthmatic lung	-3.72
asthmatic lung ODO4928	29325	34.27	8.96	17.92	asthmatic lung	-5.81
endo cells KC	control	40	0	0.00	endo cells	
endo VEGF KC		40	0	0.00	endo VEGF	0.00
endo bFGF KC		40	0	0.00	endo bFGF	0.00
heart Clontech	normal	35.53	4.19	8.38	heart	
heart (T-1) ischemic	29417	34	10.5	21.00	heart T-1	2.51
heart (T-14) non-obstructive DCM	29422	31.16	58.24	116.48	heart T-14	13.90
heart (T-3399) DCM	29426	28.35	317.67	635.34	heart T-3399	75.82

adenoid GW99-269	26162	31.52	46.93	93.86	adenoid	
tonsil GW98-280	22582	30.82	71.35	142.70	tonsil	
T cells PC00314	28453	34.36	8.47	16.94	T cells	
PBMNC		40	0	0.00	PBMNC	
monocyte		40	0	0.00	monocyte	
B cells PC00665	28455	40	0	0.00	B cells	
dendritic cells 28441		31.52	47.02	94.04	dendritic cells	
neutrophils	28440	36.13	2.91	2.91	neutrophils	
eosinophils	28446	40	0	0.00	eosinophils	
BM unstim		40	0	0.00	BM unstim	
BM stim		40	0	0.00	BM stim	0.00
osteodif		40	0	0.00	osteodif	0.00
osteoundif		40	0	0.00	osteoundif	
chondrocytes		40	0	0.00	chondrocytes	
OA Synovium IP12/01	29462	32.08	33.47	33.47	OA Synovium	
OA Synovium NP10/01	29461	31.43	49.5	99.00	OA Synovium	
OA Synovium NP57/00	28464	30.42	91.04	182.08	OA Synovium	
RA Synovium NP03/01	28466	32.11	32.84	65.68	RA Synovium	
RA Synovium NP71/00	28467	31.07	61.51	123.02	RA Synovium	
RA Synovium NP45/00	28475	36.21	2.78	5.56	RA Synovium	
OA bone (biobank)	29217	31.49	47.85	47.85	OA bone (biobank)	
OA bone Sample 1	J. Emory	30.11	109.44	218.88	OA bone	
OA bone Sample 2	J. Emory	32.6	24.52	49.04	OA bone	
Cartilage (pool)	Normal	32.09	33.26	66.52	Cartilage (pool)	
Cartilage (pool)	OA	33.1	18.07	36.14	Cartilage (pool)	-1.84
PBL uninfected	28441	27.68	474.91	949.82	PBL uninfected	
PBL HIV IIIB	28442	31.76	40.5	81.00	PBL HIV IIIB	-11.73
MRC5 uninfected (100%)	29158	40	0	0.00	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	34.15	9.61	19.22	MRC5 HSV strain F	19.22
W12 cells	29179	40	0	0.00	W12 cells	
Keratinocytes	29180	38.16	0.85	1.70	Keratinocytes	
B-actin control		27.02	707.5			
genomic		26.1	1232.73			
1.00E+05		18.64	100000			
1.00E+05		18.95	100000			
1.00E+04		22.4	10000			
1.00E+04		22.17	10000			
1.00E+03		26.34	1000			
1.00E+03		25.94	1000			
1.00E+02		31.03	100			
1.00E+02		32.83	100			
1.00E+01		33.21	10			
1.00E+01		32.93	10			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			

Gene Name sbg960509cbrecept

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-2.51
colon tumor	1.57
colon tumor	-1.25
colon tumor	-20.13
lung tumor	-41.69
lung tumor	10.00
lung tumor	-4.82
lung tumor	3.66
breast tumor	2.22
breast tumor	8.92
breast tumor	1.84
breast tumor	-25.88
brain stage 5 ALZ	-41.28
brain stage 5 ALZ	-3.49
brain stage 5 ALZ	-1.16
brain stage 5 ALZ	-41.28
lung 24	-104.07
lung 28	-104.07
lung 23	-16.16
asthmatic lung	-200.14
asthmatic lung	-4.11
asthmatic lung	-3.72
asthmatic lung	-5.81
endo VEGF	0.00
endo bFGF	0.00
heart T-1	2.51
heart T-14	13.90
heart T-3399	75.82
BM stim	0.00
osteo undif	0.00
Cartilage (pool)	-1.84
PBL HIV IIIB	-11.73
MRC5 HSV strain F	19.22

5 Gene Name sbg614126complfH

Moderate to low overall expression in normal and disease samples. Highest normal expression in liver and fetal liver. Lower (but still significant expression) is seen in the whole brain, ovary, and uterus. Highest disease expression in 2 of the breast tumor samples, one of the normal brain samples, one of the normal lungs, one of the OA synovium samples, and the HSV-infected MRC5 cells. Upregulation in 1 of 4 colon tumors suggests a role in cancer of the colon. Downregulation in 2 of 4 lung tumors and upregulation in 1 of 4 breast tumors suggest roles in cancers of the lung and breast. Downregulation in 3 of 3 COPD lung samples as well as downregulation in 4 of 4 asthmatic lungs implies an involvement in chronic obstructive pulmonary disease and asthma. Upregulation in 1 of 3 heart samples suggests a role in DCM. Upregulation in HSV implicates involvement in herpes simplex virus as a potential host factor. Moderate to low expression in immune cells, RA and OA synovium bone, and chondrocytes.

Sample sbg614126complfH	Ct (sample 1)	Mean GOI	Mean GOI	Average GOI	18S rRNA	50 ng/18S	copies of
----------------------------	------------------	-------------	-------------	----------------	-------------	--------------	--------------

	and 2)	copies (sample 1)	copies (sample 2)	Copies	(ng)	rRNA (ng)	mRNA detected/50 ng total RNA
Subcutaneous Adipocytes Zenbio	40, 40	0	0	0.00	3.06	16.34	0.00
Subcutaneous Adipose Zenbio	40, 40	0	0	0.00	0.96	52.36	0.00
Adrenal Gland Clontech	40, 40	0	0	0.00	0.61	81.97	0.00
Whole Brain Clontech	32.34, 31.88	46.5	61.71	54.11	7.24	6.91	373.65
Fetal Brain Clontech	40, 40	0	0	0.00	0.48	103.95	0.00
Cerebellum Clontech	40, 40	0	0	0.00	2.17	23.04	0.00
Cervix	40, 35.04	0	8.88	4.44	2.42	20.66	91.74
Colon	40, 40	0	0	0.00	2.71	18.45	0.00
Endometrium	40, 40	0	0	0.00	0.73	68.21	0.00
Esophagus	40, 40	0	0	0.00	1.37	36.50	0.00
Heart Clontech	40, 40	0	0	0.00	1.32	37.88	0.00
Hypothalamus	40, 39.79	0	0.48	0.24	0.32	155.28	37.27
Ileum	40, 36.32	0	4.04	2.02	2.58	19.38	39.15
Jejunum	33.25, 34.19	26.6	14.98	20.79	6.60	7.58	157.50
Kidney	40, 40	0	0	0.00	2.12	23.58	0.00
Liver	28.77, 28.81	417.4	407.38	412.39	1.50	33.33	13746. 33
Fetal Liver Clontech	29.63, 29.5	246.38	266.67	256.53	10.40	4.81	1233.2 9
Lung	40, 40	0	0	0.00	2.57	19.46	0.00
Mammary Gland Clontech	34.19, 40	14.9	0	7.45	13.00	3.85	28.65
Myometrium	35.76, 40	5.7	0	2.85	2.34	21.37	60.90
Omentum	36.04, 33.62	4.81	21.16	12.99	3.94	12.69	164.78
Ovary	34.29, 32.95	14.02	31.93	22.98	4.34	11.52	264.69
Pancreas	40, 40	0	0	0.00	0.81	61.80	0.00
Head of Pancreas	38.98, 35.35	0.79	7.32	4.06	1.57	31.85	129.14
Parotid Gland	34.58, 33.83	11.74	18.68	15.21	5.48	9.12	138.78
Placenta Clontech	35.73, 35.66	5.82	6.06	5.94	5.26	9.51	56.46
Prostate	40, 40	0	0	0.00	3.00	16.67	0.00
Rectum	40, 40	0.38	0	0.19	1.23	40.65	7.72
Salivary Gland Clontech	40, 40	0.3	0	0.15	7.31	6.84	1.03
Skeletal Muscle Clontech	40, 40	0	0.28	0.14	1.26	39.68	5.56
Skin	40, 40	0	0.33	0.17	1.21	41.32	6.82
Small Intestine Clontech	40, 40	0	0	0.00	0.98	51.07	0.00
Spleen	40, 40	0	0	0.00	4.92	10.16	0.00
Stomach	40, 36	0	4.92	2.46	2.73	18.32	45.05
Testis Clontech	40, 40	0	0	0.00	0.57	87.87	0.00

Thymus Clontech	40, 37.06	0	2.56	1.28	9.89	5.06	6.47
Thyroid	40, 40	0	0.31	0.16	2.77	18.05	2.80
Trachea Clontech	40, 40	0.28	0	0.14	9.71	5.15	0.72
Urinary Bladder	40, 34.13	0	15.53	7.77	5.47	9.14	70.98
Uterus	33.21, 32.79	27.27	35.32	31.30	5.34	9.36	293.02
genomic	26.93	1288.98					
b-actin	27.55	878.74					
1.00E+05	20.07	100000					
1.00E+05	20.14	100000					
1.00E+04	23.43	10000					
1.00E+04	23.34	10000					
1.00E+03	26.84	1000					
1.00E+03	27.02	1000					
1.00E+02	31.72	100					
1.00E+02	31.32	100					
1.00E+01	33.78	10					
1.00E+01	35.79	10					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg614126complfH	Reg number (GSK identifier)	Ct	Mean GOI copies	copies of mRNA detec- ted/50 ng total RNA	Sample	Fold Change in Disease Popula- tion
colon normal GW98-167	21941	34.6	13.63	27.26	colon normal	
colon tumor GW98-166	21940	35.71	7.35	14.70	colon tumor	-1.85
colon normal GW98-178	22080	40	0	0.00	colon normal	
colon tumor GW98-177	22060	39.81	0.75	1.50	colon tumor	1.50
colon normal GW98-561	23514	38.61	1.45	2.90	colon normal	
colon tumor GW98-560	23513	34.84	11.95	23.90	colon tumor	8.24
colon normal GW98-894	24691	39.05	1.14	2.28	colon normal	
colon tumor GW98-893	24690	40	0	0.00	colon tumor	-2.28
lung normal GW98-3	20742	35.78	7.04	14.08	lung normal	
lung tumor GW98-2	20741	40	0	0.00	lung tumor	-14.08
lung normal GW97-179	20677	33.99	19.21	38.42	lung normal	
lung tumor GW97-178	20676	40	0.49	0.98	lung tumor	-39.20
lung normal GW98-165	21922	39.63	0.82	1.64	lung normal	
lung tumor GW98-164	21921	38.89	1.24	2.48	lung tumor	1.51
lung normal GW98-282	22584	40	0	0.00	lung normal	
lung tumor GW98-281	22583	40	0	0.00	lung tumor	0.00

breast normal GW00-392	28750	32.71	39.28	39.28	breast normal	
breast tumor GW00-391	28746	31.65	70.89	141.78	breast tumor	3.61
breast normal GW00-413	28798	35.83	6.88	6.88	breast normal	
breast tumor GW00-412	28797	33.17	30.3	60.60	breast tumor	8.81
breast normal GW00-235:238	27592-95	36.73	4.16	4.16	breast normal	
breast tumor GW00-231:234	27588-91	35.98	6.33	6.33	breast tumor	1.52
breast normal GW98-621	23656	37.38	2.89	5.78	breast normal	
breast tumor GW98-620	23655	34.95	11.23	22.46	breast tumor	3.89
brain normal BB99-542	25507	32.26	50.34	100.68	brain normal	
brain normal BB99-406	25509	40	0.57	1.14	brain normal	
brain normal BB99-904	25546	34.68	13.04	26.08	brain normal	
brain stage 5 ALZ BB99-874	25502	40	0	0.00	brain stage 5 ALZ	-42.63
brain stage 5 ALZ BB99-887	25503	35.87	6.73	13.46	brain stage 5 ALZ	-3.17
brain stage 5 ALZ BB99-862	25504	39.2	1.05	2.10	brain stage 5 ALZ	-20.30
brain stage 5 ALZ BB99-927	25542	40	0	0.00	brain stage 5 ALZ	-42.63
CT lung KC	normal	39.4	0.93	1.86	CT lung	
lung 26 KC	normal				lung 26	
lung 27 KC	normal	40	0	0.00	lung 27	
lung 24 KC	COPD	40	0	0.00	lung 24	-0.62
lung 28 KC	COPD	40	0	0.00	lung 28	-0.62
lung 23 KC	COPD	40	0	0.00	lung 23	-0.62
lung 25 KC	normal	40	0	0.00	lung 25	
asthmatic lung ODO3112	29321	36.52	4.68	4.68	asthmatic lung	7.55
asthmatic lung ODO3433	29323	40	0	0.00	asthmatic lung	-0.62
asthmatic lung ODO3397	29322	40	0	0.00	asthmatic lung	-0.62
asthmatic lung ODO4928	29325	38.18	1.85	3.70	asthmatic lung	5.97
endo cells KC	control	40	0	0.00	endo cells	
endo VEGF KC		40	0	0.00	endo VEGF	0.00
endo bFGF KC		40	0	0.00	endo bFGF	0.00
heart Clontech	normal	40	0	0.00	heart	
heart (T-1) ischemic	29417	40	0	0.00	heart T-1	0.00
heart (T-14) non-obstructive DCM	29422	40	0	0.00	heart T-14	0.00
heart (T-3399) DCM	29426	36.03	6.13	12.26	heart T-3399	12.26
adenoid GW99-269	26162	34.08	18.19	36.38	adenoid	
tonsil GW98-280	22582	37.46	2.77	5.54	tonsil	
T cells PC00314	28453	40	0	0.00	T cells	
PBMNC		40	0	0.00	PBMNC	
monocyte		40	0	0.00	monocyte	

B cells PC00665	28455	34.56	13.99	27.98	B cells	
dendritic cells 28441		40	0	0.00	dendritic cells	
neutrophils	28440	33.76	21.85	21.85	neutrophils	
eosinophils	28446	40	0	0.00	eosinophils	
BM unstim		40	0	0.00	BM unstim	
BM stim		40	0	0.00	BM stim	0.00
osteodif		40	0	0.00	osteodif	0.00
osteoundif		40	0	0.00	osteoundif	
chondrocytes		34.25	16.55	41.38	chondrocytes	
OA Synovium IP12/01	29462	40	0	0.00	OA Synovium	
OA Synovium NP10/01	29461	40	0	0.00	OA Synovium	
OA Synovium NP57/00	28464	33.1	31.54	63.08	OA Synovium	
RA Synovium NP03/01	28466	40	0	0.00	RA Synovium	
RA Synovium NP71/00	28467	40	0	0.00	RA Synovium	
RA Synovium NP45/00	28475	40	0	0.00	RA Synovium	
OA bone (biobank)	29217	40	0	0.00	OA bone (biobank)	
OA bone Sample 1	J. Emory	40	0	0.00	OA bone	
OA bone Sample 2	J. Emory	40	0	0.00	OA bone	
Cartilage (pool)	Normal	40	0	0.00	Cartilage (pool)	
Cartilage (pool)	OA	40	0	0.00	Cartilage (pool)	0.00
PBL uninfected	28441	36.12	5.84	11.68	PBL uninfected	
PBL HIV IIIB	28442	36.1	5.9	11.80	PBL HIV IIIB	1.01
MRC5 uninfected (100%)	29158	40	0	0.00	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	31.83	64.08	128.16	MRC5 HSV strain F	128.16
W12 cells	29179	40	0	0.00	W12 cells	
Keratinocytes	29180	40	0	0.00	Keratinocytes	
B-actin control		27.26	820.77			
genomic		26.18	1496.25			
1.00E+05		19.13	100000			
1.00E+05		19.38	100000			
1.00E+04		22.56	10000			
1.00E+04		22.67	10000			
1.00E+03		26.01	1000			
1.00E+03		26.44	1000			
1.00E+02		30.93	100			
1.00E+02		30.1	100			
1.00E+01		38.59	10			
1.00E+01		33.26	10			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			

Gene Name sbg614126complfH

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-1.85
colon tumor	1.50
colon tumor	8.24
colon tumor	-2.28
lung tumor	-14.08
lung tumor	-39.20
lung tumor	1.51
lung tumor	0.00
breast tumor	3.61
breast tumor	8.81
breast tumor	1.52
breast tumor	3.89
brain stage 5 ALZ	-42.63
brain stage 5 ALZ	-3.17
brain stage 5 ALZ	-20.30
brain stage 5 ALZ	-42.63
lung 24	-0.62
lung 28	-0.62
lung 23	-0.62
asthmatic lung	7.55
asthmatic lung	-0.62
asthmatic lung	-0.62
asthmatic lung	5.97
endo VEGF	0.00
endo bFGF	0.00
heart T-1	0.00
heart T-14	0.00
heart T-3399	12.26
BM stim	0.00
osteo undif	0.00
Cartilage (pool)	0.00
PBL HIV IIIB	1.01
MRC5 HSV strain F	128.16

Gene Name sbg120703RNase

5 Moderate to low overall expression in normal and disease samples. Highest normal expression in whole brain and salivary gland. Moderate expression in the fetal liver and the thymus. Highest disease expression in 2 of the normal lung samples, one of the lung tumor samples, the normal cartilage pool, and the HSV-infected MRC5 cells. Upregulation in 1 of 4 colon tumors suggests a role in cancer of the colon. Downregulation in 2 of 4 lung tumor samples suggests possible implication in lung cancer. Upregulation in 2 of 4 breast tumors implies an involvement in cancers of the breast. Downregulation in 3 of 3 COPD lung samples implies an involvement in COPD.

10 Upregulation in 3 of 3 heart samples implicates this gene in diseases of the heart such as DCM and ischemia. High expression in the OA and RA synovium and the OA bone samples suggests a possible involvement in osteoarthritis and rheumatoid arthritis. Upregulation in HSV implicates this gene in herpes simplex virus as a potential host factor. Moderate to low expression in immune cells.

15

Sample sbg120703RNase	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Averag e GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detecte d/50 ng total RNA
Subcutaneous Adipocytes Zenbio	40, 36.24	0	2.54	1.27	3.06	16.34	20.75
Subcutaneous Adipose Zenbio	36.58, 40	2.07	0	1.04	0.96	52.36	54.19
Adrenal Gland Clontech	40, 40	0.22	0	0.11	0.61	81.97	9.02
Whole Brain Clontech	28.62, 28.6	245.21	247.41	246.31	7.24	6.91	1701.04
Fetal Brain Clontech	40, 40	0.3	0	0.15	0.48	103.95	15.59
Cerebellum Clontech	40, 40	0.29	0	0.15	2.17	23.04	3.34
Cervix	35.3, 40	4.45	0	2.23	2.42	20.66	45.97
Colon	40, 40	0.26	0	0.13	2.71	18.45	2.40
Endometrium	40, 38.38	0	0.7	0.35	0.73	68.21	23.87
Esophagus	36.11, 37.01	2.74	1.6	2.17	1.37	36.50	79.20
Heart Clontech	40, 40	0	0	0.00	1.32	37.88	0.00
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	39.31, 36.07	0.4	2.8	1.60	2.58	19.38	31.01
Jejunum	34.13, 39.51	8.98	0.36	4.67	6.60	7.58	35.38
Kidney	40, 40	0.48	0	0.24	2.12	23.58	5.66
Liver	34.4, 36.04	7.64	2.86	5.25	1.50	33.33	175.00
Fetal Liver Clontech	31.46, 31.39	44.65	46.4	45.53	10.40	4.81	218.87
Lung	34.21, 35.61	8.59	3.71	6.15	2.57	19.46	119.65
Mammary Gland Clontech	34.9, 35.65	5.67	3.6	4.64	13.00	3.85	17.83
Myometrium	40, 38.99	0	0.49	0.25	2.34	21.37	5.24
Omentum	38.39, 34.35	0.7	7.89	4.30	3.94	12.69	54.51
Ovary	35, 33.21	5.34	15.64	10.49	4.34	11.52	120.85
Pancreas	40	0	0	0.00	0.81	61.80	0.00
Head of Pancreas	40	0	0	0.00	1.57	31.85	0.00
Parotid Gland	32.22, 33.49	28.28	13.18	20.73	5.48	9.12	189.14
Placenta Clontech	37, 39.59	1.6	0.34	0.97	5.26	9.51	9.22
Prostate	35.03, 35.75	5.23	3.4	4.32	3.00	16.67	71.92
Rectum	38.25, 40	0.76	0.21	0.49	1.23	40.65	19.72
Salivary Gland Clontech	30.01, 29.73	106.25	125.78	116.02	7.31	6.84	793.54
Skeletal Muscle Clontech	40, 39.16	0.41	0.44	0.43	1.26	39.68	16.87
Skin	37.21, 35.01	1.42	5.31	3.37	1.21	41.32	139.05
Small Intestine Clontech	40, 40	0	0.19	0.10	0.98	51.07	4.85
Spleen	35.4, 35.9	4.2	3.11	3.66	4.92	10.16	37.14
Stomach	36.12, 40	2.73	0.21	1.47	2.73	18.32	26.92
Testis Clontech	40, 40	0	0	0.00	0.57	87.87	0.00

Thymus Clontech	31.88, 31.42	34.61	45.62	40.12	9.89	5.06	202.81
Thyroid	40, 35.22	0	4.67	2.34	2.77	18.05	42.15
Trachea Clontech	35.38, 37.52	4.26	1.17	2.72	9.71	5.15	13.98
Urinary Bladder	38.77, 40	0.56	0.31	0.44	5.47	9.14	3.98
Uterus	33.66, 37.55	11.93	1.16	6.55	5.34	9.36	61.28
genomic	25.78	1342.66					
b-actin	27.27	551.42					
1.00E+05	19.03	100000					
1.00E+05	19.08	100000					
1.00E+04	22.28	10000					
1.00E+04	22.27	10000					
1.00E+03	25.85	1000					
1.00E+03	25.6	1000					
1.00E+02	30.44	100					
1.00E+02	29.33	100					
1.00E+01	34.4	10					
1.00E+01	34.48	10					
1.00E-00							
1.00E-00							
NTC	40	-1					
NTC	40	0					

Sample sbg120703RNase	Reg number (GSK identifier)	Ct	Mean GOI copies	copies of mRNA detected/ 50 ng total RNA	Sample	Fold Change in Disease Population
colon normal GW98-167	21941	29.03	142.85	285.70	colon normal	
colon tumor GW98-166	21940	28.31	226.87	453.74	colon tumor	1.59
colon normal GW98-178	22080	33.08	10.78	21.56	colon normal	
colon tumor GW98-177	22060	29.33	118.09	236.18	colon tumor	10.95
colon normal GW98-561	23514	30.02	76.09	152.18	colon normal	
colon tumor GW98-560	23513	30.42	58.89	117.78	colon tumor	-1.29
colon normal GW98-894	24691	29.07	139.29	278.58	colon normal	
colon tumor GW98-893	24690	30.3	63.5	127.00	colon tumor	-2.19
lung normal GW98-3	20742	26.86	574.4	1148.80	lung normal	
lung tumor GW98-2	20741	30.07	73.89	147.78	lung tumor	-7.77
lung normal GW97-179	20677	29.74	90.79	181.58	lung normal	
lung tumor GW97-178	20676	27.63	351.24	702.48	lung tumor	3.87
lung normal GW98-165	21922	26.63	663.94	1327.88	lung normal	
lung tumor GW98-164	21921	29.38	114.52	229.04	lung tumor	-5.80
lung normal GW98-282	22584	30	77.02	154.04	lung normal	
lung tumor GW98-281	22583	29.64	97.04	194.08	lung tumor	1.26
breast normal GW00-392	28750	29.08	138.57	138.57	breast normal	
breast tumor GW00-391	28746	28.77	169.53	339.06	breast tumor	2.45
breast normal GW00-413	28798	32.72	13.55	13.55	breast normal	
breast tumor GW00-412	28797	31.01	40.4	80.80	breast tumor	5.96

breast normal GW00-235:238	27592-95	34.39	4.68	4.68	breast normal	
breast tumor GW00-231:234	27588-91	31.4	31.48	31.48	breast tumor	6.73
breast normal GW98-621	23656	28.54	195.6	391.20	breast normal	
breast tumor GW98-620	23655	30.37	60.84	121.68	breast tumor	-3.21
brain normal BB99-542	25507	32.94	11.79	23.58	brain normal	
brain normal BB99-406	25509	32.22	18.66	37.32	brain normal	
brain normal BB99-904	25546	32.3	17.71	35.42	brain normal	
brain stage 5 ALZ BB99-874	25502	32.82	12.76	25.52	brain stage 5 ALZ	-1.26
brain stage 5 ALZ BB99-887	25503	30.31	63.18	126.36	brain stage 5 ALZ	3.94
brain stage 5 ALZ BB99-862	25504	31.42	31.08	62.16	brain stage 5 ALZ	1.94
brain stage 5 ALZ BB99-927	25542	33.35	9.08	18.16	brain stage 5 ALZ	-1.77
CT lung KC	normal	30.41	59.49	118.98	CT lung	
lung 26 KC	normal				lung 26	
lung 27 KC	normal	37.69	0.57	0.57	lung 27	
lung 24 KC	COPD	40	0	0.00	lung 24	-40.17
lung 28 KC	COPD	40	0	0.00	lung 28	-40.17
lung 23 KC	COPD	40	0	0.00	lung 23	-40.17
lung 25 KC	normal	36.86	0.97	0.97	lung 25	
asthmatic lung ODO3112	29321	33.08	10.79	10.79	asthmatic lung	-3.72
asthmatic lung ODO3433	29323	29.94	80.31	160.62	asthmatic lung	4.00
asthmatic lung ODO3397	29322	29.79	87.94	175.88	asthmatic lung	4.38
asthmatic lung ODO4928	29325	30.08	73.39	146.78	asthmatic lung	3.65
endo cells KC	control	40	0.13	0.13	endo cells	
endo VEGF KC		40	0	0.00	endo VEGF	-0.13
endo bFGF KC		40	0.12	0.12	endo bFGF	-1.08
heart Clontech	normal	34.66	3.95	7.90	heart	
heart (T-1) ischemic	29417	30.43	58.48	116.96	heart T-1	14.81
heart (T-14) non-obstructive DCM	29422	30.3	63.76	127.52	heart T-14	16.14
heart (T-3399) DCM	29426	31.14	37.27	74.54	heart T-3399	9.44
adenoid GW99-269	26162	33.15	10.31	20.62	adenoid	
tonsil GW98-280	22582	30.26	65.22	130.44	tonsil	
T cells PC00314	28453	33.29	9.45	18.90	T cells	
PBMNC		40	0	0.00	PBMNC	
monocyte		40	0	0.00	monocyte	
B cells PC00665	28455	32.25	18.35	36.70	B cells	
dendritic cells 28441		30.52	55.34	110.68	dendritic cells	
neutrophils	28440	31.61	27.61	27.61	neutrophils	
eosinophils	28446	33.2	10.01	20.02	eosinophils	
BM unstim		40	0	0.00	BM unstim	
BM stim		40	0	0.00	BM stim	0.00
osteo dif		40	0	0.00	osteo dif	0.00
osteo undif		40	0	0.00	osteo undif	
chondrocytes		29.65	96.25	240.63	chondrocytes	

OA Synovium IP12/01	29462	28.59	190.09	190.09	OA Synovium	
OA Synovium NP10/01	29461	29.06	140.66	281.32	OA Synovium	
OA Synovium NP57/00	28464	28.38	216.61	433.22	OA Synovium	
RA Synovium NP03/01	28466	29.43	111	222.00	RA Synovium	
RA Synovium NP71/00	28467	28.35	220.48	440.96	RA Synovium	
RA Synovium NP45/00	28475	28.7	176.79	353.58	RA Synovium	
OA bone (biobank)	29217	30.6	52.6	52.60	OA bone (biobank)	
OA bone Sample 1	J. Emory	29.64	97.1	194.20	OA bone	
OA bone Sample 2	J. Emory	30.85	44.71	89.42	OA bone	
Cartilage (pool)	Normal	28.07	264.86	529.72	Cartilage (pool)	
Cartilage (pool)	OA	30.47	56.97	113.94	Cartilage (pool)	-4.65
PBL uninfected	28441	33.41	8.73	17.46	PBL uninfected	
PBL HIV IIIB	28442	32.1	20.17	40.34	PBL HIV IIIB	2.31
MRC5 uninfected (100%)	29158	31.09	38.5	77.00	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	28.24	237.46	474.92	MRC5 HSV strain F	6.17
W12 cells	29179	28.83	162.45	324.90	W12 cells	
Keratinocytes	29180	29.21	127.89	255.78	Keratinocytes	
B-actin control		26.99	528.52			
genomic		25.66	1229.15			
1.00E+05		18.76	100000			
1.00E+05		19.03	100000			
1.00E+04		22.01	10000			
1.00E+04		22.05	10000			
1.00E+03		26.01	1000			
1.00E+03		25.68	1000			
1.00E+02		30.57	100			
1.00E+02		30.32	100			
1.00E+01		32.24	10			
1.00E+01		40	0			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			

Gene Name sbg120703RNase

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	1.59
colon tumor	10.95
colon tumor	-1.29
colon tumor	-2.19
lung tumor	-7.77

lung tumor	3.87
lung tumor	-5.80
lung tumor	1.26
breast tumor	2.45
breast tumor	5.96
breast tumor	6.73
breast tumor	-3.21
brain stage 5 ALZ	-1.26
brain stage 5 ALZ	3.94
brain stage 5 ALZ	1.94
brain stage 5 ALZ	-1.77
lung 24	-40.17
lung 28	-40.17
lung 23	-40.17
asthmatic lung	-3.72
asthmatic lung	4.00
asthmatic lung	4.38
asthmatic lung	3.65
endo VEGF	-0.13
endo bFGF	-1.08
heart T-1	14.81
heart T-14	16.14
heart T-3399	9.44
BM stim	0.00
osteo undif	0.00
Cartilage (pool)	-4.65
PBL HIV IIIB	2.31
MRC5 HSV strain F	6.17

Gene Name sbg98530TS

5 Moderate overall expression in normal and disease samples. Highest normal expression in whole brain, endometrium, and testis. Moderate expression in normal heart, skeletal muscle, and esophagus. Shows expression in most of the GI tract samples as well as the female reproductive tract samples. Highest disease expression in one of the colon tumor samples, all 3 of the heart samples, and the chondrocytes. Data predominantly shows a muscle-specific pattern of expression. Upregulation in 1 of 4 colon tumors and upregulation in 2 of 4 breast tumors implies an involvement in cancers of the colon and breast. Downregulation in 3 of 3 COPD samples implies a role in chronic obstructive pulmonary disease. Downregulation in HSV implicates involvement in herpes simplex virus as a potential host factor. Moderate to low overall expression in immune cells. High expression in chondrocytes and OA and RA synovium suggests possible involvement in osteoarthritis and rheumatoid arthritis.

10

15

Sample sbg98530TS	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Averag e GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detecte d/50 ng total RNA
Subcutaneous Adipocytes Zenbio	40, 36.35	0	4.22	2.11	3.06	16.34	34.48
Subcutaneous Adipose Zenbio	35.78, 40	5.89	0	2.95	0.96	52.36	154.19
Adrenal Gland Clontech	40, 40	0	0	0.00	0.61	81.97	0.00

Whole Brain Clontech	26.63, 26.42	1253.02	1414.2	1333.61	7.24	6.91	9210.01
Fetal Brain Clontech	40, 37.33	0	2.38	1.19	0.48	103.95	123.70
Cerebellum Clontech	35.9, 40	5.5	0	2.75	2.17	23.04	63.36
Cervix	33.47, 34.27	22.86	14.26	18.56	2.42	20.66	383.47
Colon	34.49, 34.05	12.58	16.28	14.43	2.71	18.45	266.24
Endometrium	33.28, 32.94	25.41	31.15	28.28	0.73	68.21	1929.06
Esophagus	33.61, 32.9	21.02	31.85	26.44	1.37	36.50	964.78
Heart Clontech	33.32, 33.03	24.91	29.42	27.17	1.32	37.88	1028.98
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	35.89, 33.37	5.53	24.14	14.84	2.58	19.38	287.50
Jejunum	31.55, 31.42	70.2	75.71	72.96	6.60	7.58	552.69
Kidney	40, 35.5	0	6.96	3.48	2.12	23.58	82.08
Liver	34.29, 33.63	14.07	20.78	17.43	1.50	33.33	580.83
Fetal Liver Clontech	32.16, 32.92	49.02	31.52	40.27	10.40	4.81	193.61
Lung	40, 35.78	0		2.95	2.57	19.46	57.30
Mammary Gland Clontech	31.42, 32.08	75.62	51.54	63.58	13.00	3.85	244.54
Myometrium	32.93, 32.03	31.21	52.84	42.03	2.34	21.37	897.97
Omentum	35.21, 40	8.23	0	4.12	3.94	12.69	52.22
Ovary	35.36, 35.51	7.53	6.89	7.21	4.34	11.52	83.06
Pancreas	40, 40	0	0	0.00	0.81	61.80	0.00
Head of Pancreas	40, 37.54	0	2.11	1.06	1.57	31.85	33.60
Parotid Gland	31.67, 31.01	65.33	96.46	80.90	5.48	9.12	738.09
Placenta Clontech	33.13, 32.05	27.88	52.3	40.09	5.26	9.51	381.08
Prostate	35.03, 40	9.13	5.22	7.18	3.00	16.67	119.58
Rectum	40, 35.19	0	8.32	4.16	1.23	40.65	169.11
Salivary Gland Clontech	32.41, 34.06	42.32	16.15	29.24	7.31	6.84	199.97
Skeletal Muscle Clontech	33.93, 33.76	17.41	19.28	18.35	1.26	39.68	727.98
Skin	40, 40	0	0	0.00	1.21	41.32	0.00
Small Intestine Clontech	34.11	11.73	15.7	13.72	0.98	51.07	700.46
Spleen	36.08, 40	4.94	0.37	2.66	4.92	10.16	26.98
Stomach	40, 40	0	0	0.00	2.73	18.32	0.00
Testis Clontech	35.54, 33.26	6.79	25.83	16.31	0.57	87.87	1433.22
Thymus Clontech	33.66, 34.12	20.35	15.62	17.99	9.89	5.06	90.93
Thyroid	40, 35.46	0	7.12	3.56	2.77	18.05	64.26
Trachea Clontech	32.08, 31.84	51.54	59.21	55.38	9.71	5.15	285.14
Urinary Bladder	34.75, 36.99	10.8	2.91	6.86	5.47	9.14	62.66
Uterus	31.79, 32.2	60.97	47.95	54.46	5.34	9.36	509.93
genomic	26.8	1133.17					
b-actin	27.6	706.62					
1.00E+05	19.53	100000					
1.00E+05	19.54	100000					
1.00E+04	22.8	10000					
1.00E+04	23.02	10000					
1.00E+03	26.14	1000					
1.00E+03	26.59	1000					

1.00E+02	31.41	100					
1.00E+02	30.97	100					
1.00E+01	40	0					
1.00E+01	35.24	10					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg98530TS	Reg number (GSK identifier)	Ct	Mean GOI copies	copies of mRNA detecte d/50 ng total RNA	Sample	Fold Change in Disease Populat ion
colon normal GW98-167	21941	26.26	1792.89	3585.78	colon normal	
colon tumor GW98-166	21940	26.2	1856.22	3712.44	colon tumor	1.04
colon normal GW98-178	22080	27.25	986.8	1973.60	colon normal	
colon tumor GW98-177	22060	26.7	1369.12	2738.24	colon tumor	1.39
colon normal GW98-561	23514	27.55	821.35	1642.70	colon normal	
colon tumor GW98-560	23513	24.64	4748.96	9497.92	colon tumor	5.78
colon normal GW98-894	24691	27.27	971.87	1943.74	colon normal	
colon tumor GW98-893	24690	25.35	3093.47	6186.94	colon tumor	3.18
lung normal GW98-3	20742	27.02	1133.68	2267.36	lung normal	
lung tumor GW98-2	20741	27.26	981.94	1963.88	lung tumor	-1.15
lung normal GW97-179	20677	29.14	315.07	630.14	lung normal	
lung tumor GW97-178	20676	28.15	571.76	1143.52	lung tumor	1.81
lung normal GW98-165	21922	27.86	682.2	1364.40	lung normal	
lung tumor GW98-164	21921	27.45	871.19	1742.38	lung tumor	1.28
lung normal GW98-282	22584	28.12	581.74	1163.48	lung normal	
lung tumor GW98-281	22583	29.32	283.71	567.42	lung tumor	-2.05
breast normal GW00-392	28750	27.85	687.38	687.38	breast normal	
breast tumor GW00-391	28746	26.61	1444.19	2888.38	breast tumor	4.20
breast normal GW00-413	28798	28.43	483.03	483.03	breast normal	
breast tumor GW00-412	28797	25.49	2836.66	5673.32	breast tumor	11.75
breast normal GW00-235:238	27592-95	32.26	48.29	48.29	breast normal	
breast tumor GW00-231:234	27588-91	29.07	328.46	328.46	breast tumor	6.80
breast normal GW98-621	23656	26.82	1279.07	2558.14	breast normal	
breast tumor GW98-620	23655	26.8	1289.27	2578.54	breast tumor	1.01
brain normal BB99-542	25507	29.03	337.63	675.26	brain normal	
brain normal BB99-406	25509	29.19	305.6	611.20	brain normal	
brain normal BB99-904	25546	30.44	144.55	289.10	brain normal	
brain stage 5 ALZ BB99-874	25502	28.47	471.8	943.60	brain stage 5 ALZ	1.80
brain stage 5 ALZ BB99-887	25503	27.3	955.52	1911.04	brain stage 5 ALZ	3.64

brain stage 5 ALZ BB99-862	25504	27.42	891.77	1783.54	brain stage 5 ALZ	3.40
brain stage 5 ALZ BB99-927	25542	29.31	285.16	570.32	brain stage 5 ALZ	1.09
CT lung KC	normal	27.96	643.88	1287.76	CT lung	
lung 26 KC	normal	35.82	5.66	5.66	lung 26	
lung 27 KC	normal	40	0	0.00	lung 27	
lung 24 KC	COPD	40	0	0.00	lung 24	-325.52
lung 28 KC	COPD	35.3	7.73	7.73	lung 28	-42.11
lung 23 KC	COPD	36.67	3.39	3.39	lung 23	-96.02
lung 25 KC	normal	35.11	8.67	8.67	lung 25	
asthmatic lung ODO3112	29321	31.01	102.08	102.08	asthmatic lung	-3.19
asthmatic lung ODO3433	29323	29.76	216.81	433.62	asthmatic lung	1.33
asthmatic lung ODO3397	29322	29.83	208.08	416.16	asthmatic lung	1.28
asthmatic lung ODO4928	29325	30.37	150.17	300.34	asthmatic lung	-1.08
endo cells KC	control	37.54	2	2.00	endo cells	
endo VEGF KC		35.77	5.83	5.83	endo VEGF	2.92
endo bFGF KC		40	0	0.00	endo bFGF	-2.00
heart Clontech	normal	26.09	1982.44	3964.88	heart	
heart (T-1) ischemic	29417	24	6956.27	13912.5 ₄	heart T-1	3.51
heart (T-14) non-obstructive DCM	29422	24.55	5010.03	10020.0 ₆	heart T-14	2.53
heart (T-3399) DCM	29426	24.05	6766.57	13533.1 ₄	heart T-3399	3.41
adenoid GW99-269	26162	30.56	134.11	268.22	adenoid	
tonsil GW98-280	22582	27.94	651.01	1302.02	tonsil	
T cells PC00314	28453	29.8	212.45	424.90	T cells	
PBMNC		33.01	30.69	30.69	PBMNC	
monocyte		33.42	23.9	47.80	monocyte	
B cells PC00665	28455	33.52	22.59	45.18	B cells	
dendritic cells 28441		29.07	329.58	659.16	dendritic cells	
neutrophils	28440	30.39	149	149.00	neutrophils	
eosinophils	28446	35.41	7.25	14.50	eosinophils	
BM unstim		34.24	14.65	14.65	BM unstim	
BM stim		36.61	3.51	3.51	BM stim	-4.17
osteodif		30.55	135.33	135.33	osteodif	3.02
osteoundif		32.38	44.88	44.88	osteoundif	
chondrocytes		25.35	3089.54	7723.85	chondrocytes	
OA Synovium IP12/01	29462	28.75	398.53	398.53	OA Synovium	
OA Synovium NP10/01	29461	27.04	1119.77	2239.54	OA Synovium	
OA Synovium NP57/00	28464	28.85	375.92	751.84	OA Synovium	
RA Synovium NP03/01	28466	28.14	574.66	1149.32	RA Synovium	
RA Synovium NP71/00	28467	27.58	806.11	1612.22	RA Synovium	
RA Synovium NP45/00	28475	28.04	611.1	1222.20	RA Synovium	
OA bone (biobank)	29217	30.25	161.3	161.30	OA bone (biobank)	
OA bone Sample 1	J. Emory	31.24	89.29	178.58	OA bone	
OA bone Sample 2	J. Emory	30.98	104.34	208.68	OA bone	

Cartilage (pool)	Normal	29.86	204.47	408.94	Cartilage (pool)	
Cartilage (pool)	OA	29.37	275.09	550.18	Cartilage (pool)	1.35
PBL uninfected	28441	26.45	1598.39	3196.78	PBL uninfected	
PBL HIV IIIB	28442	27.57	814.58	1629.16	PBL HIV IIIB	-1.96
MRC5 uninfected (100%)	29158	25.13	3539.95	7079.90	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	30.49	139.89	279.78	MRC5 HSV strain F	-25.31
W12 cells	29179	26.72	1359.04	2718.08	W12 cells	
Keratinocytes	29180	26.41	1633.77	3267.54	Keratinocytes	
B-actin control		27.87	678.8			
genomic		26.9	1214.71			
1.00E+05		19.86	100000			
1.00E+05		19.82	100000			
1.00E+04		23.15	10000			
1.00E+04		23.21	10000			
1.00E+03		26.62	1000			
1.00E+03		26.79	1000			
1.00E+02		31.2	100			
1.00E+02		32.2	100			
1.00E+01		40	0			
1.00E+01		34.53	10			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			

Gene Name sbg98530TS

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	1.04
colon tumor	1.39
colon tumor	5.78
colon tumor	3.18
lung tumor	-1.15
lung tumor	1.81
lung tumor	1.28
lung tumor	-2.05
breast tumor	4.20
breast tumor	11.75
breast tumor	6.80
breast tumor	1.01
brain stage 5 ALZ	1.80
brain stage 5 ALZ	3.64
brain stage 5 ALZ	3.40
brain stage 5 ALZ	1.09
lung 24	-325.52
lung 28	-42.11
lung 23	-96.02
asthmatic lung	-3.19
asthmatic lung	1.33

asthmatic lung	1.28
asthmatic lung	-1.08
endo VEGF	2.92
endo bFGF	-2.00
heart T-1	3.51
heart T-14	2.53
heart T-3399	3.41
BM stim	-4.17
osteo undif	3.02
Cartilage (pool)	1.35
PBL HIV IIIB	-1.96
MRC5 HSV strain F	-25.31

Gene Name sbg563917RDP

5 Moderate to low overall expression in normal and disease samples. Highest normal expression in testis liver, trachea, and whole brain. Shows good expression in most of the GI tract samples. Highest disease expression in T cells, B cells, neutrophils, and eosinophils. Upregulation in 1 of 4 breast tumors implies involvement in cancer of the breast. Downregulation in 3 of 3 COPD lungs suggests an involvement in chronic obstructive pulmonary disease. Downregulation in the ischemic heart sample implicates this gene in ischemic heart disease. Downregulation in the VEGF and bFGF-treated endothelial cells suggests a role in angiogenesis. Upregulation in HSV implicates involvement in herpes simplex virus as a potential host factor.

10

Sample sbg563917RDP	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Avera ge GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detecte d/50 ng total RNA
Subcutaneous Adipocytes Zenbio	35.34, 40	3.66	0	1.83	3.06	16.34	29.90
Subcutaneous Adipose Zenbio	40, 40	0		0.00	0.96	52.36	0.00
Adrenal Gland Clontech	40, 40	0	0	0.00	0.61	81.97	0.00
Whole Brain Clontech	30.09, 30.01	91.85	96.8	94.33	7.24	6.91	651.42
Fetal Brain Clontech	40, 40	0	0	0.00	0.48	103.95	0.00
Cerebellum Clontech	35.19, 40	4.03	0	2.02	2.17	23.04	46.43
Cervix	36.08, 40	2.33	0	1.17	2.42	20.66	24.07
Colon	36.07, 35.1	2.35	4.24	3.30	2.71	18.45	60.79
Endometrium	35.01, 40	4.49	0	2.25	0.73	68.21	153.14
Esophagus	34.94, 40	4.68	0	2.34	1.37	36.50	85.40
Heart Clontech	40, 40	0	0	0.00	1.32	37.88	0.00
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	35.24, 40	3.89	0	1.95	2.58	19.38	37.69
Jejunum	35.37, 33.35	3.6	12.44	8.02	6.60	7.58	60.76
Kidney	40, 34.97	0	4.6	2.30	2.12	23.58	54.25
Liver	33.51, 34.6	11.25	5.78	8.52	1.50	33.33	283.83
Fetal Liver Clontech	33.19, 35.54	13.75	3.25	8.50	10.40	4.81	40.87
Lung	34.32	6.84	2.28	4.56	2.57	19.46	88.72
Mammary Gland Clontech	40, 35.14	0	4.15	2.08	13.00	3.85	7.98

Myometrium	40, 40	0	0.09	0.05	2.34	21.37	0.96
Omentum	36.17, 33.01	2.2	15.32	8.76	3.94	12.69	111.17
Ovary	40, 40	0	0	0.00	4.34	11.52	0.00
Pancreas	40, 40	0	0	0.00	0.81	61.80	0.00
Head of Pancreas	40, 40	0	0	0.00	1.57	31.85	0.00
Parotid Gland	35.43, 39.81	3.46	0.24	1.85	5.48	9.12	16.88
Placenta Clontech	33.7, 35.45	10.02	3.42	6.72	5.26	9.51	63.88
Prostate	40, 40	0	0	0.00	3.00	16.67	0.00
Rectum	40, 40	0	0	0.00	1.23	40.65	0.00
Salivary Gland Clontech	34.89, 40	4.83	0	2.42	7.31	6.84	16.52
Skeletal Muscle Clontech	40, 40	0	0	0.00	1.26	39.68	0.00
Skin	40, 40	0	0	0.00	1.21	41.32	0.00
Small Intestine Clontech	40, 40	0	0	0.00	0.98	51.07	0.00
Spleen	35.01, 33.36	4.48	12.38	8.43	4.92	10.16	85.67
Stomach	33.38, 34.18	12.18	7.48	9.83	2.73	18.32	180.04
Testis Clontech	34.25, 32.86	7.17	16.84	12.01	0.57	87.87	1054.92
Thymus Clontech	32.14, 33.25	26.17	13.24	19.71	9.89	5.06	99.62
Thyroid	40, 40	0	0.09	0.05	2.77	18.05	0.81
Trachea Clontech	31.41, 31	41.04	52.65	46.85	9.71	5.15	241.22
Urinary Bladder	40, 35.05	0	4.38	2.19	5.47	9.14	20.02
Uterus	33.77, 33.41	9.62	12	10.81	5.34	9.36	101.22
genomic	26.54	813.56					
b-actin	27.39	481.34					
1.00E+05	18.71	100000					
1.00E+05	18.92	100000					
1.00E+04	22.44	10000					
1.00E+04	22.11	10000					
1.00E+03	26.05	1000					
1.00E+03	26.11	1000					
1.00E+02	30.4	100					
1.00E+02	30.17	100					
1.00E+01	33.87	10					
1.00E+01	33.26	10					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg563917RDP	Reg number (GSK identifier)	Ct	Mean GOI copies	copies of mRNA detected /50 ng total RNA	Sample	Fold Change in Disease Population
colon normal GW98-167	21941	30.39	148.35	296.70	colon normal	

colon tumor GW98-166	21940	30.93	110.14	220.28	colon tumor	-1.35
colon normal GW98-178	22080	32.93	36.71	73.42	colon normal	
colon tumor GW98-177	22060	34.8	13.09	26.18	colon tumor	-2.80
colon normal GW98-561	23514	31.41	84.68	169.36	colon normal	
colon tumor GW98-560	23513	32.09	58.33	116.66	colon tumor	-1.45
colon normal GW98-894	24691	30.02	182.15	364.30	colon normal	
colon tumor GW98-893	24690	31.12	99.26	198.52	colon tumor	-1.84
lung normal GW98-3	20742	28.4	443.99	887.98	lung normal	
lung tumor GW98-2	20741	33.59	25.44	50.88	lung tumor	-17.45
lung normal GW97-179	20677	28.63	391.85	783.70	lung normal	
lung tumor GW97-178	20676	29.16	292.08	584.16	lung tumor	-1.34
lung normal GW98-165	21922	29.13	296.8	593.60	lung normal	
lung tumor GW98-164	21921	30.22	163.43	326.86	lung tumor	-1.82
lung normal GW98-282	22584	31.71	71.72	143.44	lung normal	
lung tumor GW98-281	22583	31.74	70.77	141.54	lung tumor	-1.01
breast normal GW00-392	28750	31.49	81.02	81.02	breast normal	
breast tumor GW00-391	28746	33.58	25.62	51.24	breast tumor	-1.58
breast normal GW00-413	28798	35.07	11.31	11.31	breast normal	
breast tumor GW00-412	28797	31.99	61.52	123.04	breast tumor	10.88
breast normal GW00-235:238	27592-95	35.63	8.3	8.30	breast normal	
breast tumor GW00-231:234	27588-91	34.33	16.97	16.97	breast tumor	2.04
breast normal GW98-621	23656	32.07	58.95	117.90	breast normal	
breast tumor GW98-620	23655	32.71	41.33	82.66	breast tumor	-1.43
brain normal BB99-542	25507	30.16	168.86	337.72	brain normal	
brain normal BB99-406	25509	31.12	99.35	198.70	brain normal	
brain normal BB99-904	25546	31.14	98.44	196.88	brain normal	
brain stage 5 ALZ BB99-874	25502	33.16	32.39	64.78	brain stage 5 ALZ	-3.77
brain stage 5 ALZ BB99-887	25503	29.32	267.28	534.56	brain stage 5 ALZ	2.19
brain stage 5 ALZ BB99-862	25504	30.36	150.72	301.44	brain stage 5 ALZ	1.23
brain stage 5 ALZ BB99-927	25542	30.1	174.01	348.02	brain stage 5 ALZ	1.42
CT lung KC	normal	31.06	102.88	205.76	CT lung	
lung 26 KC	normal	32.15	56.21	56.21	lung 26	
lung 27 KC	normal	35.96	6.92	6.92	lung 27	
lung 24 KC	COPD	40	0	0.00	lung 24	-70.34
lung 28 KC	COPD	36.21	6.05	6.05	lung 28	-11.63
lung 23 KC	COPD	34.83	12.87	12.87	lung 23	-5.47
lung 25 KC	normal	34.89	12.45	12.45	lung 25	
asthmatic lung ODO3112	29321	32.57	44.76	44.76	asthmatic lung	-1.57
asthmatic lung ODO3433	29323	32.4	49.04	98.08	asthmatic lung	1.39
asthmatic lung ODO3397	29322	31.79	68.64	137.28	asthmatic lung	1.95
asthmatic lung ODO4928	29325	31.34	88.11	176.22	asthmatic lung	2.51
endo cells KC	control	35.77	7.68	7.68	endo cells	
endo VEGF KC		40	0	0.00	endo VEGF	-7.68

endo bFGF KC		40	0	0.00	endo bFGF	-7.68
heart Clontech	normal	31.09	100.75	201.50	heart	
heart (T-1) ischemic	29417	34.75	13.46	26.92	heart T-1	-7.49
heart (T-14) non-obstructive DCM	29422	33.69	24.17	48.34	heart T-14	-4.17
heart (T-3399) DCM	29426	33.48	27.16	54.32	heart T-3399	-3.71
adenoid GW99-269	26162	30.49	140.7	281.40	adenoid	
tonsil GW98-280	22582	30.07	177.32	354.64	tonsil	
T cells PC00314	28453	27.79	622.1	1244.20	T cells	
PBMNC		36.19	6.11	6.11	PBMNC	
monocyte		33.24	30.91	61.82	monocyte	
B cells PC00665	28455	26.37	1355.2	2710.40	B cells	
dendritic cells 28441		28.69	378.62	757.24	dendritic cells	
neutrophils	28440	23.28	7420.47	7420.47	neutrophils	
eosinophils	28446	25.33	2408.94	4817.88	eosinophils	
BM unstim		32.24	53.57	53.57	BM unstim	
BM stim		31.92	64.05	64.05	BM stim	1.20
osteodif		40	0	0.00	osteodif	0.00
osteoundif		40	0	0.00	osteoundif	
chondrocytes		37.59	2.82	7.05	chondrocytes	
OA Synovium IP12/01	29462	31.77	69.48	69.48	OA Synovium	
OA Synovium NP10/01	29461	31.16	96.93	193.86	OA Synovium	
OA Synovium NP57/00	28464	30.84	115.69	231.38	OA Synovium	
RA Synovium NP03/01	28466	30.96	108.37	216.74	RA Synovium	
RA Synovium NP71/00	28467	29.2	285.91	571.82	RA Synovium	
RA Synovium NP45/00	28475	29.87	198.12	396.24	RA Synovium	
OA bone (biobank)	29217	29.67	220.64	220.64	OA bone (biobank)	
OA bone Sample 1	J. Emory	30.54	136.41	272.82	OA bone	
OA bone Sample 2	J. Emory	29.38	259.07	518.14	OA bone	
Cartilage (pool)	Normal	31.34	87.88	175.76	Cartilage (pool)	
Cartilage (pool)	OA	32.9	37.23	74.46	Cartilage (pool)	-2.36
PBL uninfected	28441	30.55	135.85	271.70	PBL uninfected	
PBL HIV IIIB	28442	31.02	104.8	209.60	PBL HIV IIIB	-1.30
MRC5 uninfected (100%)	29158	35.11	11.06	22.12	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	29.63	226.14	452.28	MRC5 HSV strain F	20.45
W12 cells	29179	37.87	2.42	4.84	W12 cells	
Keratinocytes	29180	36.14	6.26	12.52	Keratinocytes	
B-actin control		27.14	887.42			
genomic		26.16	1520.17			
1.00E+05		19.22	100000			
1.00E+05		19.2	100000			
1.00E+04		22.49	10000			
1.00E+04		22.62	10000			
1.00E+03		26.23	1000			
1.00E+03		26.05	1000			
1.00E+02		30.26	100			

1.00E+02		31.03	100				
1.00E+01		38.68	10				
1.00E+01		33.47	10				
1.00E-00		40	0				
1.00E-00		40	0				
NTC		40	0				

Gene Name sbg563917RDP

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-1.35
colon tumor	-2.80
colon tumor	-1.45
colon tumor	-1.84
lung tumor	-17.45
lung tumor	-1.34
lung tumor	-1.82
lung tumor	-1.01
breast tumor	-1.58
breast tumor	10.88
breast tumor	2.04
breast tumor	-1.43
brain stage 5 ALZ	-3.77
brain stage 5 ALZ	2.19
brain stage 5 ALZ	1.23
brain stage 5 ALZ	1.42
lung 24	-70.34
lung 28	-11.63
lung 23	-5.47
asthmatic lung	-1.57
asthmatic lung	1.39
asthmatic lung	1.95
asthmatic lung	2.51
endo VEGF	-7.68
endo bFGF	-7.68
heart T-1	-7.49
heart T-14	-4.17
heart T-3399	-3.71
BM stim	1.20
osteo undif	0.00
Cartilage (pool)	-2.36
PBL HIV IIIB	-1.30
MRC5 HSV strain F	20.45

5 Gene Name sbg618069LRR
 Low overall expression in normal and disease samples. Highest normal expression in whole brain, fetal brain, cerebellum, and thymus. Highest disease expression in one of the colon tumor samples, one of the lung tumor samples, and the uninfected PBL cells. Downregulation in 2 of 4 colon tumors suggests a role in cancer of the colon. Upregulation in 1 of 4 lung tumors and upregulation in 2 of 4 breast tumors suggest roles in cancers of the lung and breast. Downregulation in 3 of 3 COPD lung samples implicates a role for this gene in COPD. Upregulation in the stimulated bone marrow. Downregulation in an HIV-infected cell line as well as moderate expression in immune

10

cells suggests an involvement in HIV. Upregulation in HSV implicates involvement in herpes simplex virus as a potential host factor.

Sample sbg618069LRR	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detec- ted/50 ng total RNA
Subcutaneous Adipocytes Zenbio	35.24, 34.33	4.38	7.65	6.02	3.06	16.34	98.28
Subcutaneous Adipose Zenbio	40, 40	0	0.08	0.04	0.96	52.36	2.09
Adrenal Gland Clontech	39.9, 38.74	0.13	0.51	0.32	0.61	81.97	26.23
Whole Brain Clontech	27.02, 26.51	673.36	916.93	795.15	7.24	6.91	5491.33
Fetal Brain Clontech	40, 40	0.13	6.01	3.07	0.48	103.95	319.13
Cerebellum Clontech	32.15, 32.13	28.98	29.44	29.21	2.17	23.04	673.04
Cervix	40, 40	0	0	0.00	2.42	20.66	0.00
Colon	36.53, 39.88	1.98	0.25	1.12	2.71	18.45	20.57
Endometrium	37.98, 40	0.82	0.19	0.51	0.73	68.21	34.45
Esophagus	38.86, 40	0.48	0.15	0.32	1.37	36.50	11.50
Heart Clontech	34.17, 34.72	8.41	6.03	7.22	1.32	37.88	273.48
Hypothalamus	40, 40	0	0.07	0.04	0.32	155.28	5.43
Ileum	40, 40	0.17	0.11	0.14	2.58	19.38	2.71
Jejunum	33.07, 34.34	16.52	7.58	12.05	6.60	7.58	91.29
Kidney	36.05, 40	2.67	0.21	1.44	2.12	23.58	33.96
Liver	38.72, 40	0.52	0.61	0.57	1.50	33.33	18.83
Fetal Liver Clontech	33.28, 36.35	14.52	2.22	8.37	10.40	4.81	40.24
Lung	40, 40	0.13	0.08	0.11	2.57	19.46	2.04
Mammary Gland Clontech	40, 34.19	0	8.33	4.17	13.00	3.85	16.02
Myometrium	40, 40	0.28	0	0.14	2.34	21.37	2.99
Omentum	35.01, 35.36	5.04	4.07	4.56	3.94	12.69	57.80
Ovary	34.24, 40	8.07	0.26	4.17	4.34	11.52	47.98
Pancreas	40, 40	0.11	0.13	0.12	0.81	61.80	7.42
Head of Pancreas	40, 40	0	0	0.00	1.57	31.85	0.00
Parotid Gland	34.01, 34.28	9.31	7.9	8.61	5.48	9.12	78.51
Placenta Clontech	40, 40	0	0.07	0.04	5.26	9.51	0.33
Prostate	40, 39.13	0.15	0.4	0.28	3.00	16.67	4.58
Rectum	40, 39.55	0.21	0.31	0.26	1.23	40.65	10.57
Salivary Gland Clontech	32.35, 33.08	25.74	16.45	21.10	7.31	6.84	144.29
Skeletal Muscle Clontech	34.78, 40	5.81	0.27	3.04	1.26	39.68	120.63
Skin	40, 40	0	0	0.00	1.21	41.32	0.00
Small Intestine Clontech	40, 40	0.16	0	0.08	0.98	51.07	4.09
Spleen	35.59, 40	3.53	0.59	2.06	4.92	10.16	20.93
Stomach	36.73, 40	1.76	0.11	0.94	2.73	18.32	17.12
Testis Clontech	37.91, 40	0.86	0.1	0.48	0.57	87.87	42.18

Thymus Clontech	30.22, 29.94	94.88	112.23	103.56	9.89	5.06	523.53
Thyroid	35.15, 40	4.62	0	2.31	2.77	18.05	41.70
Trachea Clontech	33.49, 34.21	12.75	8.22	10.49	9.71	5.15	53.99
Urinary Bladder	40, 40	0.09	0.08	0.09	5.47	9.14	0.78
Uterus	35.26, 33.03	4.31	16.97	10.64	5.34	9.36	99.63
genomic	26.04	1229.54					
b-actin	27.25	584.19					
1.00E+05	19.09	100000					
1.00E+05	19.04	100000					
1.00E+04	22.35	10000					
1.00E+04	22.35	10000					
1.00E+03	26.07	1000					
1.00E+03	26.26	1000					
1.00E+02	30.64	100					
1.00E+02	30.38	100					
1.00E+01	34.04	10					
1.00E+01	33.52	10					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg618069LRR	Reg number (GSK identifier)	Ct	Mean GOI copies	copies of mRNA detec- ted/50 ng total RNA	Sample	Fold Change in Disease Popula- tion
colon normal GW98-167	21941	29.52	176.51	353.02	colon normal	
colon tumor GW98-166	21940	33.45	18.5	37.00	colon tumor	-9.54
colon normal GW98-178	22080	31.82	47.14	94.28	colon normal	
colon tumor GW98-177	22060	29.68	160.67	321.34	colon tumor	3.41
colon normal GW98-561	23514	30.33	110.78	221.56	colon normal	
colon tumor GW98-560	23513	33.11	22.39	44.78	colon tumor	-4.95
colon normal GW98-894	24691	28.1	396.95	793.90	colon normal	
colon tumor GW98-893	24690	26.93	779.99	1559.98	colon tumor	1.96
lung normal GW98-3	20742	30.41	105.78	211.56	lung normal	
lung tumor GW98-2	20741	26.28	1128.28	2256.56	lung tumor	10.67
lung normal GW97-179	20677	29.28	201.91	403.82	lung normal	
lung tumor GW97-178	20676	28.35	345.36	690.72	lung tumor	1.71
lung normal GW98-165	21922	28.42	331.95	663.90	lung normal	
lung tumor GW98-164	21921	30.98	76.05	152.10	lung tumor	-4.36
lung normal GW98-282	22584	34.15	12.36	24.72	lung normal	
lung tumor GW98-281	22583	32.08	40.6	81.20	lung tumor	3.28
breast normal GW00-392	28750	29.67	161.68	161.68	breast normal	
breast tumor GW00-391	28746	28.98	239.65	479.30	breast tumor	2.96
breast normal GW00-413	28798	31.78	48.04	48.04	breast normal	

breast tumor GW00-412	28797	29.69	159.55	319.10	breast tumor	6.64
breast normal GW00-235:238	27592-95	34.18	12.14	12.14	breast normal	
breast tumor GW00-231:234	27588-91	29.2	211.28	211.28	breast tumor	17.40
breast normal GW98-621	23656	29.72	157.4	314.80	breast normal	
breast tumor GW98-620	23655	31.12	70.17	140.34	breast tumor	-2.24
brain normal BB99-542	25507	30.81	83.89	167.78	brain normal	
brain normal BB99-406	25509	31.02	74.28	148.56	brain normal	
brain normal BB99-904	25546	31.39	60.08	120.16	brain normal	
brain stage 5 ALZ BB99-874	25502	32.54	31.07	62.14	brain stage 5 ALZ	-2.34
brain stage 5 ALZ BB99-887	25503	30.65	92.1	184.20	brain stage 5 ALZ	1.27
brain stage 5 ALZ BB99-862	25504	31.68	50.92	101.84	brain stage 5 ALZ	-1.43
brain stage 5 ALZ BB99-927	25542	31.39	60.36	120.72	brain stage 5 ALZ	-1.21
CT lung KC	normal	30.47	101.87	203.74	CT lung	
lung 26 KC	normal				lung 26	
lung 27 KC	normal	39.27	0.65	0.65	lung 27	
lung 24 KC	COPD	40	0	0.00	lung 24	-68.13
lung 28 KC	COPD	37.38	1.93	1.93	lung 28	-35.30
lung 23 KC	COPD	34.28	11.47	11.47	lung 23	-5.94
lung 25 KC	normal	40	0	0.00	lung 25	
asthmatic lung ODO3112	29321	33.17	21.73	21.73	asthmatic lung	-3.14
asthmatic lung ODO3433	29323	32.35	34.64	69.28	asthmatic lung	1.02
asthmatic lung ODO3397	29322	30.83	83.1	166.20	asthmatic lung	2.44
asthmatic lung ODO4928	29325	30.94	77.99	155.98	asthmatic lung	2.29
endo cells KC	control	40	0	0.00	endo cells	
endo VEGF KC		40	0	0.00	endo VEGF	0.00
endo bFGF KC		40	0	0.00	endo bFGF	0.00
heart Clontech	normal	30.52	99.45	198.90	heart	
heart (T-1) ischemic	29417	28.78	270.18	540.36	heart T-1	2.72
heart (T-14) non-obstructive DCM	29422	29.62	166.76	333.52	heart T-14	1.68
heart (T-3399) DCM	29426	30.05	129.76	259.52	heart T-3399	1.30
adenoid GW99-269	26162	29.05	230.93	461.86	adenoid	
tonsil GW98-280	22582	29.77	152.22	304.44	tonsil	
T cells PC00314	28453	31.6	53.48	106.96	T cells	
PBMNC		39.8	0.48	0.48	PBMNC	
monocyte		40	0	0.00	monocyte	
B cells PC00665	28455	31.56	54.77	109.54	B cells	
dendritic cells 28441		34.09	12.8	25.60	dendritic cells	
neutrophils	28440	34.03	13.21	13.21	neutrophils	
eosinophils	28446	40	0	0.00	eosinophils	
BM unstim		40	0	0.00	BM unstim	
BM stim		35.71	5.04	5.04	BM stim	5.04
osteo dif		40	0	0.00	osteo dif	0.00
osteo undif		40	0	0.00	osteo undif	

chondrocytes		33.5	17.89	44.73	chondrocytes	
OA Synovium IP12/01	29462	32.24	37.02	37.02	OA Synovium	
OA Synovium NP10/01	29461	27.95	434.95	869.90	OA Synovium	
OA Synovium NP57/00	28464	30.9	79.82	159.64	OA Synovium	
RA Synovium NP03/01	28466	31.79	47.9	95.80	RA Synovium	
RA Synovium NP71/00	28467	33.06	23.05	46.10	RA Synovium	
RA Synovium NP45/00	28475	32.76	27.41	54.82	RA Synovium	
OA bone (biobank)	29217	32.02	42.02	42.02	OA bone (biobank)	
OA bone Sample 1	J. Emory	31.32	62.63	125.26	OA bone	
OA bone Sample 2	J. Emory	33.13	22.24	44.48	OA bone	
Cartilage (pool)	Normal	30.76	86.51	173.02	Cartilage (pool)	
Cartilage (pool)	OA	33.13	22.15	44.30	Cartilage (pool)	-3.91
PBL uninfected	28441	26.78	847.01	1694.02	PBL uninfected	
PBL HIV IIIB	28442	28.21	374.26	748.52	PBL HIV IIIB	-2.26
MRC5 uninfected (100%)	29158	40	0	0.00	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	31.26	64.96	129.92	MRC5 HSV strain F	129.92
W12 cells	29179	40	0	0.00	W12 cells	
Keratinocytes	29180	39.77	0.49	0.98	Keratinocytes	
B-actin control		27.18	675.17			
genomic		25.96	1358.6			
1.00E+05		18.58	100000			
1.00E+05		18.53	100000			
1.00E+04		22.04	10000			
1.00E+04		22.1	10000			
1.00E+03		25.85	1000			
1.00E+03		26.11	1000			
1.00E+02		34.02	100			
1.00E+02		30.53	100			
1.00E+01		32.98	10			
1.00E+01		40	0			
1.00E-00		40	0			
1.00E-00		38.21	1			
NTC		40	0			

Gene Name sbg618069LRR

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-9.54
colon tumor	3.41
colon tumor	-4.95
colon tumor	1.96
lung tumor	10.67
lung tumor	1.71
lung tumor	-4.36
lung tumor	3.28

breast tumor	2.96
breast tumor	6.64
breast tumor	17.40
breast tumor	-2.24
brain stage 5 ALZ	-2.34
brain stage 5 ALZ	1.27
brain stage 5 ALZ	-1.43
brain stage 5 ALZ	-1.21
lung 24	-68.13
lung 28	-35.30
lung 23	-5.94
asthmatic lung	-3.14
asthmatic lung	1.02
asthmatic lung	2.44
asthmatic lung	2.29
endo VEGF	0.00
endo bFGF	0.00
heart T-1	2.72
heart T-14	1.68
heart T-3399	1.30
BM stim	5.04
osteo dif	0.00
Cartilage (pool)	-3.91
PBL HIV IIIB	-2.26
MRC5 HSV strain F	129.92

Gene Name sbg934114Relaxin

5 Low overall expression in normal and disease samples. Highest normal expression in testis, liver, and whole brain. Highest disease expression in 3 of the normal lung samples, one of the normal tumor samples, the HSV-infected MRC5 cells, the adenoid, and the T cells. Highest disease expression in 2 of the normal lung samples, one of the lung tumor samples, 1 of the normal breast samples, 1 of the breast tumor samples, and the uninfected PBL samples. Downregulation in 1 of 4 colon tumors and downregulation in 2 of 4 lung tumors imply roles in cancers of the colon and lung.

10 Downregulation in 3 of 3 COPD lung samples and upregulation in 3 of 4 asthmatic lung samples implicates this gene in COPD and asthma. Upregulation in 2 of 3 heart samples proposes roles in non-obstructive and obstructive DCM. Downregulation in the OA cartilage pool and low expression in RA and OA synovium, OA bone, and chondrocytes suggests an involvement in osteoarthritis and rheumatoid arthritis. Downregulation in an HIV-infected primary cell line suggests an involvement in HIV. Upregulation in HSV implicates involvement in herpes simplex virus as a potential host factor.

Sample sbg934114Relaxin	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detecte d/50 ng total RNA
Subcutaneous Adipocytes Zenbio	37.4, 40	5.41	0	2.71	3.06	16.34	44.20

Subcutaneous Adipose Zenbio	40, 40	0.73	0	0.37	0.96	52.36	19.11
Adrenal Gland Clontech	40, 40	0.73	0.69	0.71	0.61	81.97	58.20
Whole Brain Clontech	33.52, 34.72	47.76	24.26	36.01	7.24	6.91	248.69
Fetal Brain Clontech	39.51, 40	1.65	0.86	1.26	0.48	103.95	130.46
Cerebellum Clontech	40, 39.84	0.99	1.37	1.18	2.17	23.04	27.19
Cervix	40, 40	1.05	0	0.53	2.42	20.66	10.85
Colon	40, 37.31	0	5.7	2.85	2.71	18.45	52.58
Endometrium	40, 40	0	0	0.00	0.73	68.21	0.00
Esophagus	40, 40	0	0	0.00	1.37	36.50	0.00
Heart Clontech	38.11, 40	3.63	1.31	2.47	1.32	37.88	93.56
Hypothalamus	40, 40	0	1.06	0.53	0.32	155.28	82.30
Ileum	40, 36.79	0	7.62	3.81	2.58	19.38	73.84
Jejunum	35.14, 35.9	19.25	12.54	15.90	6.60	7.58	120.42
Kidney	40, 40	0	0	0.00	2.12	23.58	0.00
Liver	37.25, 35.17	5.88	18.92	12.40	1.50	33.33	413.33
Fetal Liver Clontech	40, 37.38	0.73	5.47	3.10	10.40	4.81	14.90
Lung	37.07, 40	6.52	0	3.26	2.57	19.46	63.42
Mammary Gland Clontech	40, 40	0	0	0.00	13.00	3.85	0.00
Myometrium	37.95, 40	3.98	0	1.99	2.34	21.37	42.52
Omentum	36.24, 37.04	10.39	6.63	8.51	3.94	12.69	107.99
Ovary	35.29, 36.26	17.66	10.28	13.97	4.34	11.52	160.94
Pancreas	39.48, 40	1.69	0	0.85	0.81	61.80	52.22
Head of Pancreas	36.17, 39.82	10.79	1.39	6.09	1.57	31.85	193.95
Parotid Gland	40, 38.66	0	2.67	1.34	5.48	9.12	12.18
Placenta Clontech	40, 36.57	0	8.63	4.32	5.26	9.51	41.02
Prostate	36.91, 40	7.14	0	3.57	3.00	16.67	59.50
Rectum	40, 37.34	0	5.61	2.81	1.23	40.65	114.02
Salivary Gland Clontech	40, 40	0	0	0.00	7.31	6.84	0.00
Skeletal Muscle Clontech	40, 39.45	0	1.71	0.86	1.26	39.68	33.93
Skin	39.2, 40	1.98	0	0.99	1.21	41.32	40.91
Small Intestine Clontech	40, 40	0	0	0.00	0.98	51.07	0.00
Spleen	36, 40	11.84	0	5.92	4.92	10.16	60.16
Stomach	35.48, 39.19	15.9	1.98	8.94	2.73	18.32	163.74
Testis Clontech	40, 36.09	0	11.27	5.64	0.57	87.87	495.17
Thymus Clontech	34.34, 36.66	30.03	8.2	19.12	9.89	5.06	96.64
Thyroid	40, 40	0	0	0.00	2.77	18.05	0.00
Trachea Clontech	40, 37.8	0	4.33	2.17	9.71	5.15	11.15
Urinary Bladder	40, 40	0	0	0.00	5.47	9.14	0.00
Uterus	37.11, 35.16	6.36	18.96	12.66	5.34	9.36	118.54
genomic	27.61	1307.98					
b-actin	27.15	1697.68					
1.00E+05	19.88	100000					
1.00E+05	20.05	100000					
1.00E+04	24.01	10000					

1.00E+04	23.92	10000					
1.00E+03	27.98	1000					
1.00E+03	27.6	1000					
1.00E+02	32.89	100					
1.00E+02	32.2	100					
1.00E+01	36.1	10					
1.00E+01							
1.00E-00							
1.00E-00							
NTC	40	0					
NTC	40	0					

Sample sbg934114Relaxin	Reg number (GSK identifier)	Ct	Mean GOI copies	copies of mRNA detecte d/50 ng total RNA	Sample	Fold Change in Disease Populati on
colon normal GW98-167	21941	36.1	22.33	44.66	colon normal	
colon tumor GW98-166	21940	36.47	18.37	36.74	colon tumor	-1.22
colon normal GW98-178	22080	35.7	27.58	55.16	colon normal	
colon tumor GW98-177	22060	38.05	7.98	15.96	colon tumor	-3.46
colon normal GW98-561	23514	33.57	84.85	169.70	colon normal	
colon tumor GW98-560	23513	37.66	9.8	19.60	colon tumor	-8.66
colon normal GW98-894	24691	36.39	19.09	38.18	colon normal	
colon tumor GW98-893	24690	36.43	18.74	37.48	colon tumor	-1.02
lung normal GW98-3	20742	32.48	150.6	301.20	lung normal	
lung tumor GW98-2	20741	36.65	16.64	33.28	lung tumor	-9.05
lung normal GW97-179	20677	33.22	102.07	204.14	lung normal	
lung tumor GW97-178	20676	32.31	164.63	329.26	lung tumor	1.61
lung normal GW98-165	21922	32.08	185.96	371.92	lung normal	
lung tumor GW98-164	21921	35.14	37.09	74.18	lung tumor	-5.01
lung normal GW98-282	22584	36.41	18.93	37.86	lung normal	
lung tumor GW98-281	22583	35.24	35.13	70.26	lung tumor	1.86
breast normal GW00-392	28750	34.04	66.25	66.25	breast normal	
breast tumor GW00-391	28746	37.9	8.61	17.22	breast tumor	-3.85
breast normal GW00-413	28798	36.36	19.44	19.44	breast normal	
breast tumor GW00-412	28797	36.79	15.49	30.98	breast tumor	1.59
breast normal GW00- 235:238	27592-95	36.91	14.52	14.52	breast normal	
breast tumor GW00- 231:234	27588-91	35.43	31.71	31.71	breast tumor	2.18
breast normal GW98-621	23656	36.26	20.51	41.02	breast normal	
breast tumor GW98-620	23655	35.76	26.68	53.36	breast tumor	1.30
brain normal BB99-542	25507	37.99	8.21	16.42	brain normal	
brain normal BB99-406	25509	40	1.41	2.82	brain normal	
brain normal BB99-904	25546	40	0	0.00	brain normal	
brain stage 5 ALZ BB99-	25502	38.65	5.82	11.64	brain stage 5 ALZ	1.81

874						
brain stage 5 ALZ BB99-887	25503	37	13.9	27.80	brain stage 5 ALZ	4.33
brain stage 5 ALZ BB99-862	25504	37.4	11.24	22.48	brain stage 5 ALZ	3.51
brain stage 5 ALZ BB99-927	25542	38	8.19	16.38	brain stage 5 ALZ	2.55
CT lung KC	normal	35.32	33.59	67.18	CT lung	
lung 26 KC	normal	37.02	13.72	13.72	lung 26	
lung 27 KC	normal	40	0	0.00	lung 27	
lung 24 KC	COPD	39.97	2.78	2.78	lung 24	-7.81
lung 28 KC	COPD	40	0	0.00	lung 28	-21.71
lung 23 KC	COPD	39.06	4.67	4.67	lung 23	-4.65
lung 25 KC	normal	38.61	5.92	5.92	lung 25	
asthmatic lung ODO3112	29321	36.02	23.31	23.31	asthmatic lung	1.07
asthmatic lung ODO3433	29323	34.12	63.36	126.72	asthmatic lung	5.84
asthmatic lung ODO3397	29322	33.99	68.06	136.12	asthmatic lung	6.27
asthmatic lung ODO4928	29325	33.77	76.08	152.16	asthmatic lung	7.01
endo cells KC	control	40	0	0.00	endo cells	
endo VEGF KC		40	0	0.00	endo VEGF	0.00
endo bFGF KC		38.16	7.54	7.54	endo bFGF	7.54
heart Clontech	normal	40	0	0.00	heart	
heart (T-1) ischemic	29417	40	1.36	2.72	heart T-1	2.72
heart (T-14) non-obstructive DCM	29422	36.31	20.01	40.02	heart T-14	40.02
heart (T-3399) DCM	29426	37.17	12.7	25.40	heart T-3399	25.40
adenoid GW99-269	26162	33.33	96.07	192.14	adenoid	
tonsil GW98-280	22582	34.86	42.85	85.70	tonsil	
T cells PC00314	28453	33.48	88.65	177.30	T cells	
PBMNC		40	0	0.00	PBMNC	
monocyte		40	0	0.00	monocyte	
B cells PC00665	28455	32.44	153.68	307.36	B cells	
dendritic cells 28441		35.78	26.47	52.94	dendritic cells	
neutrophils	28440	36.18	21.43	21.43	neutrophils	
eosinophils	28446	39.2	4.34	8.68	eosinophils	
BM unstim		39.56	3.6	3.60	BM unstim	
BM stim		40	1.34	1.34	BM stim	-2.69
osteо dif		40	0	0.00	osteо dif	0.00
osteо undif		40	0	0.00	osteо undif	
chondrocytes		36.64	16.79	41.98	chondrocytes	
OA Synovium IP12/01	29462	34.75	45.45	45.45	OA Synovium	
OA Synovium NP10/01	29461	36.02	23.28	46.56	OA Synovium	
OA Synovium NP57/00	28464	34.24	59.37	118.74	OA Synovium	
RA Synovium NP03/01	28466	37.88	8.71	17.42	RA Synovium	
RA Synovium NP71/00	28467	36.02	23.22	46.44	RA Synovium	
RA Synovium NP45/00	28475	34.9	41.9	83.80	RA Synovium	
OA bone (biobank)	29217	33.59	83.75	83.75	OA bone (biobank)	
OA bone Sample 1	J. Emory	37.31	11.8	23.60	OA bone	

OA bone Sample 2	J. Emory	37.47	10.81	21.62	OA bone	
Cartilage (pool)	Normal	34.61	49.07	98.14	Cartilage (pool)	
Cartilage (pool)	OA	40	0	0.00	Cartilage (pool)	-98.14
PBL uninfected	28441	33.86	72.8	145.60	PBL uninfected	
PBL HIV IIIB	28442	37.08	13.28	26.56	PBL HIV IIIB	-5.48
MRC5 uninfected (100%)	29158	39.01	4.81	9.62	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	31.5	252.68	505.36	MRC5 HSV strain F	52.53
W12 cells	29179	39.84	3.1	6.20	W12 cells	
Keratinocytes	29180	39.07	4.64	9.28	Keratinocytes	
B-actin control		27.9	1683.49			
genomic		28.13	1492.71			
1.00E+05		20.5	100000			
1.00E+05		20.61	100000			
1.00E+04		24.56	10000			
1.00E+04		24.17	10000			
1.00E+03		28.14	1000			
1.00E+03		28.32	1000			
1.00E+02		34.26	100			
1.00E+02		32.76	100			
1.00E+01		38.07	10			
1.00E+01		37.53	10			
1.00E-00		40	0			
1.00E-00		40	1			
NTC		38.42	-1			

Gene Name sbg934114Relaxin

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-1.22
colon tumor	-3.46
colon tumor	-8.66
colon tumor	-1.02
lung tumor	-9.05
lung tumor	1.61
lung tumor	-5.01
lung tumor	1.86
breast tumor	-3.85
breast tumor	1.59
breast tumor	2.18
breast tumor	1.30
brain stage 5 ALZ	1.81
brain stage 5 ALZ	4.33
brain stage 5 ALZ	3.51
brain stage 5 ALZ	2.55
lung 24	-7.81
lung 28	-21.71
lung 23	-4.65
asthmatic lung	1.07

asthmatic lung	5.84
asthmatic lung	6.27
asthmatic lung	7.01
endo VEGF	0.00
endo bFGF	7.54
heart T-1	2.72
heart T-14	40.02
heart T-3399	25.40
BM stim	-2.69
osteo dif	0.00
Cartilage (pool)	-98.14
PBL HIV IIIB	-5.48
MRC5 HSV strain F	52.53

Gene Name sbg99174LOX-like

5 Moderate overall expression in normal and disease samples. Highest normal expression in whole brain, liver, skin, spleen, testis. Shows relatively good expression in the female reproductive samples as well as the GI tract samples. Highest disease expression in one of the normal lung samples, one of the asthmatic lung samples, neutrophils, eosinophils, 2 of the RA synovium samples, and one of the OA bone samples. Downregulation in 1 of 4 lung tumor samples suggests possible implication in lung cancer. Upregulation in 2 of 4 breast tumors implies an involvement in cancers of the breast. Downregulation in 1 of 4 AD brains along with the high expression seen in the brain suggests an involvement in Alzheimer's disease. Downregulation in 2 of 3 COPD lung samples implies an involvement in chronic obstructive pulmonary disease. Upregulation in 1 of 4 asthmatic lung samples implies a role in asthma. Downregulation in OA cartilage and high expression in OA and RA synovium suggests possible involvement in osteoarthritis and rheumatoid arthritis. Corroborating high expression in the T cells provides additional evidence for a role in RA/OA. Moderate expression in other immune cells.

10

15

Sample sbg99174LOX-like	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detected/50 ng total RNA
Subcutaneous Adipocytes Zenbio	39.67, 34.48	0.53	11.91	6.22	3.06	16.34	101.63
Subcutaneous Adipose Zenbio	40, 39.75	0.39	0.51	0.45	0.96	52.36	23.56
Adrenal Gland Clontech	38.61, 37.69	1	1.75	1.38	0.61	81.97	112.70
Whole Brain Clontech	30.59, 31.07	122.95	92.57	107.76	7.24	6.91	744.20
Fetal Brain Clontech	40, 40	0	0.29	0.15	0.48	103.95	15.07
Cerebellum Clontech	40, 40	0.4	0.4	0.40	2.17	23.04	9.22
Cervix	35.77, 40	5.52	0.62	3.07	2.42	20.66	63.43
Colon	40, 39.41	0.34	0.62	0.48	2.71	18.45	8.86
Endometrium	40, 38.65	0	0.98	0.49	0.73	68.21	33.42
Esophagus	40, 40	0.35	0.41	0.38	1.37	36.50	13.87
Heart Clontech	39.33, 40	0.65	0	0.33	1.32	37.88	12.31
Hypothalamus	40, 39.54	0	0.58	0.29	0.32	155.28	45.03
Ileum	35.42, 35.76	6.79	5.55	6.17	2.58	19.38	119.57
Jejunum	34.13, 33.4	14.77	22.9	18.84	6.60	7.58	142.69

Kidney	40, 37.22	0.68	2.32	1.50	2.12	23.58	35.38
Liver	33.5, 33.86	21.47	17.3	19.39	1.50	33.33	646.17
Fetal Liver Clontech	32.78, 33.23	33.08	25.33	29.21	10.40	4.81	140.41
Lung	33.96, 34.44	16.33	12.25	14.29	2.57	19.46	278.02
Mammary Gland Clontech	35.05, 36.02	8.51	4.76	6.64	13.00	3.85	25.52
Myometrium	35.08, 35.49	8.34	6.52	7.43	2.34	21.37	158.76
Omentum	37.6, 35.05	1.83	8.49	5.16	3.94	12.69	65.48
Ovary	35.57, 32.76	6.21	33.46	19.84	4.34	11.52	228.51
Pancreas	40, 40	0	0.42	0.21	0.81	61.80	12.98
Head of Pancreas	40, 38.65	0.56	0.98	0.77	1.57	31.85	24.52
Parotid Gland	35.28, 40	7.4	0.64	4.02	5.48	9.12	36.68
Placenta Clontech	40, 39.17	0.32	0.72	0.52	5.26	9.51	4.94
Prostate	40, 35.34	0	7.15	3.58	3.00	16.67	59.58
Rectum	37.29, 39.02	2.22	0.78	1.50	1.23	40.65	60.98
Salivary Gland Clontech	40, 38.15	0.27	1.32	0.80	7.31	6.84	5.44
Skeletal Muscle Clontech	40, 38.56	0.56	1.03	0.80	1.26	39.68	31.55
Skin	35.1, 34.19	8.22	14.22	11.22	1.21	41.32	463.64
Small Intestine Clontech	40, 40	0	0.85	0.43	0.98	51.07	21.71
Spleen	32.2, 32.08	46.76	50.49	48.63	4.92	10.16	494.16
Stomach	34.28, 34.07	13.5	15.3	14.40	2.73	18.32	263.74
Testis Clontech	34.05, 32.7	15.46	34.82	25.14	0.57	87.87	2209.14
Thymus Clontech	33.85, 32.4	17.44	41.71	29.58	9.89	5.06	149.52
Thyroid	34.22, 34.29	13.93	13.37	13.65	2.77	18.05	246.39
Trachea Clontech	32.51, 32.4	38.89	41.53	40.21	9.71	5.15	207.05
Urinary Bladder	35.47, 40	6.6	0	3.30	5.47	9.14	30.16
Uterus	33.8, 33.6	18.01	20.22	19.12	5.34	9.36	178.98
genomic	26.31	1603.29					
b-actin	27.35	860.96					
1.00E+05	19.71	100000					
1.00E+05	19.88	100000					
1.00E+04	22.98	10000					
1.00E+04	23.01	10000					
1.00E+03	26.44	1000					
1.00E+03	26.54	1000					
1.00E+02	31.28	100					
1.00E+02	31.29	100					
1.00E+01	35.79	10					
1.00E+01	34.36	10					
1.00E-00	38.32	1					
1.00E-00	40	1					
NTC	40	0					
NTC	40	0					

Sample sbg99174LOX-like	Reg number	Ct	Mean GOI	copies of	Sample	Fold Change
----------------------------	---------------	----	-------------	--------------	--------	----------------

	(GSK identifier)		copies	mRNA detecte d/50 ng total RNA		in Disease Population
colon normal GW98-167	21941	29.81	184.31	368.62	colon normal	
colon tumor GW98-166	21940	29.25	254.48	508.96	colon tumor	1.38
colon normal GW98-178	22080	32.06	50.31	100.62	colon normal	
colon tumor GW98-177	22060	31.77	59.28	118.56	colon tumor	1.18
colon normal GW98-561	23514	33.21	25.83	51.66	colon normal	
colon tumor GW98-560	23513	31.74	60.51	121.02	colon tumor	2.34
colon normal GW98-894	24691	30.17	149.84	299.68	colon normal	
colon tumor GW98-893	24690	29.41	232.23	464.46	colon tumor	1.55
lung normal GW98-3	20742	25.76	1914.72	3829.44	lung normal	
lung tumor GW98-2	20741	30.12	154.63	309.26	lung tumor	-12.38
lung normal GW97-179	20677	29.59	209.5	419.00	lung normal	
lung tumor GW97-178	20676	27.2	835.04	1670.08	lung tumor	3.99
lung normal GW98-165	21922	28.22	462.22	924.44	lung normal	
lung tumor GW98-164	21921	29.27	251.87	503.74	lung tumor	-1.84
lung normal GW98-282	22584	30.18	149.17	298.34	lung normal	
lung tumor GW98-281	22583	28.47	399.41	798.82	lung tumor	2.68
breast normal GW00-392	28750	30.24	143.58	143.58	breast normal	
breast tumor GW00-391	28746	30.16	151.08	302.16	breast tumor	2.10
breast normal GW00-413	28798	31.51	68.87	68.87	breast normal	
breast tumor GW00-412	28797	28.91	310.66	621.32	breast tumor	9.02
breast normal GW00-235:238	27592-95	40	0	0.00	breast normal	
breast tumor GW00-231:234	27588-91	33.55	21.28	21.28	breast tumor	21.28
breast normal GW98-621	23656	31.57	66.56	133.12	breast normal	
breast tumor GW98-620	23655	31.15	84.8	169.60	breast tumor	1.27
brain normal BB99-542	25507	29.55	214.38	428.76	brain normal	
brain normal BB99-406	25509	29.15	270.89	541.78	brain normal	
brain normal BB99-904	25546	30.48	124.98	249.96	brain normal	
brain stage 5 ALZ BB99-874	25502	33.57	20.99	41.98	brain stage 5 ALZ	-9.69
brain stage 5 ALZ BB99-887	25503	29.89	176.42	352.84	brain stage 5 ALZ	-1.15
brain stage 5 ALZ BB99-862	25504	31.65	63.83	127.66	brain stage 5 ALZ	-3.19
brain stage 5 ALZ BB99-927	25542	31.04	90.73	181.46	brain stage 5 ALZ	-2.24
CT lung KC	normal	29.94	170.8	341.60	CT lung	
lung 26 KC	normal	30.63	115.04	115.04	lung 26	
lung 27 KC	normal	32.22	45.83	45.83	lung 27	
lung 24 KC	COPD	34.16	14.91	14.91	lung 24	-9.21
lung 28 KC	COPD	33.51	21.7	21.70	lung 28	-6.33
lung 23 KC	COPD	32.51	38.67	38.67	lung 23	-3.55
lung 25 KC	normal	32.18	46.79	46.79	lung 25	
asthmatic lung ODO3112	29321	31.84	56.95	56.95	asthmatic lung	-2.41

asthmatic lung ODO3433	29323	31.12	86.42	172.84	asthmatic lung	1.26
asthmatic lung ODO3397	29322	27.13	867.31	1734.62	asthmatic lung	12.63
asthmatic lung ODO4928	29325	30.25	142.92	285.84	asthmatic lung	2.08
endo cells KC	control	31.23	81.05	81.05	endo cells	
endo VEGF KC		31.87	56.15	56.15	endo VEGF	-1.44
endo bFGF KC		32.64	35.97	35.97	endo bFGF	-2.25
heart Clontech	normal	35.46	7.06	14.12	heart	
heart (T-1) ischemic	29417	35.73	6.03	12.06	heart T-1	-1.17
heart (T-14) non-obstructive DCM	29422	34.34	13.49	26.98	heart T-14	1.91
heart (T-3399) DCM	29426	33.65	20.01	40.02	heart T-3399	2.83
adenoid GW99-269	26162	31.2	82.69	165.38	adenoid	
tonsil GW98-280	22582	30.8	103.96	207.92	tonsil	
T cells PC00314	28453	28.16	480.4	960.80	T cells	
PBMNC		30.25	143.11	143.11	PBMNC	
monocyte		30.05	160.68	321.36	monocyte	
B cells PC00665	28455	30.75	107.02	214.04	B cells	
dendritic cells 28441		30.32	137.17	274.34	dendritic cells	
neutrophils	28440	26.32	1390.87	1390.87	neutrophils	
eosinophils	28446	25.07	2854.44	5708.88	eosinophils	
BM unstim		30.72	109.05	109.05	BM unstim	
BM stim		28.61	369.2	369.20	BM stim	3.39
osteo dif		40	0	0.00	osteo dif	-0.28
osteo undif		40	0.28	0.28	osteo undif	
chondrocytes		34.3	13.76	34.40	chondrocytes	
OA Synovium IP12/01	29462	27.56	676.63	676.63	OA Synovium	
OA Synovium NP10/01	29461	31.41	73.19	146.38	OA Synovium	
OA Synovium NP57/00	28464	28.02	518.05	1036.10	OA Synovium	
RA Synovium NP03/01	28466	27.03	921.88	1843.76	RA Synovium	
RA Synovium NP71/00	28467	27.04	914.02	1828.04	RA Synovium	
RA Synovium NP45/00	28475	29.06	285.08	570.16	RA Synovium	
OA bone (biobank)	29217	26.78	1065.84	1065.84	OA bone (biobank)	
OA bone Sample 1	J. Emory	30.27	141.07	282.14	OA bone	
OA bone Sample 2	J. Emory	27.04	917.04	1834.08	OA bone	
Cartilage (pool)	Normal	28.23	461.21	922.42	Cartilage (pool)	
Cartilage (pool)	OA	33.16	26.65	53.30	Cartilage (pool)	-17.31
PBL uninfected	28441	28.72	346.97	693.94	PBL uninfected	
PBL HIV IIIB	28442	28.54	384.02	768.04	PBL HIV IIIB	1.11
MRC5 uninfected (100%)	29158	31.64	64.07	128.14	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	31.53	68.31	136.62	MRC5 HSV strain F	1.07
W12 cells	29179	34.44	12.72	25.44	W12 cells	
Keratinocytes	29180	36.02	5.1	10.20	Keratinocytes	
B-actin control		27.2	835.98			
genomic		26.76	1073.72			
1.00E+05		19.13	100000			
1.00E+05		19.61	100000			

1.00E+04		22.79	10000				
1.00E+04		22.5	10000				
1.00E+03		26.36	1000				
1.00E+03		26.23	1000				
1.00E+02		31.25	100				
1.00E+02		30.82	100				
1.00E+01		35.02	10				
1.00E+01		35.15	10				
1.00E-00		40	0				
1.00E-00		40	0				
NTC		40	0				

Gene Name sbg99174LOX-like

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	1.38
colon tumor	1.18
colon tumor	2.34
colon tumor	1.55
lung tumor	-12.38
lung tumor	3.99
lung tumor	-1.84
lung tumor	2.68
breast tumor	2.10
breast tumor	9.02
breast tumor	21.28
breast tumor	1.27
brain stage 5 ALZ	-9.69
brain stage 5 ALZ	-1.15
brain stage 5 ALZ	-3.19
brain stage 5 ALZ	-2.24
lung 24	-9.21
lung 28	-6.33
lung 23	-3.55
asthmatic lung	-2.41
asthmatic lung	1.26
asthmatic lung	12.63
asthmatic lung	2.08
endo VEGF	-1.44
endo bFGF	-2.25
heart T-1	-1.17
heart T-14	1.91
heart T-3399	2.83
BM stim	3.39
osteo dif	-0.28
Cartilage (pool)	-17.31
PBL HIV IIIB	1.11
MRC5 HSV strain F	1.07

Extremely low overall expression in normal and disease samples. Highest normal expression in the colon and the parotid gland. Highest disease expression in the one of the lung tumors and one of the colon tumors. Upregulation in 1 of 4 colon tumors and 1 of 4 lung tumors imply roles in cancers of the colon and lung. Downregulation in 3 of 4 AD brain samples as well as high expression in whole brain suggests an involvement in Alzheimer's disease. Downregulation in 3 of 3 COPD lung samples implicates this gene in COPD. Downregulation in the ischemic and non-obstructive DCM heart samples suggests a role for this gene in cardiovascular disease. Upregulation in the stimulated bone marrow sample. Upregulation in HSV implicates involvement in herpes simplex virus as a potential host factor. High expression in neutrophils and eosinophils.

5

10

Sample sbg995002PIGR	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detec- ted/50 ng total RNA
Subcutaneous Adipocytes Zenbio	40, 40	0	0	0.00	3.06	16.34	0.00
Subcutaneous Adipose Zenbio	40, 40	0	0	0.00	0.96	52.36	0.00
Adrenal Gland Clontech	40, 40	0	0	0.00	0.61	81.97	0.00
Whole Brain Clontech	36.78, 40	11.16	0	5.58	7.24	6.91	38.54
Fetal Brain Clontech	40, 40	0	0	0.00	0.48	103.95	0.00
Cerebellum Clontech	40, 40	0	0	0.00	2.17	23.04	0.00
Cervix	40, 40	0	0	0.00	2.42	20.66	0.00
Colon	37.16, 37.12	8.81	9.05	8.93	2.71	18.45	164.76
Endometrium	40, 40	0	0	0.00	0.73	68.21	0.00
Esophagus	40, 40	0	0	0.00	1.37	36.50	0.00
Heart Clontech	40, 40	0	0	0.00	1.32	37.88	0.00
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	40, 40	0	0	0.00	2.58	19.38	0.00
Jejunum	40, 40	0	0	0.00	6.60	7.58	0.00
Kidney	40, 40	0	0	0.00	2.12	23.58	0.00
Liver	40, 39.16	0	2.58	1.29	1.50	33.33	43.00
Fetal Liver Clontech	40, 40	0	0	0.00	10.40	4.81	0.00
Lung	40, 40	0	0	0.00	2.57	19.46	0.00
Mammary Gland Clontech	40, 39.18	0	2.55	1.28	13.00	3.85	4.90
Myometrium	40, 40	0	0	0.00	2.34	21.37	0.00
Omentum	40, 38.04	0	5.15	2.58	3.94	12.69	32.68
Ovary	39.29, 40	2.37	0	1.19	4.34	11.52	13.65
Pancreas	40, 40	0	0	0.00	0.81	61.80	0.00
Head of Pancreas	40, 40	0	0	0.00	1.57	31.85	0.00
Parotid Gland	36.7, 37.94	11.72	5.46	8.59	5.48	9.12	78.38
Placenta Clontech	40, 40	0	0	0.00	5.26	9.51	0.00
Prostate	40, 40	0	0	0.00	3.00	16.67	0.00
Rectum	40, 40	0	0	0.00	1.23	40.65	0.00
Salivary Gland Clontech	37.23, 39.21	8.45	2.5	5.48	7.31	6.84	37.45
Skeletal Muscle Clontech	40, 40	0	0	0.00	1.26	39.68	0.00

Skin	40, 40	0	0	0.00	1.21	41.32	0.00
Small Intestine Clontech	40, 40	0	0	0.00	0.98	51.07	0.00
Spleen	40, 38.76	1.25	3.3	2.28	4.92	10.16	23.12
Stomach	40, 39.25	1.25	2.43	1.84	2.73	18.32	33.70
Testis Clontech	40, 40	0	0	0.00	0.57	87.87	0.00
Thymus Clontech	37.82, 40	5.88	0	2.94	9.89	5.06	14.86
Thyroid	40, 40	0	0	0.00	2.77	18.05	0.00
Trachea Clontech	40, 40	0	0	0.00	9.71	5.15	0.00
Urinary Bladder	40, 40	0	0	0.00	5.47	9.14	0.00
Uterus	38.34, 40	4.27	0	2.14	5.34	9.36	19.99
genomic	29.66	888.99					
b-actin	30.72	462.87					
1.00E+05	22.2	100000					
1.00E+05	22.14	100000					
1.00E+04	25.72	10000					
1.00E+04	25.66	10000					
1.00E+03	29.16	1000					
1.00E+03	29.07	1000					
1.00E+02	32.37	100					
1.00E+02	34.12	100					
1.00E+01	37.12	10					
1.00E+01	37.11	10					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	38.03	-1					

Sample sbg995002PIGR	Reg number (GSK identifier)	Ct	Mean GOI copies	copies of mRNA detecte d/50 ng total RNA	Sample	Fold Change in Disease Populati on
colon normal GW98-167	21941	33.43	149.84	299.68	colon normal	
colon tumor GW98-166	21940	32.49	274.64	549.28	colon tumor	1.83
colon normal GW98-178	22080	40	0	0.00	colon normal	
colon tumor GW98-177	22060	31.11	675.8	1351.60	colon tumor	1351.60
colon normal GW98-561	23514	37.74	9.09	18.18	colon normal	
colon tumor GW98-560	23513	35.81	31.94	63.88	colon tumor	3.51
colon normal GW98-894	24691	33.17	177.11	354.22	colon normal	
colon tumor GW98-893	24690	31.61	488.49	976.98	colon tumor	2.76
lung normal GW98-3	20742	35.48	39.55	79.10	lung normal	
lung tumor GW98-2	20741	28.32	4121.56	8243.12	lung tumor	104.21
lung normal GW97-179	20677	36.47	20.69	41.38	lung normal	
lung tumor GW97-178	20676	37.24	12.59	25.18	lung tumor	-1.64
lung normal GW98-165	21922	37.32	11.96	23.92	lung normal	
lung tumor GW98-164	21921	36.07	26.9	53.80	lung tumor	2.25

lung normal GW98-282	22584	38.49	5.58	11.16	lung normal	
lung tumor GW98-281	22583	37.89	8.24	16.48	lung tumor	1.48
breast normal GW00-392	28750	39.03	3.93	3.93	breast normal	
breast tumor GW00-391	28746	38.01	7.65	15.30	breast tumor	3.89
breast normal GW00-413	28798	40	0	0.00	breast normal	
breast tumor GW00-412	28797	38.67	4.98	9.96	breast tumor	9.96
breast normal GW00-235:238	27592-95	40	0	0.00	breast normal	
breast tumor GW00-231:234	27588-91	40	0	0.00	breast tumor	0.00
breast normal GW98-621	23656	36.12	26.13	52.26	breast normal	
breast tumor GW98-620	23655	40	0	0.00	breast tumor	-52.26
brain normal BB99-542	25507	37.14	13.43	26.86	brain normal	
brain normal BB99-406	25509	40	0	0.00	brain normal	
brain normal BB99-904	25546	40	0	0.00	brain normal	
brain stage 5 ALZ BB99-874	25502	40	0	0.00	brain stage 5 ALZ	-8.95
brain stage 5 ALZ BB99-887	25503	40	0.51	1.02	brain stage 5 ALZ	-8.78
brain stage 5 ALZ BB99-862	25504	40	0.88	1.76	brain stage 5 ALZ	-5.09
brain stage 5 ALZ BB99-927	25542	40	1.9	3.80	brain stage 5 ALZ	-2.36
CT lung KC	normal	36.59	19.23	38.46	CT lung	
lung 26 KC	normal	40	0	0.00	lung 26	
lung 27 KC	normal	40	0	0.00	lung 27	
lung 24 KC	COPD	40	0	0.00	lung 24	-9.62
lung 28 KC	COPD	40	0	0.00	lung 28	-9.62
lung 23 KC	COPD	40	0	0.00	lung 23	-9.62
lung 25 KC	normal	40	0	0.00	lung 25	
asthmatic lung ODO3112	29321	40	0	0.00	asthmatic lung	-9.62
asthmatic lung ODO3433	29323	38.36	6.1	12.20	asthmatic lung	1.27
asthmatic lung ODO3397	29322	37.29	12.16	24.32	asthmatic lung	2.53
asthmatic lung ODO4928	29325	38.01	7.64	15.28	asthmatic lung	1.59
endo cells KC	control	40	0	0.00	endo cells	
endo VEGF KC		40	0	0.00	endo VEGF	0.00
endo bFGF KC		40	0	0.00	endo bFGF	0.00
heart Clontech	normal	37.85	8.49	16.98	heart	
heart (T-1) ischemic	29417	40	0	0.00	heart T-1	-16.98
heart (T-14) non-obstructive DCM	29422	40	0	0.00	heart T-14	-16.98
heart (T-3399) DCM	29426	39.5	2.9	5.80	heart T-3399	-2.93
adenoid GW99-269	26162	40	0	0.00	adenoid	
tonsil GW98-280	22582	36.35	22.46	44.92	tonsil	
T cells PC00314	28453	36.17	25.23	50.46	T cells	
PBMNC		40	0	0.00	PBMNC	
monocyte		40	0.45	0.90	monocyte	
B cells PC00665	28455	40	0.6	1.20	B cells	
dendritic cells 28441		38.07	7.37	14.74	dendritic cells	
neutrophils	28440	32.73	236.09	236.09	neutrophils	

eosinophils	28446	33.68	126.65	253.30	eosinophils	
BM unstim		40	0	0.00	BM unstim	
BM stim		36.52	20.1	20.10	BM stim	20.10
osteodif		40	0	0.00	osteodif	0.00
osteo undif		40	0	0.00	osteo undif	
chondrocytes		39.61	2.7	6.75	chondrocytes	
OA Synovium IP12/01	29462	39.91	1.59	1.59	OA Synovium	
OA Synovium NP10/01	29461	38.98	4.07	8.14	OA Synovium	
OA Synovium NP57/00	28464	36.29	23.27	46.54	OA Synovium	
RA Synovium NP03/01	28466	35.81	31.94	63.88	RA Synovium	
RA Synovium NP71/00	28467	34.79	61.79	123.58	RA Synovium	
RA Synovium NP45/00	28475	35.08	51.15	102.30	RA Synovium	
OA bone (biobank)	29217	40	1.12	1.12	OA bone (biobank)	
OA bone Sample 1	J. Emory	36.8	16.77	33.54	OA bone	
OA bone Sample 2	J. Emory	34.72	64.74	129.48	OA bone	
Cartilage (pool)	Normal	37.46	10.93	21.86	Cartilage (pool)	
Cartilage (pool)	OA	40	0	0.00	Cartilage (pool)	-21.86
PBL uninfected	28441	35.05	52.27	104.54	PBL uninfected	
PBL HIV IIIB	28442	37.31	12.04	24.08	PBL HIV IIIB	-4.34
MRC5 uninfected (100%)	29158	40	0	0.00	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	38.19	6.8	13.60	MRC5 HSV strain F	13.60
W12 cells	29179	40	0	0.00	W12 cells	
Keratinocytes	29180	40	0	0.00	Keratinocytes	
B-actin control	B-actin control	29.77	1604.25			
genomic	genomic	30.5	1001.61			
1.00E+05	1.00E+05	22.95	100000			
1.00E+05	1.00E+05	22.91	100000			
1.00E+04	1.00E+04	26.49	10000			
1.00E+04	1.00E+04	26.66	10000			
1.00E+03	1.00E+03	30.62	1000			
1.00E+03	1.00E+03	30.43	1000			
1.00E+02	1.00E+02	36.12	100			
1.00E+02	1.00E+02	34.73	100			
1.00E+01	1.00E+01	38.58	10			
1.00E+01	1.00E+01	38.82	10			
1.00E-00	1.00E-00	40	0			
1.00E-00	1.00E-00	37.86	1			
NTC	NTC	40	0			

Gene Name sbg995002PIGR

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	1.83

colon tumor	1351.60
colon tumor	3.51
colon tumor	2.76
lung tumor	104.21
lung tumor	-1.64
lung tumor	2.25
lung tumor	1.48
breast tumor	3.89
breast tumor	9.96
breast tumor	0.00
breast tumor	-52.26
brain stage 5 ALZ	-8.95
brain stage 5 ALZ	-8.78
brain stage 5 ALZ	-5.09
brain stage 5 ALZ	-2.36
lung 24	-9.62
lung 28	-9.62
lung 23	-9.62
asthmatic lung	-9.62
asthmatic lung	1.27
asthmatic lung	2.53
asthmatic lung	1.59
endo VEGF	0.00
endo bFGF	0.00
heart T-1	-16.98
heart T-14	-16.98
heart T-3399	-2.93
BM stim	20.10
osteo dif	0.00
Cartilage (pool)	-21.86
PBL HIV IIIB	-4.34
MRC5 HSV strain F	13.60

Gene Name sbg1033026C1q

5 Low to moderate overall expression in normal and disease samples. Highest normal expression in the subcutaneous adipocytes, subcutaneous adipose, whole brain, and heart. Highest disease expression in the 3 heart samples. Downregulation in 1 of 4 lung tumor samples and upregulation in 2 of 4 breast tumor samples indicates a role for this gene in cancers of the lung and breast. Upregulation in 2 of 4 AD brain samples suggests an involvement in Alzheimer's disease.

10 Upregulation in 3 of 3 heart samples implies an involvement in cardiovascular diseases such as non-obstructive and obstructive DCM as well as ischemia. Low expression in all of the immune cells. Low to moderate expression in the OA synovium and bone samples as well as in the RA synovium samples.

Sample sbg1033026C1q	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detecte d/50 ng total RNA
Subcutaneous Adipocytes Zenbio	32.32, 31.18	11.99	24.91	18.45	3.06	16.34	301.47
Subcutaneous Adipose Zenbio	34.95, 33.78	2.2	4.69	3.45	0.96	52.36	180.37

Adrenal Gland Clontech	40, 40	0	0	0.00	0.61	81.97	0.00
Whole Brain Clontech	28.5, 28.04	140.11	187.98	164.05	7.24	6.91	1132.91
Fetal Brain Clontech	40, 40	0	0	0.00	0.48	103.95	0.00
Cerebellum Clontech	40, 40	0	0	0.00	2.17	23.04	0.00
Cervix	40, 40	0	0	0.00	2.42	20.66	0.00
Colon	34.82, 38.44	2.39	0.23	1.31	2.71	18.45	24.17
Endometrium	40, 35.09	0	2.01	1.01	0.73	68.21	68.55
Esophagus	40, 40	0	0	0.00	1.37	36.50	0.00
Heart Clontech	32.53, 34.31	10.45	3.32	6.89	1.32	37.88	260.80
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	40, 34.55	0	2.85	1.43	2.58	19.38	27.62
Jejunum	33.04, 34.86	7.51	2.33	4.92	6.60	7.58	37.27
Kidney	40, 40	0	0	0.00	2.12	23.58	0.00
Liver	35.81, 33.92	1.26	4.28	2.77	1.50	33.33	92.33
Fetal Liver Clontech	32.05, 40	14.25	0	7.13	10.40	4.81	34.25
Lung	40, 33.51	0	5.58	2.79	2.57	19.46	54.28
Mammary Gland Clontech	31.05, 30.69	27.02	34.2	30.61	13.00	3.85	117.73
Myometrium	33.29, 35.1	6.42	2	4.21	2.34	21.37	89.96
Omentum	34.44, 40	3.07	0	1.54	3.94	12.69	19.48
Ovary	32.59, 35.04	10.03	2.07	6.05	4.34	11.52	69.70
Pancreas	40, 40	0	0	0.00	0.81	61.80	0.00
Head of Pancreas	40, 40	0	0	0.00	1.57	31.85	0.00
Parotid Gland	34.63, 33.09	2.71	7.29	5.00	5.48	9.12	45.62
Placenta Clontech	32.77, 33.01	8.94	7.7	8.32	5.26	9.51	79.09
Prostate	40, 40	0	0	0.00	3.00	16.67	0.00
Rectum	40, 34.44	0	3.06	1.53	1.23	40.65	62.20
Salivary Gland Clontech	32.96, 40	7.94	0	3.97	7.31	6.84	27.15
Skeletal Muscle Clontech	40, 40	0	0	0.00	1.26	39.68	0.00
Skin	40, 33.46	0.6	5.75	3.18	1.21	41.32	131.20
Small Intestine Clontech	40, 40	0	0	0.00	0.98	51.07	0.00
Spleen	35.65, 35	1.4	2.13	1.77	4.92	10.16	17.94
Stomach	40, 34.73	0	2.54	1.27	2.73	18.32	23.26
Testis Clontech	40, 35.12	0	1.98	0.99	0.57	87.87	86.99
Thymus Clontech	32.44, 31.57	11.11	19.37	15.24	9.89	5.06	77.05
Thyroid	40, 40	0	0	0.00	2.77	18.05	0.00
Trachea Clontech	34.58, 33.56	2.79	5.4	4.10	9.71	5.15	21.09
Urinary Bladder	33.45, 33.34	5.8	6.21	6.01	5.47	9.14	54.89
Uterus	33.19, 32.41	6.82	11.32	9.07	5.34	9.36	84.93
genomic	25.47	981.57					
b-actin	26.87	398.61					
1.00E+05	18.24	100000					
1.00E+05	18.35	100000					
1.00E+04	21.53	10000					
1.00E+04	21.62	10000					

1.00E+03	25.17	1000					
1.00E+03	25.03	1000					
1.00E+02	30.53	100					
1.00E+02	30.49	100					
1.00E+01	30.85	10					
1.00E+01	40	10					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg1033026C1q	Reg number (GSK identifier)	Ct	Mean GOI copies	copies of mRNA detec- ted/50 ng total RNA	Sample	Fold Change in Disease Popula- tion
colon normal GW98-167	21941	27.03	397.15	794.30	colon normal	
colon tumor GW98-166	21940	29.53	91.39	182.78	colon tumor	-4.35
colon normal GW98-178	22080	30.3	57.81	115.62	colon normal	
colon tumor GW98-177	22060	29.31	103.84	207.68	colon tumor	1.80
colon normal GW98-561	23514	28.79	140.64	281.28	colon normal	
colon tumor GW98-560	23513	30.18	62.18	124.36	colon tumor	-2.26
colon normal GW98-894	24691	28.31	187.28	374.56	colon normal	
colon tumor GW98-893	24690	28.75	143.93	287.86	colon tumor	-1.30
lung normal GW98-3	20742	28.18	201.78	403.56	lung normal	
lung tumor GW98-2	20741	32.35	17.41	34.82	lung tumor	-11.59
lung normal GW97-179	20677	29.94	71.52	143.04	lung normal	
lung tumor GW97-178	20676	28.76	143.36	286.72	lung tumor	2.00
lung normal GW98-165	21922	28.69	149.49	298.98	lung normal	
lung tumor GW98-164	21921	31.28	32.63	65.26	lung tumor	-4.58
lung normal GW98-282	22584	31.42	30.07	60.14	lung normal	
lung tumor GW98-281	22583	30.33	56.83	113.66	lung tumor	1.89
breast normal GW00-392	28750	28.72	146.7	146.70	breast normal	
breast tumor GW00-391	28746	27.02	398.56	797.12	breast tumor	5.43
breast normal GW00-413	28798	30.95	39.63	39.63	breast normal	
breast tumor GW00-412	28797	30.58	49.03	98.06	breast tumor	2.47
breast normal GW00- 235:238	27592-95	32.53	15.6	15.60	breast normal	
breast tumor GW00- 231:234	27588-91	29.58	88.49	88.49	breast tumor	5.67
breast normal GW98-621	23656	27.5	300.39	600.78	breast normal	
breast tumor GW98-620	23655	29.28	105.43	210.86	breast tumor	-2.85
brain normal BB99-542	25507	30.67	46.59	93.18	brain normal	
brain normal BB99-406	25509	29.54	90.66	181.32	brain normal	
brain normal BB99-904	25546	31.13	35.58	71.16	brain normal	
brain stage 5 ALZ BB99- 874	25502	31.4	30.36	60.72	brain stage 5 ALZ	-1.90

brain stage 5 ALZ BB99-887	25503	28.39	177.94	355.88	brain stage 5 ALZ	3.09
brain stage 5 ALZ BB99-862	25504	28.92	130.19	260.38	brain stage 5 ALZ	2.26
brain stage 5 ALZ BB99-927	25542	28.2	198.98	397.96	brain stage 5 ALZ	3.45
CT lung KC	normal	31.24	33.37	66.74	CT lung	
lung 26 KC	normal	33.59	8.37	8.37	lung 26	
lung 27 KC	normal	37.8	0.7	0.70	lung 27	
lung 24 KC	COPD	34.56	4.73	4.73	lung 24	-4.39
lung 28 KC	COPD	35.39	2.91	2.91	lung 28	-7.13
lung 23 KC	COPD	34.74	4.26	4.26	lung 23	-4.87
lung 25 KC	normal	33.85	7.19	7.19	lung 25	
asthmatic lung ODO3112	29321	35.04	3.57	3.57	asthmatic lung	-5.81
asthmatic lung ODO3433	29323	32.44	16.48	32.96	asthmatic lung	1.59
asthmatic lung ODO3397	29322	29.4	98.44	196.88	asthmatic lung	9.49
asthmatic lung ODO4928	29325	31.1	36.23	72.46	asthmatic lung	3.49
endo cells KC	control	40	0	0.00	endo cells	
endo VEGF KC		40	0	0.00	endo VEGF	0.00
endo bFGF KC		35.4	2.89	2.89	endo bFGF	2.89
heart Clontech	normal	29.05	120.78	241.56	heart	
heart (T-1) ischemic	29417	26.23	633.79	1267.58	heart T-1	5.25
heart (T-14) non-obstructive DCM	29422	25.74	847.85	1695.70	heart T-14	7.02
heart (T-3399) DCM	29426	25.03	1289.37	2578.74	heart T-3399	10.68
adenoid GW99-269	26162	35.24	3.17	6.34	adenoid	
tonsil GW98-280	22582	31	38.35	76.70	tonsil	
T cells PC00314	28453	31.75	24.69	49.38	T cells	
PBMNC		40	0	0.00	PBMNC	
monocyte		40	0	0.00	monocyte	
B cells PC00665	28455	31.35	31.31	62.62	B cells	
dendritic cells 28441		32.81	13.25	26.50	dendritic cells	
neutrophils	28440	31.76	24.51	24.51	neutrophils	
eosinophils	28446	33.08	11.29	22.58	eosinophils	
BM unstim		36.9	1.19	1.19	BM unstim	
BM stim		38.86	0.38	0.38	BM stim	-3.13
osteо dif		37.77	0.72	0.72	osteо dif	0.72
osteо undif		40	0	0.00	osteо undif	
chondrocytes		33.14	10.88	27.20	chondrocytes	
OA Synovium IP12/01	29462	30.61	48.28	48.28	OA Synovium	
OA Synovium NP10/01	29461	27.5	300.97	601.94	OA Synovium	
OA Synovium NP57/00	28464	29.28	105.55	211.10	OA Synovium	
RA Synovium NP03/01	28466	30.18	62.3	124.60	RA Synovium	
RA Synovium NP71/00	28467	29.22	109.5	219.00	RA Synovium	
RA Synovium NP45/00	28475	30.06	66.71	133.42	RA Synovium	
OA bone (biobank)	29217	32.6	14.99	14.99	OA bone (biobank)	
OA bone Sample 1	J. Emory	30.48	52.25	104.50	OA bone	
OA bone Sample 2	J. Emory	32.31	17.76	35.52	OA bone	
Cartilage (pool)	Normal	30.45	53.05	106.10	Cartilage (pool)	

Cartilage (pool)	OA	30.81	43.01	86.02	Cartilage (pool)	-1.23
PBL uninfected	28441	30.19	61.92	123.84	PBL uninfected	
PBL HIV IIIB	28442	31.19	34.35	68.70	PBL HIV IIIB	-1.80
MRC5 uninfected (100%)	29158	30.19	62.02	124.04	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	31.13	35.48	70.96	MRC5 HSV strain F	-1.75
W12 cells	29179	32	21.32	42.64	W12 cells	
Keratinocytes	29180	33.3	9.92	19.84	Keratinocytes	
B-actin control		26.66	492.23			
genomic		24.83	1443.91			
1.00E+05		18.12	100000			
1.00E+05		18.12	100000			
1.00E+04		21.28	10000			
1.00E+04		21.31	10000			
1.00E+03		24.92	1000			
1.00E+03		24.9	1000			
1.00E+02		29.22	100			
1.00E+02		29.26	100			
1.00E+01		33.13	10			
1.00E+01		34.32	10			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			

Gene Name sbg1033026C1q

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-4.35
colon tumor	1.80
colon tumor	-2.26
colon tumor	-1.30
lung tumor	-11.59
lung tumor	2.00
lung tumor	-4.58
lung tumor	1.89
breast tumor	5.43
breast tumor	2.47
breast tumor	5.67
breast tumor	-2.85
brain stage 5 ALZ	-1.90
brain stage 5 ALZ	3.09
brain stage 5 ALZ	2.26
brain stage 5 ALZ	3.45
lung 24	-4.39
lung 28	-7.13
lung 23	-4.87
asthmatic lung	-5.81
asthmatic lung	1.59
asthmatic lung	9.49

asthmatic lung	3.49
endo VEGF	0.00
endo bFGF	2.89
heart T-1	5.25
heart T-14	7.02
heart T-3399	10.68
BM stim	-3.13
osteo dif	0.72
Cartilage (pool)	-1.23
PBL HIV IIIB	-1.80
MRC5 HSV strain F	-1.75

Gene Name sbg1003675Rnase

FAILED

5 **Gene Name sbg1015258PLM**

Low overall expression in normal and disease samples. Highest normal expression in the endometrium, hypothalamus, liver small intestine, and the testis. Highest disease expression in one of the breast normal/tumor pairs, one of the normal brain samples, two of the Alzheimer's disease brain samples, the B cells and the HSV-infected MRC5 cells. Downregulation in 1 of 4 lung tumor samples is sufficient to claim a role in cancer of the lung. Upregulation in 2 of 4 breast tumor samples indicates an involvement in cancer of the breast. Downregulation in 2 of 3 COPD samples and in 1 of 4 asthmatic lung samples implies a role in chronic obstructive pulmonary disease and asthma. Upregulation in the obstructive DCM heart sample suggests a potential role in cardiovascular disease. Downregulation in the stimulated bone marrow sample. Downregulation in the OA cartilage pool implicates this gene in osteoarthritis. Upregulation in the HSV-infected MRC5 cells suggests that this gene may be a host factor in HSV. Low expression in all immune cells except the B cells which show moderate expression.

Sample sbg1015258PLM	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detected/ 50 ng total RNA
Subcutaneous Adipocytes Zenbio	39.96, 39.32	0.39	0.73	0.56	3.06	16.34	9.15
Subcutaneous Adipose Zenbio	39.61, 37.77	0.62	1.84	1.23	0.96	52.36	64.40
Adrenal Gland Clontech	36.89, 37.65	3.12	1.98	2.55	0.61	81.97	209.02
Whole Brain Clontech	32.77, 33.06	36.18	30.37	33.28	7.24	6.91	229.80
Fetal Brain Clontech	38.01, 37.52	1.6	2.14	1.87	0.48	103.95	194.39
Cerebellum Clontech	38.34, 37.8	1.31	1.81	1.56	2.17	23.04	35.94
Cervix	36.9, 37.17	3.1	2.64	2.87	2.42	20.66	59.30
Colon	35.93, 37.95	5.51	1.66	3.59	2.71	18.45	66.14
Endometrium	34.62, 37.51	12.02	2.15	7.09	0.73	68.21	483.29
Esophagus	35.76, 37.39	6.1	2.31	4.21	1.37	36.50	153.47
Heart Clontech	36.78, 38.53	3.33	1.17	2.25	1.32	37.88	85.23
Hypothalamus	37.12, 36.52	2.71	3.87	3.29	0.32	155.28	510.87
Ileum	36.15, 36.19	4.84	4.72	4.78	2.58	19.38	92.64
Jejunum	34.6, 33.48	12.14	23.65	17.90	6.60	7.58	135.57
Kidney	37.16, 37.9	2.65	1.7	2.18	2.12	23.58	51.30

Liver	34.6, 36.06	12.13	5.11	8.62	1.50	33.33	287.33
Fetal Liver Clontech	34.32, 36.91	14.35	3.07	8.71	10.40	4.81	41.88
Lung	36.94, 35.31	3.02	7.98	5.50	2.57	19.46	107.00
Mammary Gland Clontech	38.03, 36.89	1.58	3.11	2.35	13.00	3.85	9.02
Myometrium	38.44, 38	1.24	1.6	1.42	2.34	21.37	30.34
Omentum	35.41, 35.38	7.51	7.64	7.58	3.94	12.69	96.13
Omentum							
Ovary	34.32, 34.36	14.4	14.07	14.24	4.34	11.52	164.00
Pancreas	36.44, 36.82	4.07	3.25	3.66	0.81	61.80	226.21
Head of Pancreas	37.54, 36.96	2.11	2.98	2.55	1.57	31.85	81.05
Parotid Gland	37.1, 35.46	2.75	7.29	5.02	5.48	9.12	45.80
Placenta Clontech	36.07, 35.36	5.08	7.74	6.41	5.26	9.51	60.93
Prostate	37.4, 37.82	2.3	1.79	2.05	3.00	16.67	34.08
Rectum	36.65, 37.39	3.59	2.32	2.96	1.23	40.65	120.12
Salivary Gland Clontech	38.55, 39.31	1.16	0.74	0.95	7.31	6.84	6.50
Skeletal Muscle Clontech	37.59, 36.87	2.06	3.15	2.61	1.26	39.68	103.37
Skin	38.36, 36.33	1.3	4.34	2.82	1.21	41.32	116.53
Small Intestine Clontech	36.05, 36.76	5.14	3.37	4.26	0.98	51.07	217.31
Spleen	37.62, 35.34	2.02	7.83	4.93	4.92	10.16	50.05
Stomach	35.8, 35.15	5.95	8.76	7.36	2.73	18.32	134.71
Testis Clontech	35.14, 37.08	8.82	2.77	5.80	0.57	87.87	509.23
Thymus Clontech	35.89, 35.06	5.65	9.22	7.44	9.89	5.06	37.59
Thyroid	37.59, 37.2	2.06	2.59	2.33	2.77	18.05	41.97
Trachea Clontech	37.52, 37.95	2.14	1.66	1.90	9.71	5.15	9.78
Urinary Bladder	37.47, 35.44	2.2	7.38	4.79	5.47	9.14	43.78
Uterus	34.17, 34.12	15.66	16.17	15.92	5.34	9.36	149.02
genomic	27.03	1097.52					
b-actin	27.23	974.77					
1.00E+05	19.25	100000					
1.00E+05	19.2	100000					
1.00E+04	22.99	10000					
1.00E+04	22.94	10000					
1.00E+03	27.09	1000					
1.00E+03	27.28	1000					
1.00E+02	31.49	100					
1.00E+02	31.46	100					
1.00E+01	37.86	10					
1.00E+01	35.45	10					
1.00E-00	37.08	1					
1.00E-00	37.4	1					
NTC	36.45	-1					
NTC	36.15	-1					

Sample sbg1015258PLM	Reg number	Ct	Mean GOI	copies of mRNA	Sample	Fold Change in
-------------------------	---------------	----	-------------	-------------------	--------	-------------------

	(GSK identifier)		copies	detected/ 50 ng total RNA		Disease Population
colon normal GW98-167	21941	35.4	9.91	19.82	colon normal	
colon tumor GW98-166	21940	35.13	11.61	23.22	colon tumor	1.17
colon normal GW98-178	22080	34.84	13.83	27.66	colon normal	
colon tumor GW98-177	22060	35	12.59	25.18	colon tumor	-1.10
colon normal GW98-561	23514	35.48	9.4	18.80	colon normal	
colon tumor GW98-560	23513	36.2	6.14	12.28	colon tumor	-1.53
colon normal GW98-894	24691	34.53	16.62	33.24	colon normal	
colon tumor GW98-893	24690	34.29	19.25	38.50	colon tumor	1.16
lung normal GW98-3	20742	34.53	16.69	33.38	lung normal	
lung tumor GW98-2	20741	37.87	2.25	4.50	lung tumor	-7.42
lung normal GW97-179	20677	34.59	16.02	32.04	lung normal	
lung tumor GW97-178	20676	34.45	17.43	34.86	lung tumor	1.09
lung normal GW98-165	21922	33.89	24.39	48.78	lung normal	
lung tumor GW98-164	21921	35.48	9.43	18.86	lung tumor	-2.59
lung normal GW98-282	22584	36.67	4.62	9.24	lung normal	
lung tumor GW98-281	22583	37.87	2.26	4.52	lung tumor	-2.04
breast normal GW00-392	28750	34.17	20.64	20.64	breast normal	
breast tumor GW00-391	28746	33.54	30.09	60.18	breast tumor	2.92
breast normal GW00-413	28798	39.05	1.11	1.11	breast normal	
breast tumor GW00-412	28797	35.01	12.46	24.92	breast tumor	22.45
breast normal GW00-235:238	27592-95	40	0.55	0.55	breast normal	
breast tumor GW00-231:234	27588-91	35.07	12.02	12.02	breast tumor	21.85
breast normal GW98-621	23656	33	41.58	83.16	breast normal	
breast tumor GW98-620	23655	33.05	40.47	80.94	breast tumor	-1.03
brain normal BB99-542	25507	32.73	48.93	97.86	brain normal	
brain normal BB99-406	25509	33.97	23.34	46.68	brain normal	
brain normal BB99-904	25546	37.88	2.24	4.48	brain normal	
brain stage 5 ALZ BB99-874	25502	35.92	7.25	14.50	brain stage 5 ALZ	-3.43
brain stage 5 ALZ BB99-887	25503	31.57	97.99	195.98	brain stage 5 ALZ	3.95
brain stage 5 ALZ BB99-862	25504	36.08	6.57	13.14	brain stage 5 ALZ	-3.78
brain stage 5 ALZ BB99-927	25542	32.66	50.98	101.96	brain stage 5 ALZ	2.05
CT lung KC	normal	37.37	3.04	6.08	CT lung	
lung 26 KC	normal				lung 26	
lung 27 KC	normal	38.52	1.52	1.52	lung 27	
lung 24 KC	COPD	40	0	0.00	lung 24	-3.07
lung 28 KC	COPD	37.4	2.99	2.99	lung 28	-1.03
lung 23 KC	COPD	39.56	0.82	0.82	lung 23	-3.74
lung 25 KC	normal	38.43	1.61	1.61	lung 25	

asthmatic lung ODO3112	29321	39.45	0.88	0.88	asthmatic lung	-3.49
asthmatic lung ODO3433	29323	36.48	5.19	10.38	asthmatic lung	3.38
asthmatic lung ODO3397	29322	35.56	8.99	17.98	asthmatic lung	5.86
asthmatic lung ODO4928	29325	37.06	3.66	7.32	asthmatic lung	2.38
endo cells KC	control	39.29	0.96	0.96	endo cells	
endo VEGF KC		37.65	2.57	2.57	endo VEGF	2.68
endo bFGF KC		40	0.48	0.48	endo bFGF	-2.00
heart Clontech	normal	40	0.68	1.36	heart	
heart (T-1) ischemic	29417	39.29	0.96	1.92	heart T-1	1.41
heart (T-14) non- obstructive DCM	29422	38.21	1.84	3.68	heart T-14	2.71
heart (T-3399) DCM	29426	35.49	9.35	18.70	heart T-3399	13.75
adenoid GW99-269	26162	39.63	0.78	1.56	adenoid	
tonsil GW98-280	22582	34.5	16.92	33.84	tonsil	
T cells PC00314	28453	34.57	16.25	32.50	T cells	
PBMNC		37.32	3.13	3.13	PBMNC	
monocyte		37.74	2.44	4.88	monocyte	
B cells PC00665	28455	33.32	34.36	68.72	B cells	
dendritic cells 28441		37.29	3.19	6.38	dendritic cells	
neutrophils	28440	36.01	6.85	6.85	neutrophils	
eosinophils	28446	35.38	9.98	19.96	eosinophils	
BM unstim		37.44	2.91	2.91	BM unstim	
BM stim		40	0.53	0.53	BM stim	-5.49
osteo dif		38.15	1.91	1.91	osteo dif	-1.38
osteo undif		37.6	2.64	2.64	osteo undif	
chondrocytes		36.1	6.51	16.28	chondrocytes	
OA Synovium IP12/01	29462	35.58	8.86	8.86	OA Synovium	
OA Synovium NP10/01	29461	35.46	9.54	19.08	OA Synovium	
OA Synovium NP57/00	28464	34.05	22.23	44.46	OA Synovium	
RA Synovium NP03/01	28466	37.92	2.19	4.38	RA Synovium	
RA Synovium NP71/00	28467	35.39	9.92	19.84	RA Synovium	
RA Synovium NP45/00	28475	35.03	12.37	24.74	RA Synovium	
OA bone (biobank)	29217	39.98	0.67	0.67	OA bone (biobank)	
OA bone Sample 1	J. Emory	36.06	6.68	13.36	OA bone	
OA bone Sample 2	J. Emory	39.89	0.67	1.34	OA bone	
Cartilage (pool)	Normal	35.57	8.92	17.84	Cartilage (pool)	
Cartilage (pool)	OA	39.5	0.85	1.70	Cartilage (pool)	-10.49
PBL uninfected	28441	36.65	4.67	9.34	PBL uninfected	
PBL HIV IIIB	28442	36.94	3.92	7.84	PBL HIV IIIB	-1.19
MRC5 uninfected (100%)	29158	37.54	2.74	5.48	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	33.19	37.18	74.36	MRC5 HSV strain F	13.57
W12 cells	29179	37.23	3.3	6.60	W12 cells	
Keratinocytes	29180	37.18	3.4	6.80	Keratinocytes	

B-actin control		27.26	1296.8 7			
genomic		27.2	1345.3 4			
1.00E+05		19.44	100000			
1.00E+05		19.81	100000			
1.00E+04		23.63	10000			
1.00E+04		23.41	10000			
1.00E+03		27.77	1000			
1.00E+03		27.89	1000			
1.00E+02		32.32	100			
1.00E+02		32.3	100			
1.00E+01		36.77	10			
1.00E+01		36.39	10			
1.00E-00		38.06	1			
1.00E-00		37.56	1			
NTC		38.18	-1			

Gene Name sbg1015258PLM

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	1.17
colon tumor	-1.10
colon tumor	-1.53
colon tumor	1.16
lung tumor	-7.42
lung tumor	1.09
lung tumor	-2.59
lung tumor	-2.04
breast tumor	2.92
breast tumor	22.45
breast tumor	21.85
breast tumor	-1.03
brain stage 5 ALZ	-3.43
brain stage 5 ALZ	3.95
brain stage 5 ALZ	-3.78
brain stage 5 ALZ	2.05
lung 24	-3.07
lung 28	-1.03
lung 23	-3.74
asthmatic lung	-3.49
asthmatic lung	3.38
asthmatic lung	5.86
asthmatic lung	2.38
endo VEGF	2.68
endo bFGF	-2.00

heart T-1	1.41
heart T-14	2.71
heart T-3399	13.75
BM stim	-5.49
osteo dif	-1.38
Cartilage (pool)	-10.49
PBL HIV IIIB	-1.19
MRC5 HSV strain F	13.57

Gene Name sbg1003328IG (Taqman)

5 Moderate overall expression. Highest normal expression in whole brain, fetal brain, and cerebellum with slightly lower levels of expression in the colon and mammary gland. Highest disease expression in the colon and lung tumor pairs as well as the normal and Alzheimer's brain. Significant upregulation in 2 of 4 breast tumor samples with slight upregulation in 1 of 4 breast tumor samples implicates this gene in breast cancer. Downregulation in 3 of 3 COPD samples may suggest an involvement in chronic obstructive pulmonary disease. Downregulation in 1 of 4 asthma samples suggests a potential role for this gene in asthma. Downregulation in the HSV-infected 10 MRC5 cells suggests that this gene may play a role in HSV. High expression in 3 of 3 OA synovium samples, 3 of 3 RA synovium samples, 2 of 2 OA bone samples, and corroborating high expression in the T cells and B cells implicates this gene in osteoarthritis and rheumatoid arthritis.

Sample sbg1003328IG	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detected /50 ng total RNA
Subcutaneous Adipocytes Zenbio	32.35, 32.1	109.15	127.12	118.14	3.06	16.34	1930.31
Subcutaneous Adipose Zenbio	37.92, 40	3.84	0	1.92	0.96	52.36	100.52
Adrenal Gland Clontech	38.07, 35.73	3.5	14.32	8.91	0.61	81.97	730.33
Whole Brain Clontech	22.72, 23.09	35640.5	28576.52	32108.51	7.24	6.91	221743. 85
Fetal Brain Clontech	33.39, 34.06	58.43	39.04	48.74	0.48	103.95	5066.01
Cerebellum Clontech	31.32, 31.02	202.49	242.95	222.72	2.17	23.04	5131.80
Cervix	36.36, 35.6	9.78	15.49	12.64	2.42	20.66	261.05
Colon	30.74, 32.11	286.9	125.78	206.34	2.71	18.45	3807.01
Endometrium	34.58, 36.01	28.47	12.11	20.29	0.73	68.21	1384.04
Esophagus	37.54, 36.05	4.82	11.78	8.30	1.37	36.50	302.92
Heart Clontech	36.23, 36.85	10.56	7.3	8.93	1.32	37.88	338.26
Hypothalamus	40, 36.96	0	6.81	3.41	0.32	155.28	528.73
Ileum	34.79, 34.48	25.09	30.4	27.75	2.58	19.38	537.69
Jejunum	30.14, 31.02	412.72	242.47	327.60	6.60	7.58	2481.78
Kidney	33.94, 34.61	41.89	28.12	35.01	2.12	23.58	825.59
Liver	36.11, 35.38	11.41	17.61	14.51	1.50	33.33	483.67
Fetal Liver Clontech	30.24, 30.27	388.12	381.28	384.70	10.40	4.81	1849.52
Lung	35.59, 35.09	15.59	20.98	18.29	2.57	19.46	355.74
Mammary Gland Clontech	29.21, 28.52	718.74	1090.18	904.46	13.00	3.85	3478.69

Myometrium	33.7, 34.11	48.42	37.85	43.14	2.34	21.37	921.69
Omentum	33.83, 33.57	44.75	52.27	48.51	3.94	12.69	615.61
Ovary	32.47, 32.34	101.42	109.96	105.69	4.34	11.52	1217.63
Pancreas	38.16, 40	3.31	0	1.66	0.81	61.80	102.29
Head of Pancreas	40, 36.68	0	8.07	4.04	1.57	31.85	128.50
Parotid Gland	31.68, 31.03	162.92	241.11	202.02	5.48	9.12	1843.20
Placenta Clontech	30.48, 30.82	335.37	274.53	304.95	5.26	9.51	2898.76
Prostate	33.39, 32.15	58.39	122.82	90.61	3.00	16.67	1510.08
Rectum	35.95, 35.32	12.5	18.32	15.41	1.23	40.65	626.42
Salivary Gland Clontech	31.25, 30.65	211.88	303.2	257.54	7.31	6.84	1761.56
Skeletal Muscle Clontech	36.61, 37.62	8.44	4.6	6.52	1.26	39.68	258.73
Skin	36.37, 36.08	9.71	11.56	10.64	1.21	41.32	439.46
Small Intestine Clontech	36.74, 34.51	7.79	29.79	18.79	0.98	51.07	959.65
Spleen	34.78, 35.63	25.25	15.18	20.22	4.92	10.16	205.44
Stomach	40, 35.13	0.88	20.56	10.72	2.73	18.32	196.34
Testis Clontech	35.01, 39.68	22.07	1.33	11.70	0.57	87.87	1028.12
Thymus Clontech	29.15, 29.2	749.23	724.61	736.92	9.89	5.06	3725.58
Thyroid	32.02, 32.14	133.23	123.77	128.50	2.77	18.05	2319.49
Trachea Clontech	31.28, 30.17	207.67	405.04	306.36	9.71	5.15	1577.52
Urinary Bladder	33.07, 32.91	70.6	78.07	74.34	5.47	9.14	679.48
Uterus	33.01, 33.15	73.56	67.48	70.52	5.34	9.36	660.30
genomic	29.15	746.77					
b-actin	30.2	397.52					
1.00E+05	21.06	100000					
1.00E+05	20.94	100000					
1.00E+04	25.06	10000					
1.00E+04	24.54	10000					
1.00E+03	28.32	1000					
1.00E+03	28.77	1000					
1.00E+02	33	100					
1.00E+02	32.74	100					
1.00E+01	35.9	10					
1.00E+01	40	0					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg1003328IG	Reg number (GSK identifie r)	Ct	Mean GOI copies	copies of mRNA detected/ 50 ng total RNA	Sample	Fold Change in Disease Populati on
colon normal GW98-167	21941	24.26	15509.01	31018.02	colon normal	

colon tumor GW98-166	21940	24.5	13727.44	27454.88	colon tumor	-1.13
colon normal GW98-178	22080	28.01	2276.97	4553.94	colon normal	
colon tumor GW98-177	22060	27.11	3618.2	7236.40	colon tumor	1.59
colon normal GW98-561	23514	24.47	13993.67	27987.34	colon normal	
colon tumor GW98-560	23513	25.32	9040.47	18080.94	colon tumor	-1.55
colon normal GW98-894	24691	24.17	16251.61	32503.22	colon normal	
colon tumor GW98-893	24690	25.15	9872.46	19744.92	colon tumor	-1.65
lung normal GW98-3	20742	24.4	14498.52	28997.04	lung normal	
lung tumor GW98-2	20741	24.66	12640.32	25280.64	lung tumor	-1.15
lung normal GW97-179	20677	24.12	16680.84	33361.68	lung normal	
lung tumor GW97-178	20676	24.69	12468.91	24937.82	lung tumor	-1.34
lung normal GW98-165	21922	25.09	10168.18	20336.36	lung normal	
lung tumor GW98-164	21921	25.49	8296.37	16592.74	lung tumor	-1.23
lung normal GW98-282	22584	26.85	4131.52	8263.04	lung normal	
lung tumor GW98-281	22583	26.59	4702	9404.00	lung tumor	1.14
breast normal GW00-392	28750	25.9	6719.98	6719.98	breast normal	
breast tumor GW00-391	28746	25.04	10402.11	20804.22	breast tumor	3.10
breast normal GW00-413	28798	32.51	226.94	226.94	breast normal	
breast tumor GW00-412	28797	26.37	5261.73	10523.46	breast tumor	46.37
breast normal GW00-235:238	27592-95	34.58	78.63	78.63	breast normal	
breast tumor GW00-231:234	27588-91	28.45	1812.86	1812.86	breast tumor	23.06
breast normal GW98-621	23656	25.26	9289.36	18578.72	breast normal	
breast tumor GW98-620	23655	25.66	7579.13	15158.26	breast tumor	-1.23
brain normal BB99-542	25507	22.52	37845.47	75690.94	brain normal	
brain normal BB99-406	25509	23.07	28574.8	57149.60	brain normal	
brain normal BB99-904	25546	23.85	19214.49	38428.98	brain normal	
brain stage 5 ALZ BB99-874	25502	25.98	6442.51	12885.02	brain stage 5 ALZ	-4.43
brain stage 5 ALZ BB99-887	25503	23.19	26936.06	53872.12	brain stage 5 ALZ	-1.06
brain stage 5 ALZ BB99-862	25504	23.42	23948.83	47897.66	brain stage 5 ALZ	-1.19
brain stage 5 ALZ BB99-927	25542	24.15	16419.33	32838.66	brain stage 5 ALZ	-1.74
CT lung KC	normal	25.63	7714.35	15428.70	CT lung	
lung 26 KC	normal	32.34	247.99	247.99	lung 26	
lung 27 KC	normal	33.71	122.77	122.77	lung 27	
lung 24 KC	COPD	32.47	231.47	231.47	lung 24	-17.21
lung 28 KC	COPD	32.63	213.14	213.14	lung 28	-18.70
lung 23 KC	COPD	31.2	444.95	444.95	lung 23	-8.96
lung 25 KC	normal	33.46	139.4	139.40	lung 25	
asthmatic lung ODO3112	29321	31.6	360.95	360.95	asthmatic lung	-11.04
asthmatic lung ODO3433	29323	28.66	1634.71	3269.42	asthmatic lung	-1.22
asthmatic lung	29322	26.36	5294.26	10588.52	asthmatic lung	2.66

ODO3397						
asthmatic lung ODO4928	29325	28.23	2033.93	4067.86	asthmatic lung	1.02 ..
endo cells KC	control	30.68	580.47	580.47	endo cells	
endo VEGF KC		31.08	471.26	471.26	endo VEGF	-1.23
endo bFGF KC		32.25	259.04	259.04	endo bFGF	-2.24
heart Clontech	normal	27.28	3312.82	6625.64	heart	
heart (T-1) ischemic	29417	27.48	2979.22	5958.44	heart T-1	-1.11
heart (T-14) non- obstructive DCM	29422	27.74	2613.8	5227.60	heart T-14	-1.27
heart (T-3399) DCM	29426	26.66	4541.38	9082.76	heart T-3399	1.37
adenoid GW99-269	26162	27.83	2493.31	4986.62	adenoid	
tonsil GW98-280	22582	25.68	7506.04	15012.08	tonsil	
T cells PC00314	28453	27.18	3487.61	6975.22	T cells	
PBMNC		32.6	216.73	216.73	PBMNC	
monocyte		32.27	256.89	513.78	monocyte	
B cells PC00665	28455	27.83	2492.12	4984.24	B cells	
dendritic cells 28441		26.67	4528.97	9057.94	dendritic cells	
neutrophils	28440	28.4	1862.35	1862.35	neutrophils	
eosinophils	28446	31.69	344.59	689.18	eosinophils	
BM unstim		32.04	289.03	289.03	BM unstim	
BM stim		30.59	607.18	607.18	BM stim	2.10
osteо dif		28.43	1831.57	1831.57	osteо dif	3.42
osteо undif		30.83	536	536.00	osteо undif	
chondrocytes		26.74	4368.46	10921.15	chondrocytes	
OA Synovium IP12/01	29462	27.91	2391.03	2391.03	OA Synovium	
OA Synovium NP10/01	29461	27.4	3109.93	6219.86	OA Synovium	
OA Synovium NP57/00	28464	27.05	3729.47	7458.94	OA Synovium	
RA Synovium NP03/01	28466	25.53	8116.96	16233.92	RA Synovium	
RA Synovium NP71/00	28467	26.06	6167.42	12334.84	RA Synovium	
RA Synovium NP45/00	28475	25.35	8888.66	17777.32	RA Synovium	
OA bone (biobank)	29217	30.23	729.87	729.87	OA bone (biobank)	
OA bone Sample 1	J. Emory	27.65	2743.38	5486.76	OA bone	
OA bone Sample 2	J. Emory	28.02	2258.96	4517.92	OA bone	
Cartilage (pool)	Normal	25.82	7006.64	14013.28	Cartilage (pool)	
Cartilage (pool)	OA	27.22	3408.61	6817.22	Cartilage (pool)	-2.06
PBL uninfected	28441	24.24	15680.49	31360.98	PBL uninfected	
PBL HIV IIIB	28442	25.43	8521.98	17043.96	PBL HIV IIIB	-1.84
MRC5 uninfected (100%)	29158	25.58	7922.19	15844.38	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	32.02	291.12	582.24	MRC5 HSV strain F	-27.21
W12 cells	29179	26.03	6269.24	12538.48	W12 cells	
Keratinocytes	29180	25.43	8538.15	17076.30	Keratinocytes	
B-actin control		29.74	938.61			
genomic		28.79	1522.16			
1.00E+05		20.84	100000			
1.00E+05		21.4	100000			

1.00E+04		24.5	10000				
1.00E+04		25.2	10000				
1.00E+03		28.45	1000				
1.00E+03		29.25	1000				
1.00E+02		35.34	100				
1.00E+02		33.61	100				
1.00E+01		38.95	10				
1.00E+01		40	0				
1.00E-00		40	0				
1.00E-00		40	0				
NTC		40	0				

Gene Name sbg1003328IG

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-1.13
colon tumor	1.59
colon tumor	-1.55
colon tumor	-1.65
lung tumor	-1.15
lung tumor	-1.34
lung tumor	-1.23
lung tumor	1.14
breast tumor	3.10
breast tumor	46.37
breast tumor	23.06
breast tumor	-1.23
brain stage 5 ALZ	-4.43
brain stage 5 ALZ	-1.06
brain stage 5 ALZ	-1.19
brain stage 5 ALZ	-1.74
lung 24	-17.21
lung 28	-18.70
lung 23	-8.96
asthmatic lung	-11.04
asthmatic lung	-1.22
asthmatic lung	2.66
asthmatic lung	1.02
endo VEGF	-1.23
endo bFGF	-2.24
heart T-1	-1.11
heart T-14	-1.27
heart T-3399	1.37
BM stim	2.10
osteо dif	3.42

Cartilage (pool)	-2.06
PBL HIV IIIB	-1.84
MRC5 HSV strain F	-27.21

Gene Name sbg1020829SGLT

5 Low overall expression in normal and disease samples. Highest normal expression in the whole brain, kidney, and thymus. Highest disease expression in the adenoid, tonsil, T cells, B cells, and eosinophils. Highly immune cell specific. Downregulation in 1 of 4 lung tumor samples and upregulation in 1 of 4 breast tumor samples indicates involvement in cancers of the lung and breast. Upregulation in 3 of 4 AD brain samples suggests an involvement in Alzheimer's disease. Downregulation in 3 of 3 COPD samples implies a role in chronic obstructive pulmonary disease. Downregulation in the stimulated bone marrow sample. Upregulation in the 10 differentiated osteoblast sample. Upregulation in the HSV-infected MRC5 cells suggests that this gene may be a host factor in HSV. Moderate to high expression in the OA and RA samples indicates a potential role in osteoarthritis and rheumatoid arthritis.

Sample sbg1020829SGLT	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detecte d/50 ng total RNA
Subcutaneous Adipocytes Zenbio	37.07, 40	7.33	0	3.67	3.06	16.34	59.89
Subcutaneous Adipose Zenbio	40, 40	0	0	0.00	0.96	52.36	0.00
Adrenal Gland Clontech	40, 40	0	0	0.00	0.61	81.97	0.00
Whole Brain Clontech	32.13, 32.38	138.5	119.48	128.99	7.24	6.91	890.81
Fetal Brain Clontech	40, 40	0	0	0.00	0.48	103.95	0.00
Cerebellum Clontech	40, 40	0	0	0.00	2.17	23.04	0.00
Cervix	36.13, 40	12.82	0	6.41	2.42	20.66	132.44
Colon	36.93, 36.84	7.97	8.41	8.19	2.71	18.45	151.11
Endometrium	37.45, 37.41	5.84	5.98	5.91	0.73	68.21	403.14
Esophagus	40, 40	0	0	0.00	1.37	36.50	0.00
Heart Clontech	40, 40	0	0	0.00	1.32	37.88	0.00
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	36.53, 35.17	10.09	22.67	16.38	2.58	19.38	317.44
Jejunum	40, 35.73	0	16.2	8.10	6.60	7.58	61.36
Kidney	31.93, 31.01	155.27	269.39	212.33	2.12	23.58	5007.78
Liver	36.1, 35.88	13.05	14.82	13.94	1.50	33.33	464.50
Fetal Liver Clontech	35.06, 34.36	24.26	36.78	30.52	10.40	4.81	146.73
Lung	37.24, 40	6.63	0	3.32	2.57	19.46	64.49
Mammary Gland Clontech	34.25, 34.21	39.27	40.17	39.72	13.00	3.85	152.77
Myometrium	38.48, 35.31	3.16	20.87	12.02	2.34	21.37	256.73
Omentum	40, 38.91	0	2.45	1.23	3.94	12.69	15.55
Ovary	37.87, 37.06	4.56	7.37	5.97	4.34	11.52	68.72
Pancreas	40, 40	0	0	0.00	0.81	61.80	0.00
Head of Pancreas	40, 40	0	0	0.00	1.57	31.85	0.00

Parotid Gland	36.06, 37.07	13.32	7.31	10.32	5.48	9.12	94.11
Placenta Clontech	35.98, 38.73	13.96	2.72	8.34	5.26	9.51	79.28
Prostate	40, 40	0	0	0.00	3.00	16.67	0.00
Rectum	40, 40	0	0	0.00	1.23	40.65	0.00
Salivary Gland Clontech	37.05, 37.06	7.4	7.36	7.38	7.31	6.84	50.48
Skeletal Muscle Clontech	40, 40	0	0	0.00	1.26	39.68	0.00
Skin	40, 40	0	0	0.00	1.21	41.32	0.00
Small Intestine Clontech	40, 40	0	0	0.00	0.98	51.07	0.00
Spleen	35.62, 35.72	17.34	16.35	16.85	4.92	10.16	171.19
Stomach	40, 40	0	1.61	0.81	2.73	18.32	14.74
Testis Clontech	40, 40	0	0	0.00	0.57	87.87	0.00
Thymus Clontech	31.3, 31.09	226.24	257.15	241.70	9.89	5.06	1221.92
Thyroid	40, 40	0	0	0.00	2.77	18.05	0.00
Trachea Clontech	36.6, 36.64	9.68	9.44	9.56	9.71	5.15	49.23
Urinary Bladder	40, 40	0	0	0.00	5.47	9.14	0.00
Uterus	34.64, 36.65	31.06	9.41	20.24	5.34	9.36	189.47
genomic	29.07	853.08					
b-actin	27.08	2793.5					
1.00E+05	20.85	100000					
1.00E+05	21.11	100000					
1.00E+04	24.81	10000					
1.00E+04	24.95	10000					
1.00E+03	28.39	1000					
1.00E+03	28.9	1000					
1.00E+02	34.1	100					
1.00E+02	32.86	100					
1.00E+01	35.52	10					
1.00E+01	40	0					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg1020829SGLT	Reg number (GSK identifier)	Ct	Mean GOI copies	copies of mRNA detected/ 50 ng total RNA	Sample	Fold Change in Disease Populat ion
colon normal GW98-167	21941	31.06	206.55	413.10	colon normal	
colon tumor GW98-166	21940	31.18	193.59	387.18	colon tumor	-1.07
colon normal GW98-178	22080	30.74	244.37	488.74	colon normal	
colon tumor GW98-177	22060	30.37	299.28	598.56	colon tumor	1.22
colon normal GW98-561	23514	29.31	527.04	1054.08	colon normal	
colon tumor GW98-560	23513	31.86	134.48	268.96	colon tumor	-3.92

colon normal GW98-894	24691	31.84	135.33	270.66	colon normal	
colon tumor GW98-893	24690	31.9	131.57	263.14	colon tumor	-1.03
lung normal GW98-3	20742	28.81	689.14	1378.28	lung normal	
lung tumor GW98-2	20741	31.91	130.71	261.42	lung tumor	-5.27
lung normal GW97-179	20677	30.04	356.26	712.52	lung normal	
lung tumor GW97-178	20676	29.05	605.73	1211.46	lung tumor	1.70
lung normal GW98-165	21922	28.42	852.41	1704.82	lung normal	
lung tumor GW98-164	21921	30.51	277.13	554.26	lung tumor	-3.08
lung normal GW98-282	22584	31.23	188.34	376.68	lung normal	
lung tumor GW98-281	22583	30.46	285	570.00	lung tumor	1.51
breast normal GW00-392	28750	31.14	197.15	197.15	breast normal	
breast tumor GW00-391	28746	32.15	114.65	229.30	breast tumor	1.16
breast normal GW00-413	28798	34.87	26.64	26.64	breast normal	
breast tumor GW00-412	28797	31.83	136.42	272.84	breast tumor	10.24
breast normal GW00-235:238	27592-95	36.34	12.09	12.09	breast normal	
breast tumor GW00-231:234	27588-91	33.48	56.11	56.11	breast tumor	4.64
breast normal GW98-621	23656	32.39	100.78	201.56	breast normal	
breast tumor GW98-620	23655	31.4	171.82	343.64	breast tumor	1.70
brain normal BB99-542	25507	34.49	32.75	65.50	brain normal	
brain normal BB99-406	25509	34.01	42.2	84.40	brain normal	
brain normal BB99-904	25546	36.17	13.3	26.60	brain normal	
brain stage 5 ALZ BB99-874	25502	31.16	195.23	390.46	brain stage 5 ALZ	6.64
brain stage 5 ALZ BB99-887	25503	31.56	157.33	314.66	brain stage 5 ALZ	5.35
brain stage 5 ALZ BB99-862	25504	32.62	89.2	178.40	brain stage 5 ALZ	3.03
brain stage 5 ALZ BB99-927	25542	33.26	63.43	126.86	brain stage 5 ALZ	2.16
CT lung KC	normal	30.82	234.88	469.76	CT lung	
lung 26 KC	normal	30.21	325.42	325.42	lung 26	
lung 27 KC	normal	36.89	9	9.00	lung 27	
lung 24 KC	COPD	36.17	13.24	13.24	lung 24	-15.84
lung 28 KC	COPD	38.38	4.06	4.06	lung 28	-51.66
lung 23 KC	COPD	35.53	18.67	18.67	lung 23	-11.23
lung 25 KC	normal	34.37	34.83	34.83	lung 25	
asthmatic lung ODO3112	29321	33.65	51.41	51.41	asthmatic lung	-4.08
asthmatic lung ODO3433	29323	30.62	260.95	521.90	asthmatic lung	2.49
asthmatic lung ODO3397	29322	31.31	180.14	360.28	asthmatic lung	1.72
asthmatic lung ODO4928	29325	31.14	197.09	394.18	asthmatic lung	1.88
endo cells KC	control	32.56	92.23	92.23	endo cells	
endo VEGF KC		33.29	62.39	62.39	endo VEGF	-1.48
endo bFGF KC		32.55	92.65	92.65	endo bFGF	1.00
heart Clontech	normal	33.17	66.25	132.50	heart	
heart (T-1) ischemic	29417	33.07	70.16	140.32	heart T-1	1.06
heart (T-14) non-obstructive DCM	29422	34.64	30.13	60.26	heart T-14	-2.20
heart (T-3399) DCM	29426	32.53	93.63	187.26	heart T-3399	1.41

adenoid GW99-269	26162	28.92	650.55	1301.10	adenoid	
tonsil GW98-280	22582	27.11	1719.42	3438.84	tonsil	
T cells PC00314	28453	28.05	1037.04	2074.08	T cells	
PBMNC		36.57	10.71	10.71	PBMNC	
monocyte		33.22	64.68	129.36	monocyte	
B cells PC00665	28455	27.07	1757.79	3515.58	B cells	
dendritic cells 28441		33.77	48.05	96.10	dendritic cells	
neutrophils	28440	30.71	248.56	248.56	neutrophils	
eosinophils	28446	27.3	1549.7	3099.40	eosinophils	
BM unstim		30.06	352.26	352.26	BM unstim	
BM stim		34.14	39.39	39.39	BM stim	-8.94
osteо dif		36.29	12.42	12.42	osteо dif	12.42
osteо undif		40	0	0.00	osteо undif	
chondrocytes		32.11	117.39	293.48	chondrocytes	
OA Synovium IP12/01	29462	30.17	331.7	331.70	OA Synovium	
OA Synovium NP10/01	29461	32.05	120.98	241.96	OA Synovium	
OA Synovium NP57/00	28464	30.13	339.03	678.06	OA Synovium	
RA Synovium NP03/01	28466	31.28	182.96	365.92	RA Synovium	
RA Synovium NP71/00	28467	29.81	402.34	804.68	RA Synovium	
RA Synovium NP45/00	28475	30.22	324.14	648.28	RA Synovium	
OA bone (biobank)	29217	28.45	837.78	837.78	OA bone (biobank)	
OA bone Sample 1	J. Emory	30.21	325.03	650.06	OA bone	
OA bone Sample 2	J. Emory	29.8	406	812.00	OA bone	
Cartilage (pool)	Normal	31.09	203.28	406.56	Cartilage (pool)	
Cartilage (pool)	OA	32.18	112.77	225.54	Cartilage (pool)	-1.80
PBL uninfected	28441	29.17	567.22	1134.44	PBL uninfected	
PBL HIV IIIB	28442	30.73	246.69	493.38	PBL HIV IIIB	-2.30
MRC5 uninfected (100%)	29158	35.54	18.61	37.22	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	30.54	272.3	544.60	MRC5 HSV strain F	14.63
W12 cells	29179	32.28	107.25	214.50	W12 cells	
Keratinocytes	29180	34.27	36.84	73.68	Keratinocytes	
B-actin control		27.03	1793.92			
genomic		27.77	1204.8			
1.00E+05		19.84	100000			
1.00E+05		19.86	100000			
1.00E+04		23.46	10000			
1.00E+04		23.8	10000			
1.00E+03		27.45	1000			
1.00E+03		27.94	1000			
1.00E+02		33.86	100			
1.00E+02		31.41	100			
1.00E+01		40	0			
1.00E+01		36.88	10			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			

Gene Name sbg1020829SGLT

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-1.07
colon tumor	1.22
colon tumor	-3.92
colon tumor	-1.03
lung tumor	-5.27
lung tumor	1.70
lung tumor	-3.08
lung tumor	1.51
breast tumor	1.16
breast tumor	10.24
breast tumor	4.64
breast tumor	1.70
brain stage 5 ALZ	6.64
brain stage 5 ALZ	5.35
brain stage 5 ALZ	3.03
brain stage 5 ALZ	2.16
lung 24	-15.84
lung 28	-51.66
lung 23	-11.23
asthmatic lung	-4.08
asthmatic lung	2.49
asthmatic lung	1.72
asthmatic lung	1.88
endo VEGF	-1.48
endo bFGF	1.00
heart T-1	1.06
heart T-14	-2.20
heart T-3399	1.41
BM stim	-8.94
osteo dif	12.42
Cartilage (pool)	-1.80
PBL HIV IIIB	-2.30
MRC5 HSV strain F	14.63

5 Gene Name sbg1005450UDPGT

Low to moderate overall expression. Highest normal expression in endometrium, esophagus, and spleen with lower levels of expression in cerebellum, hypothalamus, rectum, and uterus. Highest disease expression in one of the OA synovium samples. Downregulation in 1 of 4 colon tumor samples is sufficient to make a disease claim in cancer of the colon. Upregulation in 1 of 4 lung tumor samples indicates a potential role for this gene in cancer of the lung. Downregulation in 2 of 4 AD brain samples suggests an involvement in Alzheimer's disease. Downregulation in 3 of 3 COPD lung samples and 4 of 4 asthmatic lung samples suggests involvement in chronic obstructive

pulmonary disease and asthma. Upregulation in the HSV-infected MRC5 cells suggests that this gene may be a host factor in HSV. Moderate expression in the B cells and the dendritic cells.

Sample sbg1005450UDPGT	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Averag e GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detecte d/50 ng total RNA
Subcutaneous Adipocytes Zenbio	40, 40	0.15	0.17	0.16	3.06	16.34	2.61
Subcutaneous Adipose Zenbio	40, 40	0	0	0.00	0.96	52.36	0.00
Adrenal Gland Clontech	40, 40	0	0.14	0.07	0.61	81.97	5.74
Whole Brain Clontech	33.74, 40	12.07	0	6.04	7.24	6.91	41.68
Fetal Brain Clontech	40, 40	0	0	0.00	0.48	103.95	0.00
Cerebellum Clontech	32.07, 33.2	32.85	16.64	24.75	2.17	23.04	570.16
Cervix	40, 40	0	0	0.00	2.42	20.66	0.00
Colon	40; 35.16	0	5.12	2.56	2.71	18.45	47.23
Endometrium	32.73, 31.85	22.19	37.5	29.85	0.73	68.21	2035.81
Esophagus	32.67, 29.39	22.91	165.34	94.13	1.37	36.50	3435.22
Heart Clontech	37.12, 35.03	1.58	5.55	3.57	1.32	37.88	135.04
Hypothalamus	34.08, 40	9.84	0	4.92	0.32	155.28	763.98
Ileum	34.35	8.33		8.33	2.58	19.38	161.43
Jejunum	40, 40	0	0	0.00	6.60	7.58	0.00
Kidney	38.89, 40	0.54	0	0.27	2.12	23.58	6.37
Liver	36.32, 40	2.55	0	1.28	1.50	33.33	42.50
Fetal Liver Clontech	36.96	1.74		1.74	10.40	4.81	8.37
Lung	40, 40	0	0	0.00	2.57	19.46	0.00
Mammary Gland Clontech	40, 40	0	0	0.00	13.00	3.85	0.00
Myometrium	40, 38.22	0	0.82	0.41	2.34	21.37	8.76
Omentum	36.17, 40	2.8	0	1.40	3.94	12.69	17.77
Ovary	40, 40	0	0	0.00	4.34	11.52	0.00
Pancreas	40, 40	0	0	0.00	0.81	61.80	0.00
Head of Pancreas	40, 38.35	0	0.75	0.38	1.57	31.85	11.94
Parotid Gland	40, 40	0	0	0.00	5.48	9.12	0.00
Placenta Clontech	39.06, 35.49	0.49	4.22	2.36	5.26	9.51	22.39
Prostate	38.81, 40	0.57	0	0.29	3.00	16.67	4.75
Rectum	35.22, 33.25	4.94	16.2	10.57	1.23	40.65	429.67
Salivary Gland Clontech	32.56, 34.56	24.55	7.36	15.96	7.31	6.84	109.13
Skeletal Muscle Clontech	40, 40	0	0	0.00	1.26	39.68	0.00
Skin	34.26, 40	8.8	0	4.40	1.21	41.32	181.82
Small Intestine Clontech	40	0	6.23	3.12	0.98	51.07	159.09
Spleen	40, 27.36	0	560.92	280.46	4.92	10.16	2850.20
Stomach	33.49, 39.12	13.98	0.47	7.23	2.73	18.32	132.33

Testis Clontech	40, 40	0	0	0.00	0.57	87.87	0.00
Thymus Clontech	40, 35.33	0	4.64	2.32	9.89	5.06	11.73
Thyroid	37.18, 35.52	1.53	4.13	2.83	2.77	18.05	51.08
Trachea Clontech	40, 40	0	0	0.00	9.71	5.15	0.00
Urinary Bladder	40, 40	0	0.16	0.08	5.47	9.14	0.73
Uterus	30.11	106.94	0	53.47	5.34	9.36	500.66
genomic	35.81	3.47					
b-actin	26.86	757.01					
1.00E+05	18.99	100000					
1.00E+05	19.13	100000					
1.00E+04	22.43	10000					
1.00E+04	22.31	10000					
1.00E+03	25.74	1000					
1.00E+03	25.99	1000					
1.00E+02	31.47	100					
1.00E+02	29.82	100					
1.00E+01	40	0					
1.00E+01	40	0					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	26.02	-1					
NTC	40	0					

Sample sbg1005450UDPGT	Reg number (GSK identifie r)	Ct	Mean GOI copies	copies of mRNA detecte d/50 ng total RNA	Sample	Fold Change in Disease Populati on
colon normal GW98-167	21941	40	0.17	0.34	colon normal	
colon tumor GW98-166	21940	39.88	0.29	0.58	colon tumor	1.71
colon normal GW98-178	22080	40	0	0.00	colon normal	
colon tumor GW98-177	22060	40	0	0.00	colon tumor	0.00
colon normal GW98-561	23514	40	0	0.00	colon normal	
colon tumor GW98-560	23513	40	0	0.00	colon tumor	0.00
colon normal GW98-894	24691	33.84	10.47	20.94	colon normal	
colon tumor GW98-893	24690	40	0	0.00	colon tumor	-20.94
lung normal GW98-3	20742	40	0	0.00	lung normal	
lung tumor GW98-2	20741	40	0	0.00	lung tumor	0.00
lung normal GW97-179	20677	31.67	37.94	75.88	lung normal	
lung tumor GW97-178	20676	33.08	16.47	32.94	lung tumor	-2.30
lung normal GW98-165	21922	40	0	0.00	lung normal	
lung tumor GW98-164	21921	40	0	0.00	lung tumor	0.00
lung normal GW98-282	22584	40	0	0.00	lung normal	
lung tumor GW98-281	22583	35.03	5.16	10.32	lung tumor	10.32
breast normal GW00-392	28750	32.64	21.38	21.38	breast normal	

breast tumor GW00-391	28746	31.67	37.98	75.96	breast tumor	3.55
breast normal GW00-413	28798	32.54	22.63	22.63	breast normal	
breast tumor GW00-412	28797	29.23	161.71	323.42	breast tumor	14.29
breast normal GW00-235:238	27592-95	37.05	1.55	1.55	breast normal	
breast tumor GW00-231:234	27588-91	35.03	5.17	5.17	breast tumor	3.34
breast normal GW98-621	23656	34.12	8.87	17.74	breast normal	
breast tumor GW98-620	23655	40	0	0.00	breast tumor	-17.74
brain normal BB99-542	25507	34.28	8.05	16.10	brain normal	
brain normal BB99-406	25509	40	0	0.00	brain normal	
brain normal BB99-904	25546	40	0	0.00	brain normal	
brain stage 5 ALZ BB99-874	25502	38.8	0.55	1.10	brain stage 5 ALZ	-4.88
brain stage 5 ALZ BB99-887	25503	40	0	0.00	brain stage 5 ALZ	-5.37
brain stage 5 ALZ BB99-862	25504	36.16	2.64	5.28	brain stage 5 ALZ	-1.02
brain stage 5 ALZ BB99-927	25542	40	0	0.00	brain stage 5 ALZ	-5.37
CT lung KC	normal	36.61	2.02	4.04	CT lung	
lung 26 KC	normal				lung 26	
lung 27 KC	normal	40	0	0.00	lung 27	
lung 24 KC	COPD	40	0	0.00	lung 24	-1.35
lung 28 KC	COPD	40	0	0.00	lung 28	-1.35
lung 23 KC	COPD	40	0	0.00	lung 23	-1.35
lung 25 KC	normal	40	0	0.00	lung 25	
asthmatic lung ODO3112	29321	38.19	0.79	0.79	asthmatic lung	-1.70
asthmatic lung ODO3433	29323	36.09	2.76	5.52	asthmatic lung	4.10
asthmatic lung ODO3397	29322	40	0	0.00	asthmatic lung	-1.35
asthmatic lung ODO4928	29325	40	0	0.00	asthmatic lung	-1.35
endo cells KC	control	40	0	0.00	endo cells	
endo VEGF KC		40	0	0.00	endo VEGF	0.00
endo bFGF KC		40	0	0.00	endo bFGF	0.00
heart Clontech	normal	40	0	0.00	heart	
heart (T-1) ischemic	29417	38.36	0.71	1.42	heart T-1	1.42
heart (T-14) non-obstructive DCM	29422	40	0	0.00	heart T-14	0.00
heart (T-3399) DCM	29426	40	0	0.00	heart T-3399	0.00
adenoid GW99-269	26162	38.96	0.5	1.00	adenoid	
tonsil GW98-280	22582	35.44	4.04	8.08	tonsil	
T cells PC00314	28453	38.83	0.54	1.08	T cells	
PBMNC		40	0	0.00	PBMNC	
monocyte		35.1	4.94	9.88	monocyte	
B cells PC00665	28455	33.32	14.31	28.62	B cells	
dendritic cells 28441		32.53	22.85	45.70	dendritic cells	
neutrophils	28440	34.43	7.39	7.39	neutrophils	
eosinophils	28446	40	0	0.00	eosinophils	
BM unstim		40	0	0.00	BM unstim	
BM stim		34.12	8.87	8.87	BM stim	8.87

osteo dif		40	0	0.00	osteo dif	0.00
osteo undif		40	0	0.00	osteo undif	
chondrocytes		34.51	7.05	17.63	chondrocytes	
OA Synovium IP12/01	29462	40	0	0.00	OA Synovium	
OA Synovium NP10/01	29461	27.21	538.51	1077.02	OA Synovium	
OA Synovium NP57/00	28464	33.5	12.85	25.70	OA Synovium	
RA Synovium NP03/01	28466	39.09	0.46	0.92	RA Synovium	
RA Synovium NP71/00	28467	40	0	0.00	RA Synovium	
RA Synovium NP45/00	28475	40	0	0.00	RA Synovium	
OA bone (biobank)	29217	40	0	0.00	OA bone (biobank)	
OA bone Sample 1	J. Emory	35.23	4.59	9.18	OA bone	
OA bone Sample 2	J. Emory	37.1	1.51	3.02	OA bone	
Cartilage (pool)	Normal	35.45	4.01	8.02	Cartilage (pool)	
Cartilage (pool)	OA	40	0	0.00	Cartilage (pool)	-8.02
PBL uninfected	28441	40	0	0.00	PBL uninfected	
PBL HIV IIIB	28442	40	0	0.00	PBL HIV IIIB	0.00
MRC5 uninfected (100%)	29158	40	0.17	0.34	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	30.15	93.76	187.52	MRC5 HSV strain F	551.53
W12 cells	29179	40	0	0.00	W12 cells	
Keratinocytes	29180	35.72	3.44	6.88	Keratinocytes	
B-actin control		26.57	788.4			
genomic		25.69	1326.94			
1.00E+05		18.72	100000			
1.00E+05		18.74	100000			
1.00E+04		22.11	10000			
1.00E+04		22.15	10000			
1.00E+03		25.57	1000			
1.00E+03		25.54	1000			
1.00E+02		31.37	100			
1.00E+02		29.65	100			
1.00E+01		40	0			
1.00E+01		40	0			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			

Gene Name sbg1005450UDPGT

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	1.71
colon tumor	0.00
colon tumor	0.00
colon tumor	-20.94

lung tumor	0.00
lung tumor	-2.30
lung tumor	0.00
lung tumor	10.32
breast tumor	3.55
breast tumor	14.29
breast tumor	3.34
breast tumor	-17.74
brain stage 5 ALZ	-4.88
brain stage 5 ALZ	-5.37
brain stage 5 ALZ	-1.02
brain stage 5 ALZ	-5.37
lung 24	-1.35
lung 28	-1.35
lung 23	-1.35
asthmatic lung	-1.70
asthmatic lung	4.10
asthmatic lung	-1.35
asthmatic lung	-1.35
endo VEGF	0.00
endo bFGF	0.00
heart T-1	1.42
heart T-14	0.00
heart T-3399	0.00
BM stim	8.87
osteo undif	0.00
Cartilage (pool)	-8.02
PBL HIV IIIB	0.00
MRC5 HSV strain F	551.53

5 **Gene Name** sbg1002620Tia

Moderate overall expression. Highest normal expression in the whole brain, endometrium, myometrium, placenta, and rectum. Highest disease expression in the one of the colon normal/tumor pairs, the normal lung samples, one of the asthmatic lung samples, the neutrophils, the eosinophils, and one of the RA synovium samples. Expressed at high levels in all of the samples representative of the GI tract indicating a potential role for this gene in IBS, IBD, and Crohn's disease. Downregulation in 1 of 3 COPD lung samples suggests involvement in chronic obstructive

10 pulmonary disease. Upregulation in 1 of 4 asthmatic lung samples implies a role in asthma. High expression in the OA synovium and bone samples as well as in the RA synovium samples. Also high expression in the chondrocytes. Variable expression in the immune cells with highest expression in the neutrophils and eosinophils and lowest expression in the dendritic cells. Corroborating high expression in B and T cells as well as OA samples implicates this gene in

15 osteoarthritis and rheumatoid arthritis.

Sample sbg1002620Tia	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18 S rRNA (ng)	copies of mRNA detected/ 50 ng total RNA

Subcutaneous Adipocytes Zenbio	35.04, 34.4	201.66	274.43	238.05	3.06	16.34	3889.62
Subcutaneous Adipose Zenbio	38.03, 38.45	48.67	39.85	44.26	0.96	52.36	2317.28
Adrenal Gland Clontech	38.71, 38.14	35.25	46.23	40.74	0.61	81.97	3339.34
Whole Brain Clontech	29.27, 29.32	3152.23	3071.49	3111.86	7.24	6.91	21490.75
Fetal Brain Clontech	40, 37.57	0	60.7	30.35	0.48	103.95	3154.89
Cerebellum Clontech	39.37, 39.14	25.78	28.75	27.27	2.17	23.04	628.23
Cervix	34.05, 34.32	323.57	285.02	304.30	2.42	20.66	6287.09
Colon	32.64, 32.98	633.12	537.54	585.33	2.71	18.45	10799.45
Endometrium	34.44, 33.84	269.09	357.16	313.13	0.73	68.21	21359.14
Esophagus	35.48, 35.21	163.52	186.15	174.84	1.37	36.50	6380.84
Heart Clontech	38.67, 39.08	35.94	29.52	32.73	1.32	37.88	1239.77
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	33.07, 32.9	516.19	559.94	538.07	2.58	19.38	10427.62
Jejunum	30.58, 30.66	1688.39	1625.61	1657.00	6.60	7.58	12553.03
Kidney	34.9, 33.68	216.07	385.19	300.63	2.12	23.58	7090.33
Liver	37.17, 36.49	73.4	101.31	87.36	1.50	33.33	2911.83
Fetal Liver Clontech	33.99, 34.79	332.15	227.82	279.99	10.40	4.81	1346.08
Lung	34.67, 34.06	240.47	321.54	281.01	2.57	19.46	5467.02
Mammary Gland Clontech	29.3, 29.19	3098.36	3272.39	3185.38	13.00	3.85	12251.44
Myometrium	32.45, 31.79	692.54	946.75	819.65	2.34	21.37	17513.78
Omentum	32.88, 33.43	563.23	434.44	498.84	3.94	12.69	6330.39
Ovary	33.02, 32.92	528.43	553.26	540.85	4.34	11.52	6230.93
Pancreas	37.31, 39.81	68.49	20.84	44.67	0.81	61.80	2760.51
Head of Pancreas	38.5, 39.16	38.99	28.45	33.72	1.57	31.85	1073.89
Parotid Gland	34.48, 34.22	263.15	298.49	280.82	5.48	9.12	2562.23
Placenta Clontech	31.16, 30.91	1280.82	1442.99	1361.91	5.26	9.51	12945.87
Prostate	33.5, 33.11	420.13	506.76	463.45	3.00	16.67	7724.08
Rectum	34.48, 33.88	263.61	350.22	306.92	1.23	40.65	12476.22
Salivary Gland Clontech	34.48, 34.32	263.4	284.18	273.79	7.31	6.84	1872.71
Skeletal Muscle Clontech	40, 39.37	0	25.73	12.87	1.26	39.68	510.52
Skin	35.52, 35.13	160.58	193.62	177.10	1.21	41.32	7318.18
Small Intestine Clontech	36.79, 36.59	87.74	96.5	92.12	0.98	51.07	4704.80
Spleen	34.45, 34.51	267.45	260	263.73	4.92	10.16	2680.13
Stomach	35.16, 33.89	191.03	348.48	269.76	2.73	18.32	4940.57
Testis Clontech	38.19, 37.07	45.22	76.91	61.07	0.57	87.87	5365.99
Thymus Clontech	33.74, 33.57	374.59	406.79	390.69	9.89	5.06	1975.18
Thyroid	34.18, 33.46	304.38	427.57	365.98	2.77	18.05	6606.05
Trachea Clontech	32.67, 31.27	623.94	1213.65	918.80	9.71	5.15	4731.18
Urinary Bladder	32.07, 31.34	830.04	1176.15	1003.10	5.47	9.14	9169.06
Uterus	31.75, 31.37	968.5	1157.09	1062.80	5.34	9.36	9951.26
genomic	31.33	1181.44					
b-actin	28.56	4411.32					
1.00E+05	22.12	100000					

1.00E+05	22.12	100000					
1.00E+04	26.72	10000					
1.00E+04	26.91	10000					
1.00E+03	31.28	1000					
1.00E+03	31.5	1000					
1.00E+02	36.35	100					
1.00E+02	37.09	100					
1.00E+01	40	10					
1.00E+01	40	10					
1.00E-00	40	1					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg1002620T1a	Reg number (GSK identifie r)	Ct	Mean GOI copies	copies of mRNA detected/ 50 ng total RNA	Sample	Fold Change in Disease Populati on
colon normal GW98-167	21941	24.54	22693.01	45386.02	colon normal	
colon tumor GW98-166	21940	24.18	26862.61	53725.22	colon tumor	1.18
colon normal GW98-178	22080	27.08	6895.34	13790.68	colon normal	
colon tumor GW98-177	22060	28.41	3692.19	7384.38	colon tumor	-1.87
colon normal GW98-561	23514	26.58	8698.68	17397.36	colon normal	
colon tumor GW98-560	23513	27.85	4799.22	9598.44	colon tumor	-1.81
colon normal GW98-894	24691	25.9	11972.57	23945.14	colon normal	
colon tumor GW98-893	24690	28.04	4396.4	8792.80	colon tumor	-2.72
lung normal GW98-3	20742	24.25	26016.9	52033.80	lung normal	
lung tumor GW98-2	20741	27.64	5300.37	10600.74	lung tumor	-4.91
lung normal GW97-179	20677	25.1	17476.66	34953.32	lung normal	
lung tumor GW97-178	20676	25.53	14274.54	28549.08	lung tumor	-1.22
lung normal GW98-165	21922	24.62	21917.37	43834.74	lung normal	
lung tumor GW98-164	21921	25.64	13526.49	27052.98	lung tumor	-1.62
lung normal GW98-282	22584	27.08	6884.03	13768.06	lung normal	
lung tumor GW98-281	22583	25.37	15385.8	30771.60	lung tumor	2.23
breast normal GW00-392	28750	26.07	11065.25	11065.25	breast normal	
breast tumor GW00-391	28746	26.87	7611.48	15222.96	breast tumor	1.38
breast normal GW00-413	28798	28.65	3294.68	3294.68	breast normal	
breast tumor GW00-412	28797	28.52	3496.94	6993.88	breast tumor	2.12
breast normal GW00-235:238	27592-95	29.47	2243.69	2243.69	breast normal	
breast tumor GW00-231:234	27588-91	25.83	12385.23	12385.23	breast tumor	5.52
breast normal GW98-621	23656	26.05	11188.07	22376.14	breast normal	
breast tumor GW98-620	23655	26.03	11303.95	22607.90	breast tumor	1.01

brain normal BB99-542	25507	27.68	5198.79	10397.58	brain normal	
brain normal BB99-406	25509	29.81	1909.01	3818.02	brain normal	
brain normal BB99-904	25546	31.84	735.25	1470.50	brain normal	
brain stage 5 ALZ BB99-874	25502	28.43	3650.66	7301.32	brain stage 5 ALZ	1.40
brain stage 5 ALZ BB99-887	25503	29.01	2785.56	5571.12	brain stage 5 ALZ	1.07
brain stage 5 ALZ BB99-862	25504	29.65	2059.62	4119.24	brain stage 5 ALZ	-1.27
brain stage 5 ALZ BB99-927	25542	30.01	1742.3	3484.60	brain stage 5 ALZ	-1.50
CT lung KC	normal	25.49	14553.17	29106.34	CT lung	
lung 26 KC	normal	31.8	749.93	749.93	lung 26	
lung 27 KC	normal	33.35	362.66	362.66	lung 27	
lung 24 KC	COPD	30.67	1275.68	1275.68	lung 24	-6.03
lung 28 KC	COPD	29.25	2490.39	2490.39	lung 28	-3.09
lung 23 KC	COPD	30.11	1661.24	1661.24	lung 23	-4.63
lung 25 KC	normal	32.45	553.75	553.75	lung 25	
asthmatic lung ODO3112	29321	27.3	6215.19	6215.19	asthmatic lung	-1.24
asthmatic lung ODO3433	29323	26.66	8407.3	16814.60	asthmatic lung	2.19
asthmatic lung ODO3397	29322	24.06	28466.73	56933.46	asthmatic lung	7.40
asthmatic lung ODO4928	29325	26.22	10313.71	20627.42	asthmatic lung	2.68
endo cells KC	control	40	0	0.00	endo cells	
endo VEGF KC		40	0	0.00	endo VEGF	0.00
endo bFGF KC		40	0	0.00	endo bFGF	0.00
heart Clontech	normal	27.58	5449.78	10899.56	heart	
heart (T-1) ischemic	29417	28.42	3670.86	7341.72	heart T-1	-1.48
heart (T-14) non- obstructive DCM	29422	27.18	6570.11	13140.22	heart T-14	1.21
heart (T-3399) DCM	29426	26.23	10277.2	20554.40	heart T-3399	1.89
adenoid GW99-269	26162	31.98	688.86	1377.72	adenoid	
tonsil GW98-280	22582	29.31	2421.67	4843.34	tonsil	
T cells PC00314	28453	29.53	2178.21	4356.42	T cells	
PBMNC		33.23	383.88	383.88	PBMNC	
monocyte		31.07	1057.9	2115.80	monocyte	
B cells PC00665	28455	35.97	106.01	212.02	B cells	
dendritic cells 28441		33.56	328.62	657.24	dendritic cells	
neutrophils	28440	22.32	64510.36	64510.36	neutrophils	
eosinophils	28446	24.18	26910.17	53820.34	eosinophils	
BM unstim		30.35	1480.07	1480.07	BM unstim	
BM stim		31.71	782.56	782.56	BM stim	-1.89
osteodif		31.42	895.71	895.71	osteodif	2.03
osteounif		32.93	440.66	440.66	osteounif	
chondrocytes		28.98	2820.8	7052.00	chondrocytes	
OA Synovium IP12/01	29462	25.37	15383.84	15383.84	OA Synovium	
OA Synovium NP10/01	29461	27.12	6763.44	13526.88	OA Synovium	

OA Synovium NP57/00	28464	26.48	9130.81	18261.62	OA Synovium	
RA Synovium NP03/01	28466	27.78	4967.23	9934.46	RA Synovium	
RA Synovium NP71/00	28467	24.72	20923.66	41847.32	RA Synovium	
RA Synovium NP45/00	28475	26.15	10658.82	21317.64	RA Synovium	
OA bone (biobank)	29217	28.68	3248.19	3248.19	OA bone (biobank)	
OA bone Sample 1	J. Emory	27.19	6545.82	13091.64	OA bone	
OA bone Sample 2	J. Emory	27.24	6384.92	12769.84	OA bone	
Cartilage (pool)	Normal	26.28	10016.65	20033.30	Cartilage (pool)	
Cartilage (pool)	OA	26.67	8342.92	16685.84	Cartilage (pool)	-1.20
PBL uninfected	28441	31.05	1069.84	2139.68	PBL uninfected	
PBL HIV IIIB	28442	31.7	788.06	1576.12	PBL HIV IIIB	-1.36
MRC5 uninfected (100%)	29158	26.37	9631.13	19262.26	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	28.38	3747.38	7494.76	MRC5 HSV strain F	-2.57
W12 cells	29179	35.15	155.25	310.50	W12 cells	
Keratinocytes	29180	34.93	172.87	345.74	Keratinocytes	
B-actin control		28.06	4342.74			
genomic		30.54	1356.79			
1.00E+05		21.39	100000			
1.00E+05		21.64	100000			
1.00E+04		26.21	10000			
1.00E+04		26.24	10000			
1.00E+03		30.9	1000			
1.00E+03		30.97	1000			
1.00E+02		36.34	100			
1.00E+02		36.22	100			
1.00E+01		40	10			
1.00E+01		40	0			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			

Gene Name sbg1002620T1a

5

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	1.18
colon tumor	-1.87
colon tumor	-1.81
colon tumor	-2.72
lung tumor	-4.91
lung tumor	-1.22
lung tumor	-1.62
lung tumor	2.23
breast tumor	1.38

breast tumor	2.12
breast tumor	5.52
breast tumor	1.01
brain stage 5 ALZ	1.40
brain stage 5 ALZ	1.07
brain stage 5 ALZ	-1.27
brain stage 5 ALZ	-1.50
lung 24	-6.03
lung 28	-3.09
lung 23	-4.63
asthmatic lung	-1.24
asthmatic lung	2.19
asthmatic lung	7.40
asthmatic lung	2.68
endo VEGF	0.00
endo bFGF	0.00
heart T-1	-1.48
heart T-14	1.21
heart T-3399	1.89
BM stim	-1.89
osteo dif	2.03
Cartilage (pool)	-1.20
PBL HIV IIIB	-1.36
MRC5 HSV strain F	-2.57

Gene Name sbg1002620T1b

5 Moderate to high overall expression. Highest normal expression in whole brain, endometrium, jejunum, placenta, thymus, and urinary bladder. Highest disease expression in one of the colon normal/tumor pairs, one of the normal lung samples, one of the asthmatic lung samples, the neutrophils, and the eosinophils. Strong expression in all of the GI tract samples implicates this gene in IBS, IBD, and Crohn's disease. Downregulation in 1 of 4 lung tumor samples is sufficient to make a disease claim in cancer of the lung. Downregulation in 3 of 3 COPD lung samples suggests involvement in chronic obstructive pulmonary disease. Upregulation in 1 of 4 asthmatic lung samples implies a role in asthma. Upregulation in 2 of 3 heart samples suggests this gene may play a role in non-obstructive and obstructive dilated cardiac myopathy. High expression in the RA and OA synovium samples as well as high expression in the chondrocytes and T cells implicates this gene in osteoarthritis and rheumatoid arthritis.

10

15

Sample sbg1002620T1b	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Averag e GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detected /50 ng total RNA
Subcutaneous Adipocytes Zenbio	31.35, 31.44	58.54	55.11	56.83	3.06	16.34	928.51
Subcutaneous Adipose Zenbio	35.12, 34.21	5	9.05	7.03	0.96	52.36	367.80
Adrenal Gland Clontech	40, 34.29	0	8.61	4.31	0.61	81.97	352.87
Whole Brain Clontech	26.02, 26.06	1897.9	1849.19	1873.55	7.24	6.91	12938.85

Fetal Brain Clontech	40, 36.43	0	2.13	1.07	0.48	103.95	110.71
Cerebellum Clontech	40, 36.05	0	2.74	1.37	2.17	23.04	31.57
Cervix	32.23, 33.04	33.11	19.47	26.29	2.42	20.66	543.18
Colon	30.44, 30.45	105.93	105.29	105.61	2.71	18.45	1948.52
Endometrium	30.86, 30.56	80.75	97.92	89.34	0.73	68.21	6093.79
Esophagus	33.03, 32.34	19.62	30.66	25.14	1.37	36.50	917.52
Heart Clontech	40, 35.05	0	5.26	2.63	1.32	37.88	99.62
Hypothalamus	40, 36.17	0	2.53	1.27	0.32	155.28	196.43
Ileum	31.25, 30.31	62.52	115.58	89.05	2.58	19.38	1725.78
Jejunum	27.75, 27.93	612.01	543.46	577.74	6.60	7.58	4376.78
Kidney	32.59, 31.86	26.03	42.14	34.09	2.12	23.58	803.89
Liver	34.66, 34.5	6.77	7.52	7.15	1.50	33.33	238.17
Fetal Liver Clontech	29.08, 28.58	256.83	356.67	306.75	10.40	4.81	1474.76
Lung	30.74, 30.68	87.44	90.91	89.18	2.57	19.46	1734.92
Mammary Gland Clontech	27.49, 26.81	725.02	1132.42	928.72	13.00	3.85	3572.00
Myometrium	31.2, 30.29	64.54	117.26	90.90	2.34	21.37	1942.31
Omentum	31.19, 30.12	65.05	130.86	97.96	3.94	12.69	1243.08
Ovary	30.24, 30.54	120.95	99.3	110.13	4.34	11.52	1268.72
Pancreas	36.01, 36.55	2.81	1.97	2.39	0.81	61.80	147.71
Head of Pancreas	33.95, 35.73	10.72	3.36	7.04	1.57	31.85	224.20
Parotid Gland	32.16, 33.16	34.51	18.05	26.28	5.48	9.12	239.78
Placenta Clontech	28.42, 28.02	395.01	512.77	453.89	5.26	9.51	4314.54
Prostate	30.61, 31.28	95.23	61.5	78.37	3.00	16.67	1306.08
Rectum	30.5, 30.93	101.73	76.9	89.32	1.23	40.65	3630.69
Salivary Gland Clontech	31.17, 31.07	65.95	70.23	68.09	7.31	6.84	465.73
Skeletal Muscle Clontech	40, 40	0	0	0.00	1.26	39.68	0.00
Skin	34.37, 33.12	8.18	18.53	13.36	1.21	41.32	551.86
Small Intestine Clontech	36.71, 34.96	1.78	5.55	3.67	0.98	51.07	187.18
Spleen	30.54, 31.29	99.47	60.88	80.18	4.92	10.16	814.79
Stomach	32.4, 31.53	29.49	52	40.75	2.73	18.32	746.25
Testis Clontech	34.4, 35.19	8.03	4.79	6.41	0.57	87.87	563.27
Thymus Clontech	27.18, 27.12	888.84	924.29	906.57	9.89	5.06	4583.24
Thyroid	32.17, 30.89	34.36	79.27	56.82	2.77	18.05	1025.54
Trachea Clontech	30.01, 29.25	140.31	230.28	185.30	9.71	5.15	954.15
Urinary Bladder	28.33, 27.87	420.47	565.71	493.09	5.47	9.14	4507.22
Uterus	29.09, 28.81	255.27	308	281.64	5.34	9.36	2637.03
genomic	27.16	900.78					
b-actin	27.4	769.87					
1.00E+05	19.87	100000					
1.00E+05	19.95	100000					
1.00E+04	23.4	10000					
1.00E+04	23.39	10000					
1.00E+03	26.94	1000					
1.00E+03	26.95	1000					
1.00E+02	31.02	100					

1.00E+02	30.96	100						
1.00E+01	33.46	10						
1.00E+01	40	0						
1.00E-00	40	0						
1.00E-00	40	0						
NTC	40	0						
NTC	40	0						

Sample sbg1002620T1b	Reg number (GSK identifier)	Ct	Mean GOI copies	copies of mRNA detected /50 ng total RNA	Sample	Fold Chang e in Diseas e Popula tion
colon normal GW98-167	21941	22.85	18631.2	37262.40	colon normal	
colon tumor GW98-166	21940	22.51	23090.96	46181.92	colon tumor	1.24
colon normal GW98-178	22080	25.49	3620.45	7240.90	colon normal	
colon tumor GW98-177	22060	26.88	1527.3	3054.60	colon tumor	-2.37
colon normal GW98-561	23514	25.37	3901.36	7802.72	colon normal	
colon tumor GW98-560	23513	26.08	2512.21	5024.42	colon tumor	-1.55
colon normal GW98-894	24691	23.78	10441.49	20882.98	colon normal	
colon tumor GW98-893	24690	25.54	3515.48	7030.96	colon tumor	-2.97
lung normal GW98-3	20742	22.6	21810.56	43621.12	lung normal	
lung tumor GW98-2	20741	26.19	2349.32	4698.64	lung tumor	-9.28
lung normal GW97-179	20677	23.38	13423.28	26846.56	lung normal	
lung tumor GW97-178	20676	24.51	6653.03	13306.06	lung tumor	-2.02
lung normal GW98-165	21922	23.68	11120.91	22241.82	lung normal	
lung tumor GW98-164	21921	24.37	7242.32	14484.64	lung tumor	-1.54
lung normal GW98-282	22584	25.05	4745.83	9491.66	lung normal	
lung tumor GW98-281	22583	23.57	11943.28	23886.56	lung tumor	2.52
breast normal GW00-392	28750	24.84	5415.88	5415.88	breast normal	
breast tumor GW00-391	28746	24.98	4973.9	9947.80	breast tumor	1.84
breast normal GW00-413	28798	24.69	5954.77	5954.77	breast normal	
breast tumor GW00-412	28797	26.38	2081.99	4163.98	breast tumor	-1.43
breast normal GW00-235:238	27592-95	25.04	4792.18	4792.18	breast normal	
breast tumor GW00-231:234	27588-91	23.63	11520.86	11520.86	breast tumor	2.40
breast normal GW98-621	23656	23.22	14836.24	29672.48	breast normal	
breast tumor GW98-620	23655	24.24	7879	15758.00	breast tumor	-1.88
brain normal BB99-542	25507	25.16	4447.15	8894.30	brain normal	
brain normal BB99-406	25509	27.05	1377.71	2755.42	brain normal	
brain normal BB99-904	25546	29.35	330.53	661.06	brain normal	
brain stage 5 ALZ BB99-874	25502	27.64	956.16	1912.32	brain stage 5 ALZ	-2.15
brain stage 5 ALZ	25503	27.02	1400.04	2800.08	brain stage 5	-1.47

BB99-887					ALZ	
brain stage 5 ALZ	25504	27.4	1105.21	2210.42	brain stage 5 ALZ	-1.86
BB99-862						
brain stage 5 ALZ	25542	27.1	1336.02	2672.04	brain stage 5 ALZ	-1.54
BB99-927						
CT lung KC	normal	23.52	12295.29	24590.58	CT lung	
lung 26 KC	normal	31.42	91.19	91.19	lung 26	
lung 27 KC	normal	32.34	51.71	51.71	lung 27	
lung 24 KC	COPD	31.27	100.29	100.29	lung 24	-61.80
lung 28 KC	COPD	28.64	511.37	511.37	lung 28	-12.12
lung 23 KC	COPD	30.52	159.17	159.17	lung 23	-38.94
lung 25 KC	normal	32.15	57.91	57.91	lung 25	
asthmatic lung ODO3112	29321	23.19	15086.65	15086.65	asthmatic lung	2.43
asthmatic lung ODO3433	29323	24.76	5706.9	11413.80	asthmatic lung	1.84
asthmatic lung ODO3397	29322	21.71	37760.01	75520.02	asthmatic lung	12.18
asthmatic lung ODO4928	29325	24.16	8255.16	16510.32	asthmatic lung	2.66
endo cells KC	control	37.31	2.36	2.36	endo cells	
endo VEGF KC		40	0	0.00	endo VEGF	-2.36
endo bFGF KC		35.67	6.54	6.54	endo bFGF	2.77
heart Clontech	normal	26.32	2170.24	4340.48	heart	
heart (T-1) ischemic	29417	25.87	2863.04	5726.08	heart T-1	1.32
heart (T-14) non-obstructive DCM	29422	24.62	6200.03	12400.06	heart T-14	2.86
heart (T-3399) DCM	29426	24.06	8775.18	17550.36	heart T-3399	4.04
adenoid GW99-269	26162	29.2	362.88	725.76	adenoid	
tonsil GW98-280	22582	27.24	1222.33	2444.66	tonsil	
T cells PC00314	28453	28.09	723.06	1446.12	T cells	
PBMNC		30.67	145.75	145.75	PBMNC	
monocyte		28.42	587.16	1174.32	monocyte	
B cells PC00665	28455	34.17	16.57	33.14	B cells	
dendritic cells 28441		31.78	72.95	145.90	dendritic cells	
neutrophils	28440	21.46	44297.23	44297.23	neutrophils	
eosinophils	28446	22.79	19332.21	38664.42	eosinophils	
BM unstim		29.22	358.53	358.53	BM unstim	
BM stim		31.27	100.39	100.39	BM stim	-3.57
osteo dif		30.14	202.25	202.25	osteo dif	4.97
osteo undif		32.72	40.67	40.67	osteo undif	
chondrocytes		27.3	1178.3	2945.75	chondrocytes	
OA Synovium IP12/01	29462	23.33	13860.23	13860.23	OA Synovium	
OA Synovium NP10/01	29461	25.3	4080.49	8160.98	OA Synovium	
OA Synovium NP57/00	28464	25.23	4253.8	8507.60	OA Synovium	
RA Synovium NP03/01	28466	25.46	3686.62	7373.24	RA Synovium	
RA Synovium NP71/00	28467	23.31	14036.44	28072.88	RA Synovium	
RA Synovium NP45/00	28475	24.28	7658.52	15317.04	RA Synovium	
OA bone (biobank)	29217	26.48	1958.1	1958.10	OA bone (biobank)	

OA bone Sample 1	J. Emory	25.28	4131.76	8263.52	OA bone	
OA bone Sample 2	J. Emory	25.23	4242.9	8485.80	OA bone	
Cartilage (pool)	Normal	24.05	8829.67	17659.34	Cartilage (pool)	
Cartilage (pool)	OA	24.28	7685.44	15370.88	Cartilage (pool)	-1.15
PBL uninfected	28441	29.33	334.71	669.42	PBL uninfected	
PBL HIV IIIB	28442	29.59	283.96	567.92	PBL HIV IIIB	-1.18
MRC5 uninfected (100%)	29158	23.92	9595.12	19190.24	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	25.2	4341.36	8682.72	MRC5 HSV strain F	-2.21
W12 cells	29179	30.43	168.9	337.80	W12 cells	
Keratinocytes	29180	29.66	272.9	545.80	Keratinocytes	
B-actin control		27.64	956.41			
genomic		27.35	1143.39			
1.00E+05		20.14	100000			
1.00E+05		20.26	100000			
1.00E+04		23.6	10000			
1.00E+04		24.02	10000			
1.00E+03		27.49	1000			
1.00E+03		27.5	1000			
1.00E+02		31.66	100			
1.00E+02		31.01	100			
1.00E+01		40	0			
1.00E+01		40	0			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			

Gene Name sbg1002620T1b

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	1.24
colon tumor	-2.37
colon tumor	-1.55
colon tumor	-2.97
lung tumor	-9.28
lung tumor	-2.02
lung tumor	-1.54
lung tumor	2.52
breast tumor	1.84
breast tumor	-1.43
breast tumor	2.40
breast tumor	-1.88
brain stage 5 ALZ	-2.15
brain stage 5 ALZ	-1.47
brain stage 5 ALZ	-1.86
brain stage 5 ALZ	-1.54
lung 24	-61.80
lung 28	-12.12

lung 23	-38.94
asthmatic lung	2.43
asthmatic lung	1.84
asthmatic lung	12.18
asthmatic lung	2.66
endo VEGF	-2.36
endo bFGF	2.77
heart T-1	1.32
heart T-14	2.86
heart T-3399	4.04
BM stim	-3.57
osteo dif	4.97
Cartilage (pool)	-1.15
PBL HIV IIIB	-1.18
MRC5 HSV strain F	-2.21

Gene Name sbg102200MCTa

5 Moderate to low overall expression. Highest normal expression in the subcutaneous adipose tissue, whole brain, fetal brain, cerebellum, and fetal liver. Highest disease expression in 2 of 4 lung tumor samples, one of the normal lung samples, one of the normal breast samples, and the CT lung sample. Downregulation in 1 of 4 breast cancer samples implicates this gene in cancer of the breast.

10 Downregulation in 3 of 3 COPD lung samples suggests involvement in chronic obstructive pulmonary disease. Moderate expression in the OA and RA synovium as well as the PBLs, adenoid, tonsil, T cells, B cells, and the chondrocytes indicates involvement in osteoarthritis and rheumatoid arthritis.

Sample sbg102200MCTa	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detected/50 ng total RNA
Subcutaneous Adipocytes Zenbio	36.01, 34.76	3.83	8.04	5.94	3.06	16.34	96.98
Subcutaneous Adipose Zenbio	34.85, 33.96	7.63	12.94	10.29	0.96	52.36	538.48
Adrenal Gland Clontech	40, 40	0	0	0.00	0.61	81.97	0.00
Whole Brain Clontech	26.05, 26.18	1434.25	1331.2	1382.73	7.24	6.91	9549.21
Fetal Brain Clontech	40, 34.46	0	9.63	4.82	0.48	103.95	500.52
Cerebellum Clontech	31.7, 32.73	49.65	26.9	38.28	2.17	23.04	881.91
Cervix	40, 40	0	0	0.00	2.42	20.66	0.00
Colon	38.55, 38.57	0.84	0.83	0.84	2.71	18.45	15.41
Endometrium	40, 40	0	0	0.00	0.73	68.21	0.00
Esophagus	35.23, 40	6.09	0	3.05	1.37	36.50	111.13
Heart Clontech	40, 40	0	0	0.00	1.32	37.88	0.00
Hypothalamus	39.8, 40	0.4	0	0.20	0.32	155.28	31.06
Ileum	34.16, 40	11.53	0	5.77	2.58	19.38	111.72
Jejunum	32.82, 33.18	25.46	20.6	23.03	6.60	7.58	174.47
Kidney	34.23, 34.1	11.02	11.9	11.46	2.12	23.58	270.28
Liver	35.35, 37.28	5.65	1.79	3.72	1.50	33.33	124.00
Fetal Liver Clontech	29.45, 28.98	189.89	250.96	220.43	10.40	4.81	1059.74

Lung	34.99, 33.43	7.04	17.81	12.43	2.57	19.46	241.73
Mammary Gland Clontech	31.76, 31.05	48.02	73.18	60.60	13.00	3.85	233.08
Myometrium	34.46, 35.22	9.64	6.12	7.88	2.34	21.37	168.38
Omentum	37.94, 34.13	1.21	11.71	6.46	3.94	12.69	81.98
Ovary	34.03, 33.43	12.44	17.77	15.11	4.34	11.52	174.02
Pancreas	40, 40	0	0	0.00	0.81	61.80	0.00
Head of Pancreas	40, 40	0	0	0.00	1.57	31.85	0.00
Parotid Gland	32.56, 31.81	29.88	46.65	38.27	5.48	9.12	349.13
Placenta Clontech	40, 40	0	0	0.00	5.26	9.51	0.00
Prostate	40, 36.21	0	3.39	1.70	3.00	16.67	28.25
Rectum	40, 39.37	0	0.52	0.26	1.23	40.65	10.57
Salivary Gland Clontech	30.6, 31.77	95.89	47.76	71.83	7.31	6.84	491.28
Skeletal Muscle Clontech	40, 40	0	0	0.00	1.26	39.68	0.00
Skin	34.47, 35.32	9.58	5.75	7.67	1.21	41.32	316.74
Small Intestine Clontech	40, 40	0	0	0.00	0.98	51.07	0.00
Spleen	34.1, 36.49	11.93	2.87	7.40	4.92	10.16	75.20
Stomach	35.17, 36.07	6.3	3.68	4.99	2.73	18.32	91.39
Testis Clontech	37.98, 40	1.19	0	0.60	0.57	87.87	52.28
Thymus Clontech	31.28, 30.4	63.69	108.05	85.87	9.89	5.06	434.13
Thyroid	33.08, 32.96	21.88	23.47	22.68	2.77	18.05	409.30
Trachea Clontech	32.54, 31.34	30.14	61.71	45.93	9.71	5.15	236.48
Urinary Bladder	33.91, 40	13.32	0	6.66	5.47	9.14	60.88
Uterus	33.71, 32.43	15.04	32.13	23.59	5.34	9.36	220.83
genomic	26.3	1237.42					
b-actin	27.49	610.72					
1.00E+05	19.18	100000					
1.00E+05	19.45	100000					
1.00E+04	22.6	10000					
1.00E+04	22.53	10000					
1.00E+03	26.17	1000					
1.00E+03	26.19	1000					
1.00E+02	30.61	100					
1.00E+02	30.53	100					
1.00E+01	40	0					
1.00E+01	34.91	10					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg102200MCTa	Reg number (GSK identifier)	Ct	Mean GOI copies	copies of mRNA detecte	Sample	Fold Change in Disease Populatio

)			d/50 ng total RNA		n
colon normal GW98-167	21941	28.58	519.72	1039.44	colon normal	
colon tumor GW98-166	21940	30.18	202.86	405.72	colon tumor	-2.56
colon normal GW98-178	22080	31.39	100.15	200.30	colon normal	
colon tumor GW98-177	22060	29.62	282.42	564.84	colon tumor	2.82
colon normal GW98-561	23514	30.36	183.13	366.26	colon normal	
colon tumor GW98-560	23513	30.45	173.87	347.74	colon tumor	-1.05
colon normal GW98-894	24691	30.23	196.98	393.96	colon normal	
colon tumor GW98-893	24690	30.35	183.76	367.52	colon tumor	-1.07
lung normal GW98-3	20742	26.68	1575.72	3151.44	lung normal	
lung tumor GW98-2	20741	28.8	456.47	912.94	lung tumor	-3.45
lung normal GW97-179	20677	27.94	754.47	1508.94	lung normal	
lung tumor GW97-178	20676	26.27	2002.28	4004.56	lung tumor	2.65
lung normal GW98-165	21922	26.87	1411.09	2822.18	lung normal	
lung tumor GW98-164	21921	29.38	325.51	651.02	lung tumor	-4.34
lung normal GW98-282	22584	30	225.32	450.64	lung normal	
lung tumor GW98-281	22583	28.64	502.02	1004.04	lung tumor	2.23
breast normal GW00-392	28750	28.32	602.59	602.59	breast normal	
breast tumor GW00-391	28746	28.05	709.37	1418.74	breast tumor	2.35
breast normal GW00-413	28798	29.56	292.43	292.43	breast normal	
breast tumor GW00-412	28797	30.05	218.89	437.78	breast tumor	1.50
breast normal GW00-235:238	27592-95	30.96	128.91	128.91	breast normal	
breast tumor GW00-231:234	27588-91	30.57	161.3	161.30	breast tumor	1.25
breast normal GW98-621	23656	27.04	1275.81	2551.62	breast normal	
breast tumor GW98-620	23655	31.35	102.26	204.52	breast tumor	-12.48
brain normal BB99-542	25507	28.44	564.32	1128.64	brain normal	
brain normal BB99-406	25509	29.01	402.37	804.74	brain normal	
brain normal BB99-904	25546	29.67	274.03	548.06	brain normal	
brain stage 5 ALZ BB99-874	25502	29.6	284.82	569.64	brain stage 5 ALZ	-1.45
brain stage 5 ALZ BB99-887	25503	27.92	765.16	1530.32	brain stage 5 ALZ	1.85
brain stage 5 ALZ BB99-862	25504	28.74	472.27	944.54	brain stage 5 ALZ	1.14
brain stage 5 ALZ BB99-927	25542	29.3	340.25	680.50	brain stage 5 ALZ	-1.22
CT lung KC	normal	26.69	1569.87	3139.74	CT lung	
lung 26 KC	normal	31.07	120.9	120.90	lung 26	
lung 27 KC	normal	31.17	113.69	113.69	lung 27	
lung 24 KC	COPD	31.8	78.78	78.78	lung 24	-10.98
lung 28 KC	COPD	32.79	44.02	44.02	lung 28	-19.65
lung 23 KC	COPD	31.35	102.33	102.33	lung 23	-8.45
lung 25 KC	normal	31.66	85.57	85.57	lung 25	
asthmatic lung ODO3112	29321	28.76	467.45	467.45	asthmatic lung	-1.85
asthmatic lung ODO3433	29323	27.73	851.21	1702.42	asthmatic lung	1.97
asthmatic lung ODO3397	29322	27.81	812.68	1625.36	asthmatic lung	1.88

asthmatic lung ODO4928	29325	29.42	317.12	634.24	asthmatic lung	-1.36
endo cells KC	control	33.06	37.57	37.57	endo cells	
endo VEGF KC		33.9	22.97	22.97	endo VEGF	-1.64
endo bFGF KC		33.13	36.03	36.03	endo bFGF	-1.04
heart Clontech	normal	31.1	118.18	236.36	heart	
heart (T-1) ischemic	29417	31.16	114.67	229.34	heart T-1	-1.03
heart (T-14) non-obstructive DCM	29422	30.52	166.47	332.94	heart T-14	1.41
heart (T-3399) DCM	29426	30.14	208.3	416.60	heart T-3399	1.76
adenoid GW99-269	26162	29.07	388.9	777.80	adenoid	
tonsil GW98-280	22582	28.29	614.82	1229.64	tonsil	
T cells PC00314	28453	29.78	256.1	512.20	T cells	
PBMNC		33.73	25.44	25.44	PBMNC	
monocyte		33.52	28.71	57.42	monocyte	
B cells PC00665	28455	28.66	495.36	990.72	B cells	
dendritic cells 28441		30.81	140.17	280.34	dendritic cells	
neutrophils	28440	30.17	204.92	204.92	neutrophils	
eosinophils	28446	34.19	19.39	38.78	eosinophils	
BM unstim		35.9	7.11	7.11	BM unstim	
BM stim		35.77	7.7	7.70	BM stim	1.08
osteodif		34.98	12.18	12.18	osteodif	2.55
osteoundif		36.59	4.77	4.77	osteoundif	
chondrocytes		32.91	41.03	102.58	chondrocytes	
OA Synovium IP12/01	29462	29.16	370.33	370.33	OA Synovium	
OA Synovium NP10/01	29461	30.69	151.13	302.26	OA Synovium	
OA Synovium NP57/00	28464	29.51	301.55	603.10	OA Synovium	
RA Synovium NP03/01	28466	30.36	183.35	366.70	RA Synovium	
RA Synovium NP71/00	28467	29.27	346.61	693.22	RA Synovium	
RA Synovium NP45/00	28475	29.13	376.88	753.76	RA Synovium	
OA bone (biobank)	29217	30.47	171.6	171.60	OA bone (biobank)	
OA bone Sample 1	J. Emory	30.05	219.19	438.38	OA bone	
OA bone Sample 2	J. Emory	31.13	116.62	233.24	OA bone	
Cartilage (pool)	Normal	30.65	154.56	309.12	Cartilage (pool)	
Cartilage (pool)	OA	32.01	69.39	138.78	Cartilage (pool)	-2.23
PBL uninfected	28441	27.91	769.91	1539.82	PBL uninfected	
PBL HIV IIIB	28442	28.14	672.12	1344.24	PBL HIV IIIB	-1.15
MRC5 uninfected (100%)	29158	31.66	85.38	170.76	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	30.08	214.88	429.76	MRC5 HSV strain F	2.52
W12 cells	29179	33.33	32.15	64.30	W12 cells	
Keratinocytes	29180	30.64	155.16	310.32	Keratinocytes	
B-actin control		27.55	946.64			
genomic		26.82	1451.22			
1.00E+05		19.71	100000			
1.00E+05		19.95	100000			
1.00E+04		23.43	10000			
1.00E+04		23.38	10000			

1.00E+03		26.88	1000			
1.00E+03		26.8	1000			
1.00E+02		31.99	100			
1.00E+02		32.15	100			
1.00E+01		34.99	10			
1.00E+01		40	0			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			

Gene Name sbg102200MCTa

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-2.56
colon tumor	2.82
colon tumor	-1.05
colon tumor	-1.07
lung tumor	-3.45
lung tumor	2.65
lung tumor	-4.34
lung tumor	2.23
breast tumor	2.35
breast tumor	1.50
breast tumor	1.25
breast tumor	-12.48
brain stage 5 ALZ	-1.45
brain stage 5 ALZ	1.85
brain stage 5 ALZ	1.14
brain stage 5 ALZ	-1.22
lung 24	-10.98
lung 28	-19.65
lung 23	-8.45
asthmatic lung	-1.85
asthmatic lung	1.97
asthmatic lung	1.88
asthmatic lung	-1.36
endo VEGF	-1.64
endo bFGF	-1.04
heart T-1	-1.03
heart T-14	1.41
heart T-3399	1.76
BM stim	1.08
osteoblast	2.55
Cartilage (pool)	-2.23
PBL HIV IIIB	-1.15
MRC5 HSV strain F	2.52

Gene Name sbg102200MCTb

5 High to moderate overall expression. Highest normal expression in the whole brain, liver, fetal liver, and thymus. Highest disease expression in one of the colon normal/tumor pairs, one of the lung normal/tumor pairs, one of the asthmatic lung samples, the dendritic cells, and the uninfected and HIV-infected PBL cells. Upregulation in 2 of 4 breast tumor samples is sufficient to make a disease claim in cancer of the breast. Upregulation in 1 of 4 AD brain samples indicates a potential role in Alzheimer's disease. Downregulation in 3 of 3 COPD lung samples suggests involvement in chronic obstructive pulmonary disease. Upregulation in 1 of 4 asthmatic lung samples indicates a potential role for this gene in lung cancer. High expression in all of the immune cells. Also high to moderate expression in the OA and RA synovium samples, the OA bone samples, and in the chondrocytes suggests an involvement in osteoarthritis and rheumatoid arthritis.

10

Sample sbg102200MCTb	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detecte d/50 ng total RNA
Subcutaneous Adipocytes Zenbio	35.66, 34.05	3.76	10.2	6.98	3.06	16.34	114.05
Subcutaneous Adipose Zenbio	40, 36	0.17	3.07	1.62	0.96	52.36	84.82
Adrenal Gland Clontech	40, 40	0	0	0.00	0.61	81.97	0.00
Whole Brain Clontech	26.32, 26.41	1192.66	1124.69	1158.68	7.24	6.91	8001.90
Fetal Brain Clontech	40, 35.84	0	3.38	1.69	0.48	103.95	175.68
Cerebellum Clontech	34.51, 34.28	7.68	8.8	8.24	2.17	23.04	189.86
Cervix	40, 34.34	3.17	8.5	5.84	2.42	20.66	120.56
Colon	33.67, 35.6	12.86	3.91	8.39	2.71	18.45	154.70
Endometrium	35.32, 34.43	4.66	8.05	6.36	0.73	68.21	433.49
Esophagus	34.27, 35.14	8.86	5.19	7.03	1.37	36.50	256.39
Heart Clontech	40, 35.05	0	5.5	2.75	1.32	37.88	104.17
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	35.29, 33.68	4.74	12.8	8.77	2.58	19.38	169.96
Jejunum	31.23, 30.98	57.65	67.22	62.44	6.60	7.58	472.99
Kidney	34.67, 34.21	6.95	9.2	8.08	2.12	23.58	190.45
Liver	30.76, 30.65	77.12	82.56	79.84	1.50	33.33	2661.33
Fetal Liver Clontech	26.8, 27.1	885.14	734.31	809.73	10.40	4.81	3892.91
Lung	40, 40	0	0.17	0.09	2.57	19.46	1.65
Mammary Gland Clontech	31.28, 31.37	56.1	52.95	54.53	13.00	3.85	209.71
Myometrium	34.16, 36.28	9.48	2.57	6.03	2.34	21.37	128.74
Omentum	34.18, 33.42	9.38	15	12.19	3.94	12.69	154.70
Ovary	34.21, 34.18	9.24	9.39	9.32	4.34	11.52	107.32
Pancreas	40, 40	0	0.14	0.07	0.81	61.80	4.33
Head of Pancreas	40, 35.02	0	5.59	2.80	1.57	31.85	89.01
Parotid Gland	31.23, 31.9	57.68	38.33	48.01	5.48	9.12	438.00
Placenta Clontech	31.77, 33.13	41.33	17.94	29.64	5.26	9.51	281.70
Prostate	39.72, 35.03	0.31	5.56	2.94	3.00	16.67	48.92
Rectum	35.36, 34.34	4.53	8.5	6.52	1.23	40.65	264.84
Salivary Gland Clontech	30.52, 30.54	89.5	88.43	88.97	7.31	6.84	608.52

Skeletal Muscle Clontech	40, 40	0	0	0.00	1.26	39.68	0.00
Skin	40, 40	0	0	0.00	1.21	41.32	0.00
Small Intestine Clontech	40, 39.27	0	0.41	0.21	0.98	51.07	10.47
Spleen	34.21, 33.54	9.2	13.91	11.56	4.92	10.16	117.43
Stomach	35.05, 33.62	5.51	13.22	9.37	2.73	18.32	171.52
Testis Clontech	40, 40	0	0	0.00	0.57	87.87	0.00
Thymus Clontech	28.56, 28.44	299.45	322.02	310.74	9.89	5.06	1570.96
Thyroid	31.65, 32.3	44.76	29.81	37.29	2.77	18.05	673.01
Trachea Clontech	32.3, 31.9	29.9	38.28	34.09	9.71	5.15	175.54
Urinary Bladder	34.34, 35.02	8.49	5.59	7.04	5.47	9.14	64.35
Uterus	33.07, 34.56	18.62	7.45	13.04	5.34	9.36	122.05
genomic	25.84	1597.08					
b-actin	27.32	643.56					
1.00E+05	19.22	100000					
1.00E+05	19.33	100000					
1.00E+04	22.48	10000					
1.00E+04	22.95	10000					
1.00E+03	26.19	1000					
1.00E+03	26.37	1000					
1.00E+02	31.23	100					
1.00E+02	30.48	100					
1.00E+01	32.76	10					
1.00E+01	35.02	10					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg102200MCTb	Reg number (GSK identifie r)	Ct	Mean GOI copies	copies of mRNA detected /50 ng total RNA	Sample	Fold Change in Disease Populati on
colon normal GW98-167	21941	26.48	1723.59	3447.18	colon normal	
colon tumor GW98-166	21940	26.06	2195.04	4390.08	colon tumor	1.27
colon normal GW98-178	22080	29.03	389.88	779.76	colon normal	
colon tumor GW98-177	22060	27.39	1015.65	2031.30	colon tumor	2.61
colon normal GW98-561	23514	26.74	1478.76	2957.52	colon normal	
colon tumor GW98-560	23513	26.37	1831.8	3663.60	colon tumor	1.24
colon normal GW98-894	24691	25.58	2918.02	5836.04	colon normal	
colon tumor GW98-893	24690	25	4089.75	8179.50	colon tumor	1.40
lung normal GW98-3	20742	24.59	5183.31	10366.62	lung normal	
lung tumor GW98-2	20741	24.94	4232.23	8464.46	lung tumor	-1.22
lung normal GW97-179	20677	25.73	2672.73	5345.46	lung normal	
lung tumor GW97-178	20676	25.36	3307.37	6614.74	lung tumor	1.24
lung normal GW98-165	21922	26.13	2109.28	4218.56	lung normal	

lung tumor GW98-164	21921	25.54	2973.82	5947.64	lung tumor	1.41
lung normal GW98-282	22584	27.08	1212.64	2425.28	lung normal	
lung tumor GW98-281	22583	27.45	979.82	1959.64	lung tumor	-1.24
breast normal GW00-392	28750	26.68	1536.57	1536.57	breast normal	
breast tumor GW00-391	28746	26.58	1626.58	3253.16	breast tumor	2.12
breast normal GW00-413	28798	31.71	81.9	81.90	breast normal	
breast tumor GW00-412	28797	26.57	1632	3264.00	breast tumor	39.85
breast normal GW00-235:238	27592-95	32.52	51.1	51.10	breast normal	
breast tumor GW00-231:234	27588-91	29.67	268.7	268.70	breast tumor	5.26
breast normal GW98-621	23656	26.48	1727.44	3454.88	breast normal	
breast tumor GW98-620	23655	25.65	2793.6	5587.20	breast tumor	1.62
brain normal BB99-542	25507	28.62	494	988.00	brain normal	
brain normal BB99-406	25509	29.45	304.68	609.36	brain normal	
brain normal BB99-904	25546	30.08	211.25	422.50	brain normal	
brain stage 5 ALZ BB99-874	25502	28.75	458.64	917.28	brain stage 5 ALZ	1.36
brain stage 5 ALZ BB99-887	25503	26.86	1383.71	2767.42	brain stage 5 ALZ	4.11
brain stage 5 ALZ BB99-862	25504	28.02	702.59	1405.18	brain stage 5 ALZ	2.09
brain stage 5 ALZ BB99-927	25542	29.57	284.31	568.62	brain stage 5 ALZ	-1.18
CT lung KC	normal	26.58	1624.29	3248.58	CT lung	
lung 26 KC	normal	34.19	19.27	19.27	lung 26	
lung 27 KC	normal	32.45	53.23	53.23	lung 27	
lung 24 KC	COPD	33	38.6	38.60	lung 24	-21.75
lung 28 KC	COPD	32.24	59.95	59.95	lung 28	-14.01
lung 23 KC	COPD	32.87	41.63	41.63	lung 23	-20.17
lung 25 KC	normal	33.04	37.52	37.52	lung 25	
asthmatic lung ODO3112	29321	30.13	205.46	205.46	asthmatic lung	-4.09
asthmatic lung ODO3433	29323	27.82	788.82	1577.64	asthmatic lung	1.88
asthmatic lung ODO3397	29322	25.17	3695.43	7390.86	asthmatic lung	8.80
asthmatic lung ODO4928	29325	27.6	894.3	1788.60	asthmatic lung	2.13
endo cells KC	control	28.2	633.43	633.43	endo cells	
endo VEGF KC		28.86	429.51	429.51	endo VEGF	-1.47
endo bFGF KC		28.97	403.08	403.08	endo bFGF	-1.57
heart Clontech	normal	28.83	437.62	875.24	heart	
heart (T-1) ischemic	29417	28.42	557.54	1115.08	heart T-1	1.27
heart (T-14) non-obstructive DCM	29422	27.72	835.11	1670.22	heart T-14	1.91
heart (T-3399) DCM	29426	28.63	493.01	986.02	heart T-3399	1.13
adenoid GW99-269	26162	27	1269.75	2539.50	adenoid	
tonsil GW98-280	22582	26.33	1876.29	3752.58	tonsil	
T cells PC00314	28453	29.15	363.35	726.70	T cells	
PBMNC		33.05	37.41	37.41	PBMNC	
monocyte		31.49	92.84	185.68	monocyte	
B cells PC00665	28455	26.5	1700.87	3401.74	B cells	
dendritic cells 28441		24.2	6511.17	13022.34	dendritic cells	

neutrophils	28440	27.01	1262.74	1262.74	neutrophils	
eosinophils	28446	29.23	347.08	694.16	eosinophils	
BM unstim		30.85	135.01	135.01	BM unstim	
BM stim		28.68	478.5	478.50	BM stim	3.54
osteо dif		31.03	121.2	121.20	osteо dif	3.93
osteо undif		33.38	30.85	30.85	osteо undif	
chondrocytes		26.63	1579.73	3949.33	chondrocytes	
OA Synovium IP12/01	29462	29.11	371.98	371.98	OA Synovium	
OA Synovium NP10/01	29461	29.45	304.55	609.10	OA Synovium	
OA Synovium NP57/00	28464	27.83	784.87	1569.74	OA Synovium	
RA Synovium NP03/01	28466	27.31	1063.77	2127.54	RA Synovium	
RA Synovium NP71/00	28467	27.08	1217.21	2434.42	RA Synovium	
RA Synovium NP45/00	28475	26.6	1606.41	3212.82	RA Synovium	
OA bone (biobank)	29217	28.65	485.63	485.63	OA bone (biobank)	
OA bone Sample 1	J. Emory	28.78	451.74	903.48	OA bone	
OA bone Sample 2	J. Emory	28.27	607.15	1214.30	OA bone	
Cartilage (pool)	Normal	29.42	310.76	621.52	Cartilage (pool)	
Cartilage (pool)	OA	30.09	209.7	419.40	Cartilage (pool)	-1.48
PBL uninfected	28441	23.85	7997.03	15994.06	PBL uninfected	
PBL HIV IIIB	28442	24.85	4447.34	8894.68	PBL HIV IIIB	-1.80
MRC5 uninfected (100%)	29158	27.02	1258.46	2516.92	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	29.6	278.84	557.68	MRC5 HSV strain F	-4.51
W12 cells	29179	27.21	1122.77	2245.54	W12 cells	
Keratinocytes	29180	25.64	2815.12	5630.24	Keratinocytes	
B-actin control		27.78	807.72			
genomic		27.04	1246.22			
1.00E+05		19.69	100000			
1.00E+05		20.01	100000			
1.00E+04		23.15	10000			
1.00E+04		23.2	10000			
1.00E+03		27.02	1000			
1.00E+03		26.76	1000			
1.00E+02		31.45	100			
1.00E+02		32.39	100			
1.00E+01		35.72	10			
1.00E+01		34.74	10			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			

Gene Name sbg102200MCTb

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	1.27
colon tumor	2.61
colon tumor	1.24

colon tumor	1.40
lung tumor	-1.22
lung tumor	1.24
lung tumor	1.41
lung tumor	-1.24
breast tumor	2.12
breast tumor	39.85
breast tumor	5.26
breast tumor	1.62
brain stage 5 ALZ	1.36
brain stage 5 ALZ	4.11
brain stage 5 ALZ	2.09
brain stage 5 ALZ	-1.18
lung 24	-21.75
lung 28	-14.01
lung 23	-20.17
asthmatic lung	-4.09
asthmatic lung	1.88
asthmatic lung	8.80
asthmatic lung	2.13
endo VEGF	-1.47
endo bFGF	-1.57
heart T-1	1.27
heart T-14	-0.01
heart T-3399	1.15
BM stim	3.54
osteo dif	3.93
Cartilage (pool)	-1.48
PBL HIV IIIB	-1.80
MRC5 HSV strain F	-4.51

Gene Name sbg1020380LYG**Failed**

5

Gene Name sbg1007026SGLT

Good to moderate overall expression. The highest normal expression is seen in the whole brain, cerebellum, hypothalamus, jejunum, fetal liver, rectum, and uterus. This gene shows system specific expression in samples representing the central nervous system, the female reproductive organs, and the GI tract. The expression seen in the disease samples confirms that seen in the normal samples with the highest levels of expression seen in the normal and Alzheimer's brain samples.

Upregulation in 1 of 4 colon tumor samples and 2 of 4 breast tumor samples as well as downregulation in 1 of 4 lung tumors poses a potential role for this gene in cancers of the colon and breast. Downregulation in 2 of 4 Alzheimer's brain samples implies involvement in Alzheimer's disease. Downregulation in 3 of 3 COPD samples and upregulation in 2 of 4 asthmatic lung samples suggests a potential role for this gene in chronic obstructive pulmonary disorder. Upregulation in the VEGF-treated endothelial cell line implicates a possible role for this gene in angiogenesis. Downregulated in the stimulated bone marrow sample. High expression in the RA and OA synovium samples, the OA bone samples, and the chondrocytes with corroborating high expression in the T cells, B cells, neutrophils, and eosinophils implicates this gene in osteoarthritis and rheumatoid arthritis.

Sample sbg1007026SGLT	Ct (sample 1 and 2)	Mean GOI	Mean GOI	Average GOI	18S rRNA	50 ng/18	copies of mRNA
--------------------------	------------------------	-------------	-------------	----------------	-------------	-------------	-------------------

		copies (sample 1)	copies (sample 2)	Copies	(ng)	S rRNA (ng)	detected/ 50 ng total RNA
Subcutaneous Adipocytes Zenbio	40, 40	0	0	0.00	3.06	16.34	0.00
Subcutaneous Adipose Zenbio	40, 40	0	0.1	0.05	0.96	52.36	2.62
Adrenal Gland Clontech	40, 38.76	0	0.31	0.16	0.61	81.97	12.70
Whole Brain Clontech	23.01, 22.63	3438.45	4301.69	3870.07	7.24	6.91	26727.00
Fetal Brain Clontech	35.91, 39.16	1.66	0.24	0.95	0.48	107.95	98.75
Cerebellum Clontech	34.55, 32.7	3.71	11.08	7.40	2.17	23.04	170.39
Cervix	34.21, 34.61	4.54	3.58	4.06	2.47	20.66	83.88
Colon	33.44, 33.7	7.16	6.14	6.65	2.71	18.45	122.69
Endometrium	34.88, 40	3.05	0.1	1.58	0.73	68.21	107.44
Esophagus	40, 40	0	0.1	0.07	1.37	36.50	1.82
Heart Clontech	39.63, 39.53	0.18	0.19	0.19	1.32	37.88	7.01
Hypothalamus	40, 35.34	0	2.33	1.17	0.32	155.28	180.90
Ileum	40, 40	0	0	0.00	2.58	19.38	0.00
Jejunum	30.1, 30.34	51.59	44.92	48.26	6.60	7.58	365.57
Kidney	33.49, 40	6.97	0	3.48	2.12	23.58	82.08
Liver	40, 33.7	0	6.15	3.08	1.50	33.33	102.50
Fetal Liver Clontech	29.58, 29.41	70.26	77.58	73.92	10.40	4.81	355.38
Lung	35.51, 37.83	1.98	0.53	1.26	2.57	19.46	24.42
Mammary Gland Clontech	33.05, 34.04	9.02	5.03	7.03	13.00	3.85	27.02
Myometrium	33.63, 34.13	6.38	4.77	5.58	2.34	21.37	119.12
Omentum	40, 40	0	0	0.00	3.94	12.69	0.00
Ovary	35.38, 37.6	2.27	0.61	1.44	4.34	11.52	16.59
Pancreas	40, 37.1	0	0.82	0.41	0.81	61.80	25.34
Head of Pancreas	35.45, 36.72	2.18	1.03	1.61	1.57	31.85	51.11
Parotid Gland	36.88, 40	0.94	0	0.47	5.48	9.12	4.29
Placenta Clontech	33.84, 38.46	5.66	0.37	3.02	5.26	9.51	28.66
Prostate	38.76, 37.12	0.31	0.81	0.56	3.00	16.67	9.33
Rectum	36.18, 33.82	1.42	5.7	3.56	1.23	40.65	144.72
Salivary Gland Clontech	38.36, 39.93	0.39	0.12	0.26	7.31	6.84	1.74
Skeletal Muscle Clontech	35.69, 36.23	1.9	1.38	1.64	1.26	39.68	65.08
Skin	39.51, 40	0.2	0.09	0.15	1.21	41.32	5.99
Small Intestine Clontech	40, 36.04	0.1	1.53	0.82	0.98	51.07	41.62
Spleen	33.51, 38.51	6.87	0.36	3.62	4.92	10.16	36.74
Stomach	34.14, 34.19	4.73	4.59	4.66	2.73	18.32	85.35
Testis Clontech	35.81, 40	1.76	0.11	0.94	0.57	87.87	82.16
Thymus Clontech	33.26, 32.49	7.96	12.55	10.26	9.89	5.06	51.85
Thyroid	40, 39.9	0.08	0.16	0.12	2.77	18.05	2.17
Trachea Clontech	34.25, 33.8	4.42	5.77	5.10	9.71	5.15	26.24
Urinary Bladder	39.95, 36.54	0.1	1.14	0.62	5.47	9.14	5.67
Uterus	33, 31.23	9.3	26.52	17.91	5.34	9.36	167.70
genomic	24.72	1251.19					

b-actin	25.89	625.04					
1.00E+05	17.54	100000					
1.00E+05	17.65	100000					
1.00E+04	21.03	10000					
1.00E+04	20.92	10000					
1.00E+03	24.87	1000					
1.00E+03	24.96	1000					
1.00E+02	29.1	100					
1.00E+02	29.04	100					
1.00E+01	32.05	10					
1.00E+01	33.51	10					
1.00E-00	36.41	1					
1.00E-00	37.41	1					
NTC	40	0					
NTC	40	-1					

Sample sbg1007026SGLT	Reg. number (GSK identifier)	Ct	Mean GOI copies	copies of mRNA detected/ 50 ng total RNA	Sample	Fold Change in Disease Populati on
colon normal GW98-167	21941	29.22	127.1	254.20	colon normal	
colon tumor GW98-166	21940	31.07	44.11	88.22	colon tumor	-2.88
colon normal GW98-178	22080	38.41	0.65	1.30	colon normal	
colon tumor GW98-177	22060	31.17	41.5	83.00	colon tumor	63.85
colon normal GW98-561	23514	31.21	40.69	81.38	colon normal	
colon tumor GW98-560	23513	33.06	14.04	28.08	colon tumor	-2.90
colon normal GW98-894	24691	29.63	100.41	200.82	colon normal	
colon tumor GW98-893	24690	32.22	22.7	45.40	colon tumor	-4.42
lung normal GW98-3	20742	29.8	91.46	182.92	lung normal	
lung tumor GW98-2	20741	34.26	7.02	14.04	lung tumor	-13.03
lung normal GW97-179	20677	29.59	103.13	206.26	lung normal	
lung tumor GW97-178	20676	29.84	89.09	178.18	lung tumor	-1.16
lung normal GW98-165	21922	29.6	102.46	204.92	lung normal	
lung tumor GW98-164	21921	30.8	51.53	103.06	lung tumor	-1.99
lung normal GW98-282	22584	32.53	18.97	37.94	lung normal	
lung tumor GW98-281	22583	32.29	21.8	43.60	lung tumor	1.15
breast normal GW00-392	28750	28.77	164.85	164.85	breast normal	
breast tumor GW00-391	28746	30.64	56.21	112.42	breast tumor	-1.47
breast normal GW00-413	28798	34.49	6.17	6.17	breast normal	
breast tumor GW00-412	28797	30.37	65.97	131.94	breast tumor	21.38
breast normal GW00-235:238	27592-95	32.87	15.66	15.66	breast normal	
breast tumor GW00-231:234	27588-91	29.8	91.07	91.07	breast tumor	5.82
breast normal GW98-621	23656	28.95	149.19	298.38	breast normal	
breast tumor GW98-620	23655	29.62	101.25	202.50	breast tumor	-1.47
brain normal BB99-542	25507	24.5	1917.28	3834.56	brain normal	

brain normal BB99-406	25509	21.35	11736.92	23473.84	brain normal	
brain normal BB99-904	25546	25.25	1248.68	2497.36	brain normal	
brain stage 5 ALZ BB99-874	25502	27.29	386.81	773.62	brain stage 5 ALZ	-12.84
brain stage 5 ALZ BB99-887	25503	23.61	3196.37	6392.74	brain stage 5 ALZ	-1.55
brain stage 5 ALZ BB99-862	25504	25.56	1045.09	2090.18	brain stage 5 ALZ	-4.75
brain stage 5 ALZ BB99-927	25542	24.45	1976.24	3952.48	brain stage 5 ALZ	-2.51
CT lung	normal	31.07	44.03	88.06	CT lung Nml	
lung 26	normal	24.93	1496.87		lung 26 Nml	
lung 27	normal	34.06	7.92	7.92	lung 27 Nml	
lung 24	COPD	34.58	5.87	5.87	lung 24 COPD	-5.45
lung 28	COPD	40	0	0.00	lung 28 COPD	-31.99
lung 23	COPD	40	0	0.00	lung 23 COPD	-31.99
lung 25	normal	40	0	0.00	lung 25 Nml	
asthmatic lung ODO3112	29321	33.19	13.04	13.04	asthmatic lung	-2.45
asthmatic lung ODO3433	29323	30.61	57.38	114.76	asthmatic lung	3.59
asthmatic lung ODO3397	29322	29.2	129.16	258.32	asthmatic lung	8.07
asthmatic lung ODO4928	29325	30.32	67.67	135.34	asthmatic lung	4.23
endo cells	control	35.09	4.37	4.37	endo cells	
endo VEGF		32.22	22.7	22.70	endo VEGF	5.19
endo bFGF		33.23	12.7	12.70	endo bFGF	2.91
heart Clontech	normal	33.53	10.71	21.42	heart	
heart (T-1) ischemic	29417	33.43	11.37	22.74	heart (T-1) ischemic	1.06
heart (T-14) non-obstructive DCM	29422	34.45	6.32	12.64	heart (T-14) non-obstructive DCM	-1.69
heart (T-3399) DCM	29426	31.98	26.02	52.04	heart (T-3399) DCM	2.43
adenoid GW99-269	26162	29.56	104.93	209.86	adenoid	
tonsil GW98-280	22582	29	144.55	289.10	tonsil	
T cells PC00314	28453	32.03	25.34	50.68	T cells	
PBMNC		37.71	0.97	0.97	PBMNC	
monocyte		37.49	1.1	2.20	monocyte	
B cells PC00665	28455	27.18	410.49	820.98	B cells	
dendritic cells	28441	33.7	9.73	19.46	dendritic cells	
neutrophils	28440	32.48	19.6	19.60	neutrophils	
eosinophils	28446	32.44	20.08	40.16	eosinophils	
BM unstim		33.8	9.17	9.17	BM unstim	
BM stim	treated	38.89	0.49	0.49	BM stim	-18.71
osteо dif	treated	37.26	1.26	1.26	osteо dif	1.26
osteо undif		40	0	0.00	osteо undif	
chondrocytes		32.07	24.82	62.05	chondrocytes	
OA Synovium IP12/01	29462	30.31	68.26	68.26	OA Synovium	
OA Synovium NP10/01	29461	30.74	53.26	106.52	OA Synovium	
OA Synovium NP57/00	28464	31.3	38.48	76.96	OA Synovium	
RA Synovium NP03/01	28466	31.08	43.89	87.78	RA Synovium	
RA Synovium NP71/00	28467	31.35	37.58	75.16	RA Synovium	

RA Synovium NP45/00	28475	30.74	53.21	106.42	RA Synovium	
OA bone (biobank)	29217	30.47	61.99	61.99	OA bone (biobank)	
OA bone Sample 1	J. Emory	29.92	85.09	170.18	OA bone	
OA bone Sample 2	J. Emory	30.91	48.27	96.54	OA bone	
Cartilage (pool)	Normal	31.34	37.68	75.36	Nml Cartilage (pool)	
Cartilage (pool)	OA	31.72	30.35	60.70	OA Cartilage (pool)	-1.24
PBL uninfected	28441	30.8	51.54	103.08	PBL uninfected	
PBL HIV IIIB	28442	32.03	25.38	50.76	PBL HIV IIIB	-2.03
MRC5 uninfected (100%)	29158	32.29	21.85	43.70	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	31.21	40.73	81.46	MRC5 HSV strain F	1.86
W12 cells	29179	33.12	13.52	27.04	W12 cells	
Keratinocytes	29180	32.35	21.06	42.12	Keratinocytes	
B-actin control		25.63	1002.01			
genomic		25.19	1290.48			
1.00E+05		17.86	100000			
1.00E+05		17.85	100000			
1.00E+04		21.44	10000			
1.00E+04		21.51	10000			
1.00E+03		25.33	1000			
1.00E+03		25.26	1000			
1.00E+02		29.62	100			
1.00E+02		30.55	100			
1.00E+01		32.93	10			
1.00E+01		33.46	10			
1.00E-00		38.18	1			
1.00E-00		40	0			
NTC		38.28	-1			
*lung 26 Normal has been omitted due to multiple amplification failures from that sample						

Gene Name sbg1007026SGLT

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-2.88
colon tumor	63.85
colon tumor	-2.90
colon tumor	-4.42
lung tumor	-13.03
lung tumor	-1.16
lung tumor	-1.99
lung tumor	1.15
breast tumor	-1.47
breast tumor	21.38

breast tumor	5.82
breast tumor	-1.47
brain stage 5 ALZ	-12.84
brain stage 5 ALZ	-1.55
brain stage 5 ALZ	-4.75
brain stage 5 ALZ	-2.51
lung 24	-5.45
lung 28	-31.99
lung 23	-31.99
asthmatic lung	-2.45
asthmatic lung	3.59
asthmatic lung	8.07
asthmatic lung	4.23
endo VEGF	5.19
endo bFGF	2.91
heart T-1	1.06
heart T-14	-1.69
heart T-3399	2.43
BM stim	-18.71
osteo dif	1.26
Cartilage (pool)	-1.24
PBL HIV IIIB	-2.03
MRC5 HSV strain F	1.86

Gene Name sbg1012732GLUT

5 High to moderate overall expression. This gene is expressed fairly ubiquitously in all normal samples analyzed with highest levels of expression seen in the whole brain, fetal brain cerebellum, kidney, fetal liver, and the placenta. This gene is also expressed fairly ubiquitously in the disease samples. Downregulation in 3 of 3 COPD samples suggests a potential role for this gene in chronic obstructive pulmonary disorder. Upregulation in 3 of 3 disease heart samples implies an involvement in cardiovascular diseases such as non-obstructive and obstructive DCM and ischemia. Downregulation in the HSV-infected MRC5 cells suggests that this gene may play a role.

10 Upregulated in the differentiated osteoblasts. High expression in the RA and OA synovium samples, the OA bone samples, and the chondrocytes with corroborating high expression in the T cells, B cells, dendritic cells, neutrophils, and eosinophils implicates this gene in osteoarthritis and rheumatoid arthritis.

Sample sbg1012732GLUT	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detected/ 50 ng total RNA
Subcutaneous Adipocytes Zenbio	30.84, 30.49	46.76	57.63	52.20	3.06	16.34	852.86
Subcutaneous Adipose Zenbio	34.89, 35.19	4.31	3.62	3.97	0.96	52.36	207.59
Adrenal Gland Clontech	33.79, 32.74	8.27	15.31	11.79	0.61	81.97	966.39
Whole Brain Clontech	22.02, 21.91	8374.61	8944.05	8659.33	7.24	6.91	59802.00
Fetal Brain Clontech	32.03, 32.85	23.23	14.34	18.79	0.48	103.95	1952.70
Cerebellum Clontech	28.2, 28.26	221.12	213.07	217.10	2.17	23.04	5002.19
Cervix	32.91, 34.54	13.81	5.31	9.56	2.42	20.66	197.52
Colon	30.88, 32.48	45.58	17.87	31.73	2.71	18.45	585.33
Endometrium	36.13, 32.5	2.08	17.6	9.84	0.73	68.21	671.21

Esophagus	32.19, 33.5	21.15	9.77	15.46	1.37	36.50	564.23
Heart Clontech	31.93, 31.73	24.67	27.76	26.22	1.32	37.88	992.99
Hypothalamus	40, 32.77	0	15.04	7.52	0.32	155.28	1167.70
Ileum	30.94, 30.52	44.17	56.37	50.27	2.58	19.38	974.22
Jejunum	30.04, 29.34	75.03	113.25	94.14	6.60	7.58	713.18
Kidney	29.72, 29.18	90.58	124.19	107.39	2.12	23.58	2532.67
Liver	34.81, 32.2	4.52	21.05	12.79	1.50	33.33	426.17
Fetal Liver Clontech	26.6, 26.85	567.46	488.36	527.91	10.40	4.81	2538.03
Lung	31.61, 30.52	29.69	56.54	43.12	2.57	19.46	838.81
Mammary Gland Clontech	28.06, 27.59	239.58	316.2	277.89	13.00	3.85	1068.81
Myometrium	30.44, 29.88	59.31	82.52	70.92	2.34	21.37	1515.28
Omentum	31.7, 30.82	28.2	47.35	37.78	3.94	12.69	479.38
Ovary	30.92, 31.56	44.74	30.55	37.65	4.34	11.52	433.70
Pancreas	33.08, 32.66	12.54	16.03	14.29	0.81	61.80	882.88
Head of Pancreas	33.98, 34.1	7.36	6.89	7.13	1.57	31.85	226.91
Parotid Gland	29.5, 30.55	102.86	55.41	79.14	5.48	9.12	722.03
Placenta Clontech	25.63, 25.87	1002.18	869.55	935.87	5.26	9.51	8896.06
Prostate	30.23, 31.17	67.04	38.48	52.76	3.00	16.67	879.33
Rectum	31.29, 31.15	35.89	38.94	37.42	1.23	40.65	1520.93
Salivary Gland Clontech	28.82, 28.83	153.9	152.53	153.22	7.31	6.84	1047.98
Skeletal Muscle Clontech	33.23, 32.66	11.48	16.02	13.75	1.26	39.68	545.63
Skin	32.62, 32.57	16.46	16.96	16.71	1.21	41.32	690.50
Small Intestine Clontech	34.63, 32.82	5.03	14.62	9.83	0.98	51.07	501.79
Spleen	31.45, 32.71	32.66	15.56	24.11	4.92	10.16	245.02
Stomach	32.38, 32.43	18.93	18.41	18.67	2.73	18.32	341.94
Testis Clontech	32.32, 32.27	19.58	20.17	19.88	0.57	87.87	1746.49
Thymus Clontech	27.24, 26.75	388.32	518.55	453.44	9.89	5.06	2292.39
Thyroid	30.48, 29.44	57.86	106.5	82.18	2.77	18.05	1483.39
Trachea Clontech	29.96, 30.29	78.48	64.81	71.65	9.71	5.15	368.92
Urinary Bladder	30.59, 30.1	54.25	72.45	63.35	5.47	9.14	579.07
Uterus	30.62, 29.73	53.18	89.72	71.45	5.34	9.36	669.01
genomic	25.15	1330.24					
b-actin	26.01	800.58					
1.00E+05	18.01	100000					
1.00E+05	18.19	100000					
1.00E+04	21.35	10000					
1.00E+04	21.3	10000					
1.00E+03	25.59	1000					
1.00E+03	25.51	1000					
1.00E+02	29.95	100					
1.00E+02	29.37	100					
1.00E+01	34.05	10					
1.00E+01	33.22	10					
1.00E-00	37.19	1					
1.00E-00	40	0					
NTC	40	0					

NTC	40	0					
-----	----	---	--	--	--	--	--

Sample sbg1012732GLUT	Reg number (GSK identifier)	Ct	Mean GOI copies	copies of mRNA detected/ 50 ng total RNA	Sample	Fold Change in Disease Populati on
colon normal GW98-167	21941	25.38	1695.47	3390.94	colon normal	
colon tumor GW98-166	21940	25.51	1576.91	3153.82	colon tumor	-1.08
colon normal GW98-178	22080	26.8	765.5	1531.00	colon normal	
colon tumor GW98-177	22060	25.86	1297.34	2594.68	colon tumor	1.69
colon normal GW98-561	23514	26.12	1120.64	2241.28	colon normal	
colon tumor GW98-560	23513	26.12	1121.89	2243.78	colon tumor	1.00
colon normal GW98-894	24691	24.85	2283.56	4567.12	colon normal	
colon tumor GW98-893	24690	24.37	2989.5	5979.00	colon tumor	1.31
lung normal GW98-3	20742	24.37	2984.11	5968.22	lung normal	
lung tumor GW98-2	20741	25.38	1691.06	3382.12	lung tumor	-1.76
lung normal GW97-179	20677	25.07	2020.52	4041.04	lung normal	
lung tumor GW97-178	20676	24.61	2607.03	5214.06	lung tumor	1.29
lung normal GW98-165	21922	24.92	2195.85	4391.70	lung normal	
lung tumor GW98-164	21921	25.36	1712.62	3425.24	lung tumor	-1.28
lung normal GW98-282	22584	26.24	1049.97	2099.94	lung normal	
lung tumor GW98-281	22583	25.94	1241.8	2483.60	lung tumor	1.18
breast normal GW00-392	28750	25.26	1813.7	1813.70	breast normal	
breast tumor GW00-391	28746	24.87	2259.54	4519.08	breast tumor	2.49
breast normal GW00-413	28798	25.4	1672.46	1672.46	breast normal	
breast tumor GW00-412	28797	25.21	1864.18	3728.36	breast tumor	2.23
breast normal GW00-235:238	27592-95	25.68	1435.2	1435.20	breast normal	
breast tumor GW00-231:234	27588-91	24.08	3510.78	3510.78	breast tumor	2.45
breast normal GW98-621	23656	24.16	3363.26	6726.52	breast normal	
breast tumor GW98-620	23655	24.19	3300.23	6600.46	breast tumor	-1.02
brain normal BB99-542	25507	22.64	7880.57	15761.14	brain normal	
brain normal BB99-406	25509	23.32	5357.05	10714.10	brain normal	
brain normal BB99-904	25546	23.66	4436.27	8872.54	brain normal	
brain stage 5 ALZ BB99-874	25502	24.7	2474.23	4948.46	brain stage 5 ALZ	-2.38
brain stage 5 ALZ BB99-887	25503	23.22	5674.88	11349.76	brain stage 5 ALZ	-1.04
brain stage 5 ALZ BB99-862	25504	23.5	4868.6	9737.20	brain stage 5 ALZ	-1.21
brain stage 5 ALZ BB99-927	25542	23.17	5843.2	11686.40	brain stage 5 ALZ	-1.01
CT lung	normal	25.61	1486.99	2973.98	CT lung Nml	
lung 26	normal	26.55	879.91		lung 26 Nml	
lung 27	normal	29.44	174.3	174.30	lung 27 Nml	

lung 24	COPD	29.99	128.5	128.50	lung 24 COPD	-8.67
lung 28	COPD	29.56	163.34	163.34	lung 28 COPD	-6.82
lung 23	COPD	29.59	160.67	160.67	lung 23 COPD	-6.94
lung 25	normal	29.24	194.83	194.83	lung 25 Nml	
asthmatic lung ODO3112	29321	27.22	604.38	604.38	asthmatic lung	-1.84
asthmatic lung ODO3433	29323	26.46	923.43	1846.86	asthmatic lung	1.66
asthmatic lung ODO3397	29322	26.16	1094.36	2188.72	asthmatic lung	1.96
asthmatic lung ODO4928	29325	25.51	1576.72	3153.44	asthmatic lung	2.83
endo cells	control	29.09	211.78	211.78	endo cells	
endo VEGF		30.07	122.67	122.67	endo VEGF	-1.73
endo bFGF		29.93	132.63	132.63	endo bFGF	-1.60
heart Clontech	normal	27.35	561.26	1122.52	heart	
heart (T-1) ischemic	29417	23.82	4053.65	8107.30	heart (T-1) ischemic	7.22
heart (T-14) non-obstructive DCM	29422	23.96	3746.25	7492.50	heart (T-14) non-obstructive DCM	6.67
heart (T-3399) DCM	29426	23.35	5282.35	10564.70	heart (T-3399) DCM	9.41
adenoid GW99-269	26162	25.71	1405.41	2810.82	adenoid	
tonsil GW98-280	22582	23.97	3725.77	7451.54	tonsil	
T cells PC00314	28453	25.03	2062.68	4125.36	T cells	
PBMNC		30.16	116.69	116.69	PBMNC	
monocyte		30.15	117.05	234.10	monocyte	
B cells PC00665	28455	23.22	5673.63	11347.26	B cells	
dendritic cells	28441	25.74	1385.65	2771.30	dendritic cells	
neutrophils	28440	27.14	631.86	631.86	neutrophils	
eosinophils	28446	28.27	335.66	671.32	eosinophils	
BM unstim		30.08	122.25	122.25	BM unstim	
BM stim	treated	29.57	162.71	162.71	BM stim	1.33
osteо dif	treated	29.07	214.84	214.84	osteо dif	2.91
osteо undif		30.98	73.85	73.85	osteо undif	
chondrocytes		25.41	1667.28	4168.20	chondrocytes	
OA Synovium IP12/01	29462	24.65	2554.39	2554.39	OA Synovium	
OA Synovium NP10/01	29461	25.72	1399	2798.00	OA Synovium	
OA Synovium NP57/00	28464	25.24	1828.2	3656.40	OA Synovium	
RA Synovium NP03/01	28466	25.69	1422.61	2845.22	RA Synovium	
RA Synovium NP71/00	28467	25.25	1818.15	3636.30	RA Synovium	
RA Synovium NP45/00	28475	25.22	1857.13	3714.26	RA Synovium	
OA bone (biobank)	29217	26.19	1074.74	1074.74	OA bone (biobank)	
OA bone Sample 1	J. Emory	26.71	805.65	1611.30	OA bone	
OA bone Sample 2	J. Emory	26.96	700.88	1401.76	OA bone	
Cartilage (pool)	Normal	26.38	968.45	1936.90	Nml Cartilage (pool)	
Cartilage (pool)	OA	28.07	376.23	752.46	OA Cartilage (pool)	-2.57
PBL uninfected	28441	25.09	1997.75	3995.50	PBL uninfected	
PBL HIV IIIB	28442	25.36	1710.81	3421.62	PBL HIV IIIB	-1.17
MRC5 uninfected (100%)	29158	25.28	1788.71	3577.42	MRC5 uninfected (100%)	

MRC5 HSV strain F	29178	30.17	116.17	232.34	MRC5 HSV strain F	-15.40
W12 cells	29179	27.6	489.01	978.02	W12 cells	
Keratinocytes	29180	26.4	959.61	1919.22	Keratinocytes	
B-actin control		25.62	1482.86			
genomic		25.42	1657.68			
1.00E+05		18.49	100000			
1.00E+05		18.49	100000			
1.00E+04		21.94	10000			
1.00E+04		21.98	10000			
1.00E+03		25.34	1000			
1.00E+03		25.39	1000			
1.00E+02		30.59	100			
1.00E+02		30.9	100			
1.00E+01		32.51	10			
1.00E+01		39.12	10			
1.00E-00		39.07	1			
1.00E-00		36.71	1			
NTC		39.63	-1			
*lung 26 Normal has been omitted due to multiple amplification failures from that sample						

Gene Name sbg1012732GLUT

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-1.08
colon tumor	1.69
colon tumor	1.00
colon tumor	1.31
lung tumor	-1.76
lung tumor	1.29
lung tumor	-1.28
lung tumor	1.18
breast tumor	2.49
breast tumor	2.23
breast tumor	2.45
breast tumor	-1.02
brain stage 5 ALZ	-2.38
brain stage 5 ALZ	-1.04
brain stage 5 ALZ	-1.21
brain stage 5 ALZ	-1.01
lung 24	-8.67
lung 28	-6.82
lung 23	-6.94
asthmatic lung	-1.84
asthmatic lung	1.66
asthmatic lung	1.96
asthmatic lung	2.83
endo VEGF	-1.73

endo bFGF	-1.60
heart T-1	7.22
heart T-14	6.67
heart T-3399	9.41
BM stim	1.33
osteо dif	2.91
Cartilage (pool)	-2.57
PBL HIV IIIB	-1.17
MRC5 HSV strain F	-15.40

Gene Name sbg1012732GLUTb

The same as sbg1012732GLUT.

5

Gene Name sbg1018172CSP

10 Moderate to low overall expression. Highest normal expression is seen in the whole brain, kidney, thyroid, and uterus. This gene is expressed in all of the samples representing the female reproductive system. Highest disease expression is seen in many of the normal/tumor lung samples and the asthmatic lung samples. Downregulation in 2 of 4 lung tumor samples and upregulation in 2 of 4 breast tumor samples suggests an involvement in cancers of the lung and breast.

15 Downregulation in 3 of 3 COPD samples suggests a potential role for this gene in chronic obstructive pulmonary disorder. Upregulation in 2 of 4 asthmatic lung samples implies an involvement in asthma. Upregulation in 1 of 3 disease heart samples implies an involvement in cardiovascular disease such as obstructive DCM. Downregulation in the OA cartilage pool with corroborating low expression in the immune cells (T and B cells in particular) implicates this gene in osteoarthritis and rheumatoid arthritis. Upregulation in the HSV-infected MRC5 cells suggests that this gene may be a host factor in HSV.

20

Sample sbg1018172CSP	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detected/50 ng total RNA
Subcutaneous Adipocytes Zenbio	35.54, 34.87	7.65	11.21	9.43	3.06	16.34	154.08
Subcutaneous Adipose Zenbio	40, 40	0.4	0	0.20	0.96	52.36	10.47
Adrenal Gland Clontech	40, 40	0	0	0.00	0.61	81.97	0.00
Whole Brain Clontech	25.71, 25.78	1950.98	1867.58	1909.28	7.24	6.91	13185.64
Fetal Brain Clontech	40, 40	0	0	0.00	0.48	103.95	0.00
Cerebellum Clontech	36.32, 35.16	4.95	9.48	7.22	2.17	23.04	166.24
Cervix	36.76, 36.16	3.85	5.42	4.64	2.42	20.66	95.76
Colon	36.52, 36.41	4.41	4.7	4.56	2.71	18.45	84.04
Endometrium	36.4, 35.92	4.73	6.19	5.46	0.73	68.21	372.44
Esophagus	40, 40	0	0	0.00	1.37	36.50	0.00
Heart Clontech	40, 40	0	0	0.00	1.32	37.88	0.00
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	40, 40	0	0	0.00	2.58	19.38	0.00
Jejunum	36.53, 33.22	4.38	28.28	16.33	6.60	7.58	123.71

Kidney	32.81, 32.45	35.74	43.67	39.71	2.12	23.58	936.44
Liver	35.92, 36.2	6.19	5.29	5.74	1.50	33.33	191.33
Fetal Liver Clontech	31.57, 30.46	71.69	134.34	103.02	10.40	4.81	495.26
Lung	33.35, 36.86	26.32	3.65	14.99	2.57	19.46	291.54
Mammary Gland Clontech	32.99, 32.17	32.23	51.27	41.75	13.00	3.85	160.58
Myometrium	34.99, 40	10.44	0	5.22	2.34	21.37	111.54
Omentum	35.61, 40	7.37	0	3.69	3.94	12.69	46.76
Ovary	35.83, 35.54	6.53	7.67	7.10	4.34	11.52	81.80
Pancreas	35.86, 40	6.39	0	3.20	0.81	61.80	197.47
Head of Pancreas	40, 40	0	0	0.00	1.57	31.85	0.00
Parotid Gland	34.26, 34.03	15.73	17.96	16.85	5.48	9.12	153.70
Placenta Clontech	32.64, 33.16	39.34	29.26	34.30	5.26	9.51	326.05
Prostate	35.71, 40	6.95	0	3.48	3.00	16.67	57.92
Rectum	33.84, 34.42	19.99	14.41	17.20	1.23	40.65	699.19
Salivary Gland Clontech	40, 40	0	0	0.00	7.31	6.84	0.00
Skeletal Muscle Clontech	34.2, 40	16.33	0	8.17	1.26	39.68	324.01
Skin	35.02, 40	10.31	0.48	5.40	1.21	41.32	222.93
Small Intestine Clontech	40, 40	0	0	0.29	0.98	51.07	14.81
Spleen	40, 35.31	0	8.71	4.36	4.92	10.16	44.26
Stomach	40, 35.4	0	8.3	4.15	2.73	18.32	76.01
Testis Clontech	40, 37.31	0	2.82	1.41	0.57	87.87	123.90
Thymus Clontech	30.9, 31.1	104.45	93.52	98.99	9.89	5.06	500.43
Thyroid	31.62, 31.57	69.89	71.93	70.91	2.77	18.05	1279.96
Trachea Clontech	34.19, 34.08	16.41	17.49	16.95	9.71	5.15	87.28
Urinary Bladder	40, 34.4	0	14.55	7.28	5.47	9.14	66.50
Uterus	30.63, 30.6	122.13	123.57	122.85	5.34	9.36	1150.28
genomic	26.58	1190.6					
b-actin	27.38	758.43					
1.00E+05	19.07	100000					
1.00E+05	19.35	100000					
1.00E+04	22.57	10000					
1.00E+04	22.59	10000					
1.00E+03	26.24	1000					
1.00E+03	26.31	1000					
1.00E+02	30.18	100					
1.00E+02	31.64	100					
1.00E+01	35.9	10					
1.00E+01	40	0					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg1018172CSP	Reg number	Ct	Mean GOI	copies of mRNA	Sample	Fold Change
-------------------------	---------------	----	-------------	-------------------	--------	----------------

	(GSK identifier)		copies	detected/ 50 ng total RNA		in Disease Population
colon normal GW98-167	21941	27.29	1064.89	2129.78	colon normal	
colon tumor GW98-166	21940	26.18	2023.11	4046.22	colon tumor	1.90
colon normal GW98-178	22080	30.45	168.68	337.36	colon normal	
colon tumor GW98-177	22060	29.33	324.49	648.98	colon tumor	1.92
colon normal GW98-561	23514	30.36	177.62	355.24	colon normal	
colon tumor GW98-560	23513	32.27	58.7	117.40	colon tumor	-3.03
colon normal GW98-894	24691	30.71	145.57	291.14	colon normal	
colon tumor GW98-893	24690	32.3	57.43	114.86	colon tumor	-2.53
lung normal GW98-3	20742	24.82	4478.67	8957.34	lung normal	
lung tumor GW98-2	20741	33.61	26.86	53.72	lung tumor	-166.74
lung normal GW97-179	20677	26.31	1874.25	3748.50	lung normal	
lung tumor GW97-178	20676	24.52	5311.72	10623.44	lung tumor	2.83
lung normal GW98-165	21922	24.99	4042.28	8084.56	lung normal	
lung tumor GW98-164	21921	27.19	1127.26	2254.52	lung tumor	-3.59
lung normal GW98-282	22584	25.51	2990.53	5981.06	lung normal	
lung tumor GW98-281	22583	26.67	1522.51	3045.02	lung tumor	-1.96
breast normal GW00-392	28750	32.25	59.17	59.17	breast normal	
breast tumor GW00-391	28746	30.48	165.82	331.64	breast tumor	5.60
breast normal GW00-413	28798	34.58	15.31	15.31	breast normal	
breast tumor GW00-412	28797	30.05	213.4	426.80	breast tumor	27.88
breast normal GW00-235:238	27592-95	34.41	16.85	16.85	breast normal	
breast tumor GW00-231:234	27588-91	33.52	28.31	28.31	breast tumor	1.68
breast normal GW98-621	23656	28.22	618.19	1236.38	breast normal	
breast tumor GW98-620	23655	32.02	67.94	135.88	breast tumor	-9.10
brain normal BB99-542	25507	29.11	367.88	735.76	brain normal	
brain normal BB99-406	25509	28.05	682.39	1364.78	brain normal	
brain normal BB99-904	25546	29.06	379.07	758.14	brain normal	
brain stage 5 ALZ BB99-874	25502	30.06	211.81	423.62	brain stage 5 ALZ	-2.25
brain stage 5 ALZ BB99-887	25503	26.97	1280.13	2560.26	brain stage 5 ALZ	2.69
brain stage 5 ALZ BB99-862	25504	29.85	239.03	478.06	brain stage 5 ALZ	-1.99
brain stage 5 ALZ BB99-927	25542	28.13	652.56	1305.12	brain stage 5 ALZ	1.37
CT lung	normal	26.97	1280.81	2561.62	CT lung Nml	
lung 26	normal	32.21	60.75		lung 26 Nml	
lung 27	normal	34	21.39	21.39	lung 27 Nml	
lung 24	COPD	32.11	64.11	64.11	lung 24 COPD	-13.87
lung 28	COPD	33.01	38.18	38.18	lung 28 COPD	-23.29
lung 23	COPD	32.84	42.15	42.15	lung 23 COPD	-21.10
lung 25	normal	31.63	84.78	84.78	lung 25 Nml	
asthmatic lung ODO3112	29321	29.4	310.75	310.75	asthmatic lung	-2.86
asthmatic lung ODO3433	29323	27.02	1242.79	2485.58	asthmatic lung	2.80

asthmatic lung ODO3397	29322	25.97	2289.74	4579.48	asthmatic lung	5.15
asthmatic lung ODO4928	29325	26.84	1380.5	2761.00	asthmatic lung	3.10
endo cells	control	40	0	0.00	endo cells	
endo VEGF		40	0	0.00	endo VEGF	0.00
endo bFGF		40	1.01	1.01	endo bFGF	1.01
heart Clontech	normal	33.02	37.93	75.86	heart	
heart (T-1) ischemic	29417	34.34	17.51	35.02	heart (T-1) ischemic	-2.17
heart (T-14) non-obstructive DCM	29422	34.85	13.07	26.14	heart (T-14) non-obstructive DCM	-2.90
heart (T-3399) DCM	29426	29.74	254.69	509.38	heart (T-3399) DCM	6.71
adenoid GW99-269	26162	35.07	11.5	23.00	adenoid	
tonsil GW98-280	22582	40	0	0.00	tonsil	
T cells PC00314	28453	36.12	6.22	12.44	T cells	
PBMNC		40	0	0.00	PBMNC	
monocyte		40	0	0.00	monocyte	
B cells PC00665	28455	40	0	0.00	B cells	
dendritic cells	28441	40	0	0.00	dendritic cells	
neutrophils	28440	35.43	9.3	9.30	neutrophils	
eosinophils	28446	40	1.32	2.64	eosinophils	
BM unstim		40	0	0.00	BM unstim	
BM stim	treated	40	0	0.00	BM stim	0.00
osteo dif	treated	40	0	0.00	osteo dif	0.00
osteo undif		40	0	0.00	osteo undif	
chondrocytes		33.23	33.49	83.73	chondrocytes	
OA Synovium IP12/01	29462	34.9	12.68	12.68	OA Synovium	
OA Synovium NP10/01	29461	28.55	510.63	1021.26	OA Synovium	
OA Synovium NP57/00	28464	34	21.41	42.82	OA Synovium	
RA Synovium NP03/01	28466	40	0	0.00	RA Synovium	
RA Synovium NP71/00	28467	36.2	5.96	11.92	RA Synovium	
RA Synovium NP45/00	28475	36.38	5.34	10.68	RA Synovium	
OA bone (biobank)	29217	35.58	8.52	8.52	OA bone (biobank)	
OA bone Sample 1	J. Emory	33.54	27.91	55.82	OA bone	
OA bone Sample 2	J. Emory	34.92	12.54	25.08	OA bone	
Cartilage (pool)	Normal	33.88	22.98	45.96	Nml Cartilage (pool)	
Cartilage (pool)	OA	40	0	0.00	OA Cartilage (pool)	-45.96
PBL uninfected	28441	30.74	142.65	285.30	PBL uninfected	
PBL HIV IIIB	28442	32.47	52.13	104.26	PBL HIV IIIB	-2.74
MRC5 uninfected (100%)	29158	40	0	0.00	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	30.06	211.88	423.76	MRC5 HSV strain F	423.76
W12 cells	29179	39.65	0.8	1.60	W12 cells	
Keratinocytes	29180	33.76	24.58	49.16	Keratinocytes	
B-actin control		27.17	1140.82			
genomic		26.81	1405.46			

1.00E+05		19.68	100000			
1.00E+05		19.63	100000			
1.00E+04		23.15	10000			
1.00E+04		23.27	10000			
1.00E+03		27.1	1000			
1.00E+03		27.33	1000			
1.00E+02		31.34	100			
1.00E+02		32.04	100			
1.00E+01		35.09	10			
1.00E+01		40	10			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			
*lung 26 Normal has been omitted due to multiple amplification failures from that sample						

Gene Name sbg1018172CSP

Disease/tissues	Fold Change in Disease Population Relative to Normal
colon tumor	1.90
colon tumor	1.92
colon tumor	-3.03
colon tumor	-2.53
lung tumor	-166.74
lung tumor	2.83
lung tumor	-3.59
lung tumor	-1.96
breast tumor	5.60
breast tumor	27.88
breast tumor	1.68
breast tumor	-9.10
brain stage 5 ALZ	-2.25
brain stage 5 ALZ	2.69
brain stage 5 ALZ	-1.99
brain stage 5 ALZ	1.37
lung 24	-13.87
lung 28	-23.29
lung 23	-21.10
asthmatic lung	-2.86
asthmatic lung	2.80
asthmatic lung	5.15
asthmatic lung	3.10
endo VEGF	0.00
endo bFGF	1.01
heart T-1	-2.17
heart T-14	-2.90
heart T-3399	6.71
BM stim	0.00
osteo dif	0.00
Cartilage (pool)	-45.96

PBL HIV IIIB	-2.74
MRC5 HSV strain F	423.76

Gene Name sbg1004570ERGIC

5 Moderate to low overall expression. This gene is expressed fairly ubiquitously in all normal samples analyzed with highest levels of expression seen in the whole brain, hypothalamus, pancreas, and head of pancreas. This pattern of expression suggests that this gene may be involved in diabetes or other metabolic diseases. Highest disease expression is seen in the colon, breast, and lung normal/tumor pairs as well as the Alzheimer's brain samples and the T cells, B cells, dendritic cells, and eosinophils. Upregulation in 2 of 4 breast tumor samples suggests a role for this gene in breast cancer. Upregulation in 2 of 4 Alzheimer's brain samples implies an involvement in Alzheimer's disease. Downregulation in 3 of 3 COPD samples and 4 of 4 asthmatic lung samples suggests a potential role for this gene in chronic obstructive pulmonary disorder and asthma. Upregulated in the stimulated bone marrow sample.

10

Sample sbg1004570ERGIC	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detec- ted/50 ng total RNA
Subcutaneous Adipocytes Zenbio	40, 40	0	0	0.00	3.06	16.34	0.00
Subcutaneous Adipose Zenbio	39.46, 35.22	0.08	1.37	0.73	0.96	52.36	37.96
Adrenal Gland Clontech	36.91, 36.21	0.43	0.7	0.57	0.61	81.97	46.31
Whole Brain Clontech	26.46, 30.31	547.02	39.49	293.26	7.24	6.91	2025.24
Fetal Brain Clontech	36.04, 36.66	0.78	0.51	0.65	0.48	103.95	67.05
Cerebellum Clontech	35.46, 34.63	1.16	2.06	1.61	2.17	23.04	37.10
Cervix	35.63, 36.28	1.04	0.67	0.86	2.42	20.66	17.67
Colon	35.38, 34.57	1.23	2.13	1.68	2.71	18.45	31.00
Endometrium	40, 35.24	0.06	1.35	0.71	0.73	68.21	48.09
Esophagus	35.02, 36.31	1.57	0.65	1.11	1.37	36.50	40.51
Heart Clontech	37.16, 35.48	0.36	1.15	0.76	1.32	37.88	28.60
Hypothalamus	35.15, 36.01	1.44	0.8	1.12	0.32	155.28	173.91
Ileum	35.04, 35.5	1.55	1.13	1.34	2.58	19.38	25.97
Jejunum	35.14, 34.88	1.45	1.73	1.59	6.60	7.58	12.05
Kidney	35.81, 37.16	0.91	0.36	0.64	2.12	23.58	14.98
Liver	36.19, 34.39	0.71	2.42	1.57	1.50	33.33	52.17
Fetal Liver Clontech	32.94, 33.1	6.51	5.85	6.18	10.40	4.81	29.71
Lung	34.54, 35.16	2.18	1.43	1.81	2.57	19.46	35.12
Mammary Gland Clontech	34.45, 34.76	2.33	1.88	2.11	13.00	3.85	8.10
Myometrium	34.08, 34.61	2.98	2.09	2.54	2.34	21.37	54.17
Omentum	35.22, 36.18	1.37	0.71	1.04	3.94	12.69	13.20
Ovary	34.52, 34.83	2.21	1.78	2.00	4.34	11.52	22.98
Pancreas	34.45, 33.99	2.32	3.18	2.75	0.81	61.80	169.96
Head of Pancreas	33.24, 33.63	5.32	4.06	4.69	1.57	31.85	149.36
Parotid Gland	33.22, 33.08	5.38	5.9	5.64	5.48	9.12	51.46
Placenta Clontech	36.02, 35.39	0.79	1.22	1.01	5.26	9.51	9.55

Prostate	35.98, 35.07	0.81	1.51	1.16	3.00	16.67	19.33
Rectum	36.71, 37.13	0.49	0.37	0.43	1.23	40.65	17.48
Salivary Gland Clontech	33.51, 34.22	4.41	2.71	3.56	7.31	6.84	24.35
Skeletal Muscle Clontech	35.53, 34.52	1.11	2.21	1.66	1.26	39.68	65.87
Skin	36.02, 36.07	0.79	0.77	0.78	1.21	41.32	32.23
Small Intestine Clontech	35.02, 37.21	1.57	0.35	0.96	0.98	51.07	49.03
Spleen	35.64, 35.27	1.03	1.33	1.18	4.92	10.16	11.99
Stomach	35.08, 35.41	1.51	1.2	1.36	2.73	18.32	24.82
Testis Clontech	35.48, 38.1	1.15	0.19	0.67	0.57	87.87	58.88
Thymus Clontech	32.15, 31.72	11.16	14.98	13.07	9.89	5.06	66.08
Thyroid	35.61, 35.09	1.05	1.49	1.27	2.77	18.05	22.92
Trachea Clontech	35.04, 34.75	1.55	1.89	1.72	9.71	5.15	8.86
Urinary Bladder	36.11, 36.24	0.74	0.68	0.71	5.47	9.14	6.49
Uterus	35.59, 35.68	1.06	1	1.03	5.34	9.36	9.64
genomic	24.29	2416.83					
b-actin	26.09	706.6					
1.00E+05	20.09	100000					
1.00E+05	19.53	100000					
1.00E+04	21.72	10000					
1.00E+04	21.68	10000					
1.00E+03	24.13	1000					
1.00E+03	24.18	1000					
1.00E+02	29.13	100					
1.00E+02	30.16	100					
1.00E+01	31.7	10					
1.00E+01	33.16	10					
1.00E-00	36.93	1					
1.00E-00	34.75	1					
NTC	36	-1					
NTC	35.85	-1					

Sample sbg1004570ERGIC	Reg number (GSK identifier)	Ct	Mean GOI copies	copies of mRNA detecte d/50 ng total RNA	Sample	Fold Change in Disease Populati on
colon normal GW98-167	21941	30.51	38.25	76.50	colon normal	
colon tumor GW98-166	21940	31.28	23.13	46.26	colon tumor	-1.65
colon normal GW98-178	22080	31.79	16.57	33.14	colon normal	
colon tumor GW98-177	22060	31.3	22.86	45.72	colon tumor	1.38
colon normal GW98-561	23514	30.71	33.5	67.00	colon normal	
colon tumor GW98-560	23513	31.18	24.73	49.46	colon tumor	-1.35
colon normal GW98-894	24691	30.16	48.2	96.40	colon normal	
colon tumor GW98-893	24690	29.96	55	110.00	colon tumor	1.14
lung normal GW98-3	20742	30.1	50.19	100.38	lung normal	
lung tumor GW98-2	20741	32.86	8.15	16.30	lung tumor	-6.16

lung normal GW97-179	20677	31.65	18.14	36.28	lung normal	
lung tumor GW97-178	20676	31.05	26.89	53.78	lung tumor	1.48
lung normal GW98-165	21922	30.44	40.16	80.32	lung normal	
lung tumor GW98-164	21921	30.72	33.36	66.72	lung tumor	-1.20
lung normal GW98-282	22584	31.83	16.13	32.26	lung normal	
lung tumor GW98-281	22583	32.09	13.61	27.22	lung tumor	-1.19
breast normal GW00-392	28750	32.76	8.73	8.73	breast normal	
breast tumor GW00-391	28746	30.68	34.38	68.76	breast tumor	7.88
breast normal GW00-413	28798	37.11	0.5	0.50	breast normal	
breast tumor GW00-412	28797	30.8	31.72	63.44	breast tumor	126.88
breast normal GW00-235:238	27592-95	38.8	0.17	0.17	breast normal	
breast tumor GW00-231:234	27588-91	37.36	0.43	0.43	breast tumor	2.53
breast normal GW98-621	23656	31.67	17.86	35.72	breast normal	
breast tumor GW98-620	23655	32.59	9.8	19.60	breast tumor	-1.82
brain normal BB99-542	25507	33.66	4.83	9.66	brain normal	
brain normal BB99-406	25509	33.24	6.37	12.74	brain normal	
brain normal BB99-904	25546	33.2	6.54	13.08	brain normal	
brain stage 5 ALZ BB99-874	25502	33.1	6.97	13.94	brain stage 5 ALZ	1.18
brain stage 5 ALZ BB99-887	25503	30.93	29.17	58.34	brain stage 5 ALZ	4.93
brain stage 5 ALZ BB99-862	25504	31.44	20.73	41.46	brain stage 5 ALZ	3.51
brain stage 5 ALZ BB99-927	25542	32.93	7.83	15.66	brain stage 5 ALZ	1.32
CT lung	normal	32.62	9.6	19.20	CT lung Nml	
lung 26	normal				lung 26 Nml	
lung 27	normal	40	0	0.00	lung 27 Nml	
lung 24	COPD	39.15	0.13	0.13	lung 24 COPD	-49.46
lung 28	COPD	40	0.08	0.08	lung 28 COPD	-80.38
lung 23	COPD	38.59	0.19	0.19	lung 23 COPD	-33.84
lung 25	normal	40	0.09	0.09	lung 25 Nml	
asthmatic lung ODO3112	29321	40	0	0.00	asthmatic lung	-6.43
asthmatic lung ODO3433	29323	38.47	0.2	0.40	asthmatic lung	-16.08
asthmatic lung ODO3397	29322	38.01	0.28	0.56	asthmatic lung	-11.48
asthmatic lung ODO4928	29325	38.13	0.26	0.52	asthmatic lung	-12.37
endo cells	control	36.24	0.89	0.89	endo cells	
endo VEGF		39.8	0.09	0.09	endo VEGF	-9.89
endo bFGF		37.19	0.47	0.47	endo bFGF	-1.89
heart Clontech	normal	35.52	1.43	2.86	heart	
heart (T-1) ischemic	29417	33.79	4.43	8.86	heart (T-1) ischemic	3.10
heart (T-14) non-obstructive DCM	29422	34.81	2.27	4.54	heart (T-14) non-obstructive DCM	1.59
heart (T-3399) DCM	29426	34.11	3.59	7.18	heart (T-3399) DCM	2.51
adenoid GW99-269	26162	34.97	2.05	4.10	adenoid	
tonsil GW98-280	22582	33.05	7.23	14.46	tonsil	

T cells PC00314	28453	31.09	26.2	52.40	T cells	
PBMNC		38.01	0.28	0.28	PBMNC	
monocyte		36.29	0.86	1.72	monocyte	
B cells PC00665	28455	32.13	13.23	26.46	B cells	
dendritic cells	28441	31.94	14.96	29.92	dendritic cells	
neutrophils	28440	34.08	3.66	3.66	neutrophils	
eosinophils	28446	32.23	12.37	24.74	eosinophils	
BM unstim		39.73	0.09	0.09	BM unstim	
BM stim	treated	37.03	0.53	0.53	BM stim	5.89
osteodif	treated	36.8	0.61	0.61	osteodif	0.61
osteoundif		40	0	0.00	osteoundif	
chondrocytes		31.85	15.9	39.75	chondrocytes	
OA Synovium IP12/01	29462	38.61	0.19	0.19	OA Synovium	
OA Synovium NP10/01	29461	33.11	6.96	13.92	OA Synovium	
OA Synovium NP57/00	28464	33.81	4.39	8.78	OA Synovium	
RA Synovium NP03/01	28466	33.11	6.96	13.92	RA Synovium	
RA Synovium NP71/00	28467	32.03	14.14	28.28	RA Synovium	
RA Synovium NP45/00	28475	32.47	10.55	21.10	RA Synovium	
OA bone (biobank)	29217	35.25	1.7	1.70	OA bone (biobank)	
OA bone Sample 1	J. Emory	34.54	2.72	5.44	OA bone	
OA bone Sample 2	J. Emory	36.28	0.87	1.74	OA bone	
Cartilage (pool)	Normal	35.24	1.71	3.42	Nml Cartilage (pool)	
Cartilage (pool)	OA	34.45	2.87	5.74	OA Cartilage (pool)	1.68
PBL uninfected	28441	32.53	10.19	20.38	PBL uninfected	
PBL HIV IIIB	28442	31.77	16.79	33.58	PBL HIV IIIB	1.65
MRC5 uninfected (100%)	29158	33.12	6.87	13.74	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	33.76	4.54	9.08	MRC5 HSV strain F	-1.51
W12 cells	29179	33.1	6.96	13.92	W12 cells	
Keratinocytes	29180	32.67	9.29	18.58	Keratinocytes	
B-actin control		26.03	726.55			
genomic		24.63	1825.58			
1.00E+05		19.96	100000			
1.00E+05		19.27	100000			
1.00E+04		21.83	10000			
1.00E+04		21.45	10000			
1.00E+03		23.86	1000			
1.00E+03		23.84	1000			
1.00E+02		28.42	100			
1.00E+02		29.35	100			
1.00E+01		33.3	10			
1.00E+01		35.09	10			
1.00E-00		35.16	1			
1.00E-00		36.05	1			
NTC		38.24	-1			
*lung 26 Normal has						

been omitted due to multiple amplification failures from that sample							
--	--	--	--	--	--	--	--

Gene Name sbg1004570ERGIC

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-1.65
colon tumor	1.38
colon tumor	-1.35
colon tumor	1.14
lung tumor	-6.16
lung tumor	1.48
lung tumor	-1.20
lung tumor	-1.19
breast tumor	7.88
breast tumor	126.88
breast tumor	2.53
breast tumor	-1.82
brain stage 5 ALZ	1.18
brain stage 5 ALZ	4.93
brain stage 5 ALZ	3.51
brain stage 5 ALZ	1.32
lung 24	-49.46
lung 28	-80.38
lung 23	-33.84
asthmatic lung	-6.43
asthmatic lung	-16.08
asthmatic lung	-11.48
asthmatic lung	-12.37
endo VEGF	-9.89
endo bFGF	-1.89
heart T-1	3.10
heart T-14	1.59
heart T-3399	2.51
BM stim	5.89
osteo dif	0.61
Cartilage (pool)	1.68
PBL HIV IIIB	1.65
MRC5 HSV strain F	-1.51

Gene Name sbg1016995IGBrect

5 Moderate to low overall expression. Highest normal expression is seen in the whole brain in lung with slightly lower levels of expression in the endometrium, ileum, rectum, and skin. High level of expression in the skin may suggest a possible role for this gene in psoriasis and Lupus. The patterns of expression in the samples on the disease plate indicate that this gene is highly specific to the adenoid and tonsil. Downregulation in 2 of 4 lung tumor samples and upregulation in 2 of 4 breast tumor samples suggests an involvement in cancers of the lung and breast.

10 Downregulation in 3 of 3 COPD samples suggests a potential role for this gene in chronic obstructive pulmonary disorder. Upregulated in the stimulated bone marrow sample. Downregulated in the differentiated osteoblast. Upregulated in the HIV-infected PBL cells suggests that this gene may be a host factor in HIV.

15

Sample	Ct (sample)	Mean	Mean	Average	18S	50	copies of
--------	-------------	------	------	---------	-----	----	-----------

sgb1016995IGBrect	1 and 2)	GOI copies (sample 1)	GOI copies (sample 2)	GOI Copies	rRNA (ng)	ng/18S rRNA (ng)	mRNA detected/ 50 ng total RNA
Subcutaneous Adipocytes Zenbio	40, 40	0.61	0.61	0.61	3.06	16.34	9.97
Subcutaneous Adipose Zenbio	40, 40	0.59	0.56	0.58	0.96	52.36	30.10
Adrenal Gland Clontech	39.89, 39.79	0.54	0.57	0.56	0.61	81.97	45.49
Whole Brain Clontech	30.69, 30.76	108.67	104.35	106.51	7.24	6.91	735.57
Fetal Brain Clontech	39.41, 40	0.71	0.62	0.67	0.48	103.95	69.13
Cerebellum Clontech	39.33, 37.82	0.74	1.78	1.26	2.17	23.04	29.03
Cervix	36.12, 36.58	4.73	3.62	4.18	2.42	20.66	86.26
Colon	35.23, 38.35	7.9	1.31	4.61	2.71	18.45	84.96
Endometrium	35.51, 40	6.73	0	3.37	0.73	68.21	229.54
Esophagus	37.22, 38.18	2.5	1.45	1.98	1.37	36.50	72.08
Heart Clontech	40, 40	0	0	0.00	1.32	37.88	0.00
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	34.65, 34.11	11.04	15.09	13.07	2.58	19.38	253.20
Jejunum	34.84, 34.04	9.91	15.72	12.82	6.60	7.58	97.08
Kidney	38.2, 39.11	1.43	0.84	1.14	2.12	23.58	26.77
Liver	34.47, 38.59	12.26	1.14	6.70	1.50	33.33	223.33
Fetal Liver Clontech	33.51, 33.07	21.26	27.43	24.35	10.40	4.81	117.04
Lung	27.32, 37.11	755.31	2.68	379.00	2.57	19.46	7373.44
Mammary Gland Clontech	36.31, 36.4	4.24	4.03	4.14	13.00	3.85	15.90
Myometrium	40, 38.7	0.7	1.07	0.89	2.34	21.37	18.91
Omentum	35.44, 36.14	6.98	4.68	5.83	3.94	12.69	73.98
Ovary	38.76, 35.49	1.03	6.82	3.93	4.34	11.52	45.22
Pancreas	40, 38.56	0.48	1.16	0.82	0.81	61.80	50.68
Head of Pancreas	40, 40	0	0	0.00	1.57	31.85	0.00
Parotid Gland	36.8, 35.45	3.2	6.98	5.09	5.48	9.12	46.44
Placenta Clontech	35.63, 35.11	6.27	8.47	7.37	5.26	9.51	70.06
Prostate	37.4, 37.5	2.26	2.14	2.20	3.00	16.67	36.67
Rectum	35.45, 35.25	6.94	7.81	7.38	1.23	40.65	299.80
Salivary Gland Clontech	37.3, 37.06	2.4	2.75	2.58	7.31	6.84	17.61
Skeletal Muscle Clontech	40, 39.34	0	0.74	0.37	1.26	39.68	14.68
Skin	38.84, 34.56	0.98	11.63	6.31	1.21	41.32	260.54
Small Intestine Clontech	40, 40	0	0.63	0.32	0.98	51.07	16.09
Spleen	34.37, 34.89	13	9.6	11.30	4.92	10.16	114.84
Stomach	39.73, 35.52	0.59	6.67	3.63	2.73	18.32	66.48
Testis Clontech	38.91, 40	0.94	0	0.47	0.57	87.87	41.30
Thymus Clontech	31.96, 32.96	52.16	29.2	40.68	9.89	5.06	205.66
Thyroid	35.53, 40	6.66	0	3.33	2.77	18.05	60.11
Trachea Clontech	37.99, 37.69	1.61	1.91	1.76	9.71	5.15	9.06

Urinary Bladder	39.69, 39.02	0.6	0.89	0.75	5.47	9.14	6.81
Uterus	34.41, 33.56	12.67	20.75	16.71	5.34	9.36	156.46
genomic	26.31	1359.1					
b-actin	27.2	812.88					
1.00E+05	19.24	100000					
1.00E+05	19.38	100000					
1.00E+04	22.67	10000					
1.00E+04	22.67	10000					
1.00E+03	26.31	1000					
1.00E+03	26.28	1000					
1.00E+02	30.17	100					
1.00E+02	31.02	100					
1.00E+01	36.17	10					
1.00E+01	34.46	10					
1.00E-00	40	0					
1.00E-00	40	1					
NTC	40	-1					
NTC	40	-1					

Sample sbg1016995IGBrecpt	Reg number (GSK identifier)	Ct	Mean GOI copies	copies of mRNA detec- ted/50 ng total RNA	Sample	Fold Change in Disease Popula- tion
colon normal GW98-167	21941	29.45	174.86	349.72	colon normal	
colon tumor GW98-166	21940	32.1	33.44	66.88	colon tumor	-5.23
colon normal GW98-178	22080	31.77	41.07	82.14	colon normal	
colon tumor GW98-177	22060	32.66	23.5	47.00	colon tumor	-1.75
colon normal GW98-561	23514	29.15	211.24	422.48	colon normal	
colon tumor GW98-560	23513	31.25	56.95	113.90	colon tumor	-3.71
colon normal GW98-894	24691	30.68	81.3	162.60	colon normal	
colon tumor GW98-893	24690	31.33	54.12	108.24	colon tumor	-1.50
lung normal GW98-3	20742	31.86	38.92	77.84	lung normal	
lung tumor GW98-2	20741	34.55	7.25	14.50	lung tumor	-5.37
lung normal GW97-179	20677	28.38	342.07	684.14	lung normal	
lung tumor GW97-178	20676	32.1	33.52	67.04	lung tumor	-10.20
lung normal GW98-165	21922	32.2	31.46	62.92	lung normal	
lung tumor GW98-164	21921	30.5	90.8	181.60	lung tumor	2.89
lung normal GW98-282	22584	29.82	138.8	277.60	lung normal	
lung tumor GW98-281	22583	32.72	22.64	45.28	lung tumor	-6.13
breast normal GW00-392	28750	31.5	48.65	48.65	breast normal	
breast tumor GW00-391	28746	31.9	37.84	75.68	breast tumor	1.56
breast normal GW00-413	28798	34.37	8.07	8.07	breast normal	
breast tumor GW00-412	28797	29.97	126.73	253.46	breast tumor	31.41
breast normal GW00-	27592-95	35.08	5.2	5.20	breast normal	

235:238						
breast tumor GW00-231:234	27588-91	32.3	29.54	29.54	breast tumor	5.68
breast normal GW98-621	23656	31.11	61.96	123.92	breast normal	
breast tumor GW98-620	23655	31.27	56.22	112.44	breast tumor	-1.10
brain normal BB99-542	25507	33.3	15.82	31.64	brain normal	
brain normal BB99-406	25509	33.02	18.83	37.66	brain normal	
brain normal BB99-904	25546	33.93	10.62	21.24	brain normal	
brain stage 5 ALZ BB99-874	25502	32.36	28.38	56.76	brain stage 5 ALZ	1.88
brain stage 5 ALZ BB99-887	25503	31.79	40.66	81.32	brain stage 5 ALZ	2.69
brain stage 5 ALZ BB99-862	25504	32.04	34.76	69.52	brain stage 5 ALZ	2.30
brain stage 5 ALZ BB99-927	25542	31.79	40.51	81.02	brain stage 5 ALZ	2.68
CT lung	normal	33.32	15.63	31.26	CT lung Nml	
lung 26	normal	29.8	140.4		lung 26 Nml	
lung 27	normal	38.71	0.54	0.54	lung 27 Nml	
lung 24	COPD	39.31	0.37	0.37	lung 24 COPD	-29.00
lung 28	COPD	37.09	1.48	1.48	lung 28 COPD	-7.25
lung 23	COPD	38.02	0.83	0.83	lung 23 COPD	-12.93
lung 25	normal	39.22	0.39	0.39	lung 25 Nml	
asthmatic lung ODO3112	29321	37.96	0.86	0.86	asthmatic lung	-12.48
asthmatic lung ODO3433	29323	31.15	60.54	121.08	asthmatic lung	11.28
asthmatic lung ODO3397	29322	33.74	12.01	24.02	asthmatic lung	2.24
asthmatic lung ODO4928	29325	31.59	46.09	92.18	asthmatic lung	8.59
endo cells	control	36.98	1.58	1.58	endo cells	
endo VEGF		39.28	0.38	0.38	endo VEGF	-4.16
endo bFGF		37.3	1.3	1.30	endo bFGF	-1.22
heart Clontech	normal	35.73	3.45	6.90	heart	
heart (T-1) ischemic	29417	34.7	6.58	13.16	heart (T-1) ischemic	1.91
heart (T-14) non-obstructive DCM	29422	37.5	1.15	2.30	heart (T-14) non-obstructive DCM	-3.00
heart (T-3399) DCM	29426	35.15	4.96	9.92	heart (T-3399) DCM	1.44
adenoid GW99-269	26162	25.98	1528.07	3056.14	adenoid	
tonsil GW98-280	22582	24.6	3626.43	7252.86	tonsil	
T cells PC00314	28453	34.49	7.5	15.00	T cells	
PBMNC		37.58	1.09	1.09	PBMNC	
monocyte		37.4	1.22	2.44	monocyte	
B cells PC00665	28455	31.68	43.59	87.18	B cells	
dendritic cells	28441	35.05	5.28	10.56	dendritic cells	
neutrophils	28440	35.68	3.57	3.57	neutrophils	
eosinophils	28446	35.07	5.23	10.46	eosinophils	
BM unstim		38.19	0.75	0.75	BM unstim	
BM stim	treated	34.27	8.61	8.61	BM stim	11.48
osteodif	treated	40	0.09	0.09	osteodif	-5.78
osteoundif		40	0.52	0.52	osteoundif	

chondrocytes		32.86	20.79	51.98	chondrocytes	
OA Synovium IP12/01	29462	31.85	38.99	38.99	OA Synovium	
OA Synovium NP10/01	29461	34.76	6.33	12.66	OA Synovium	
OA Synovium NP57/00	28464	31.39	51.96	103.92	OA Synovium	
RA Synovium NP03/01	28466	31.1	62.3	124.60	RA Synovium	
RA Synovium NP71/00	28467	31.95	36.76	73.52	RA Synovium	
RA Synovium NP45/00	28475	32.43	27.14	54.28	RA Synovium	
OA bone (biobank)	29217	35.84	3.22	3.22	OA bone (biobank)	
OA bone Sample 1	J. Emory	35.43	4.18	8.36	OA bone	
OA bone Sample 2	J. Emory	34.86	5.95	11.90	OA bone	
Cartilage (pool)	Normal	34.79	6.21	12.42	Nml Cartilage (pool)	
Cartilage (pool)	OA	36.55	2.07	4.14	OA Cartilage (pool)	-3.00
PBL uninfected	28441	30.02	122.76	245.52	PBL uninfected	
PBL HIV IIIB	28442	28.17	388.59	777.18	PBL HIV IIIB	3.17
MRC5 uninfected (100%)	29158	34.6	7.01	14.02	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	33.27	16.13	32.26	MRC5 HSV strain F	2.30
W12 cells	29179	34.43	7.8	15.60	W12 cells	
Keratinocytes	29180	35.04	5.31	10.62	Keratinocytes	
B-actin control		27	808.77			
genomic		26.18	1353.11			
1.00E+05		19.37	100000			
1.00E+05		19.59	100000			
1.00E+04		22.75	10000			
1.00E+04		22.8	10000			
1.00E+03		26.43	1000			
1.00E+03		26.17	1000			
1.00E+02		30.09	100			
1.00E+02		30.21	100			
1.00E+01		35.27	10			
1.00E+01		35.55	10			
1.00E-00		39.31	1			
1.00E-00		34.53	1			
NTC		40	-1			
*lung 26 Normal has been omitted due to multiple amplification failures from that sample						

Gene Name sbg1016995IGBrecpt

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-5.23
colon tumor	-1.75
colon tumor	-3.71
colon tumor	-1.50

lung tumor	-5.37
lung tumor	-10.20
lung tumor	2.89
lung tumor	-6.13
breast tumor	1.56
breast tumor	31.41
breast tumor	5.68
breast tumor	-1.10
brain stage 5 ALZ	1.88
brain stage 5 ALZ	2.69
brain stage 5 ALZ	2.30
brain stage 5 ALZ	2.68
lung 24	-29.00
lung 28	-7.25
lung 23	-12.93
asthmatic lung	-12.48
asthmatic lung	11.28
asthmatic lung	2.24
asthmatic lung	8.59
endo VEGF	-4.16
endo bFGF	-1.22
heart T-1	1.91
heart T-14	-3.00
heart T-3399	1.44
BM stim	11.48
osteo dif	-5.78
Cartilage (pool)	-3.00
PBL HIV IIIB	3.17
MRC5 HSV strain F	2.30

Gene Name sbg1151bSREC

Highest overall expression in normal and disease samples. Fairly ubiquitously expressed but highest normal expression in adipocytes, adipose, whole brain, fetal brain, and endometrium.

5 Highest disease expression in one of the colon tumor samples, one of the normal lung samples, chondrocytes, and the uninfected MRC5. There are no significant changes in brains from patients with Alzheimer's disease. Downregulation in 1 of 4 lung tumors suggests possible implication in lung cancer. Upregulation in 1 of 4 breast tumor samples is sufficient to claim a role in cancer of the breast. Upregulation in 1 of 4 asthma lungs implies a role in asthma. Downregulation in HSV implicates involvement in herpes simplex virus as a potential host factor. High expression in immune cells. High expression in cartilage and bone samples from patients with OA as well as high expression in chondrocytes possible involvement in osteoarthritis and rheumatoid arthritis.

10 Additionally, the corroborating expression in immune cells (particularly B and T cells) provides additional evidence for a role in RA/OA.

15

Sample sbg1151bSREC	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detected /50 ng total RNA
Subcutaneous Adipocytes Zenbio	28.31, 28.35	477.04	466.02	471.53	3.06	16.34	7704.74
Subcutaneous Adipose Zenbio	30.79, 30.22	122.3	166.95	144.63	0.96	52.36	7571.99
Adrenal Gland Clontech	33.96, 33.47	21.39	27.97	24.68	0.61	81.97	2022.95
Whole Brain Clontech	24.07, 23.98	4889.28	5123.8	5006.54	7.24	6.91	34575.55

Fetal Brain Clontech	31.1, 32.29	103.16	53.55	78.36	0.48	103.95	8145.01
Cerebellum Clontech	31.03, 31.99	107.02	63.18	85.10	2.17	23.04	1960.83
Cervix	31.22, 30.06	96.6	182.64	139.62	2.42	20.66	2884.71
Colon	30.68, 30.53	129.52	140.99	135.26	2.71	18.45	2495.48
Endometrium	30.59, 30.44	136.06	147.8	141.93	0.73	68.21	9681.45
Esophagus	33.11, 32.17	34.08	57.32	45.70	1.37	36.50	1667.88
Heart Clontech	33.19, 32.41	32.68	50.11	41.40	1.32	37.88	1567.99
Hypothalamus	34.34, 40	17.4	0	8.70	0.32	155.28	1350.93
Ileum	31.29, 30.13	92.84	174.99	133.92	2.58	19.38	2595.25
Jejunum	29.7, 29.48	221.9	251.05	236.48	6.60	7.58	1791.48
Kidney	31.03, 30.17	107.15	171.45	139.30	2.12	23.58	3285.38
Liver	32.89, 33.16	38.61	33.17	35.89	1.50	33.33	1196.33
Fetal Liver Clontech	28.05, 28.15	550.64	518.95	534.80	10.40	4.81	2571.13
Lung	29.39, 28.63	263.85	398.99	331.42	2.57	19.46	6447.86
Mammary Gland Clontech	27.56, 27.39	717.67	789.94	753.81	13.00	3.85	2899.25
Myometrium	29.08, 28.93	312.86	339.46	326.16	2.34	21.37	6969.23
Omentum	30.72, 29.32	126.7	273.04	199.87	3.94	12.69	2536.42
Ovary	28.89, 28.68	346.91	388.02	367.47	4.34	11.52	4233.47
Pancreas	35.24, 35.75	10.59	8.02	9.31	0.81	61.80	575.09
Head of Pancreas	35.25, 33.21	10.57	32.34	21.46	1.57	31.85	683.28
Parotid Gland	28.46, 27.84	438.62	615.36	526.99	5.48	9.12	4808.30
Placenta Clontech	28.67, 28.66	391.9	393.15	392.53	5.26	9.51	3731.23
Prostate	30.55, 31.46	139.05	84.64	111.85	3.00	16.67	1864.08
Rectum	31.28, 31.43	93.33	85.92	89.63	1.23	40.65	3643.29
Salivary Gland Clontech	31.13, 30.57	101.46	138.16	119.81	7.31	6.84	819.49
Skeletal Muscle Clontech	34.05, 35.24	20.38	10.59	15.49	1.26	39.68	614.48
Skin	31.53, 31.2	81.49	97.36	89.43	1.21	41.32	3695.25
Small Intestine Clontech	34.81, 33.82	13.41	23.18	18.30	0.98	51.07	934.37
Spleen	31.01, 30.44	108.41	147.9	128.16	4.92	10.16	1302.39
Stomach	32.01, 31.1	62.6	102.97	82.79	2.73	18.32	1516.21
Testis Clontech	31.74, 32.29	72.49	53.45	62.97	0.57	87.87	5533.39
Thymus Clontech	28.84, 28.53	356.64	421.44	389.04	9.89	5.06	1966.84
Thyroid	30.12, 30.04	176.76	184.5	180.63	2.77	18.05	3260.47
Trachea Clontech	28.48, 28.38	434.3	459.42	446.86	9.71	5.15	2301.03
Urinary Bladder	29.63, 29.55	230.25	241.15	235.70	5.47	9.14	2154.48
Uterus	28.69, 28.37	387.47	461.07	424.27	5.34	9.36	3972.57
genomic	26.24	1487.44					
b-actin	27.28	839.2					
1.00E+05	18.96	100000					
1.00E+05	19.34	100000					
1.00E+04	22.64	10000					
1.00E+04	22.84	10000					
1.00E+03	26.22	1000					
1.00E+03	26.04	1000					
1.00E+02	31.04	100					

1.00E+02	30.1	100					
1.00E+01	33.33	10					
1.00E+01	39.08	10					
1.00E-00	40	0					
1.00E-00	40	1					
NTC	40	0					
NTC	40	0					

Sample sbg1151bSREC	Reg number (GSK identifie r)	Ct	Mean GOI copies	copies of mRNA detected /50 ng total RNA	Sample	Fold Change in Disease Populatio n
colon normal GW98-167	21941	24.55	5357.25	10714.50	colon normal	
colon tumor GW98-166	21940	22.61	19769.94	39539.88	colon tumor	3.69
colon normal GW98-178	22080	26.71	1252.3	2504.60	colon normal	
colon tumor GW98-177	22060	26.13	1854.49	3708.98	colon tumor	1.48
colon normal GW98-561	23514	26.82	1165.06	2330.12	colon normal	
colon tumor GW98-560	23513	25.75	2390.26	4780.52	colon tumor	2.05
colon normal GW98-894	24691	26.06	1948.57	3897.14	colon normal	
colon tumor GW98-893	24690	26.59	1362.55	2725.10	colon tumor	-1.43
lung normal GW98-3	20742	22.77	17753	35506.00	lung normal	
lung tumor GW98-2	20741	26.17	1803.8	3607.60	lung tumor	-9.84
lung normal GW97-179	20677	25.24	3370.88	6741.76	lung normal	
lung tumor GW97-178	20676	24.14	7057.92	14115.84	lung tumor	2.09
lung normal GW98-165	21922	23.87	8442.49	16884.98	lung normal	
lung tumor GW98-164	21921	24.08	7339.83	14679.66	lung tumor	-1.15
lung normal GW98-282	22584	25.51	2804.42	5608.84	lung normal	
lung tumor GW98-281	22583	24.2	6787.31	13574.62	lung tumor	2.42
breast normal GW00-392	28750	25.7	2480.5	2480.50	breast normal	
breast tumor GW00-391	28746	25.77	2364.2	4728.40	breast tumor	1.91
breast normal GW00-413	28798	26.06	1948.1	1948.10	breast normal	
breast tumor GW00-412	28797	27.21	894.11	1788.22	breast tumor	-1.09
breast normal GW00- 235:238	27592-95	26.64	1317.83	1317.83	breast normal	
breast tumor GW00- 231:234	27588-91	23.91	8225.11	8225.11	breast tumor	6.24
breast normal GW98-621	23656	24.46	5693.73	11387.46	breast normal	
breast tumor GW98-620	23655	23.91	8218.73	16437.46	breast tumor	1.44
brain normal BB99-542	25507	26.39	1553.13	3106.26	brain normal	
brain normal BB99-406	25509	26.63	1325.63	2651.26	brain normal	
brain normal BB99-904	25546	27.05	1001.6	2003.20	brain normal	
brain stage 5 ALZ BB99- 874	25502	26.97	1052.15	2104.30	brain stage 5 ALZ	-1.23
brain stage 5 ALZ BB99- 887	25503	25.28	3289.99	6579.98	brain stage 5 ALZ	2.54
brain stage 5 ALZ BB99- 862	25504	26.24	1725.06	3450.12	brain stage 5 ALZ	1.33
brain stage 5 ALZ BB99- 862	25542	26.12	1864.26	3728.52	brain stage 5 ALZ	1.44

927						
CT lung KC	normal	24.74	4711.99	9423.98	CT lung	
lung 26 KC	normal	27.78	611.36	611.36	lung 26	
lung 27 KC	normal	28.27	439.19	439.19	lung 27	
lung 24 KC	COPD	26.92	1091.11	1091.11	lung 24	-2.56
lung 28 KC	COPD	26.93	1085.65	1085.65	lung 28	-2.57
lung 23 KC	COPD	27.19	909.68	909.68	lung 23	-3.07
lung 25 KC	normal	27.62	678.79	678.79	lung 25	
asthmatic lung ODO3112	29321	25.33	3173.52	3173.52	asthmatic lung	1.14
asthmatic lung ODO3433	29323	25.36	3106.89	6213.78	asthmatic lung	2.23
asthmatic lung ODO3397	29322	23.81	8809.42	17618.84	asthmatic lung	6.32
asthmatic lung ODO4928	29325	24.76	4649.98	9299.96	asthmatic lung	3.34
endo cells KC	control	26	2021.13	2021.13	endo cells	
endo VEGF KC		25.78	2343.21	2343.21	endo VEGF	1.16
endo bFGF KC		26.7	1264.03	1264.03	endo bFGF	-1.60
heart Clontech	normal	26.62	1330.64	2661.28	heart	
heart (T-1) ischemic	29417	27.07	984.33	1968.66	heart T-1	-1.35
heart (T-14) non- obstructive DCM	29422	26.11	1877.75	3755.50	heart T-14	1.41
heart (T-3399) DCM	29426	26.34	1608.79	3217.58	heart T-3399	1.21
adenoid GW99-269	26162	27.64	670.25	1340.50	adenoid	
tonsil GW98-280	22582	27.61	684.15	1368.30	tonsil	
T cells PC00314	28453	25.95	2098.64	4197.28	T cells	
PBMNC		31.16	63.19	63.19	PBMNC	
monocyte		31.32	56.63	113.26	monocyte	
B cells PC00665	28455	26.34	1609.52	3219.04	B cells	
dendritic cells 28441		28.25	444.68	889.36	dendritic cells	
neutrophils	28440	26.11	1874.13	1874.13	neutrophils	
eosinophils	28446	26.39	1553.82	3107.64	eosinophils	
BM unstim		31.45	51.76	51.76	BM unstim	
BM stim		31.28	58.37	58.37	BM stim	1.13
osteо dif		24.62	5118.74	5118.74	osteо dif	1.70
osteо undif		25.41	3015.6	3015.60	osteо undif	
chondrocytes		22.12	27351.89	68379.73	chondrocytes	
OA Synovium IP12/01	29462	24.5	5551.61	5551.61	OA Synovium	
OA Synovium NP10/01	29461	25.1	3711.29	7422.58	OA Synovium	
OA Synovium NP57/00	28464	24.5	5537.1	11074.20	OA Synovium	
RA Synovium NP03/01	28466	26.45	1492.95	2985.90	RA Synovium	
RA Synovium NP71/00	28467	24.44	5783.96	11567.92	RA Synovium	
RA Synovium NP45/00	28475	25.94	2112.54	4225.08	RA Synovium	
OA bone (biobank)	29217	26.16	1811.72	1811.72	OA bone (biobank)	
OA bone Sample 1	J. Emory	24.54	5399.31	10798.62	OA bone	
OA bone Sample 2	J. Emory	26.07	1931.94	3863.88	OA bone	
Cartilage (pool)	Normal	25.09	3730.42	7460.84	Cartilage (pool)	
Cartilage (pool)	OA	25.79	2328.66	4657.32	Cartilage (pool)	-1.60
PBL uninfected	28441	26.95	1068.16	2136.32	PBL uninfected	
PBL HIV IIIB	28442	28.41	401.86	803.72	PBL HIV IIIB	-2.66

MRC5 uninfected (100%)	29158	22.28	24694.87	49389.74	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	29.07	256.64	513.28	MRC5 HSV strain F	-96.22
W12 cells	29179	28.37	410.68	821.36	W12 cells	
Keratinocytes	29180	29.12	249.25	498.50	Keratinocytes	
B-actin control		27.53	721.15			
genomic		26.92	1091.74			
1.00E+05		19.96	100000			
1.00E+05		20.19	100000			
1.00E+04		23.43	10000			
1.00E+04		23.34	10000			
1.00E+03		26.64	1000			
1.00E+03		26.8	1000			
1.00E+02		31.34	100			
1.00E+02		31.48	100			
1.00E+01		34.9	10			
1.00E+01		34.19	10			
1.00E-00		40	0			
1.00E-00		35.53	1			
NTC		40	0			

Gene Name sbg1151bSREC

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	3.69
colon tumor	1.48
colon tumor	2.05
colon tumor	-1.43
lung tumor	-9.84
lung tumor	2.09
lung tumor	-1.15
lung tumor	2.42
breast tumor	1.91
breast tumor	-1.09
breast tumor	6.24
breast tumor	1.44
brain stage 5 ALZ	-1.23
brain stage 5 ALZ	2.54
brain stage 5 ALZ	1.33
brain stage 5 ALZ	1.44
lung 24	-2.56
lung 28	-2.57
lung 23	-3.07
asthmatic lung	1.14
asthmatic lung	2.23
asthmatic lung	6.32
asthmatic lung	3.34
endo VEGF	1.16
endo bFGF	-1.60
heart T-1	-1.35

heart T-14	1.41
heart T-3399	1.21
BM stim	1.13
osteodif	1.70
Cartilage (pool)	-1.60
PBL HIV IIIB	-2.66
MRC5 HSV strain F	-96.22

Gene Name sbg1399854ANK

5 Low overall expression. Highest normal expression is seen in the whole brain, fetal brain, and liver. Good levels of expression are seen in all of the samples representing the female reproductive system. Highest disease expression is seen in the normal and Alzheimer's brain samples as well as in the dendritic cells. Upregulation in 2 of 4 colon tumor samples and in 2 of 4 breast tumor samples as well as downregulation in 2 of 4 lung tumor samples implicates this gene in cancers of the colon, breast, and lung. Downregulation in 3 of 3 COPD samples and in 2 of 4 asthmatic lung samples suggests a potential role for this gene in chronic obstructive pulmonary disorder and asthma. Downregulation in the OA cartilage sample as well as corroborating low expression in the normal chondrocytes and many of the immune cells suggests involvement in osteoarthritis.

10 Upregulation in the HSV-infected MRC5 cells suggests that this gene may be a host factor in HSV.

Sample sbg1399854ANK	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detected /50 ng total RNA
Subcutaneous Adipocytes Zenbio	40, 40	0	0	0.00	3.06	16.34	0.00
Subcutaneous Adipose Zenbio	40, 40	1.83	1.77	1.80	0.96	52.36	94.24
Adrenal Gland Clontech	40, 40	1.75	0	0.88	0.61	81.97	71.72
Whole Brain Clontech	28.57, 28.35	944.29	1058.09	1001.19	7.24	6.91	6914.30
Fetal Brain Clontech	36.57, 34.65	14.38	39.28	26.83	0.48	103.95	2788.98
Cerebellum Clontech	37.21, 36.71	10.3	13.37	11.84	2.17	23.04	272.70
Cervix	36.3, 40	16.52	0	8.26	2.42	20.66	170.66
Colon	36.17, 35.71	17.73	22.5	20.12	2.71	18.45	371.13
Endometrium	40, 36.1	0	18.41	9.21	0.73	68.21	627.90
Esophagus	40, 40	0	1.58	0.79	1.37	36.50	28.83
Heart Clontech	40, 40	0	0	0.00	1.32	37.88	0.00
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	40, 40	0	0	0.00	2.58	19.38	0.00
Jejunum	34.07, 34.37	53.18	45.33	49.26	6.60	7.58	373.14
Kidney	37.55, 40	8.58	0	4.29	2.12	23.58	101.18
Liver	36.53, 35.62	14.69	23.59	19.14	1.50	33.33	638.00
Fetal Liver Clontech	34.56, 34.61	41.04	40.04	40.54	10.40	4.81	194.90
Lung	40, 40	0	0	0.00	2.57	19.46	0.00
Mammary Gland Clontech	39.07, 39.45	3.89	3.18	3.54	13.00	3.85	13.60
Myometrium	39.5, 35.37	3.1	26.93	15.02	2.34	21.37	320.83
Omentum	40, 36.18	0	17.61	8.81	3.94	12.69	111.74
Ovary	35.87, 34.34	20.75	46.22	33.49	4.34	11.52	385.77

Pancreas	40, 40	0	0	0.00	0.81	61.80	0.00
Head of Pancreas	40, 39.79	0	2.66	1.33	1.57	31.85	42.36
Parotid Gland	35.2, 38.6	29.46	4.97	17.22	5.48	9.12	157.07
Placenta Clontech	40, 38.14	0	6.32	3.16	5.26	9.51	30.04
Prostate	40, 40	0	0	0.00	3.00	16.67	0.00
Rectum	40, 39.2	0	3.63	1.82	1.23	40.65	73.78
Salivary Gland Clontech	40, 39.19	2.19	3.64	2.92	7.31	6.84	19.94
Skeletal Muscle Clontech	40, 39.37	0	3.32	1.66	1.26	39.68	65.87
Skin	40, 40	0	2.09	1.05	1.21	41.32	43.18
Small Intestine Clontech	40, 40	1.44	0	0.72	0.98	51.07	36.77
Spleen	35.36, 40	27.05	1.84	14.45	4.92	10.16	146.80
Stomach	40, 37.03	1.93	11.29	6.61	2.73	18.32	121.06
Testis Clontech	40, 37.99	0	6.82	3.41	0.57	87.87	299.65
Thymus Clontech	38.47, 35.55	5.32	24.52	14.92	9.89	5.06	75.43
Thyroid	40, 40	0	2.15	1.08	2.77	18.05	19.40
Trachea Clontech	35.37, 36.67	26.97	13.66	20.32	9.71	5.15	104.61
Urinary Bladder	39.07, 40	3.89	1.42	2.66	5.47	9.14	24.27
Uterus	36.01, 33.41	19.29	75.06	47.18	5.34	9.36	441.71
genomic	29.57	558.84					
b-actin	27.57	1592.66					
1.00E+05	19.91	100000					
1.00E+05	20.08	100000					
1.00E+04	23.79	10000					
1.00E+04	24.06	10000					
1.00E+03	27.72	1000					
1.00E+03	28.29	1000					
1.00E+02	31.95	100					
1.00E+02	33.62	100					
1.00E+01	39.75	10					
1.00E+01	35.41	10					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	-1					
NTC	40	-1					

Sample sbg1399854ANK	Reg number (GSK identifier)	Ct	Mean GOI copies	copies of mRNA detecte d/50 ng total RNA	Sample	Fold Change in Disease Populati on
colon normal GW98-167	21941	35.32	22.34	44.68	colon normal	
colon tumor GW98-166	21940	34.14	47.5	95.00	colon tumor	2.13
colon normal GW98-178	22080	36.16	13.07	26.14	colon normal	
colon tumor GW98-177	22060	35.58	18.93	37.86	colon tumor	1.45

colon normal GW98-561	23514	36.58	10.03	20.06	colon normal	
colon tumor GW98-560	23513	32.61	126.48	252.96	colon tumor	12.61
colon normal GW98-894	24691	35.61	18.62	37.24	colon normal	
colon tumor GW98-893	24690	33.24	84.75	169.50	colon tumor	4.55
lung normal GW98-3	20742	34.77	31.8	63.60	lung normal	
lung tumor GW98-2	20741	33.63	66.03	132.06	lung tumor	2.08
lung normal GW97-179	20677	34.76	32.04	64.08	lung normal	
lung tumor GW97-178	20676	34.44	39.23	78.46	lung tumor	1.22
lung normal GW98-165	21922	35.18	24.44	48.88	lung normal	
lung tumor GW98-164	21921	37.99	4.06	8.12	lung tumor	-6.02
lung normal GW98-282	22584	33.64	65.37	130.74	lung normal	
lung tumor GW98-281	22583	37.3	6.34	12.68	lung tumor	-10.31
breast normal GW00-392	28750	36.29	12.08	12.08	breast normal	
breast tumor GW00-391	28746	36.14	13.29	26.58	breast tumor	2.20
breast normal GW00-413	28798	37.08	7.29	7.29	breast normal	
breast tumor GW00-412	28797	33.26	83.58	167.16	breast tumor	22.93
breast normal GW00-235:238	27592-95	38.93	2.24	2.24	breast normal	
breast tumor GW00-231:234	27588-91	36.57	10.08	10.08	breast tumor	4.50
breast normal GW98-621	23656	34.9	29.32	58.64	breast normal	
breast tumor GW98-620	23655	36.11	13.51	27.02	breast tumor	-2.17
brain normal BB99-542	25507	29.6	866.9	1733.80	brain normal	
brain normal BB99-406	25509	31.93	194.87	389.74	brain normal	
brain normal BB99-904	25546	30.38	526.58	1053.16	brain normal	
brain stage 5 ALZ BB99-874	25502	32.7	119.57	239.14	brain stage 5 ALZ	-4.43
brain stage 5 ALZ BB99-887	25503	30.08	634.97	1269.94	brain stage 5 ALZ	1.20
brain stage 5 ALZ BB99-862	25504	29.7	809.22	1618.44	brain stage 5 ALZ	1.53
brain stage 5 ALZ BB99-927	25542	29.93	700.82	1401.64	brain stage 5 ALZ	1.32
CT lung	normal	35.1	25.82	51.64	CT lung Nml	
lung 26	normal	36.74	9.07		lung 26 Nml	
lung 27	normal	40	0	0.00	lung 27 Nml	
lung 24	COPD	40	2.5	2.50	lung 24 COPD	-7.11
lung 28	COPD	40	0	0.00	lung 28 COPD	-17.77
lung 23	COPD	40	0	0.00	lung 23 COPD	-17.77
lung 25	normal	39.39	1.67	1.67	lung 25 Nml	
asthmatic lung ODO3112	29321	40	0	0.00	asthmatic lung	-17.77
asthmatic lung ODO3433	29323	37	7.68	15.36	asthmatic lung	-1.16
asthmatic lung ODO3397	29322	36.08	13.8	27.60	asthmatic lung	1.55
asthmatic lung ODO4928	29325	40	0	0.00	asthmatic lung	-17.77
endo cells	control	40	0	0.00	endo cells	
endo VEGF		40	0	0.00	endo VEGF	0.00
endo bFGF		35.68	17.77	17.77	endo bFGF	17.77
heart Clontech	normal	35.03	26.95	53.90	heart	
heart (T-1) ischemic	29417	36.36	11.53	23.06	heart (T-1) ischemic	-2.34

heart (T-14) non-obstructive DCM	29422	34.57	36.11	72.22	heart (T-14) non-obstructive DCM	1.34
heart (T-3399) DCM	29426	36.25	12.37	24.74	heart (T-3399) DCM	-2.18
adenoid GW99-269	26162	38.51	2.92	5.84	adenoid	
tonsil GW98-280	22582	35.05	26.54	53.08	tonsil	
T cells PC00314	28453	35.5	19.98	39.96	T cells	
PBMNC		40	0	0.00	PBMNC	
monocyte		40	0	0.00	monocyte	
B cells PC00665	28455	33.78	59.82	119.64	B cells	
dendritic cells	28441	29.33	1026.14	2052.28	dendritic cells	
neutrophils	28440	31.3	292.56	292.56	neutrophils	
eosinophils	28446	35.97	14.79	29.58	eosinophils	
BM unstim		35.56	19.16	19.16	BM unstim	
BM stim	treated	34.79	31.48	31.48	BM stim	1.64
osteodif	treated	40	2.59	2.59	osteodif	2.59
osteoundif		40	0	0.00	osteoundif	
chondrocytes		37.11	7.15	17.88	chondrocytes	
OA Synovium IP12/01	29462	35.95	14.93	14.93	OA Synovium	
OA Synovium NP10/01	29461	35.74	17.17	34.34	OA Synovium	
OA Synovium NP57/00	28464	39.09	2.02	4.04	OA Synovium	
RA Synovium NP03/01	28466	38.03	3.97	7.94	RA Synovium	
RA Synovium NP71/00	28467	35.08	26.03	52.06	RA Synovium	
RA Synovium NP45/00	28475	37.11	7.13	14.26	RA Synovium	
OA bone (biobank)	29217	33.76	60.54	60.54	OA bone (biobank)	
OA bone Sample 1	J. Emory	33.35	78.68	157.36	OA bone	
OA bone Sample 2	J. Emory	34.15	47.2	94.40	OA bone	
Cartilage (pool)	Normal	35.05	26.63	53.26	Nml Cartilage (pool)	
Cartilage (pool)	OA	37.42	5.87	11.74	OA Cartilage (pool)	-4.54
PBL uninfected	28441	33.95	53.63	107.26	PBL uninfected	
PBL HIV IIIB	28442	33.3	81.2	162.40	PBL HIV IIIB	1.51
MRC5 uninfected (100%)	29158	39.41	1.64	3.28	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	35.73	17.22	34.44	MRC5 HSV strain F	10.50
W12 cells	29179	35.08	26.08	52.16	W12 cells	
Keratinocytes	29180	36.69	9.33	18.66	Keratinocytes	
B-actin control		28.13	2213.67			
genomic		29.03	1240.79			
1.00E+05		22.03	100000			
1.00E+05		22.36	100000			
1.00E+04		25.68	10000			
1.00E+04		25.78	10000			
1.00E+03		29.01	1000			
1.00E+03		28.67	1000			
1.00E+02		33.46	100			
1.00E+02		40	100			

1.00E+01		38.75	10			
1.00E+01		40	10			
1.00E-00		40	0			
1.00E-00		38.6	1			
NTC		40	0			
*lung 26 Normal has been omitted due to multiple amplification failures from that sample						

Gene Name sbg1399854ANK

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	2.13
colon tumor	1.45
colon tumor	12.61
colon tumor	4.55
lung tumor	2.08
lung tumor	1.22
lung tumor	-6.02
lung tumor	-10.31
breast tumor	2.20
breast tumor	22.93
breast tumor	4.50
breast tumor	-2.17
brain stage 5 ALZ	-4.43
brain stage 5 ALZ	1.20
brain stage 5 ALZ	1.53
brain stage 5 ALZ	1.32
lung 24	-7.11
lung 28	-17.77
lung 23	-17.77
asthmatic lung	-17.77
asthmatic lung	-1.16
asthmatic lung	1.55
asthmatic lung	-17.77
endo VEGF	0.00
endo bFGF	17.77
heart T-1	-2.34
heart T-14	1.34
heart T-3399	-2.18
BM stim	1.64
osteo dif	2.59
Cartilage (pool)	-4.54
PBL HIV IIIB	1.51
MRC5 HSV strain F	10.50

Table V. Additional diseases based on mRNA expression in specific tissues

Tissue Expression	Additional Diseases
Brain	Neurological and psychiatric diseases, including Alzheimers, parasupranuclear palsey, Huntington's disease, myotonic dystrophy, anorexia, depression, schizophrenia, headache, amnesias, anxiety disorders, sleep disorders, multiple sclerosis
Heart	Cardiovascular diseases, including congestive heart failure, dilated cardiomyopathy, cardiac arrhythmias, Hodgson's Disease, myocardial infarction, cardiac arrhythmias
Lung	Respiratory diseases, including asthma, Chronic Obstructive Pulmonary Disease, cystic fibrosis, acute bronchitis, adult respiratory distress syndrome
Liver	Dyslipidemia, hypercholesterolemia, hypertriglyceridemia, cirrhosis, hepatic encephalopathy, fatty hepatocirrhosis, viral and nonviral hepatitis, Type II Diabetes Mellitis, impaired glucose tolerance
Kidney	Renal diseases, including acute and chronic renal failure, acute tubular necrosis, cystinuria, Fanconi's Syndrome, glomerulonephritis, renal cell carcinoma, renovascular hypertension
Skeletal muscle	Eulenburg's Disease, hypoglycemia, obesity, tendinitis, periodic paralyses, malignant hyperthermia, paramyotonia congenita, myotonia congenita
Intestine	Gastrointestinal diseases, including Myotonia congenita, Ileus, Intestinal Obstruction, Tropical Sprue, Pseudomembranous Enterocolitis
Spleen/lymph	Lymphangiectasia, hypersplenism, angiomas, ankylosing spondylitis, Hodgkin's Disease, macroglobulinemia, malignant lymphomas, rheumatoid arthritis
Placenta	Choriocarcinoma, hydatidiform mole, placenta previa
Testis	Testicular cancer, male reproductive diseases, including low testosterone and male infertility
Pancreas	Diabetic ketoacidosis, Type 1 & 2 diabetes, obesity, impaired glucose tolerance

What is claimed is:

1. An isolated polypeptide selected from the group consisting of:
 - 5 (a) an isolated polypeptide encoded by a polynucleotide comprising a sequence set forth in Table I;
 - (b) an isolated polypeptide comprising a polypeptide sequence set forth in Table I; and
 - (c) a polypeptide sequence of a gene set forth in Table I.
- 10 2. An isolated polynucleotide selected from the group consisting of:
 - (a) an isolated polynucleotide comprising a polynucleotide sequence set forth in Table I;
 - (b) an isolated polynucleotide of a gene set forth in Table I;
 - (c) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide set forth in Table I;
 - 15 (d) an isolated polynucleotide encoding a polypeptide set forth in Table I;
 - (e) a polynucleotide which is an RNA equivalent of the polynucleotide of (a) to (d); or a polynucleotide sequence complementary to said isolated polynucleotide.
- 20 3. An expression vector comprising a polynucleotide capable of producing a polypeptide of claim 1 when said expression vector is present in a compatible host cell.
4. A process for producing a recombinant host cell which comprises the step of introducing an expression vector comprising a polynucleotide capable of producing a polypeptide of claim 1 into a cell such that the host cell, under appropriate culture conditions, produces said polypeptide.
- 25 5. A recombinant host cell produced by the process of claim 4.
6. A membrane of a recombinant host cell of claim 5 expressing said polypeptide.
- 30 7. A process for producing a polypeptide which comprises culturing a host cell of claim 5 under conditions sufficient for the production of said polypeptide and recovering said polypeptide from the culture.

SEQUENCE LISTING

<110> SMITHKLINE BEECHAM CORPORATION
 SMITHKLINE BEECHAM p.l.c.
 GLAXO GROUP, LIMITED

<120> NOVEL COMPOUNDS

<130> GP50034

<140> TO BE ASSIGNED
 <141> 2001-09-13

<150> 60/232,463
 <151> 2000-09-13

<150> 60/232,455
 <151> 2000-09-13

<150> 60/237,293
 <151> 2000-10-02

<150> 60/246,269
 <151> 2000-11-07

<150> 60/252,049
 <151> 2000-11-20

<160> 88

<170> FastSEQ for Windows Version 4.0

<210> 1
 <211> 1707
 <212> DNA
 <213> Homo sapiens

<400> 1

atgaaggaaag	cagagatgga	cggtgaggca	gtccgctct	gcacagataa	ccagtgtgtc	60
tccctgcacc	cccaagaggt	ggactctgtg	gcaatggctc	ctgcagcccc	caagataccg	120
aggctcgttc	aggctacccc	ggcatttatg	gctgtgacct	tggtcttc	tcttgtgact	180
ctctttgtag	tggtaagcc	cccaagttcaa	cagcagacaa	gacctgttcc	gaaggctgtg	240
caagccgtaa	ttctgggaga	caacattact	gggcattttac	cttttgaacc	caacaatcat	300
caccactttg	gcagggagggc	agaaatgcga	gagcttatcc	agacattttaa	aggccacatg	360
gagaatttcca	gtgcctgggt	agtagaaatc	cagatgttga	agtgcagagt	ggacaatgtc	420
aattcgcagc	tccaggtgtc	cggtgatcat	ctggaaaca	ccaatgctga	catccagatg	480
gtaaaaggag	ttctaaagga	tgccactaca	ttgagtttgc	agacacagat	gttaaggagt	540
tccctggagg	gaaccaatgc	tgagatccag	aggctcaagg	aagaccttga	aaaggccagat	600
gctttaactt	tccagacgct	gaatttctta	aaaagcagtt	tagaaaacac	cgcatttgag	660
ctccacgtgc	taagcagagg	cttagaaaat	gcaaactctg	aaatcagat	gttgaatgcc	720
agagccaaatg	ctgagatcca	gggactaaag	gaaaatttgc	agaacacaaa	tgctttaaac	780
tcccgacccc	aggcctttat	aaaaagcagt	tttgacaaca	ctagtgctga	gatccagttc	840
ttaagaggtc	atttggaaag	agctggtgat	gaaatttcacg	tgtaaaaag	ggatttgaaa	900
atggtcacag	cccagaccca	aaaagcaaat	ggccgtctgg	accagacaga	tactcagatt	960
caggttattca	agtccagagat	ggaaaatgtg	aatacctaa	atgcccagat	tcaggtctta	1020
aatggtcata	tgaaaaatgc	cagcagagag	atacagaccc	taaaaacaagg	aatgaagaat	1080
gcttcagcct	taacttccca	gaccagatg	ttagacagca	atctgcagaa	ggccagtgcc	1140
gagatccaga	ggttaagagg	ggatctagag	aacaccaaag	ctctaaccat	ggaaatccag	1200
caggagcaga	gtcgctgaa	gaccctccat	gtggtcatta	ttcacagga	acagctacaa	1260

agaacccaaa	gtcagcttct	ccagatggc	ctgcaaggct	ggaagttcaa	tggtggaa	1320
ttatattatt	tttctagtgt	caagaagtct	tggcatgagg	ctgagcagtt	ctgcgtgtcc	1380
cagggagccc	atctgcac	tgtggctcc	aaggaggagc	aggcatttct	ggttagagttc	1440
acaagtaaa	tgtaactact	gatcggtctc	actgacaggg	gcacagaggg	ctcctggcgc	1500
tggacagatg	ggacaccatt	caacgcgc	cagaacaaag	ccctgttgt	cttcgggtt	1560
tggaaaaga	atcgtctga	caactggcg	cacaagaatg	ggcagactga	agactgtgtc	1620
caaattcagc	agaagtggaa	tgacatgacc	tgtgacacacc	cctatcgtg	ggtgtgcaag	1680
aagccatgg	gccagggtgt	gccctga				1707

<210> 2

<211> 1095

<212> DNA

<213> Homo sapiens

<400> 2

atgtcgagac	aaggaaaatt	atittctgct	tttggagtg	tttggatgtgt	aacggcaggc	60
ttgccaaagg	acgataaacac	tcctagcacc	attgcggatg	tgacacaatgg	ttatacgtg	120
aatgtttag	agcaagttct	aaaggatagt	tttgcgttat	ttttccagg	aacactttgt	180
gattttccaa	aaatacacca	tggatttctg	tatgtgaag	aaagattataa	cccttttcc	240
caagttccta	caggggaagt	tttctattac	tcctgtgaat	ataattttgt	gtctccttca	300
aaatcctttt	ggactcgcac	aacatgcaca	gaagaaggat	ggtcaccaac	accgaagtgt	360
ctcagaatgt	gttccttcc	tttgcgtaaa	aatggtcatt	ctgaatcttc	aggactaata	420
catctggaa	gtgatactgt	acaaattatt	tgcaacacag	gatacagcct	tcaaaaacat	480
gagaaaaaaca	tttcgtgtgt	agaacggggc	tggtccactc	ctccatatg	cagttcact	540
atgaaaaacat	gtggatacat	acgtgaactc	gagtcgtt	atgttcagcc	gtctgtccct	600
ccctatcaac	atggagttc	agtcgagggt	aattgcagaa	atgaatatgc	aatgattgga	660
aataacatga	ttacctgtat	taatggaaa	tggacagagc	ttcctatgtg	tggtgagtt	720
actgcata	gtggggcccc	tccatctatt	aacaatggag	ataccacctc	attcccatat	780
toagtatatac	ctccagggtc	aacagtgacg	taccgttgc	agtccctcta	taaaactccag	840
ggctctgtaa	ctgtacatg	cagaataaaa	cagtggtcag	aaccaccaag	atgcctagat	900
ccatgtgtgg	tatctgaaga	aaacatgaac	aaaataaca	tacagttaaa	atggagaaac	960
gatggaaaaac	tctatgaaa	aacagggat	gctgttgta	tccagtgtaa	attcccatat	1020
aaagcgatga	tatcatacc	accatttcga	gcaatctgtc	aggaaggaa	atttgaatata	1080
cctatatgtg	aatga					1095

<210> 3

<211> 984

<212> DNA

<213> Homo sapiens

<400> 3

atgttgcct	tattcagtgt	aatcctaatac	tcatggtat	ccactgttgg	gggagaagga	60
acactttgt	atttccaaa	aatcacccat	ggatttctgt	atgtatgaa	agattataac	120
cccttttccc	aagttccat	agggaaagt	ttctattact	cctgtgaata	taattttgt	180
tctccttcaa	aatcctttt	gactcgcata	acatgcacag	aagaaggatg	gtcaccaaca	240
ccgaagtgtc	tcagaatgt	ttccttct	tttgcgtaaa	atggtcattc	tgaatcttca	300
ggactaatac	atctggaaagg	tgatactgt	caaattattt	gcaacacagg	atacagcctt	360
caaaaacaatg	agaaaaacat	ttcgtgtgt	gaacggggc	ggtccactc	tcccatatgc	420
agcttcacta	tgaaaacatg	tggatacata	cctgaactcg	agtcggtt	tggtcagccg	480
tctgtccctc	cctatcaaca	tggagttca	gtcgagggt	atggcagaaa	tgaatatgc	540
atgattggaa	ataacatgat	tacctgtatt	aatggaaat	ggacagagct	tcctatgtgt	600
gttgagtcta	ctgcataattt	tggggcccc	ccatctat	acaatggaga	taccacccat	660
ttcccattat	cagtatatacc	tccagggtca	acagtgcac	accgttgcca	gtccttctat	720
aaactccagg	gctctgtaa	tgtacatgc	agaaataaa	agtggtcaga	accaccaaga	780
tgoctagatc	catgtgtgg	atctgaagaa	aaacatgaaca	aaaataacat	acagttaaaa	840
tggagaaaacg	atggaaaact	ctatgaaaa	acagggatg	ctgttgtaatt	ccagtgtaaa	900
ttcccacata	aagcgatgt	atcatcacca	ccatttcgag	caatctgtca	ggaaggggaaa	960
tttgaatatac	ctatatgtga	atgaa				984

<210> 4
 <211> 465
 <212> DNA
 <213> Homo sapiens

<400> 4
 atggcaccgg ccagagcagg atgctgcccc ctgctgctgc tgcttctggg gctgtgggtg 60
 gcagagggtcc tagtcagagc caagccaaag gacatgacat catctcagtg gttaaaaact 120
 cagcatgtgc agcccagccc tcaagcatgc aactcagcca tgagcatcat caataagtac 180
 acagaacggt gcaaagaccc caacaccctc ctgcacgagc ccttctccag tggggccatc 240
 acctgcccaga cccccaacat agcctgcaag aatagctgta aaaactgcca ccagagccac 300
 gggcccatgt ccctgaccat gggtagctc acctcagggg agtacccaaa ctgcagggtac 360
 aaagagaagc acctgaacac accttacata gtggcctgtg accctccaca acagggtgac 420
 ccagggtacc cacttggtcc tgtgcacttg gataaaagttg tctaa 465

<210> 5
 <211> 1509
 <212> DNA
 <213> Homo sapiens

<400> 5
 atgcgcccagec tgggaggggtc tctccgcccc ccgcgcgcgg cccacggggc cgaggccttc 60
 cccagtgcgc tggggccctg cgctgggggt gaccgggacc tgggtcgggg aaccccccgg 120
 tgggagccca ggcgcgcagg ggtcccccattc cacgagcagg tcgacccccc gcgagagggg 180
 ccccacctct tccagaacact cctgtcttc ctgtggggcc tgcgtgaactg tggtttgggg 240
 gtcagtgctc agggtccggg cgagtggacc ccgtgggtgt cctggaccccg ctgctccagc 300
 tcctgcgggc gtggcgcttc tgcgtgcagg cggcgctgcc tccgcttcc tggggaaagaa 360
 ccgtgctggg gagactccca tgagtaccgc ctctgcccgt tgccagactg ccccccagg 420
 gctgtccct tccgagaccc acagtgtgc ctgtacaatg gcccctgt cctggcacc 480
 cagaagaccc accagtgggt gccttccat ggggcgcacca accagtgcga cctcaactgc 540
 ctggctgagg ggcacgcctt ctaccacagc ttcggcgcgc tcctggacgg caccgcctgc 600
 agcccggtg cccaggggt ctgcgtggct ggcgcgtgcc ttgcgcggg ctgtatgggg 660
 ttgttgggtc cgggtgcctt cgaggaccgc tgcgtggct gcggaggcgc caacgactcg 720
 tgcctttcg tgcagcgcgt gtttgcgtac gccgggtgcct tcgcgtggta ctggAACGT 780
 accctgatcc cccaggccgc cagacacatc cgcgtggaaac acaggagccg caaccacctg 840
 ggtatcttag gatcaactgat gggggggcgt gggcgctacg tgcttaatgg gcactgggtg 900
 gtcagccac cagggaccta cgaggcggcc ggcacgcgt tggtctacac ccgagacaca 960
 gggcccccagg agacattgca agcagccggg cccacctccc atgacactgct cctacaggc 1020
 ctctgcagg agcccaaccc tggcatcgag tttagtttgc ggctccctcg ggagcgctac 1080
 agcccccctcc aggctcggt gcaggccctg ggctggccccc tgaggcagcc tcagccccgg 1140
 ggggtggagc ctcagccccc cgcagccct gctgtcaccc ctgcacagac cccaaacgcgt 1200
 gccccagtgt tccaggcccg agtgcgtggc caccaccacc aggcccagga gacccgctat 1260
 gaggtgcgcga tccagctcgat ctacaagaac cgctcgccac tgccggcactg cgagtcgtg 1320
 tgggcgcctcc gccactgccc ctgcggatg ctggcaccccc accgggacta cctgtatggct 1380
 gtcagcgtc ttgtcagccc cgacggcaca caggaccagg tgctgcgtcc ccacgcggc 1440
 tacgcccggc cctggagccc tgcggaggac agccgcatac gcctgactgc ccggcgctgt 1500
 cctggctga 1509

<210> 6
 <211> 1356
 <212> DNA
 <213> Homo sapiens

<400> 6
 atggactcgg cccctctgtt ccccaaggccc caccttcc agaacctcct gctttccctg 60
 tggccctgc tgaactgtgg tttgggggtc agtgcgtagg gtccgggcga gtggaccccg 120
 tgggtgtctt ggacccgctg ctccagctcc tgcggggcgtg ggcgtctctgt ggcgcagg 180
 cgctgcctcc ggcttcctgg ggaagaaccg tgctggggag actcccatga gtaccgcctc 240
 tgccagttgc cagactgccc cccaggggtc gtgccttcc gagacctaca gtgtgcctg 300

tacaatggcc	gccctgtcct	gggcacccag	aagacctacc	agtgggtgcc	cttecatggg	360
gcgcggcaacc	agtgcgaccc	caactgcctg	gctgaggggc	acgccttcta	ccacagctc	420
ggcccggtcc	tggacggcac	cgccctgcgc	ccgggtgcc	agggggtctg	cgtggctggc	480
cgctgcctta	gcgcggctg	tgtatgggtt	ttgggctcgg	gtgccctcga	ggaccgctgt	540
ggcccgctgcg	gaggcgccaa	cgactcgtgc	ctttcgtgc	agcgcgttt	tcgtgacgcc	600
ggtgccttcg	ctgggtactg	gaacgtgacc	ctgatcccc	agggcgccag	acacatccgc	660
gtggAACACA	ggagccgcaa	ccacctgggt	atcctaggat	cactgatggg	gggcgatggg	720
cgctacgtgc	ttaatggca	ctgggtggtc	ageccaccag	ggacctacga	ggcggccggc	780
acgcatgtgg	tctacacccg	agacacaggg	ccccaggaga	catgcaagc	agccgggccc	840
acctccatg	acctgctcct	acaggctc	ctgcaggagc	ccaaacccctgg	catcgagtt	900
gagttctggc	tccctcgga	gfcctacagc	cccttccagg	ctcgtgtca	ggccctggc	960
tggccctgt	ggcagcctca	gccccggggg	gtggagcctc	agccccccgc	agcccccgt	1020
gtcaccctgt	cacagacccc	aacgctggcc	ccagtgttcc	agggccggagt	gctgggcccac	1080
caccaccagg	cccaggagac	ccgctatgag	gtgcgcattcc	agctcgctca	caagaaccgc	1140
tcgcccactgc	gggcacgcga	gtacgtgtgg	gfcgcaggcc	actgccccctg	cccgatgtcg	1200
gcaccccaacc	gggactaccc	gatggctgtc	cagcgttcc	tcagccccga	cgccacacag	1260
gaccagctgc	tgctgccccca	cgccggctac	gccccggccct	ggageccctgc	ggaggacagc	1320
cgcatacgcc	tgactgccccg	gfcctgtcct	ggctga			1356

<210> 7

<211> 1296

<212> DNA

<213> Homo sapiens

<400> 7

atgatccgga	ccccatgtc	ggcctctgcc	catgcctgc	tcctccagg	ctcccgccg	60
cgaccccccgc	gcaacatgca	gcccacgggc	cgcgagggtt	cccgccgc	cagccgggg	120
tatctgcggc	gtctgctgct	cctgtactg	ctgctgcgtc	tgccgcagcc	ctgtacccgc	180
goggagacca	cgccggcgcc	ccccagagcc	ctctccacgc	tgggtcccc	cagcctcttc	240
accacggccgg	gtgtccccag	cgccctca	accccagcc	tcactacgccc	aggcacccccc	300
aaaaccctgg	acccctcgggg	tcgcgcgcag	gcccgtatgc	ggagtttccc	actcgtggac	360
gggtatgtag	gtctgaacag	ctctcaaaag	ctggcctgc	tcatggcgt	ggaggggtgg	420
cactcaactgg	acgcagcc	ctctgtgtc	cgcgtttct	atgtgttggg	gtgcgtac	480
ctgacactta	ccttcacttc	cagtagacca	tgggcagaga	gttccaccaa	gttcagacac	540
cacatgtaca	ccaacgtcag	cggttttgc	agctttgttgc	agaaagtatg	agaggagttg	600
aaccgcctgg	gcatgtat	agatttgtcc	tatgcacatgg	acacccttgc	aagaagggtc	660
ctggaagtgt	ctcaggctcc	tgtatgttcc	tcccactc	ctgcccagagc	tgtgtgtac	720
aattttgtga	atgttcccg	tgtatcttc	cagcttctg	agaagaacgg	ttgcacatgt	780
atggtgacac	tgccatgggg	ggtgcgtc	tgcaacctgc	ttgcttaacgt	gtccactgt	840
gcagatgatt	cgaaatcgat	ctcggttccc	gtcattggat	ctgagttcat	cgggattgg	900
ggaaaattatg	acgggactgg	ccgggtccct	caggggctgg	aggatgtgtc	cacataccca	960
gtcctgtatag	aggagttgt	gagtcgtac	tggagcgagg	aagagcttca	agggtgtc	1020
cgtggaaacc	tgctgcgggt	cttcagacaa	gtggaaaagg	tgagagagga	gagcaggggcg	1080
cagagccccc	tggaggctga	gtttccat	gggcacactga	gcacatcc	ccactcc	1140
ctcgtgcctc	agaatggaca	ccaggctact	catctggagg	tgaccaagca	gccaaccaat	1200
cgggtccct	ggaggtc	aaatgcctc	ccatacc	ttccaggc	tgtggctg	1260
gccaccatcc	caacccatcc	ccagtggtc	tgctga			1296

<210> 8

<211> 1443

<212> DNA

<213> Homo sapiens

<400> 8

atgcagccct	ccggcctcga	gggtccccggc	acgtttggc	ggtggctct	gctgagtc	60
ctgtcctgc	tgctgctgct	ccagctgtc	acctgtgc	acaccacgc	aggccccccc	120
agagccctca	ccacgctggg	cgcccccaga	gcccacacca	tgccggcac	ctacgctccc	180
tcgaccacac	tcagtagtcc	cagcacc	ggcctgca	agcaggc	ggccctgatg	240
cgggacttcc	cgctcggt	cgccacaac	gacctgccc	tggtctta	gcaggtttac	300

cagaaggc tacaggatgt	taacctgcgc aatttcagct acggccagac cagccctggac	360
aggcttagag atggcctcg	gggcgcccag ttctggtcag cctatgtgcc atgccagacc	420
caggaccggg atgcccctcg	cctcaccctg gaggcagattg acctcatacg ccgcatagtgt	480
gcctcctatt cttagctgg	gcttgtgacc tcggctaaag gtctgaacag ctctcaaaag	540
ctggcctgccc tcattggcg	ggagggtggt cactcactgg acagcagccct ctctgtgctg	600
cgcagttct atgtgtggg	ggtgccgtac ctgacactta cttcacctg cagtacacca	660
tgggcagaga gttccacca	gttcagacac cacatgtaca ccaacgtcag cggattgaca	720
agctttggtg agaaaagtgt	agaggagttg aaccgcctgg gcatgatgat agatttgtcc	780
tatgcatcg acacccgtat	aagaagggtc ctggaaagtgt ctcaggctcc tggatcttc	840
tcccactcg ctgcccagagc	tgtgtgtgac aatttggta atgttcccgat tgatatcctg	900
cagcttcgtg agaagaacgg	tggcatcgat atgggtacac tggccatggg ggtgtcgac	960
tgcaacctgc ttgtctaacgt	gtccactgtg gcagatcaact ttgaccacat cagggcagtc	1020
atggatctg agttcatcg	gattggtgga aattatgacg ggactggccg gttccctcg	1080
gggctggagg atgtgtccac	ataccctcgatc ctgatagagg agttgtctgat tcgtatgtgg	1140
agcgaggaag agttcaagg	tgtccctcgat gggaaacctgc tgccgggtctt cagacaagtg	1200
gaaaagggtga gagaggagag	cagggcgcag agccccgtgg aggctgagtt tccatatggg	1260
caactgagca catccctgcca	ctcccccaccc tcgtcctcaga atggacacca ggctactcat	1320
ctggagggtga ccaagcagcc	aaccaatcggtt gttccctggat ggtctcaaa tgcctccca	1380
taccttggttc caggccttgt	ggctgctgcc accatcccaa cttcacccca gtggctctgc	1440
tga		1443

<210> 9
<211> 1116
<212> DNA
<213> Homo

<210> 10
<211> 1779
<212> DNA
<213> Homo

```

<400> 10
atggatgcag ccacagctcc aaaggcaagcc tggccccat ggcccccgct ccttttcctc 60
ctccctcata ctggagggag cggtggcagc tgccctgtcg tgtgtgactg caccccccag 120
ccccaggctg tgctctgtgg ccacaggcaa ctggaggctg tacctggagg actcccaactg 180
gacactgagc tcctggacct gagtgggAAC cgccctgtggg ggctccagca ggaaatgctc 240
tccccctgaa gcctgtctca ggaattggac ctcagctaca accagctctc aaccctttag 300
cctggggcct tccatggct acaaaggcta ctcacccctga ggctgcaggg caatcggtctc 360

```

agaatcatgg	ggcctgggt	cttctcaggc	ctctctgctc	tgaccctgtc	ggacccctcgc	420
ctcaaccaga	ttgttctt	cctagatgga	gctttgggg	agcttaggcag	cctccagaag	480
ctggagggtt	gggacaacca	cctggtattt	gtggctccgg	gggccttgc	agggctagcc	540
aagttgagca	ccctcaccct	ggagcgctgc	aacctcagca	cagtgcctgg	cctagccctt	600
gcccgtctcc	cggcactagt	ggccctaagg	cttagagaac	tggatattgg	gaggctgcca	660
gctggggccc	tgcggggct	ggggcagctc	aaggagctgg	agatccacct	ctggccatct	720
ctggaggctc	tggaccctgg	gagcctgggt	gggctcaatc	tcagcagct	ggccatcaact	780
cgctgcaatc	tgagctcggt	gcccctccaa	gcactgtacc	acctcagctt	cctcagggtc	840
ctggatctgt	cccagaatcc	catctcagcc	atcccagccc	gaaggctcag	ccccctggtg	900
cggtccagg	agctacgcct	gtcaggggca	tgcctcacct	ccattgtgc	ccatgccttc	960
catggcttga	ctgccttcca	cctcctggat	gtggcagata	acgcccctca	gacactagag	1020
gaaacagctt	tcccttctcc	agacaaaactg	gtcaccttga	ggctgtctgg	caacccctta	1080
acctgtgact	gcccgcctct	ctggctgctc	cggtccgccc	acettggactt	tggcatgtcc	1140
ccccctgcct	gtgctggccc	ccatcatgtc	caggggaaga	gcctgaagga	gttttcagac	1200
atccctgcctc	cagggcaactt	cacctgcaaa	ccagccctga	tccgaaagtc	ggggcctcga	1260
tgggtcattt	cagaggaggg	cgggcatgct	gttttctctt	gctctggaga	tggagaccca	1320
gcccccaactg	tctcctggat	gaggcctcat	ggggcttggc	tggcaggggc	tggagagata	1380
agggtcctag	aggatgggac	actggagatc	cgctcagtc	agctacggga	cagaggggccc	1440
tatgtctgt	tggtagcaa	tgtcgctggg	aatgactccc	tgaggacact	gcttggaaagtc	1500
atccaggtgg	aaccaccaaa	cggcacactt	tctgacccca	acatcaccgt	gccaggatc	1560
ccagggcctt	ttttctggaa	tagcagaggt	gtggccatgg	tgcttggcagt	cggttcctc	1620
cccttcctca	cctcagtgac	cctctgtttt	ggcctgattt	cccttggag	caagggcaaa	1680
gtcgggtca	aacatcacat	gacccttgac	tttggcgcac	ctcgccctc	tggggataaaa	1740
aactctgggg	gtaaccgggt	cactgccaag	ctttcttga			1779

<210> 11

<211> 429

<212> DNA

<213> Homo sapiens

<400> 11

atggccaggt	acatgtctgct	gctgctcttg	gcggtatggg	tgctgaccgg	ggagctgtgg	60
ccggggactg	aggccggggc	agccgccttac	ggggtcagggc	tttgcggccgg	agaattcatc	120
cggcggatca	tcttcacctg	cgggggctcc	cggtggagac	gatcagacat	cctggcccac	180
gaggctatgg	gagatacctt	cccgatgca	gatgctgtat	aagacagtct	ggcaggcggag	240
ctggatgagg	ccatggggtc	cagcgagtgg	ctggccctga	ccaagtccacc	ccaggcctt	300
tacagggggc	gaccgcgtg	gcaaggaacc	cctgggggttc	ttcggggcag	ccgagatgtc	360
ctggctggcc	tttccagcag	ctgtgtcaag	tgggggtgt	gcaaaagtga	aatcagttagc	420
ctttgcttag						429

<210> 12

<211> 692

<212> DNA

<213> Homo sapiens

<400> 12

atgtctgaag	aagtgaccta	cgcgcacactc	acatttcagg	attctgtctgg	agcaaggaat	60
aaccggatg	gaaataaacct	aagaaaaaaa	gggcattccag	ctccatctcc	catttggcgt	120
catgtctgctc	tgggtcttgg	aactcttgc	ctgtatgttc	tgattgggt	ggtgcacgttg	180
gggatgtatgt	ttttgcagat	atctaatacgt	attaactcgt	attcagagaa	attgagtctaa	240
cttcagaaaa	ccatccaaca	gcagcaggat	aacttatacc	agcaactggg	caactccaaac	300
aacttgtcca	tggaggagga	atttctcaag	tcacagatct	ccagttctact	gaagaggcag	360
gaacaaaatgg	ccatcaaact	gtcccaagag	ctaatcatcc	atacttcaga	ccacagatgt	420
aatccatgtc	ctaagatgt	gcaatggta	caaaatagg	gctactattt	tacaacaaat	480
gaggagaaaa	cctgggctaa	cagtagaaag	gactgcata	acaagaactc	caccctagtg	540
aagatagaca	gtttggaaaga	aaaggatttt	cttatgtcac	agccattact	catgttttgc	600
ttcttttggc	tgggattatc	atgggactcc	tctggcagaa	gttgggtctg	ggaagatggc	660
tctgtccct	ctccatccct	gtacgtctct	aa			692

<210> 13
<211> 585
<212> DNA
<213> *Homo sapiens*

```

<400> 13
atgtggctgt ccccaagctct gctgcttctc atcctccca gttactccat tgccgctaaa 60
atcaactggtc caacaacagt gaatggctcg gagcagggct cattgactgt gcagtggtct 120
tatggctcag gctgggagac ctacttgaag tggcgggtgc aaggagctga ttggaaattac 180
tgtaacatcc ttgttaaaaac aaatggatca gagcaggagg taaagaagaa tcgagtttcc 240
atcagggaca atcagaaaaaa ccacatggtc accgtgacca tggagaatct caaaagagat 300
gatgctgaca gttattggtg tgggactgag agacctggaa ttgatcttgg ggtcaaaatgt 360
caagtgacca ttaaaccagg cacacaaact gcagtttcag aatggacaac cacaacagca 420
agcctggctt tcacagctgc agccacccag aagaccagca gccccctcac cagggtccccg 480
ctcaagagca cccacttcct gttcctgttc ctccctggac tgcctctgt cctgagcatg 540
ctggggacccg tcctctgggt gaacagacca caaagaaggt ttgt 585

```

<210> 14
<211> 1002
<212> DNA
<213> Homo

<400> 14	atgaggatct ggtggcttct	gcttgcatt	gaaatctgca	cagggAACat	aaactcacag	60
gacacctgcA	ggcaaggggca	ccctggaaatc	cctgggaaacc	ccggtcacaa	tggtctgcct	120
ggaagagatg	gacgagacgg	agcgaagggt	gacaaaggcg	atgcaggaga	accaggacgt	180
cctggcagcc	cggggaaagga	tgggacgagt	ggagagaagg	gagaacgagg	agcagatggA	240
aaagttgaag	caaaaaggcat	caaagggtat	caaggctaa	gaggatcccc	aggaaaacat	300
ggccccaagg	ggcttgcagg	gccccatggga	gagaagggccc	tccgaggaga	gactgggcct	360
cagggggcaga	aggggaataaa	gggtgacgtg	ggtcccactg	gtcctgaggg	gccaaggggc	420
aacattgggc	ctttgggccc	aactggtttA	ccggggccca	tgggccctat	tggaaaggct	480
ggtcccaaaag	gagaagctgg	acccacgggg	ccccagggtg	agccaggagt	ccggggaaata	540
agaggctgga	aaggagatcg	aggagagaaaa	gggaaaatcg	gtgagactct	agtcttgcca	600
aaaagtgtt	tcactgtggg	gctcacggtg	ctgagcaagt	ttccttcttc	agatatgccc	660
attaaatttg	ataagatctt	gtataacgaa	ttcaaccatt	atgatacagc	agcggggaaa	720
ttcacgtgcc	acattgtctgg	ggtctattac	ttcacctacc	acatcactgt	tttctccaga	780
aatgttcagg	tgtctttgtt	caaaaatggA	gtaaaaatac	tgcacaccaa	agatgcttac	840
atgagctctg	aggaccaggc	ctctggccgc	attgtcctgc	agctgaagct	cggggatgag	900
gtgtggctgc	aggtgacagg	aggagagagg	ttcaatggct	tgtttgctga	tgaggacgt	960
gacacaacctt	tcacagggttt	ccttctgttc	agcagccgt	ga		1002

<210> 15
<211> 678
<212> DNA
<213> *Homo sapiens*

<400> 15		
atgaggatct	ggtgtgcttct	60
gacacctgca	ggcaagggca	120
ggaagagatg	gacgagacgg	180
acggggcccc	agggtgagcc	240
gagaaaggga	aaatcggtga	300
acggtgctga	gcaagtttcc	360
aacgaattca	accattatga	420
tattacttca	cctaccacat	480
aatggagtaa	aaatactgca	540
ggccggcattg	tcctgcagct	600
gagagggtca	atggcttggt	660
ctgttcagca	gccccgtga	678

<210> 16
<211> 618
<212> DNA
<213> *Homo sapiens*

atgatgagaa ctctcatcac cacacaccca ctgcccctgc ttctattgcc gcagcagctg ctgcagctgg tgcaagttca agaggtggat acagattttg atttcccaga agaagataaa aaagaagaat ttgaagagtg tttggaaaaa ttttttagta cagggcccg cagaccacct acccaaagaaa aagtcaaaag acgtgtcctt attgaacctg gaatgccact aaatcatata gagtactgta accatgaaat catggggaaa aatgttact acaaacaccg ttgggtggca gaacattact tccttcttat gcaatatgac gagctccaaa aaatctgtta caacagatt gtccatgtta agaatggaaat taggaaatgt aacaggagca aaggtcttgtt agaaggagtg tattgttaatt taacagaagc atttggaaata ccagcgtgtt aatacgaatc actttatagg aaggggctacg tccttacac ttgttcatgg caaaatgaaa tgcaaaaaacg tatttcctcat actataaaatg atctcgtgga gccacctgaa cacagaagtt tcctcagtga ggatgggtgc tttgcataat cgccctag	60 120 180 240 300 360 420 480 540 600 618
--	--

<210> 17
<211> 288
<212> DNA
<213> *Homo sapiens*

```

<400> 17
atggaggatgg tgctgatctt tctatgcagc ctgtggccc acattgtcct ggccgatgca 60
gtttagaggg agaagcaaat tgaccctttt cattatgact accagaccct gaggattagg 120
gggttggat gtgctgtggt cctttctcc attgggatcc tccttatacct aggttgccaga 180
tgcaagtgc a gtttcaatca gaagccccagg a ccccccaggagg aggaggaagc ccaggtggag 240
aacctcatca ctgcaaatgc aacaagctc cagaagcagc agagctga 288

```

<210> 18
<211> 1788
<212> DNA
<213> *Homo sapiens*

<400> 18						
atggagggtgg	aatggggatg	ctggggcccg	gagggtctgg	tcccccaggg	gcccttgcac	60
cgcgtggctg	gcacagctgt	ctccatctcc	tgcaatgtga	ccggctatga	gggcccgtcc	120
cagcagaact	tcgagtgggt	cctgtatagg	cccgaggccc	cagataactgc	actgggcatt	180
gtcagttacca	aggataccca	gttctcttat	gctgtcttca	agtcccgggt	ggtgggggggt	240
gaggtgcagg	tgcagcgct	acaaggtgt	gcccgtgtc	tcaagatgtc	ccgcctgcag	300
gcccaggatg	ccggcattta	tgagtgcac	accccttcca	ctgataccgg	ctacctggc	360
agctacagcg	gcaagggtgg	gctgagagtt	cttccagatg	tcttccagg	gtctgtgc	420
cccccaggc	cccgaggccc	ccaggcccc	acctcacccc	cacgcata	gtgtcatgag	480
gggcaggaggc	tggcactggg	ctgcctggcg	aggacaagca	cacagaagca	cacacacctg	540
gcagtgtcct	ttggcgtatc	tgtccccgg	gcaccagg	ggcggtcaac	tctgcaggaa	600
gtgtgtggaa	tccggcgtcaga	cttggccgtg	gaggctggag	ctccctatgc	tgagcgattg	660
gctgcagggg	agcttcgtct	gggcaaggaa	gggaccgatc	ggtaccgat	ggtagtaggg	720
ggtgcccaagg	caggggacgc	aggcacctac	cactgactg	ccgctgagtg	gattcaggat	780
cctgtatggca	gctggggccca	gattgcagag	aaaaggccg	tctggccca	cgtggatgt	840
cagacgctgt	ccagccagct	ggcagtgcaca	gtggggctg	gtgaacgtcg	gatcgccca	900
ggggagccct	tggaaactgct	gtgcaatgt	tcagggcac	ttccccccagc	aggccgtcat	960
gctgcataact	ctgttaggtt	ggagatggca	cctgcggggc	acctggggcc	cggccgcctg	1020
gtagcccaagc	tggacacaga	gggtgtggc	agcctggcc	ctggctatga	gggcccacac	1080
attggccatgg	agaagggtggc	atccagaaca	taccggctac	ggctagaggc	tgccaggcct	1140
ggtgatgcgg	gcacccatccg	ctgcctcgcc	aaagcctatg	tgcagggtc	ttgggaccgg	1200
ttcgtgtgaag	cagccagtgc	ccgttccccgg	ccttccttg	tacatgtgcg	ggagggaaaggt	1260
gtgtgtctgg	aggctgtggc	atggctagca	ggaggcacag	tgtaccgcgg	ggagactgcc	1320
ccccctgtgt	gcaacatctc	tgtgcggggt	ggccccccag	gactgcggct	ggcccccac	1380

tggtgtggtgg	agcgaccaga	ggacggagag	ctcagctctg	tccctgccc	gctgggtgg	1440
ggcgtaggcc	aggatgggt	ggcagagctg	ggagtcggc	ctggaggagg	ccctgtcagc	1500
gtagagctgg	tggggccccc	aagccatgg	ctgagactac	acagttgg	gcccggat	1560
gaaggcgtgt	accactgtgc	ccccagcgc	tgggtgcagc	atccgacta	cagctgg	1620
caggcgggca	gtgcccgtc	aggcctgtt	acagtctacc	cctacatgca	tgcctggac	1680
accctatttgc	tgcctctgt	ggtgggtaca	gggggtggcc	tagtactgg	tgcactgtc	1740
cttggtagcca	tcacttgctg	ttcatgaa	aggcttcgaa	aacggtga		1788

<210> 19

<211> 1842

<212> DNA

<213> Homo sapiens

<400> 19

atggcgcccc	tcaggcccac	gctgctgccc	ccttcgtc	cgctgctgct	gctgcta	60
ctaggaatgg	gatgctggc	ccgggagggt	ctggtcccc	agggggcc	gtaccgcgt	120
gctggcacag	ctgtctccat	ctcctgcaat	gtgaccgct	atgagggccc	tgcctggcag	180
aacttcgagt	ggttccctgt	taggcccag	gccccagata	ctgca	ctgg	240
accaaggata	cccagtctc	ctatgctgc	ttcaagttcc	gagtgg	gggtgagg	300
caggtgcagc	gcctacaagg	tgtatggcgt	gtgctcaaga	ttgccc	gcaggccc	360
gatgccggca	tttatgagtg	ccacaccccc	tccactgata	cccgt	gggcagctac	420
agccggcaagg	tggagctgag	agttttcca	gatgtcctc	agggt	ctgc	480
ggggcccgag	gcccgcaggc	cccaacctca	cccccacca	tgacgg	tgagg	540
gagctggcac	tgggctgcct	ggcaggaca	agcacacaga	agcacacaca	cctggcag	600
tcctttggc	gatctgtgc	cgaggcacca	gttggcggt	caactctgca	ggaagtgg	660
ggaatccgg	cagacttggc	cgtggaggct	ggagctcc	atgctgagc	attggct	720
ggggagcttc	gtctggc	aa	gatcggtacc	gcatggtag	aggggg	780
caggcagggg	acgcaggcac	ctaccactgc	actgcccgt	agtggattca	ggatcctgat	840
ggcagctggg	cccagattgc	agagaaaagg	gcccgtc	cccacgtg	tgtgcag	900
ctgtccagcc	agctggcagt	gacagtgg	cctggta	gtcggatc	cccagg	960
cccttggaa	tcgtgtc	tgtcaggg	gca	ccgg	tcatg	1020
tactctgtag	gttggagat	ggcacctgc	ggggcac	ggccgg	cctgg	1080
cagctggaca	cagagggtgt	ggcagcctg	ggccctg	atgagg	acacatt	1140
atggagaagg	tggcatccag	aacataccgg	ctacgg	aggctg	ccag	1200
gcgggcac	accgctgc	cgccaaagcc	tgat	ttc	ccgg	1260
gaagcagcca	gtgcccgtt	ccggcctc	cctgt	atc	gg	1320
ctggaggctg	tggcatggct	agcaggaggc	acagt	gtacc	gggg	1380
ctgtgcaaca	tctctgtgc	gggtggccc	ccagg	gtc	ccgc	1440
gtggagcgc	cagaggacgg	agagctc	tctgt	ccc	ca	1500
ggccaggatg	gtgtggcaga	gctgggagtc	cg	gg	ctgt	1560
ctggtggggc	cccgaaggca	tggctgaga	ctaca	ca	gtt	1620
gtgtaccact	gtgcccc	cgcctgggt	cg	acta	gg	1680
ggcagtgc	gctcagg	tgttacagtc	cat	ca	gg	1740
tttgtgc	tcgtgg	tacagggtg	cc	cc	ac	1800
accatca	ctg	ttcat	tt	gt	cc	1842

<210> 20

<211> 1791

<212> DNA

<213> Homo sapiens

<400> 20

atggccgcca	actccaccag	cgacccac	actccccgg	cg	cg	60
atcatcgta	tcactgt	tttgc	tttgc	tttgc	tttgc	120
cggccagta	gaa	acacgg	tttgc	tttgc	tttgc	180
ccgattggag	cctcc	c	tttgc	tttgc	tttgc	240
ggctcaggcg	cg	cg	tttgc	tttgc	tttgc	300
ctgtggcac	tgg	catgggt	tttgc	tttgc	tttgc	360
cctgagat	ttc	aga	tttgc	tttgc	tttgc	420

tccctgtac	tgtctgtctt	caccaagata	tcgctggacc	tgtacgcggg	ggctctgttt	480
gtgcacatct	gcctggctg	gaacttctac	ctctccacca	tcctcacgct	cgccatcaca	540
ccccctgtaca	ccatcgagg	gggcctggct	gctgtaatct	acacggacgc	cctgcagacg	600
ctcatcatgg	ttgtggggc	tgtcatctg	acaatcaaag	cttttacca	gatcggttgt	660
tacgggcagg	ttggaggcagg	ctacgcccag	gccatttccct	ccaggaccat	tgccaaacacc	720
acctgccacc	tgccacgtac	agacggccatg	cacatgttgc	gagacccca	cacaggggac	780
ctgcccgtgga	ccgggatgac	cttggccctg	accatcatgg	ccacctggta	ctgggtgcacc	840
gaccagggtca	tcgtcagcg	atcaactgtca	gcccggacc	tgaaccatgc	caaggcgggc	900
tccatcttgg	ccagctacct	caagatgtc	cccattggcc	tgatcataat	gccgggcatg	960
atcagccgcg	cattgttccc	agatgtatgt	ggctgcgtgg	tgccgtccga	gtgcctgcgg	1020
gcctgcgggg	ccgagggtcg	ctgctccaaac	atcgccctacc	ccaaagctgt	catggaaactg	1080
atgcccattcg	gtctgcgggg	gctgatgatc	gcagtgtatgc	tggccggcgt	catgtcgctcg	1140
ctgaccctcca	tcttcaacag	cagcagcacc	cttccatcta	tgacatctg	gaggcggcgt	1200
cgtccccgc	ccggcgagcg	ggagctccgt	ctgggtggac	ggctggcat	agtggcactc	1260
atcggcggtga	gtgtggcctg	gatccccgtc	ctgcaggact	ccaaacagcgg	gcaactcttc	1320
atctacatgc	agtcaatgtac	cagctccctg	gccccaccag	tgactgcagt	ctttgtccgt	1380
ggcgtcttct	ggcgacgtgc	caacgagcag	ggggccttct	ggggcctgtat	agcaggcgt	1440
gtgggtgggg	ccacgaggct	ggtcctggaa	ttcctgaacc	cagccccacc	gtgcggagag	1500
ccagacacgc	ggccagccgt	cctgggggagc	atccactacc	tgcacttcgc	tgcggccctc	1560
tttgcactca	gtgggtgtgt	tgtgggtggct	ggaagctgc	tgacccacc	cccacagagt	1620
gtccagattt	agaacattac	ctgggtggacc	ctggctcagg	atgtgcctt	gggaactaaa	1680
gcaggtgtat	gccaacacacc	ccagaaaacac	gccttctggg	cccggtgtctg	tggcttaat	1740
gcccattctcc	tcatgtgtgt	caacatattc	ttttatgcct	acttcgcctg	a	1791

<210> 21
<211> 1182
<212> DNA
<213> Homo sapiens

<400> 21

atggattcct	taaagaatga	gaactatgtat	ctggtatgg	ttgaagcatt	tgatttctgt	60
tctttcttga	ttgctgagaa	gcttgtgaaa	ccatttgcgg	ccatttcc	caccacattc	120
ggctctttgg	attttgggct	accaagcccc	ttgtctttag	ttccagtatt	cccttccttg	180
ctgactgatc	acatggactt	ctggggccga	gtgaagaatt	ttctgtatgtt	cttttagtttgc	240
tccaggagcc	aatgggacat	gcagtctaca	tttgacaaca	ccatcaagga	gcatttccca	300
gaaggctcta	ggccaggtttt	gtctcatctt	ctactgaaag	cagagttgtg	ttttgttaac	360
tctgattttgc	cctttgattt	tgccggcc	ctgcttccca	acactgttta	tattggaggc	420
tttgcatttttgc	aaacattttaa	accacttca	caagacttgg	acaacttcat	tgccaaacttt	480
ggggatgcag	ggtttgcctt	tgtggccctt	ggctccatgt	tgaacaccca	tcaatcccg	540
gaagtccctca	agaagatgca	caatgccttgc	gcccaccc	ctcaaggagt	gatatggaca	600
tgtcagatgtt	ctcattggcc	cagatgttgc	cattttggcc	caaatgtaa	aattgtggac	660
tgccttcctc	agagtgcac	cctggctcac	cccagcatcc	gtcttttgt	cactcatgg	720
ggcagaaca	gcgtaatgg	ggccatccgt	catgggtgtc	ccatgggtgg	attaccagtc	780
aatgggatcc	agcatggaaa	catggtccga	gttagtagcca	aaaattatgg	tgtctctatc	840
cgtttaatc	aggtcacagc	cgacacactg	acacttacaa	tgaacaca	catagaagac	900
aagaggtaca	agtcggcagt	ggttggcagcc	agtgtcatcc	tgcactctca	gcccctgagc	960
cccgacacgc	ggctgggtgg	ctggatgcac	ccatccctcc	agactggggg	agcgacgcac	1020
ctcaaggccct	atgccttcca	gcagccttgg	catggcgt	acctcatttga	tgtctttgt	1080
tttctgtgttgc	ggctacttct	gggcactatgt	tggctttgtg	ggaagctgtct	gggtgtgggt	1140
gcccattctcc	tcatgtgtgt	caacatattc	ttttatgcct	acttcgcctg	a	1182

<210> 22
<211> 1572
<212> DNA
<213> Homo sapiens

<400> 22

atggttgggc	agcgggtgtct	gcttcttagtg	gccttccttc	tttctgggtt	cctgtctctca	60
gaggctgcca	aaatcctgac	aatatctaca	ctgggtggaa	gccattacct	actgttggac	120

cgggtgtctc	agattcttca	agagcatgg	cataatgtga	ctatgttca	tcagagtgg	180	
aagttttga	tcccagat	ataaagaggag	aaaaatcat	accaagttat	caggtgg	240	
tcacctgaag	atcatcaaaa	aagaattaag	aagcattt	atagctacat	agaaacagca	300	
ttggatggca	aaaaagaatc	tgaagcc	gtaaagctaa	tggaaatatt	tggactcaa	360	
tgttagttatt	tgctaagcag	aaaggatata	atggattc	taaagaatga	gaactatgat	420	
ctggtattt	ttgaagcatt	tgatttctgt	tcttc	ttgctgagaa	gcttgtgaaa	480	
ccattt	gtgg	ccatttctcc	caccacattc	ggctt	atttgggctt	accaagcccc	540
ttgtcttatg	ttccagttatt	cccttc	ctgactgatc	acatggactt	ctggggccga	600	
gtgaagaatt	ttctgatgtt	ctttagttt	tccaggagcc	aatgggacat	gcagtctaca	660	
tttgacaaca	ccatcaagga	gcatttccc	gaaggctca	ggccagttt	gtctcattt	720	
ctactgaaag	cagagtgtg	gtttgttaac	tctgattt	ccttgattt	tgcggccccc	780	
ctgcttcca	acactgttta	tattggag	ttgatggaaa	aacattttaa	accagtacca	840	
caagacttgg	acaacttcat	tgccaactt	ggggatgcag	ggttgcctt	tgtggcc	900	
ggctccatgt	tgaacaccca	tcagtc	gaagtc	agaagatgca	caatgc	960	
gccacactcc	ctcaaggagt	gatatggaca	tgtc	agagtt	ctcattggcc	cagagatgtt	1020
catttggcca	caaatgtgaa	aattgtggac	tggctt	ccttgc	agagtgc	1080	
cccagcatcc	gtctttt	cactcatgtt	gggcaga	gctaatgg	ggccatccgt	1140	
catgggtgc	ccatgggtgg	attaccagtc	aatggg	agcatggaaa	catggtccg	1200	
gtagtagcca	aaaattatgg	tgtctt	cggtt	gaatc	aggtcac	1260	
acacttacaa	tgaaacaagt	catagaagac	aagagg	tac	gttggc	1320	
agtgtcatcc	tgcacttca	gccc	ccgc	ccgcac	ggctgtgg	1380	
cacatcctcc	agactgggg	agc	cc	ccgcac	gcagcctt	1440	
catgagcagt	acctcattga	tgtctt	tttctg	ctgc	actct	1500	
tggctt	ggaagctg	gggtgtgg	gccagg	tgcgtgg	caggaagg	1560	
aagaagacat	ga					1572	

<210> 23

<211> 759

<212> DNA

<213> Homo sapiens

<400> 23

atgagctgc	tcctgggtgg	tgtcatcccc	ttggggctgc	tgttcc	ctgcggatcc	60
caaggctacc	tcctgcca	cgtca	ttagagg	tgc	tgc	120
aacgagtctc	actcccggt	ccgc	agg	atacc	agg	180
atgctgcaca	acaagctcg	gggc	agg	cacat	gg	240
acctggatg	acgaactgg	gaag	tct	gc	gtt	300
cacgggccc	ccagtctgt	gtgtccatc	ggcagaacc	tggcg	ctggggc	360
tatcgctc	cgggttca	tgtc	tgtatg	agg	at	420
ccctacccg	gcgagtca	ccc	ccat	cc	atgt	480
cactacac	agatagtt	ggcacc	aaca	atcg	ac	540
cggaa	ctgtctgg	aga	ttt	tct	ttt	600
tctccaaagg	ggaactgat	tgg	gaga	cc	tgc	660
tgcccaccc	gctatggagg	cag	ctgc	aa	actt	720
actccaaaca	cttttcaat	gaattt	gg	gttacc	gg	759

<210> 24

<211> 1494

<212> DNA

<213> Homo sapiens

<400> 24

atgagctgc	tcctgggtgg	tgtcatcccc	ttggggctgc	tgttcc	ctgcggatcc	60
caaggctacc	tcctgcca	cgtca	ttagagg	tgc	tgc	120
aacgagtctc	actcccggt	ccgc	agg	atacc	agg	180
atgctgcaca	acaagctcg	gggc	agg	cacat	gg	240
acctggatg	acgaactgg	gaag	tct	gc	gtt	300
cacgggccc	ccagtctgt	gtgtccatc	ggcagaacc	tggcg	ctggggc	360
tatcgctc	cgggttca	tgtc	tgtatg	agg	at	420

ccctacccga	gogagtgcaa	cccctggtgt	ccagagagg	gctcgccgc	catgtgcac	480
cactacacac	agatagttt	ggccaccacc	aacaagatcg	gttgtgctgt	gaacaccctgc	540
cggaagatga	ctgtctgggg	agaagttgg	gagaacgcgg	tctactttgt	ctgcaattat	600
tctccaaagg	ggaactggat	tgagaagcc	ccctacaaga	atggccggcc	ctgctctgag	660
tgcccaccca	gctatggagg	cagctgcagg	aacaacttgc	gttaccgaga	agaaacccat	720
actccaaaac	ctgaaaacgga	cgagatgaat	gaggtggaaa	cggccatccat	tcctgaagaa	780
aaccatgttt	ggctccaacc	gagggtgtat	agacccacca	agcccaagaa	aacctctgcg	840
gtcaactaca	tgacccaagt	cgtcagatgt	gacaccaaga	tgaaggacag	gtgcaaagg	900
tccacgtgt	acaggtacca	gtgcccagca	ggctgcctga	accacaaggc	gaagatctt	960
ggaactctgt	tctatgaaag	ctcgtcttagc	atatgcgcg	ccggccatcca	ctacgggatc	1020
ctggatgaca	agggaggccct	ggtggatatc	accaggaacg	ggaagggtccc	cttcttcgtg	1080
aagtctgaga	gacacggcgt	gcagtcctc	agcaaataca	aacctccag	ctcattcatg	1140
gtgtcaaaag	tgaaagtgc	ggatttggac	tgctacacga	ccgttgcgtca	gctgtgcgg	1200
tttggaaaagc	cagcaactca	ctgcccaga	atccattgtc	cggcacactg	caaagacgaa	1260
ccttcctact	gggctccgg	gtttggacc	aacatctatg	cagatacctc	aagcatctgc	1320
aagacagccg	tgcacgcggg	agtcatcagc	aacgagagt	gggggtacgt	ggacgtgtat	1380
cccggtggata	aaaagaagac	ctacgtgggc	tcgctcagg	atggagttc	gtctgaaagg	1440
ctggggactc	ctcgggatgg	aaaggccttc	cgatcttgc	ctgtcaggca	gtga	1494

<210> 25

<211> 1315

<212> DNA

<213> Homo sapiens

<400> 25

batgctgcac	aacaagcttc	ggggccaggt	gcagcctcag	gcctccaaca	tggagtacat	60
gacctggat	gacgaactgg	agaagtctgc	tgca	gctgg	gcagt	120
gcacgggccc	accagtc	tgggtccat	cgcc	gaga	catctgg	180
gtatcgctc	ccgggttcc	atgtgcagtc	ctgg	gtatg	gagg	240
cccttacccg	agcgagtgca	accctgg	tcc	agagg	actacac	300
gca	actacaca	cagatgttt	tgct	cgcc	gtgtgcac	360
ccgaaagatg	actgtctgg	gagaagttt	ggaga	acgc	gtctactt	420
ttctccaaag	gggacttgg	ttggaga	ccc	taca	tctgcaat	480
gtgcccaccc	agctatgg	gca	actt	gttacc	gagaaac	540
cactccaaa	cctgaaacgg	acgagat	tg	agg	ccat	600
aaaccatgtt	tggttccaa	cgagggt	gag	acc	ttcctgaa	660
gttcaactac	atgacca	tcgtcagat	tg	aca	atgagg	720
gtccacgtgt	aacagg	tac	agg	ctg	gtgtcaaa	780
tgaactctg	ttctatgaaa	gctcgtct	ca	at	actacgg	840
cctggatgac	aaaggaggcc	tggat	cc	agg	ccat	900
gaagtctgt	agacacggc	tgca	gtt	gg	acttcc	960
gtgtcaaaa	gtgaaagtgc	aggatttgg	ctg	ctac	accgttgc	1020
gttggaaaag	ccagcaactc	actgccc	acc	gttgc	actgtgccc	1080
acttcc	tgggtccgg	tgttggaa	gtt	gg	ccatgt	1140
caagacagcc	gtgcacgcgg	gagtc	at	gg	caagcatctg	1200
gcccggtggat	aaaagaaga	cctacgtgg	caac	gag	gggggtacgt	1260
cctggggact	cctcgggat	gaaaggcctt	ccgg	at	gtctgaaag	1315

<210> 26

<211> 927

<212> DNA

<213> Homo sapiens

<400> 26

atgggtgggg	gcgtcctcgc	ctcgctgggc	ttcg	cttct	cg	60
ctgc	atct	ac	tcg	ggc	cc	120
cccccctag	gcacccttc	gcgttacttc	tcc	ccgc	gat	180
gcgc	tcacc	gcaacgggc	ctc	tcg	ttt	240
gata	ttcg	gctgggggg	cg	ct	ccac	300

ccctgtggcg	ccctgctgct	accctggtc	cttacctggag	accffffcagc	cccaccgcgt	360
agtccccc	ctgccc	ctgg	cctgagtc	ttcacacgccc	gggccttctc	420
ctaggcacag	ccctgg	ttgg	gggggggtac	ttcg	acgtgc	480
gcttagacc	ggggc	ttgg	gggatacgg	gcagcg	tgg	540
ggggatgcgg	gcccgg	ttgg	ggctgcggg	tgg	ggctgc	600
cccgccgtgc	ttgg	cggg	actggg	ggctgtgg	ggtgggg	660
gtggccgtgg	ttgg	gggg	gggggtcccc	tgctgg	ggctgt	720
tatgggctga	gcgc	ttac	ctgg	tgta	cggg	780
ggcgtcggag	gtgt	gggt	ggccacaggg	ctgg	tgtat	840
ctctgggcc	ctcc	ctgg	aggtaaaggac	ctgag	atgc	900
tctcccc	gggt	ccgg	atccatatcc	atc	acaactat	927

<210> 27

<211> 1344

<212> DNA

<213> Homo sapiens

<400> 27

atgacccccc	agcccgcgg	accccccggat	ggggggctggg	gctgggtgg	ggcgccgcga	60
gccttcgcga	taaacgg	gtc	ctacggg	ctg	ctgcgt	120
gaccttgcgg	agca	actt	tg	cg	ctgg	180
ctggccgtgc	agcaggc	cag	ccccgtg	ggc	agc	240
cgc	cccg	tgat	gggtt	ggc	gtc	300
gca	agcg	atc	ctac	ctgg	ctgg	360
ctgg	gtt	ccct	agg	acc	cccg	420
gcgg	gtgg	ttgg	acc	ccct	cccg	480
cag	tttt	tcg	acc	tttgc	cccg	540
ctcc	ccct	ata	cc	cttgc	cccg	600
gccc	acc	tttgc	cc	ccct	cccg	660
tca	at	tcg	ccct	ccct	cccg	720
ttgg	gtt	ccat	cc	ccct	cccg	780
gtgg	gtc	tttgc	cc	ccct	cccg	840
tgg	gtt	ccct	cc	ccct	cccg	900
gtgg	gtt	ccct	cc	ccct	cccg	960
gcgg	gtt	ccat	cc	ccct	cccg	1020
cc	ccgg	ttgg	cc	ccct	cccg	1080
ag	ct	cc	cc	ccct	cccg	1140
tt	acc	cc	cc	ccct	cccg	1200
gg	tt	cc	cc	ccct	cccg	1260
ga	ac	cc	cc	ccct	cccg	1320
tcc	act	cc	cc	ccct	cccg	1344

<210> 28

<211> 1375

<212> DNA

<213> Homo sapiens

<400> 28

batggcgcgc	aggacagagc	ccccgcacgg	gggctgggga	tgggtgg	tgtctc	60
gttcttc	cg	tcgg	cg	tgtt	gggt	120
gtt	gtgg	cg	gggg	gtcc	gtcc	180
gtt	gtgg	cg	gggg	gtcg	gtcg	240
gccc	gtgg	cg	gggg	gtcc	gtcg	300
gtcc	gtgg	cg	gggg	gtcg	gtcg	360
gac	ctt	cg	gggg	gtcc	gtcg	420
cac	cc	cg	gggg	gtcc	gtcg	480
gtgg	gtgg	cg	gggg	gtcc	gtcg	540
ccac	ctt	cg	gggg	gtcc	gtcg	600
gggt	gtgg	cg	gggg	gtcc	gtcg	660

ttttggcccttc accctgatca acactggcta cttcattccc tacctccacc tggggccca	720
tctccaggac ctggattggg acccactacc tgctgccttc ctactctcag ttgttgctat	780
ttctgacctc gtggggcgtg tggctccgg atggctggg gatgcagtcc cagggcctgt	840
gacacgactc ctgatgtct ggaccacctt gactgggtg tcactagccc tggccctgt	900
agctcaggtt cccacagccc tggtggtctt ggctgtggcc tacggctca catcagggc	960
tctggcccca ctggccttc cctgtgtgc tgaactata gggactagaa ggatttactg	1020
tggcctggg ctgttgcaga tgatagagag catcggggg ctgtgtggc ctccctctc	1080
aggctacctc cgggatgtgt caggcaacta cacggcttct tttgtgtgg ctggggcctt	1140
ccttccttca gggagtggca ttctcctcac cctgcccac ttcttctgt tctcaactac	1200
tacctccggg cctcaggacc ttgttaacaga agcactagat actaaagttc ccctacccaa	1260
ggaggggctg gaaggaggac tgaactccac agagtcaggc ccagaaagcc aaagcttgc	1320
agctccaggtt ctctcttgc cacgtttgg tctccacaga accacagtgc cttaa	1375
<210> 29	
<211> 510	
<212> DNA	
<213> Homo sapiens	
<400> 29	
atgaccatga agacctctgg gcccacttgt gatgcaaaca gtgtgatgaa ctgcgggatc	60
cgcgggtctg aaatgtttgc tgagatggat ttgagggcca taaaacctta ccagactctg	120
atcaaaaaag tcgggcagag acattgcgtg gaccctgtc tcatgcagc catcatctcc	180
agggaaagcc atgggggatc tgcctgcac gacggctggg accacagggg acttaaattt	240
ggcttgatgc agcttgataa acaaacgtac caccctgtcg gtgcctggg tagcaaagag	300
caccccttac aggctactgg gattctaaca gagagaatta aggcaatcca gaaaaaatcc	360
cccacgtgga gtgtgctca gcacctcaaa ggtggctct cagctttaa gtcaggaatt	420
gaagcgattt ccacccatc ggacatagac aatgacttgc tcaatgatata cattgctcga	480
gctaagttct ataaaagaca aagcttctag	510
<210> 30	
<211> 561	
<212> DNA	
<213> Homo sapiens	
<400> 30	
atgaaggcctc acctacatcc acgcctgtac cacggctgtc atggggacat catgaccatg	60
aagacccctg gggccacttg tcatgcaaac agtgtgatga actgcgggat ccgcgggtct	120
gaaatgtttt ctgagatgga ttggagggcc ataaaacctt accagactct gatcaaaaaa	180
gtcgggcaga gacattgcgt ggacccctgtc gtcatgcag ccacatctc cagggaaagc	240
catggggatc ctgtcctgc acacggctgg gaccacaggg gacttaaattt tggcttgatg	300
cagcttgata aacaaacgtac ccacccctgtc ggtgcctggg atagcaaaga gcaccttca	360
caggctactg ggattctaact agagagaatt aaggcaatcc agaaaaatt ccccacgtgg	420
agtgttgc acgaccccaa aggtggcttc tcagctttt agtcaggaat tgaagcgatt	480
gcaccccat cggacataga caatgacttc gtcaatgata tcattgctcg agctaagttc	540
tataaaagac aaagcttcta g	561
<210> 31	
<211> 2028	
<212> DNA	
<213> Homo sapiens	
<400> 31	
atggagagcg gcaccagcg ccctcagcct ccacagttag atcccctgga tgcgtttccc	60
cagaagggct tggagctgg ggacatcgac gtgctagtc tgcgttctt ctgttgcctg	120
gctgttggac tatggtocac agtgaagacc aaaagagaca cagtggaaagg ctacttcctg	180
gctggagggg acatgggtgt gtggccagtg ggtgcacatct tggccatcg caatgttgaa	240
agtggacatt tcattggctt ggcagggtca ggtgcgtcta cgggcatttc tgcgttgc	300
tatgaactta atggcttggtt ttctgtgtc atgttggctt ggatcttctt accccatctac	360
attgtggtc aggtcaccac gatgccagaa tacctacgga agcgcttcgg tggcatcaga	420

atccccatca	tcctggctgt	actctaccta	tttatctaca	tcttcaccaa	gatctcggt	480
gacatgtatg	caggtgcacat	cttcatccag	cagtcttgc	acctggatct	gtacctggcc	540
atagttggc	tactggccat	cactgctgta	tacacgggt	ctggtggcct	ggctgctgt	600
atctacacgg	atgccctgca	gacgctgatc	atgcttata	gagcgcac	cttgatggc	660
tacagttcg	ccgcgggt	ttggatggaa	ggactgaagg	agaagtactt	tttggccctg	720
gctagcaacc	ggagtgagaa	cagcagctgc	gggctgcccc	ggaaagatgc	cttccatatt	780
ttccgagatc	cgctgacatc	tgatctcccg	ttggccgggg	tcctatattgg	aatgtccatc	840
ccatccctct	gttactgggt	cacggatcag	gtgattgtcc	agggactct	ggctgccaag	900
aacctgtccc	atgccaaagg	agggtgtctg	atggctgcat	acctgaaggt	gtgtcccc	960
ttcataatgg	tgttccctgg	gatggtcagc	cgcatccct	tcccatatca	agtggcctgt	1020
gcagatccag	agatctgcca	gaagatctgc	agcaaccct	caggctgttc	ggacatcg	1080
tatcccaaac	tcgtgctgga	actccctgc	acagggtctc	gtgggtgtat	gtggctgt	1140
atggtggcgg	ctctcatgtc	ctccctcacc	tccatctta	acagtgcac	caccatctc	1200
accatggacc	tctggaaatca	cctccggcct	cgggcatctg	agaaggagct	catgattgt	1260
ggcagggtgt	tttgctgtct	gtgggtcctg	gtctccatcc	tctggatccc	tgtggtccag	1320
gccagccagg	gcccggcagct	cttcatctat	atccagtc	tcagtcctt	cctgcagccg	1380
cctgtggcgg	ttgtcttcat	catggatgt	ttctggaaaga	ggaccaatga	aaagggtg	1440
ttctggggcc	tgatctcggg	cctgctcctg	ggcttggta	ggctggcct	ggactttatt	1500
tacgtgcagc	ctcgatgcga	ccagccagat	gagcgc	ttctggtaa	gagcattc	1560
tacctctact	tctccatgtat	cctgtccacg	gtcaccctca	tcactgtctc	caccgtg	1620
tggttcacag	agccaccctc	caaggagatg	gtcagccacc	tgacctgg	tactcgtc	1680
gaccccggtt	tccagaagga	acaagcacca	ccagcagctc	ccttgc	taccctct	1740
cagaacggga	tgccagaggg	cagcagc	agcagcgtcc	agttcgagat	ggttcaagaa	1800
aacacgtcta	aaacccacag	ctgtgacatg	accccaaa	agtccaaagt	gttgaagg	1860
atccgtggc	tctgtggat	acaggagaag	ggcaaggaag	agctcc	cagagcagaa	1920
gccatcatag	tttccctgga	agaaaacccc	ttggtaa	ccctcctgga	cgtcaac	1980
atttctgcg	tgagctgcgc	catcttata	tgggctatt	ttgttt		2028

<210> 32

<211> 1458

<212> DNA

<213> Homo sapiens

<400> 32

atggagccct	gttggggaga	aggcttgttt	catctagcac	ccccacgcca	ccatccccag	60
aaggctgact	ggcatttctg	tccacagcac	attcaggaat	tcaccaatga	gacatggc	120
gcfgtactg	gagagccact	gcccgtac	ctagtc	ttatgtgg	cctcatgt	180
tctctgtatc	ccctgggagg	ccttttgg	gcactgctt	cagg	ccatcac	240
ctgggaagga	agaagtccct	cctgtgaat	aatatctt	ttgtgtc	agcaatct	300
tttggattca	gcccggaa	aggctcc	gagatgtca	tgctgg	actgctgt	360
ggagtcaatg	cagggtgt	catgaacatc	cagccatgt	acctgggg	gagc	420
aaggagctcc	gaggagctgt	ggccatgagc	tcagccatct	ttacgg	gggatc	480
atgggacagg	ttgtcgact	cagggagctc	ctaggtg	ctcagg	ccctgt	540
ctggccagct	gcctgg	cgggcg	cagctc	ccctgc	ctccctg	600
agcccgcg	acccctcat	tgactgt	gacacc	cctgc	agcactac	660
cggctccggg	gttccggg	cttgc	gagctgg	agctgg	ggagc	720
gcctgccc	gctgg	ccggc	ttggag	tc	ccctg	780
agacaggtga	caaggctc	gttctgg	agtgccat	agctct	gtactcg	840
gtgtacgc	acgc	cgttcc	aaggc	tgccgg	gaagatcc	900
tacgcgatca	tcggg	actgg	gagctgc	cggtt	ttgtgt	960
atcgagagg	ttgg	cg	ctgct	ttt	acagc	1020
gggagcatct	tcact	ctgt	cagag	tc	ccat	1080
gccatggcc	gcat	tttgc	agctt	ttgg	ccgg	1140
gggatcc	ccac	agag	atgg	ctg	catgg	1200
ggggcg	tgt	ggat	ctc	tc	ttt	1260
gcctgtccc	actt	cctct	tgt	gt	atcat	1320
actggc	tc	ttc	ttt	gt	gg	1380
cacagactca	actt	cccc	ggcc	gg	gg	1440
cagtcaac	act	cc	ggcc	gg	gg	1458
aactctag						

<210> 33
 <211> 1491
 <212> DNA
 <213> Homo sapiens

<400> 33

atgagagcgc	tccgaagact	gattcaggc	aggatcctgc	tcctgaccat	ctgcgctgcc	60
ggcattggtg	ggactttca	gtttggctat	aacctctcta	tcatcaatgc	cccgaccttgc	120
cacattcagg	aattcaccaa	tgagacatgg	caggcgcgt	ctggagagcc	actgcccgt	180
cacctagtcc	tgcttatgt	gtccctcata	gtgtctctgt	atccccctgg	aggccttctt	240
ggagcactgc	ttgcagggtcc	cttggccatc	acgctgggaa	ggaagaagtc	cctccctgg	300
aataacatct	ttgtgggtc	agcagcaatc	ctgtttggat	tcagccgcaa	agcaggctcc	360
ttttagatga	tcatgctgg	aagactgtc	gtgggagtca	atgcagggt	gagcatgaac	420
atccagccca	tgtacactgg	ggagagcgc	cctaaggagc	tccaggaggc	tgtggccatg	480
agctcagcca	tctttacgc	tctggggatc	gtgatgggac	aggtggtcgg	actcaggggag	540
ctccctagg	gcccctaggc	ctggccctgt	ctgctggcca	gctgctgg	gccccggg	600
ctccagctcg	cctccctg	tctgctccct	gaaagccgc	gctacccct	cattgactgt	660
ggagacaccc	aggcctgcct	ggcagcacta	cggcggtcc	ggggctccg	ggacttggca	720
ggggagctgg	aggagctg	ggaggagcgc	gctgcctgc	aggctgcgg	tgcccggcgc	780
ccatggggac	tgttccagca	tcggggccctg	aggagacagg	tgacaaggct	cgtgggttc	840
ggcagtgc	tggagctctg	cggaatgac	tcgggtgtac	cctacgcctc	ctccgtgtc	900
cggaaggcag	gagtgcgg	agcgaagatc	cagtacgc	tcatcg	ttggagctgc	960
gagctgc	cggcggtgt	tagttgtgt	gtaatcgaga	gggtgggtcg	gcccgtgc	1020
ctcatcggt	ggtacagcct	gatgac	tgccggagca	tcttcactgt	ggccctgtc	1080
ctgcagagct	ccttccctg	gacactctac	ctggccatgg	cctgcacat	tgccttcatc	1140
ctcagcttg	gcattgg	tgccggagt	acggggatcc	tggccacaga	gctgtttgac	1200
cagatggca	ggcctgtgc	ctgcatgg	tgccggcgc	tcatgtggat	catgctcatc	1260
ctggcggcc	tgggatttca	ctttatcatg	gaggcctt	cccacttct	ctatgtcc	1320
ttccttgg	tctgtgtct	tggggccatc	tacactgg	tgttcc	tgagacaaa	1380
ggcaagac	tccaagagat	ctccaaggaa	ttacacagac	tcaacttccc	caggcggg	1440
caggccccca	cgtggaggag	cctggagg	atccagtc	cagaactcta	g	1491

<210> 34
 <211> 1501
 <212> DNA
 <213> Homo sapiens

<400> 34

batgctccac	gccctcctgc	gatctagaat	gattcaggc	aggatcctgc	tcctgaccat	60
ctgcgctgc	ggcattgg	ggactttca	gtttggctat	aacctctcta	tcatcaatgc	120
cccgaccttgc	cacattcagg	aattcaccaa	tgagacatgg	caggcgcgt	ctggagagcc	180
actgcccgt	cacctagtcc	tgcttatgt	gtccctcata	gtgtctctgt	atccccctgg	240
aggcctcttgc	ggagcactgc	ttgcagggtcc	cttggccatc	acgctgggaa	ggaagaagtc	300
cctcctgg	aataacatct	ttgtgggtc	agcagcaatc	ctgtttggat	tcagccgcaa	360
agcaggctcc	ttttagatga	tcatgctgg	aagactgtc	gtgggagtca	atgcagggt	420
gagcatgaac	atccagccca	tgtacctgg	ggagagcgc	cctaaggagc	tccaggagc	480
tgtggccat	agctcagcca	tcttacgc	tctggggatc	gtgatgggac	aggtggtc	540
actcaggggag	ctccttaggt	gcccctaggc	ctggccctgt	ctgctggcca	gctgcctgg	600
gccccggg	ctccagctcg	cctccctg	tctgctccct	gaaagccgc	gctacccct	660
cattgactgt	ggagacaccc	aggcctgcct	ggcagcacta	cggcggtcc	ggggctccg	720
ggacttggca	ggggagctgg	aggagctg	ggaggagcgc	gctgcctgc	agggctgc	780
tgccctggc	ccatggggac	tgttccagca	tcggggccctg	aggagacagg	tgacaaggct	840
cgtgggtct	ggcagtgc	tggagctctg	cggaatgac	tcgggtgtac	cctacgcctc	900
ctccgtgtc	cggaaggcag	gagtgcgg	agcgaagatc	cagtacgc	tcatcg	960
tgggagctgc	gagctgc	cgccgtt	tagttgtgt	gtaatcgaga	gggtgggtcg	1020
gcgcgtgt	ctcatcggt	ggtacagcct	gatgac	tcttcactgt	1080	
ggccctgtc	ctgcagagct	ccttccctg	gacactctac	ctggccatgg	cctgcacat	1140
tgccttcatc	ctcagcttg	gcattgg	tgccggagt	acggggatcc	tggccacaga	1200
gctgtttgac	cagatggca	ggcctgtgc	ctgcatgg	tgccggcgc	tcatgtggat	1260

catgctcatc	ctggtcggcc	tgggatttcc	ctttatcatg	gaggccttgt	cccaacttcct	1320
ctatgtccct	ttccttggtg	tctgtgtctg	tggggccatc	tacactggcc	tgttccttcc	1380
ttagacaaaa	ggcaagacct	tccaaagagat	ctccaaggaa	ttacacagac	tcaacttccc	1440
caggcgggccc	cagggccccca	cgtggaggag	cctggaggtt	atccagtcaa	cagaactcta	1500
g						1501

<210> 35

<211> 4077

<212> DNA

<213> Homo sapiens

<400> 35

atggtagtgg	tgaagccat	gaacacaatg	gctccggtgg	tcacccggaa	tacgggtctt	60
attctctatg	agggtcagtc	tcggcccctc	acaggccctg	caggcagtgg	tccgaaaaac	120
ttggtcatca	gcgatgagga	tgacctagaa	gcagtgcggc	tagaggtgg	ggctgggctc	180
cggcatggtc	accttgcata	tctgggtgct	tccagtggca	gctctgctcc	caagagcttt	240
acagtggctg	agctggcagc	cggccagggtg	gtctaccagc	atgatgacag	agacggctcg	300
ctgagcagaca	acctgggtgct	tcgcattggtg	gatggaggag	gcaggcacca	ggtacagttt	360
ctgttccccca	tcaccttagt	gcctgtggat	gaccagccac	ctgttctcaa	tgccaacacg	420
gggctgacac	tggcagaggg	tgaacagtg	cccatctgc	cccttccct	gagtgcact	480
gacatggatt	cagatgattc	tctgtgctt	tttggctgg	agtcaccctt	cttaactacg	540
ggccatctgc	ttctccgcca	aactcaccct	ccccatgaga	agcaggaact	tctcagaggc	600
cttggagga	aggagggggc	attttatgag	cgaacagtga	cagagtggca	gcagcaggac	660
ataaacagagg	gcaggctgtt	ctatagacac	tctgggcccc	atagtcctgg	gccagtcaca	720
gaccagttca	catttagagt	ccaggataac	catgaccctc	ctaattcagtc	cgggctacag	780
cggtttgtga	ttcgatattca	tcctgtggat	cgccctccctc	cggagctggg	cagtggctgt	840
ccccttcgta	tggtgtaca	ggaatcccag	ctcacaccac	tgaggaagaa	gtggctgcgc	900
tacactgacc	tggacacaga	tgaccgagaa	ctacgttaca	cagtgcactca	gtccccccaca	960
gacacagacg	aaaatcacct	gccagcccca	ctgggtacct	ttggcttgac	tgacaacccc	1020
tcagtcgtgg	tgacccattt	taccaagcc	cagatcaacc	atcataaaat	tgcttacaga	1080
ccccccgggtc	aagaacttggg	cgtggctact	cgagtggccc	agttccagtt	ccaggtggaa	1140
gaccgagctg	ggaatgtggc	tccaggtacc	tttacccttt	acttgcattcc	cgtggacaac	1200
cagccacactg	agatcctcaa	caccggcttc	actattcagg	agaagggtca	ccacatcctg	1260
agtggagacag	agttgcacgt	gaatgatgt	gacactgatg	ttgcccata	ctctttact	1320
ctcactcagg	cacccaaaca	tggccacatg	agagtgtctg	gacagatcct	gcatgttaggg	1380
ggtcttcc	acttggagga	cataaaacag	ggccgagttt	cctatgccc	taatggggac	1440
aagtccctga	ctgatagctg	ctccattggaa	gtcagtgaca	gacatcatgt	ggtgcccac	1500
actctcagag	taaatgtccg	gccagtggt	gatgaagtgc	ccatcactgag	ccatcctact	1560
ggcactctgg	agtcctatct	agatgtctt	gaaaatgggg	ctactgaaat	cactgccaat	1620
gttattaagg	ggaccaatga	ggaaactgtat	gacttgatgt	tgactttct	cttggaaagat	1680
ccacctttgt	atggggaaat	cttggtaat	ggcattccag	cagagcagtt	tactcaaagg	1740
gacatcttgg	agggctctgt	tgtatatacc	cacaccagt	gtgagatagg	cctattgct	1800
aaagcggatt	cttttaacct	gagtcgtca	gatatgtctc	aagaatggag	aattgggtggc	1860
aatactatcc	aaggagttac	tatatgggt	accatctgc	ctgttgatag	ccaggcccc	1920
gaaatctttg	taggtgaaca	gttgatagta	atggaaagggt	ataaaagtgt	tataacatca	1980
gtgcataata	gtgctgaaga	tgtcactcc	ctgaatgatg	acatcttgc	cactatagtt	2040
attcagccta	tttcagggtt	tgttggaaac	atttctccag	caccaggctc	tgagaaatca	2100
agagcaggga	ttgccataag	tgcttcaac	ttgaaagatc	tcaggcaggg	ccacataaac	2160
tatgtccaga	gtgtccataa	aggggtggaa	cctgtggagg	accgatttgt	atttcgttgt	2220
tctgtatggc	ttaactttt	agagagacag	ttcttccccca	tgtatcat	tcccaccaat	2280
gatgaacagc	cagagatgtt	tatgagagaa	tttatggtga	tggaaggcat	gagtctggta	2340
attgatacac	ccattctcaa	tgctgtat	gctgtatgtt	ccctggatga	ttaactttc	2400
actattaccc	aattccccac	tcatggtcac	atcatgaatc	agctgataaa	tggcacgggt	2460
ttggtcgaaa	gcttcaccc	ggatcagatc	atagaggtt	ccagcattat	ttatgagcat	2520
gatgactccg	agacccagga	agacagttt	tgatggat	taacagatgg	gaagcactct	2580
gtggaaaaga	cggtcctcat	tatgttatac	cctgttgatg	atgagacgccc	cagaatgact	2640
atcaataatg	gacttagaaat	agaaattggg	gatccaaga	ttatcaacaa	caaataattta	2700
atggcaacag	atttagattc	agaagacaaa	tctttgggtt	atattattcg	ttatgggcac	2760
ggacatggct	tattacagag	acgaaaacct	actggtgcc	ttgaaaatat	cacactgggc	2820

atgaatttta	cccaggatga	agtagacaga	aacttaattc	agtatgtcca	tttggggcaa	2880	
gagggcattc	gggaccta	aat	tttgat	gtgactgtat	gaataaaatcc	cctcatagat	2940
cgttactttt	atgtgtccat	cgggagcatt	gacattgtct	tccctgtatgt	gataagtaag	3000	
ggagtgtcct	tgaaaagaagg	tggcaagtc	actttacaa	cagacctact	aagcactagt	3060	
gacttgaaca	gtcctgtatga	aaacttgggtt	tttaccatca	ccagggctcc	catgcgaggt	3120	
cacctggaa	gtacggatca	gcctgggtgt	tccatcacgt	cttcactca	gctgcaactg	3180	
gctggaaaca	aaatctacta	catccacaca	gctgtatgt	aagtgaaaat	ggacagttt	3240	
gagttcaag	tcaccatgg	acgtaaccc	gtctttcgga	cattccgtat	ctccattagc	3300	
gatgtggaca	ataaaaagcc	agttgttacc	atccacaa	tggttgcag	tgaaagtgtaa	3360	
aacaagctga	ttactcc	ttgatctact	gtcgaagaca	gagatactcc	tgacaagagtc	3420	
ctgaaattca	ctatcacca	ggtgcctatt	catggccatc	tcctattca	caataccaga	3480	
cctgtcatgg	tttttacca	gcaagacttg	aatgaaaact	taatcagcta	caaacatgat	3540	
ggcactgagt	caagtgaaga	tagcttctcc	ttcacagtg	ctgtatggcac	ccatacagac	3600	
ttctatgttt	ttcctgtatc	gggtttgaa	acaaggagac	cccaagtgat	gaagatccag	3660	
gtcttggctg	ttgacaacag	tgtccccaa	atcgcagtga	ataagggggc	ctctacactt	3720	
cgcactctag	ccactggcca	cttgggggtt	atgtacacaa	gcaaaatatt	gaaagtggag	3780	
gacagagaca	gcttacacat	ttctttaga	tttacatgt	cagaggccc	tcaacatgaa	3840	
tatcttctca	acctggacaa	aggcaaccac	agcatcact	agttcacaca	agctgacatt	3900	
gatgacatga	aaatatgtct	tgtcttaaga	gaaggggcta	atggcacaag	tgatatgttc	3960	
tat	ttgtcgag	ttgaagatgg	ttgtaagtat	ttccctctcc	tggtagtgac	4020	
gacgcttttc	ttgggttgc	tctgtatgaca	ttattacaag	aagtcttcat	cgcaaggaga	4077	

<210> 36

<211> 9318.

<212> DNA

<213> Homo sapiens

<400> 36

atggcacat	cttggctcac	tgcaacctcc	acctccccc	ccgcgtccat	cgccaggggc	60
ttgctgtccc	ctgggttcgc	gggggctgca	gggggtccctg	ctgaggaggc	catagtgtcg	120
gogaaccgc	gactccgggt	gccttcggc	cgtgaagtt	ggctggatcc	cctgcatgac	180
ctgggtgtgc	agggtgcagcc	cggggaccgc	tgcgcggtt	cggtaactaga	caacgacgca	240
ctggcccgac	gaccggggcg	cctgagtc	aagcgcttcc	cgtgcgactt	ttggccctggc	300
gaggtgcgt	actctcacct	gggcgcgcgc	agccgcgttc	gggaccgcgt	ccggctgcag	360
ctgcgcgtat	acgcgcgcgg	aggggcagta	tgcttaccac	ttgtacttgg	ggtggaggt	420
gtcttcaccc	agctggaggt	tgtacttcgg	aacttgcctc	ttgtcggtt	agaactgtcg	480
gggaccagca	atgcccgg	cgccgcggac	ctggagttcg	ccttccagcc	cgagacagaa	540
gagtgcgcgc	ttggcattct	gtcggcgttg	ggcgcgcgtc	ctcgctatgg	agaactcctc	600
cactaccgc	aggccctgg	aggagccaga	gagggaggcg	ccccggagac	tctcctgtat	660
gactgcaaa	ctttccagga	actaggcg	cgctatcgcc	acacagccgc	cagtcgctca	720
ccaaacaggg	actggatacc	catgggtgt	gagctgcgtt	cacgagggc	ttctgtggc	780
agccctgtt	tgaaaacgcg	gcacttccag	tttctgggt	ggatccgagg	agggggccgag	840
aacactgcac	ccaaggccag	tttcgtggcc	atgtatgt	tggaggttgg	ccagtttgt	900
ctgacggccc	tgacccccc	catgtggca	gcccggatg	ctgagttcc	ctctgacctg	960
ttgatcttca	accttacttc	tccattccag	cctggccagg	gtacttgg	gagcaccgat	1020
gatcgaccc	tgcccccttc	ctccttact	cagagggatc	tgccgcctt	gaagattgccc	1080
taccagcccc	cttctgaaga	ctctgaccag	gagcgcctt	ttgaacttgg	attggaggt	1140
gtggatctag	aaggagcagc	ttcagaccct	tttgccttca	ttgtacttgg	gaagccat	1200
aacacaatgg	ctccgggtgt	cacccggaa	accggcttta	ttctctatga	gggtcgatct	1260
cggccccc	caggccctgc	aggcagtgt	ccgcggaaact	ttgtcatcg	cgtatggaggat	1320
gacctagaag	cagtgcggc	agagggtgg	gctgggc	ggcatgttca	cottgttatt	1380
ctgggtgtctt	ccagtggc	ctctgtccc	aagagctt	cagtgcgt	gtgtggcagcc	1440
ggccagggtgg	tctaccagca	tgatgacaga	gacggctc	tgagcaca	cctgggtgtt	1500
cgcatgggtgg	atggaggagg	caggcaccag	gtacagt	ttgtccccc	cacccatgt	1560
cctgtggatg	accagccacc	ttgttctcaat	gccaacacgg	ggctgacact	ggcagagggt	1620
gaaacagtgc	ccatccgtcc	ccttccctg	agtgcactg	acatggattc	agatgattct	1680
ctgtgtctt	ttgtgtcg	gtcacccttc	ttaactacgg	ggcatctgt	tctccggccaa	1740
actcaccctc	cccatgagaa	gcaggaactt	ctcagagggc	tttgaggaa	ggagggggca	1800
tttatgagc	gaacagtgc	agagtggc	cagcaggaca	taacagaggg	caggctgttc	1860

tatagacact	ctggggcccca	tagtcctggg	ccagtcacag	accagttcac	atttagagtc	1920
caggataacc	atgaccctcc	taatcagtcc	gggctacacgc	ggtttgttat	tcgttatccat	1980
cctgtggatc	gcctccctcc	ggagctgggc	agtggctgtc	cccttcgtat	ggtggcacag	2040
gaatccccagc	tcacaccact	gaggaagaag	tggctgcgt	acactgacct	ggacacagat	2100
gaccgagaac	tacgttacac	agtactcg	ccccccacag	acacagacga	aatcacctg	2160
ccagcccccac	tgggtacctt	ggtcttgact	gacaaccctt	cagtcgtgt	gaccctattt	2220
acccaagccc	agatcaacca	tcataaaatt	gcttacagac	ccccgggtca	agaactgggc	2280
gtggctactc	gagtgccca	gttccagttc	caggtggaaag	accgagctgg	gaatgtggct	2340
ccaggtacct	ttaccctta	cttgcacccc	gtggacaaacc	agccacctga	gatcctcaac	2400
acccgcttca	ctattcagga	gaagggtcac	cacatcctga	gtgagacaga	gttgcacgtg	2460
aatatgttag	acactgtatgt	tgcccatatc	tctttactc	tcactcaggc	acccaaacat	2520
ggccacatga	gagtgcttgg	acagatcctg	catgttagggg	gtcttcca	cttggaggac	2580
ataaaaacagg	gcccaggatcc	ctatgccc	aatggggaca	agtccctgac	tgatagctgc	2640
tccttggaaag	tcagtgacag	acatcatgtg	gtgcccata	ctctcagat	aaatgtccgg	2700
ccagtggatg	atgaagtgc	catactgagc	catcctactg	gcactctgg	gtccttatcta	2760
gatgtcttag	aaaatggggc	tactgaaatc	actgccaatg	ttattaaggg	gaccaatgag	2820
gaaactgtatg	acttgcgtt	gacttccctc	ttggaaagatc	caccccttga	tggggaaatc	2880
ttggtcaatg	gcattccagc	agagcagttt	actcaaaggg	acatcttgg	gggctctgtt	2940
gtatatacc	acaccagtgg	tgagataggc	ctattgccta	aaggcgattc	tttaacctg	3000
agtcgtcag	ataagtctca	agaatggaga	attggtgcc	atactatcca	aggagttact	3060
atatgggtga	ccatcctg	ttgtgtatgc	caggccccag	aaatctctgt	aggtgaacag	3120
ttgatagtaa	ttggaaagg	taaaaatgttt	ataacatcag	tgcataata	tgctgaagat	3180
gtcgactccc	tgaatgtat	catcttgc	actatagtt	ttcagcctac	ttcaggttat	3240
gttggaaaaca	tttctccagc	accaggctct	gagaaatcaa	gagcagggat	tgccataa	3300
gcttcaact	tgaaagatct	caggcaggc	cacataaact	atgtccagag	tgtccataaa	3360
gggggtggaaac	ctgtggagga	ccgatttga	tttcgttgc	ctgatggat	taactttca	3420
gagagacagt	tcttcccat	tgtaatcatt	cccaccaatg	atgaacagcc	agagatgtt	3480
atgagagaat	ttatgggtat	ggaaggcatg	agtctggtaa	ttgatacacc	cattctcaat	3540
gctgctgtat	ctgatgttcc	cctggatgt	ttaacttca	ctattacca	attccccact	3600
catggtcaca	tcatgaatca	gctgatataat	ggcacgggtt	ttggtcgaaag	cttcacctg	3660
gatcagatca	tagagatcc	cagcattatt	tatgagcatg	atgactccga	gaccaggaa	3720
gacagttttg	tgattaaact	aacagatggg	aagcactctg	tggaaaagac	ggtcctcatt	3780
atagttatcc	ctgttgatga	tgagacgccc	agaatgacta	tcaataatgg	actagaaata	3840
gaaatgggg	ataccaagat	tatcaacaac	aaaatattaa	tggcaacaga	tttagattca	3900
gaagacaaat	ctttggttt	tattattcg	tatggggccag	gacatggctt	attacagaga	3960
cgaaaaccta	ctgggtgcctt	tgaaaatatc	acactgggc	tgaattttac	ccaggatgaa	4020
gtagacagaa	acttaattca	gtatgtccat	ttggggcaag	aggcattcg	ggacctaatt	4080
aaatttgatg	tgactgtatgg	aataaattccc	ctcatagatc	gttactttt	tgtgtccatc	4140
ggggagcattt	acattgtctt	ccctgtatgt	ataagtaagg	gagtgccctt	gaaagaaggt	4200
ggcaaaagtca	ctcttacac	agacctacta	agcacttagt	acttgaacag	tcctgtatgaa	4260
aacttggttt	ttaccatcac	cagggtccc	atgcgaggc	accttggatg	cacggatcag	4320
cctgggtgtt	ccatcactgc	tttcactcg	ctgcaactgg	ctggaaacaa	aatctactac	4380
atccacacag	ctgatgtat	agtggaaatg	gacagttttt	agttcaatg	caccgatgga	4440
cgttaaccctg	tcttccggac	atccgtatc	tccattagcg	atgtggacaa	taaaaagc	4500
gtggtccacca	tccacaagat	ggttgtcagt	gaaaatgtaaa	acaagctgtat	tactccttt	4560
gagctcactg	tcgaagacac	agatactcct	gacaagctcc	tgaatttccac	tatcacccag	4620
gtgcctattc	atggccatct	ccttattcaac	aataccagac	ctgtcatgtt	ttttaccaag	4680
caagacttga	atggaaaactt	aatcagctac	aaacatgtat	gcactgagtc	aagtgaagat	4740
agtttctctt	tcacagtgc	tgatggcacc	catacagact	tctatgtttt	tcctgtatc	4800
gtgtttgaaa	caaggagacc	ccaaatgtat	aagatccagg	tcttggctgt	tgacaacagt	4860
gtccccccaaa	tcgcagtgaa	taagggggcc	tctacacttc	gcactctagc	cactggccac	4920
ttgggggttca	tgatcacaag	caaaatattt	aaagtggagg	acagagacag	tttacacatt	4980
tctcttagat	ttatcgatc	agggccccct	caacatggat	atcttctcaa	cctggacaaa	5040
ggcaaccaca	gcatcactca	tttcacacaa	gctgacattt	atgacatgaa	aatatgttat	5100
gtcttaagag	aaggggctaa	tgcacacat	gatatgttct	atttgcagt	tgaagatgtt	5160
ggtggaaaca	agttaacgtt	ccagaatttt	cgtctgaatt	gggcattggat	ctcccttggaa	5220
aaggaatatt	acctggtcaa	tgaggactcc	aaatttctat	atgtgtttt	taaacgtaga	5280
ggttacttgg	gagaaacttc	ttttataatgt	attggcacaac	gagacagaac	tgcagaaaaaa	5340
gacaaagact	tcaaggc	aaacacagaaa	caagtgcagt	tcaacccagg	ccagaccagg	5400

gcccacatggc gagtgccggat cctgagtgtat	ggggagcatg agcagtctga aacctttcag	5460
gtggtaactct cagagccgt gctggctgcc	tttgaattcc ccacagtcgc cactgtttag	5520
atcggttgc caggagatga gccaactgtg	tttattcccc agtccaaata ctccgttga	5580
gaagatgtg gtgagctgtt cattcccatc	aggaggagcg gagatgttag ccaggagg	5640
atgggtgtct gttataccca acaaggaaca	gcaactggaa ctgtgccgac ttccgttgg	5700
tcttactctg attacatata caggcctgag	gaccacacca gtgttgcgg ctttgacaaa	5760
gatgaacggg agaaactgtg tcggatagtc	ataattgtg actctttgt a cgaggaggag	5820
gaaacaccttcc atgtccttct gacatgccc	atggggggaa gaatcgatc agagttccca	5880
ggggctcaag ttacaatctg tcttgacaaa	gatgtatggc catctgattt caaatttat	5940
gttgctgaga actacagttt actgccttc	acctgtttc aagtagcat agccacggca	6000
gaggcagcca cccaggagg gggacgcagc	accagacaag tagctgcagt caaaaaagac	6060
aaagacttca agggcaaagc acagaaacaa	gtgcagttca acccaggcca gaccagg	6120
acatggcgag tgccgatcct gagtatggg	gagcatgac agtctgaaac ctttcaggtg	6180
gtactctcag agccctgtgt ggtgccttg	gaattcccc cagtcgccac tttttagatc	6240
gttgcattcg gagatgcattt cccatgggg	gaagaatcgg atcagatcc ccaggggctc	6300
aagttacaat cgttctgc aagatgtat	gtgagttacta atttacttga aaattcttt	6360
tcccggaaatg atcaacatca ggaacaactt	tctagacaga aaaaatggg atctaaaaca	6420
atgataatatac acacattttat tttatgtgag	acagaaaaagc cctgcattt ttagtgcgt	6480
gacgatgtgc tctatgagga ggttagggag	ctccgcctgg tactcgccac tccacaaagc	6540
aactctccct ttggggctgc agttgtgaa	caaaatgaaa ctctcataag gatccgagat	6600
gatgtgtata agactgttat taaatttgg	gaaaccaat ttagtgcac tgaacccaa	6660
gaacctggag agtcgggtgt tataagaatt	ccagtgttcc gccaaggaga cacttcaaag	6720
gtttccattt tgagatccca caccaggat	ggctcgccca cctctggaga agactaccac	6780
cctgtgtcaag aagaaattga gtttaaggaa	ggggaaaccc agcacgttgc taaaatcgaa	6840
gttacccctt acgggggtgag agagatgaga	gaggccttca ctgttcaccc aaaaactgtat	6900
gaaaatatga tagcagagat gcaactttcc	aactttgagc tcaccctcag ccctgtatggc	6960
acaagagttt gaaaccacaa gtgtccaaac	ctccctggatt atactgaatg gaagactcat	7020
tatggtttct tgactgtatc taccaaaaat	ccagaaataa ttggagagac atatccttac	7080
cagtacagct tgcctcatcag aggttccact	accttgcgt tctaccggaa cctgaaccta	7140
gaggcctgtt tatggagtt cgttagctac	tatgacatgt cagaactcct tgctgactgc	7200
agatcagtgt tgaatgcag catatttcat	gagatggcac ctgaaggaaa gcaaaatgaaa	7260
tgcttggtaa attctactt atactctatt	ttggatatgc atgagagcct tccaaacttt	7320
tgcatatttcag cattaaggat gggaaaatgg	agaaaaataa aaagcaaaacc atcagcacag	7380
actccatgtg ctcagaggct tcgtggttt	attgaccacc ccagaaaaca gcccctgcag	7440
caagccatgt ctgaccagg catgtcccc	gtgatcttca cttagagatc ttccaacttt	7500
gagctcaccc tcagccctga tggcacaaga	gttggaaacc acaagtgc tcaacccctg	7560
gattatactg aagtgaagac tcattatgtt	ttcttgactg atgctaccaa aaatccagaa	7620
ataatttggag agacatattcc ttaccatgt	agcttgc tcaaggatc cactacccctt	7680
cgcttctacc ggaacctgaa cctagaggcc	tttttatggg agttcgttag ctactatgac	7740
atgtcagaac tccttgcgtga ctgtgggtgc	accattggaa cagatggaca ggtcctaaac	7800
ctagtcgtgt cctatgtgc ccttcgtatc	cctctgtatg ttccctacgt gttccattcc	7860
cccggtgggg taggaggctg gcaagatcc	gacttgaatg cagatgttgc tctaactttt	7920
gtgtacgaca cgcgcattt gtggatgtat	ggaaatggca gccccccaga ggctgaactt	7980
caagggttctc tctatccaaac cagcatgcgc	atcggtgtatg agggggcgctt ggccgtgcac	8040
tcaagacag aggtcgtat ccatggctt	tttgcgtgtt cacatcccgc atcccttaca	8100
agtcgtgtatc tcatgtcagc tgatgtatcc	ggcctgacat tttccctccg cctcataagg	8160
agtgaaccaa cctataacca gcaatcag	cagtggatgt ttgtctctga ctttgcgtat	8220
cgtgactact cagggaccta tactgtgaa	gttgcgtatc gcactgcccc atcacatcag	8280
gaataccgccc tgccagtcac ctgcacccccc	agagaaccc tcaacccttgc ccttgacatc	8340
cgattccaaac aggtcgtatc tccagtggtt	gctgagttt gcttgaacac cccaaatgtac	8400
ctgtctctata agaagatgtt ctgggtgtt	gatggatcca tgggattccg gcaagagatg	8460
gatgttgcattt tgccagaagg tgatataatt	tatggtcgtg tcatgttgc tctgttccag	8520
aatctgggtt actcccttta ctgcagcatt	gagaagggtt ttctatgcac tggagctgtat	8580
ggctatgttc ccaagtatag tccaaatgtat	gcagaatatg gctgttgc cgtactcttct	8640
tcactcttata atagattaa aattgtggac	aaagctcagc cagagacaca agcgaccagt	8700
tttggaaatg tcctattaa tgccaaacta	gcaatgttgc accctgttgc cattcttta	8760
gtgaatcagc ctggatctga tggattttaa	gtcactcaaa caccactt tcaggcgt	8820
ctaggccgag aatggtataat acatacgtatc	tatacgtga gatcggaaaga caatgccaat	8880
cgaggtattt gcaaaaagaag tttggatgtatc	cattctctgg ttagtcaagg aaagccccaa	8940

tccaccacca	agagccggaa	gaagagagag	atcaggagca	caccctcact	ggcatgggag	9000
attggtgctg	aaaacagtgc	aggaacaaac	atccagcaca	ttgccttgg	ccgcaccaag	9060
aggcagatcc	cccatgggag	agcacctcca	gatggcatcc	tcccctgg	gctcaacagc	9120
cccagctctg	cagtcagcct	ggtca	gtgggaggca	ccacggtagg	gttactcacc	9180
atctgcctca	ctgtcattgc	agtgcgtatg	tgcagggca	aggaaagttt	cagggggaaag	9240
gatgccccga	aaggctccag	cagcagttag	cccatggtgc	ccccacagag	ccatcacaat	9300
gacagctcag	aagtttga					9318

<210> 37

<211> 1374

<212> DNA

<213> Homo sapiens

<400> 37

atgggggtgta	gtggagcctg	gggcttgagc	tgcccttgc	cacagacgccc	atcctgggccc	60
tggaggaaga	tgccgacgccc	atccatgagg	aaccggagtg	gcccgtgtg	gagcaggggcc	120
tctgtccctt	tctctgcctg	ggaagtagag	gtgcagatga	gggtgacggg	actggggcgc	180
cggggagccc	agggcatggc	cgtgtgtac	acccggggca	ggggccatgt	aggctctgtc	240
cttggggggc	tggcttcgt	ggacggcattc	ggatcttct	ttgactctcc	ggcagaggat	300
actcaggaca	gtccctgcatt	ccgtgtgtc	gccagcgacg	ggcacatccc	ctctgagcag	360
cctggggatg	gagctagcca	aggctgggc	tcctgtcatt	gggacttccg	gaaccggcca	420
cacccttca	gagcacggat	caccaactgg	gggcagaggg	tgcgcattgtc	cttgaacagt	480
ggcctcactc	ccagtatcc	aggtgatcc	tgtgtgtatg	tggggccct	gcttttggc	540
cctggaggtt	tctttgggt	ctcagcagcc	acccgcaccc	tggcagatga	tcatgatgtc	600
ctgtccttcc	tgaccttcag	cctgagtgag	cccaagccag	agttcccccc	tcagcccttc	660
ctggagatgc	agcacgtccg	cctggcgagg	cagctggaaag	ggctgtggc	aaggctggc	720
ttggggcacca	gggaggatgt	aactccaaa	tca	actctgt	aagctcaagg	780
aggctctttg	acctggagga	gacgtgggc	agacaccgc	ggatctgc	ggctctgcgg	840
ggtctctcca	agcagctggc	ccaggctgag	agacaatgg	agaagcagc	gggccccca	900
gccaagccag	gcctgacgga	ggctgggat	gcagctgtcc	gcatggctgc	agaagccca	960
gtctcctacc	tgcctgtgg	cattgagcat	catttcttag	agctggacca	catcctggc	1020
ctcctgcagg	aggagcttc	ggggccggcg	aaggcagcag	ccaaggcccc	ccgcccac	1080
ggccagcccc	caagggcctc	ctcgtgcctg	cagcctggca	tcttctgtt	ctaccccttc	1140
attcagactg	taggcttctt	cggctacgt	cacttcaggg	gcccgtgccc	ccggccggc	1200
aagaccatgg	cgttcatgt	gaagaccatg	gtgggcggcc	agctgaagaa	cctca	1260
agccctggag	gcggcgagga	taagggagat	ggggaca	cgccagccg	agctcaggc	1320
atgagccggg	aggagtacga	ggagtatc	aa	gcaactcg	tgaagagaa	1374

<210> 38

<211> 1581

<212> DNA

<213> Homo sapiens

<400> 38

atgcggcgg	tcagtggtcc	aggccctta	ttctgccttc	tcctctgt	cctggacccc	60
cacagccctg	agacggggtg	tcctcctcta	cgccaggttt	agtacaagct	cagcttcaa	120
ggcccaaggc	tggcattgccc	tgggctgg	atacccttct	ggagccatca	tggagacgccc	180
atccctggcc	tggaggaagt	gcccgtacg	ccatccatga	gaaaccggag	tggcccccgt	240
tggagcagg	cctctgtccc	tttctgtcc	tggaaagt	aggtgcagat	gagggtgacg	300
ggactggggc	gcccgggagc	ccaggccatg	gcccgtgtgt	acaccgggg	cagggccat	360
gtaggctctg	tccttgggg	gctggcttc	tgggacggca	tgggatctt	cttgactct	420
ccggcagagg	atactcagga	cagtcctgc	atccgtgtc	tggccagcga	cgccacatc	480
ccctctgagc	agcctgggaa	tggagctagc	caagggtctgg	gctctgtca	ttgggacttc	540
cggaaccggc	cacaccctt	cagacacgg	atcacctact	ggggcagag	gtgcgc	600
tccttgaaca	gtggcctc	tcccagtat	ccaggtgag	tctgtgtgg	tgtggggccc	660
ctgctttgg	tccctggagg	tttcttgg	gtctcagcag	ccaccggc	cctggcagat	720
gatcatgtat	tcctgtcctt	cctgaccc	agcctgagtg	agccca	agggttccc	780
cctcagccct	tcctggagat	gcagcacgtc	cgccctggc	ggcagctgg	agggctgtgg	840
gcaaggctgg	gttgggcac	cagggaggat	gtaa	ctc	tgaagctcaa	900

ggagaagggg aaaggcttt	tgacctggag	gagacgctgg	gcagacaccg	ccggatcctg	960
caggctctgc	ggggctcttc	caagcagctg	gcccagctg	agagacaatg	1020
ctggggcccc	caggccaagc	caggcctgac	ggaggctgg	ccctggatgc	1080
attccatcca	ccccagggag	ggttggccac	ctctccatgt	cactcaataa	1140
aaggtcggtg	ccctgtcca	tgacagttgg	actctgtcc	aggccctgca	1200
gatcagctg	tccgcattggc	tgcagaagcc	caggtctcct	acctgcctgt	1260
catcatttct	tagactgga	ccacatcctg	ggcctcctgc	aggaggact	1320
gcgaaggcag	cagccaaaggc	ccccggccca	cctggccagc	ccccaaaggc	1380
ctgcagcctg	gcatcttctt	gttctaccc	ctcattcaga	ctttaggctt	1440
gtgcacttca	ggcaggagct	gaacaagagc	cttcaggagt	gtctgtccac	1500
cctctgggtc	ctgcaccaca	caccccccagg	gcccctggga	ttctgaggag	1560
cctgccagca	tgcctgcctg	a			1581

<210> 39

<211> 2715

<212> DNA

<213> Homo sapiens

<400> 39

atgcctttgg	ctctatgttc	atctctggct	cttatttttgc	cagtcctgt	cagtggacag	60
cttgaggatt	cagggaacta	ctactgcaca	gctgacaatg	gctttggccc	ccagcacagt	120
gagggtggta	gtctctctgt	cactgtccct	gtgtctcattc	ctgtccctac	cctcagctct	180
gctgaggccc	tgacttttga	aggagccact	gtgacacttc	actcttcgt	gatcctgc当地	240
gctccacttt	ctgtgtttga	aggagacttc	gtggttctga	ggtgccgggc	aaaggcggaa	300
gtaaacactga	atactatgtt	caagaatggt	aacgtcctga	catttcctaa	taaaagctt	360
gacttccata	ttcatcacgc	aagtctcaaa	gacaatggt	catactactt	tactggattt	420
aacggaaagta	atttctctgt	tttttccaaac	atagtcaaa	tccaaatgttca	agagcatctc	480
ctgccccagt	ggttcctgaa	ggcacctgt	cccactgtgg	cccttagtga	gatattctca	540
gtcaatagag	gtccacttct	gacaggcaca	ggctcccgag	ttatgactcc	ctggatttac	600
ttccctactg	aggactggaa	cttcacttctt	atttccattt	ctgtggacga	tgcttgcaaa	660
aggccttgg	ctccctggc	tccttgggaa	gttggaaatc	taacaccagg	aaagagttt	720
cagcagaagg	ggaacccaga	cctgctcatg	ggcccttttgc	atgttcttca	cttgccttc	780
atcacacttt	tttgcacat	ggcagggttct	ttgttttatt	atatggact	tggagaaaaag	840
aaagatgtat	tatttggta	aggaaatggaa	agcagaagct	atcattgggtt	ccagaagttt	900
aggccttgc	gtgggcaaga	agcagatcaa	aagtgtgtt	ttccccctgg	actgtatgtt	960
caggatattt	tcatatataat	cagacaagg	gagagtgttgc	ttgttattttt	gatgttttcat	1020
caggcttaca	gacggcctgc	tggaggtt	ccagtagagc	atatgtatgt	atgggctctc	1080
agggtgataa	gttccggact	cttcgcctac	gctgtatggct	ggcttcttac	tcttttctc	1140
ctccagtc	tggacaatct	gagcccatca	actcagtc	aaacacacga	aggccatgaa	1200
aagttatgtc	ccttcctggc	catagggca	cctgacata	gcagggcag	cttgcctc	1260
gcaaagaaga	gtcttagtgc	atacatcaa	ggaaatcaac	tctccccc	tccagtagaa	1320
gacctattgc	ctaagtccca	atggccctgc	atccagggtc	ttccaggaa	tatagctgc	1380
gctgcacaca	aacctgtat	ttccgttcat	cctccatgg	ccacatttctt	caaaggagag	1440
agagtgtact	tgacttgaa	tggatttgc	ttctatgttca	cagagaaaac	aacatgtt	1500
catcggtact	actggggaga	aaagttgacc	ctgaccc	gaaacaccct	cgagggtc	1560
gaatctggac	tgtacagat	ccaggcccgg	ggctcccccac	gaagtaacc	tgtgcgtt	1620
ctcttttctt	cagggtgagaa	agagactgt	gtctctgttca	agaatctgc	tacaaatcac	1680
actccaaatgt	ccaggaagag	atccatgtt	agttctctaa	gtgcacttcc	tttcatagct	1740
cctgctctgc	gactcgactc	cttaatcctg	caggcaccat	attctgtt	tgaagggtt	1800
acattgggtt	tgagatgcca	cagaagaagg	aaagagaaat	tgactgtgt	aaaatataact	1860
tggaaatggaa	acattcttcc	catttctaat	aaaagctgg	atcttctt	cccacaagca	1920
agttcaataa	acaatggca	ttatcgatgc	attggatata	gagacgagaa	tgatgtt	1980
agatcaaaatt	tcaaataat	taaaattca	gggatccctg	tgtctggggt	gctcctggag	2040
acccagccct	cagggggcca	ggctgttgg	ggggagatgc	tggtccttgc	ctgctccgt	2100
gctgaaggca	caggggatac	cacattctcc	tggcaccgg	aggacatgc	ggagagtc	2160
gggaggaaaa	ctcagcggtt	cctgagagca	gagctggagc	ccctgtccat	cagacagagc	2220
catgcaggggg	gataactact	tacagcagac	aacagctac	gcccgttcca	gagcatgggt	2280
ctgaatgtca	ctgtgagaga	gaccccgaggc	aacagagatg	gcccgttcca	cgccggagcc	2340
actggaggggc	tgctcagtgc	tcttccttgc	gctgtggccc	tgctgtttca	ctgctggcgt	2400

cgaggaagt cagtacaccc	caaaaaggga gatttgat	actctgagat ccagactact	2460
cagtggag aagaagagga	agaaaatcat ggcaataaaaa	atcaagaact agaacttgg	2520
aatgttaggag agagtttc	tcacagggca tgcataatgg	gtactctaattt gggacttgc	2580
caaacaatcg ggggtctaa	tacccagg acacttctag	aggataagga tgtctcagg	2640
gtctactctg aggtaaagac	acaacaccca gataacttag	ctggaaagat cagctctaag	2700
gatgaagaaa gttaa			2715

<210> 40

<211> 1548

<212> DNA

<213> Homo sapiens

<400> 40			
atgtctgtgt gggcgtcctt	gctggccttt gctccagttt	gtggacaatc tgcagctgca	60
cacaaacctg tgatttcgtt	ccatccctca tggaccacat	tcttcaaaagg agagagatgg	120
actctgactt gcaatggatt	tcagttctat gcaacagaga	aaacaacatg gtatcatcg	180
cactactggg gagaaaagtt	gaccctgacc ccagggaaaca	ccctcgaggt tggggatct	240
ggactgtaca gatgccaggc	ccggggctcc ccacgaagta	accctgtgcg cttgtcttt	300
tcttcagact ccttaatctt	gcaggccacca tattctgtgt	ttgaaggtga cacattgg	360
ctgagatgcc acagaagaag	gaaagagaaa ttgactgtgt	tggaaatatac ttggaaatgga	420
aacattcttt ccatttctaa	taaaagctgg gatcttctta	tcccacaagc aagttcaaat	480
aacaatggca attatcgatg	cattggatat ggagatgaga	atgatgtatt tagatcaat	540
ttccaaataa taaaattca	agaactatcc cCACATCCAG	agctgaaagc tacagactct	600
cagcctacag aggggaattc	tgtaaaacctg agctgtgaaa	cacagcttcc tccagagcgg	660
tcagacaccc cacttcactt	caacttcttc agagatggcg	aggtcatctt gtcagactgg	720
agcacgtacc cggaactcca	gctcccaacc gtctggagag	aaaactcagg atcctattgg	780
tgtgtgtctg aaacagttag	gggttaacatc cacaaggcaca	gtccctcgct acagatccat	840
gtgcagcggg tccctgtgtc	tgggtgtctc ctggagaccc	agccctcagg gggccaggct	900
gttgaaggggg agatgtctgt	ccttgtctgc tccgtggctg	aaggcacagg ggataccaca	960
ttctcctggc accgagagga	catcgaggag agtctgggg	ggaaaactca gcgttccctg	1020
agagcagagc tggagctccc	tgccatcaga cagagccatg	caggggata ctactgtaca	1080
gcagacaaca gctacggccc	tgtccagagc atgggtctga	atgtcaatgt gagagagacc	1140
ccaggcaaca gagatggct	tgtcgcccg ggagccactg	gagggtctgt cagtgtctt	1200
ctcctggctg tggccctgt	gttcaactgc tggcgctgg	ggaagtcagg agttggttc	1260
ttgggagacg aaaccaggt	ccctcccgct ccaggcccag	gagagtccctc ccattccatc	1320
tgcctgtccc aggtggagct	tcagtcgttg tatgttgatg	tacaccccaa aaaggagat	1380
ttggtatact ctgagatcca	gactactcg ctgggagaag	aagaggaagc taatacctcc	1440
aggacacttc tagaggataa	ggatgtctca gttgtctact	ctgaggtaaa gacacaacac	1500
ccagataact cagctggaaa	gatcagctct aaggatgaag	aaagttaa	1548

<210> 41

<211> 2494

<212> DNA

<213> Homo sapiens

<400> 41			
batggctgtg ggaggaggac	acaaaggagt tagatgtctt	ccctctgtc gcagctccca	60
gggtccccacg tgctgcgtt	gctggaggca gcaaggggac	gagtgtggga ttgcgggttg	120
cgaaggcaac tccacgtct	cagagaacga ggtgtcg	aggcctggcg agtgcgcgt	180
ccgcccacggc tacttcgtt	ccaaactgcga caccaagtgc	ccgcgcctgt tctggggccc	240
cgactgcaag gagctgtgt	gctgcccaccc acacgggcag	tgcgaggacg tgacaggc	300
gtgtacttgt caccgcggc	gctggggcgc gcgctcg	catgcgtgcc agtgcgc	360
cggcacgtgc caccggcgg	ccgcgcgtg ccgcgtgt	tccggctggt gggcgcgc	420
gtgcgcgcgc gcgtgtact	gcagcgccac gtcgcgtc	gaccacaga cggcgccct	480
cctgtgcac gcaggcttgt	ggggccgcag ctgcacaaac	cagtgcgcct gcaactcg	540
tccctgtcgag cagcagacg	gccgctgtca gtgcgcgcag	cgtacgttc ggcgcgcgt	600
cgatcgctac tgccagtg	tccgcggccg ctgcacccct	gtggacggca cgtgtgc	660
cgagccggc taccgcggca	agtactgtcg cgagccgtgc	ccgcgcggct tctacgg	720
gggctgtcgc cgccgggtgt	gccagtgc aaaggatgg	ccgtgcacgg tggccgagg	780

ccgctgctg acgtgcgagc ccggctggaa cggaaccaag tgcgaccagc cttgcgccac 840
 cggtttctat ggcgaggggct gcagccaccg ctgtccgcca tgccgcgacg ggcatgcctg 900
 taaccatgtc accggcaagt gtacgcgctg caacgcgggc tggatcgccg accgggtgcga 960
 gaccaagtgt agcaatggca cttacggcga ggactgcgcc ttctgtgtgc cgcactgcgg 1020
 cagcggacac tgcgacttcc agtggggcgt ctgcctgtgc agccctggcg tccacggcc 1080
 ccactgtaac gtgacgtgcc cgccggact ccacggcgac gactgtgc tggcctgcag 1140
 ctgcccacgag gacacgtgcg accgggtcac tggatcgccg cacttagaaa ccaaccagcg 1200
 caaggcgtg atggcgcgg ggcgctgtc cgtccgtcgtc gtctgcctgc tgctctcg 1260
 gctcgctgc tgctgcgtt ggcggggcaa ggaccctacg cgccgacccc gccccccg 1320
 ggagctttcg cttgggagga agaaggcgcc gcacccgacta tgccggcgct tcaatgc 1380
 cagcatgaag ctgcccggc tcccgctccg gaggcagaaa ctacccaaag tctgtatggc 1440
 ccaccacgac ctggataaca cactcaactg cagcttcgtt gaggccaccc cagggctgga 1500
 gcagccctca ccattctggt cctctcggtt ctcttcgttcc tgctttgaca ccactgtat 1560
 aggccctgtg tactgtgtac cccatgagga ggcacccagcg gagagccggg acccccgaat 1620
 ccccaactgtc cctgcggagg cgccggcgcc tccccctgtg cccttgcac ccacggcc 1680
 cgccggaggag ggcataaccc tcccgccgtc ctcggacagc gagcgggtcg cgtccagcgt 1740
 ggagggggccc ggaggggctc tgacgcgcg cgtggcccg cgcggagggcc ggcggcc 1800
 ggcacccggc gagattgggg gcctgtcgct tgccatcg cccggacgc gggaaaccggc 1860
 gccacccgtac cccgcacca agcctaagggt tccctggatc cacggcaacg acagcggcc 1920
 tgcagctggc cgtgcgcctt caccacccgc gccaggctcc gaggccggc ccagccccag 1980
 caagagggaaa cggacgccccca ggcacaaatc ggacatcg gtcgaaacacg gcaaccccg 2040
 gaccggcgac ccaacgcgcgc gccccccggg gtcggccggag gaggcgacag ccctcgctc 2100
 gcccctcgccccc cccaggggccc gagcgcgcgc cgccggccgg cctcttggag ccacggacg 2160
 cccggcggtcc cccgcgaacg ggcggcgaggc tgccctccatg ttggccgtcg acgtgcgcgg 2220
 caagactcgc agcctggggc ggcggcgaggc tgccctgggc ggcggaggcc ccagggaaaa 2280
 gccggcgccc ccacagaaaag ccaagcgctc cgtgcgcacca gcctcgcccg cccgcgcgc 2340
 cccagcgacc gaaaccccccgg ggctgtagaa ggccggcgacc gacttgcggc cgcctgagac 2400
 ccccccggaaag aagaccccca tccagaagacc gccgcgcacca aagagccggg aggccggccgg 2460
 cgagctggc agggcgccg caccacccct gtag 2494

<210> 42

<211> 2614

<212> DNA

<213> Homo sapiens

<400> 42

batggaggggc gcagggggccc gggggggccgg gccggcgccgg cgccggggag ccggggggcc 60
 gccgtcaccgc ctgtccgt cgctgtgtc gctgctgtc ctctggatgc tgccggacac 120
 cgtggccctt caggaactga accctcgccg ccgcacacgtg tgccgtgtc cccggctccca 180
 ggtgcccacg tgctgcgtg gctggaggca gcaaggggac gagtggtggta ttgcgggtgt 240
 cgaaggcaac tccacgtgtc cagagaacga ggtgtgcgtg aggcttggcg agtgcgcgt 300
 ccgcacccggc tacttcgtt ccaactgcg caccacgtc ccgcgcacgt tctggggccc 360
 cgactgcaag gagctgtgtc gtcgcaccc acacggcgag tgccgaggacg tgacaggcca 420
 gtgtacttgtt ctcgcgcgc gctggggcgc ggcgtgcgcg catgcgtgcc agtgcgcagca 480
 cggcacgtgc caccacccggc ggcgcgcgtc ccgtgtgtc tccggctgtt ggggcgcgc 540
 gtgcgcgcgc ggcgtctact gcaacgcgc gtcgcgcgtc gaccacaca ccggcgccctg 600
 cctgtgcac gcaaggcttggt gggccgcgc ctgcacaaac cagtgcgcct gcaactcg 660
 tccctgcggag cagcagacgc gccgtgtca tgccgcgcgc cgtacgttgc ggcgcgcgt 720
 cgatcgctac tgccagtgct tccgcggccg ctgcacccct gtggacggca cgtgtgcctg 780
 cgagccgggc taccgcgcga agtactgtcg cgagccgtgc cccgcggcgt tctacggct 840
 gggctgtcgc cgccgggtgt gccaatgcac gggccacgcg ccgtgcaccc tgccggagg 900
 ccgctgtttt acgtgcgcgc ccggctggaa cggaaaccaag tgccgacccgc ctgcgcgcac 960
 cggtttctat ggccggggct gcaacccaccc ctgtccgcac tgccgcgcac ggcacgtc 1020
 taaccatgtc accggcaagt gtacgcgtc caacgcggc tggatcgccg accgggtgcga 1080
 gaccaagtgt agcaatggca cttacggcga ggactgcgc ttcgtgtgc cgcactgcgg 1140
 cagcggacac tgcgacttcc agtggggcgt ctgcctgtgc agccctggcg tccacggcc 1200
 ccactgtaac gtgcgtgcg ccggcgact ccacggcgac gactgtgc tggcctgcag 1260
 ctggccacgag gacacgtgcg accgggtcac tggatcgccg cacttagaaa ccaaccagcg 1320
 caaggcgtg atggcgcgg ggcgctgtc cgtctgcgtc gtctgcctgc tgctctcg 1380

gctcggtgc	tgcgtgcgtt	gccgcggcaa	ggaccctacg	cggccgacccc	gcccccgca	1440
ggagcttcg	cttgggagga	agaaggcgcc	gcaccgacta	tgcgggcgct	tcagtgcac	1500
cacatgaag	ctgccccgga	tcccgctccg	gagggcagaaa	ctacccaaag	tcgttagtggc	1560
ccaccacgc	ctggataaca	cactcaactg	cagcttcctg	gagccacccct	cagggctgga	1620
gcagccctca	ccatcctgg	cctctcg	ctccttctcc	tcgtttgaca	ccactgtatg	1680
agggcctgt	tactgtgtac	cccatgagga	ggcaccagcg	gagagccggg	accccgaagt	1740
ccccactgtc	cctgcccagg	cgccggcgcc	gtccccctgt	cccttgacca	cgccagcc	1800
cgccgaggag	gcatacccc	tcccccgcgtc	ctccgacagc	gagcggctgg	cgtagcgt	1860
ggagggggcc	ggaggggctc	tgtacgcgc	cgtggcccg	cgcgaggccc	ggccggcccg	1920
ggcccggggc	gagattgggg	gcctgtcgct	gtcgccatcg	cccgagcgca	gaaaccgccc	1980
gccacctgac	cccgccacca	agcttaaggt	gtcctggatc	cacggcaagc	acagcgcc	2040
tgcagctggc	cgtgcgcct	caccaccgc	gccaggctcc	gaggccgcgc	ccagccccag	2100
caagaggaaa	cggacgcaca	gcgacaaaatc	ggcgcatacg	gtcgaacacg	gcagcccccg	2160
gaccgcgcac	ccaaacgcgc	gccccccggg	gtgtcccgag	gaggcgacag	ccctcgctgc	2220
gcctcgccg	cccaggggcc	gagcgcgc	cgcgccccgg	cctcttggag	cccacggacg	2280
ccggcgtcc	cccgcgaagc	gcggcgaggc	tgcctccatg	ttggccgctg	acgtgcgcgg	2340
caagactcgc	agcctggggc	gcggcgaggt	ggccctgggc	gcbcaggccc	ccagggaaaa	2400
gcccggccc	ccacagaaag	ccaaacgcgc	cgtgcgcaca	gcctcgcccg	cccgcgcgc	2460
cccaacgcacc	gaaacccccc	ggcttgagaa	ggcggcgacc	gacttgc	cccttgagac	2520
ccccccgaaag	aagaccccca	tccagaagcc	gccgcgc	caag	aggccggg	2580
cgagctgggc	agggcgccg	caccaccc	gttag			2614

<210> 43

<211> 402

<212> DNA

<213> Homo sapiens

<400> 43						
atcgactgcc	gcgcggagca	ggggcgtacg	ccgctcatgg	tggccgtggg	gtgcggac	60
cccgcgctgc	gcgcgcgtt	cgtgcggct	ctgctcgac	agggtgctgc	agtgaac	120
cgagacgagc	gcggccgcac	cgcactcagc	ctggcgtgc	agcggaggca	cctggac	180
gtgcagctgc	tggcgtcgtt	cagcgggtac	cccggagg	ccgactctgc	ggcaac	240
ccgggtatgt	gggcggccgg	ctgcggccac	ggggcgg	tgcagttcct	gtgcgg	300
ttccggccgc	taggcctgcg	cctcgaccgc	accaaccgt	cggggctac	cgcg	360
ctggccgccc	cccgcgccca	cggac	gtgcagg	cccc		402

<210> 44

<211> 975

<212> DNA

<213> Homo sapiens

<400> 44						
atgctcaaac	ccaaggac	gtgcccc	gcggggac	gcac	ttcc	60
caggcggca	aagtgcac	tttgc	gggg	gggg	ccat	120
gactgcgcg	cggagcagg	ccgtac	ccgc	ccgt	ggat	180
gcgcgtcg	cgcgctt	cg	gg	gtgc	ggac	240
gacgagcgc	gcgc	cacc	gc	gtgc	gac	300
cagctgtcg	tgc	atc	cg	ggcc	ccgt	360
gtatgtgg	cg	cg	gg	gg	cc	420
cgccgcctag	gc	cc	gg	gtgc	cttc	480
ccgcgcgc	cg	cc	gg	gtgc	cc	540
ggcaagaatt	cg	cc	gg	gg	cc	600
atgagctgg	ct	ct	cc	gg	cc	660
ctgatggccc	tac	aa	cc	gg	cc	720
gtgttggagg	gag	cc	cc	gg	cc	780
gaggcggccc	cc	gg	cc	gg	cc	840
cccagcctgg	tc	gg	gg	gg	cc	900
ctgtctgtct	cg	gt	gg	gg	cc	960
cgtgctcagc	gg	ta	tt	tt	tt	975

<210> 45
 <211> 568
 <212> PRT
 <213> homo sapiens

<400> 45
 Met Lys Glu Ala Glu Met Asp Gly Glu Ala Val Arg Phe Cys Thr Asp
 1 5 10 15
 Asn Gln Cys Val Ser Leu His Pro Gln Glu Val Asp Ser Val Ala Met
 20 25 30
 Ala Pro Ala Ala Pro Lys Ile Pro Arg Leu Val Gln Ala Thr Pro Ala
 35 40 45
 Phe Met Ala Val Thr Leu Val Phe Ser Leu Val Thr Leu Phe Val Val
 50 55 60
 Gly Lys Pro Pro Val Gln Gln Thr Arg Pro Val Pro Lys Pro Val
 65 70 75 80
 Gln Ala Val Ile Leu Gly Asp Asn Ile Thr Gly His Leu Pro Phe Glu
 85 90 95
 Pro Asn Asn His His Phe Gly Arg Glu Ala Glu Met Arg Glu Leu
 100 105 110
 Ile Gln Thr Phe Lys Gly His Met Glu Asn Ser Ser Ala Trp Val Val
 115 120 125
 Glu Ile Gln Met Leu Lys Cys Arg Val Asp Asn Val Asn Ser Gln Leu
 130 135 140
 Gln Val Leu Gly Asp His Leu Gly Asn Thr Asn Ala Asp Ile Gln Met
 145 150 155 160
 Val Lys Gly Val Leu Lys Asp Ala Thr Thr Leu Ser Leu Gln Thr Gln
 165 170 175
 Met Leu Arg Ser Ser Leu Glu Gly Thr Asn Ala Glu Ile Gln Arg Leu
 180 185 190
 Lys Glu Asp Leu Glu Lys Ala Asp Ala Leu Thr Phe Gln Thr Leu Asn
 195 200 205
 Phe Leu Lys Ser Ser Leu Glu Asn Thr Ser Ile Glu Leu His Val Leu
 210 215 220
 Ser Arg Gly Leu Glu Asn Ala Asn Ser Glu Ile Gln Met Leu Asn Ala
 225 230 235 240
 Arg Ala Asn Ala Glu Ile Gln Gly Leu Lys Glu Asn Leu Gln Asn Thr
 245 250 255
 Asn Ala Leu Asn Ser Gln Thr Gln Ala Phe Ile Lys Ser Ser Phe Asp
 260 265 270
 Asn Thr Ser Ala Glu Ile Gln Phe Leu Arg Gly His Leu Glu Arg Ala
 275 280 285
 Gly Asp Glu Ile His Val Leu Lys Arg Asp Leu Lys Met Val Thr Ala
 290 295 300
 Gln Thr Gln Lys Ala Asn Gly Arg Leu Asp Gln Thr Asp Thr Gln Ile
 305 310 315 320
 Gln Val Phe Lys Ser Glu Met Glu Asn Val Asn Thr Leu Asn Ala Gln
 325 330 335
 Ile Gln Val Leu Asn Gly His Met Lys Asn Ala Ser Arg Glu Ile Gln
 340 345 350
 Thr Leu Lys Gln Gly Met Lys Asn Ala Ser Ala Leu Thr Ser Gln Thr
 355 360 365
 Gln Met Leu Asp Ser Asn Leu Gln Lys Ala Ser Ala Glu Ile Gln Arg
 370 375 380
 Leu Arg Gly Asp Leu Glu Asn Thr Lys Ala Leu Thr Met Glu Ile Gln
 385 390 395 400
 Gln Glu Gln Ser Arg Leu Lys Thr Leu His Val Val Ile Thr Ser Gln
 405 410 415

Glu Gln Leu Gln Arg Thr Gln Ser Gln Leu Leu Gln Met Val Leu Gln
 420 425 430
 Gly Trp Lys Phe Asn Gly Gly Ser Leu Tyr Tyr Phe Ser Ser Val Lys
 435 440 445
 Lys Ser Trp His Ala Glu Gln Phe Cys Val Ser Gln Gly Ala His
 450 455 460
 Leu Ala Ser Val Ala Ser Lys Glu Glu Gln Ala Phe Leu Val Glu Phe
 465 470 475 480
 Thr Ser Lys Val Tyr Tyr Trp Ile Gly Leu Thr Asp Arg Gly Thr Glu
 485 490 495
 Gly Ser Trp Arg Trp Thr Asp Gly Thr Pro Phe Asn Ala Ala Gln Asn
 500 505 510
 Lys Ala Pro Val Val Phe Gly Phe Trp Glu Lys Asn Gln Ser Asp Asn
 515 520 525
 Trp Arg His Lys Asn Gly Gln Thr Glu Asp Cys Val Gln Ile Gln Gln
 530 535 540
 Lys Trp Asn Asp Met Thr Cys Asp Thr Pro Tyr Gln Trp Val Cys Lys
 545 550 555 560
 Lys Pro Met Gly Gln Gly Val Ala
 565

<210> 46
 <211> 364
 <212> PRT
 <213> homo sapiens

<400> 46
 Met Ser Arg Gln Gly Lys Leu Phe Ser Ala Phe Gly Val Gly Cys Cys
 1 5 10 15
 Val Thr Ala Gly Leu Pro Lys Asp Asp Asn Thr Pro Ser Thr Ile Ala
 20 25 30
 Asp Val His Asn Gly Tyr Thr Met Asn Val Val Glu Gln Val Leu Lys
 35 40 45
 Asp Ser Phe Val Leu Phe Phe Pro Gly Thr Leu Cys Asp Phe Pro Lys
 50 55 60
 Ile His His Gly Phe Leu Tyr Asp Glu Glu Asp Tyr Asn Pro Phe Ser
 65 70 75 80
 Gln Val Pro Thr Gly Glu Val Phe Tyr Tyr Ser Cys Glu Tyr Asn Phe
 85 90 95
 Val Ser Pro Ser Lys Ser Phe Trp Thr Arg Ile Thr Cys Thr Glu Glu
 100 105 110
 Gly Trp Ser Pro Thr Pro Lys Cys Leu Arg Met Cys Ser Phe Pro Phe
 115 120 125
 Val Lys Asn Gly His Ser Glu Ser Ser Gly Leu Ile His Leu Glu Gly
 130 135 140
 Asp Thr Val Gln Ile Ile Cys Asn Thr Gly Tyr Ser Leu Gln Asn Asn
 145 150 155 160
 Glu Lys Asn Ile Ser Cys Val Glu Arg Gly Trp Ser Thr Pro Pro Ile
 165 170 175
 Cys Ser Phe Thr Met Lys Thr Cys Gly Tyr Ile Pro Glu Leu Glu Tyr
 180 185 190
 Gly Tyr Val Gln Pro Ser Val Pro Pro Tyr Gln His Gly Val Ser Val
 195 200 205
 Glu Val Asn Cys Arg Asn Glu Tyr Ala Met Ile Gly Asn Asn Met Ile
 210 215 220
 Thr Cys Ile Asn Gly Ile Trp Thr Glu Leu Pro Met Cys Val Glu Ser
 225 230 235 240
 Thr Ala Tyr Cys Gly Pro Pro Ser Ile Asn Asn Gly Asp Thr Thr

245	250	255
Ser Phe Pro Leu Ser Val Tyr Pro Pro Gly Ser Thr Val Thr Tyr Arg		
260	265	270
Cys Gln Ser Phe Tyr Lys Leu Gln Gly Ser Val Thr Val Thr Cys Arg		
275	280	285
Asn Lys Gln Trp Ser Glu Pro Pro Arg Cys Leu Asp Pro Cys Val Val		
290	295	300
Ser Glu Glu Asn Met Asn Lys Asn Asn Ile Gln Leu Lys Trp Arg Asn		
305	310	315
Asp Gly Lys Leu Tyr Ala Lys Thr Gly Asp Ala Val Glu Phe Gln Cys		320
325	330	335
Lys Phe Pro His Lys Ala Met Ile Ser Ser Pro Pro Phe Arg Ala Ile		
340	345	350
Cys Gln Glu Gly Lys Phe Glu Tyr Pro Ile Cys Glu		
355	360	

<210> 47
 <211> 327
 <212> PRT
 <213> homo sapiens

<400> 47
 Met Leu Leu Leu Phe Ser Val Ile Leu Ile Ser Trp Val Ser Thr Val
 1 5 10 15
 Gly Gly Glu Gly Thr Leu Cys Asp Phe Pro Lys Ile His His Gly Phe
 20 25 30
 Leu Tyr Asp Glu Glu Asp Tyr Asn Pro Phe Ser Gln Val Pro Thr Gly
 35 40 45
 Glu Val Phe Tyr Tyr Ser Cys Glu Tyr Asn Phe Val Ser Pro Ser Lys
 50 55 60
 Ser Phe Trp Thr Arg Ile Thr Cys Thr Glu Glu Gly Trp Ser Pro Thr
 65 70 75 80
 Pro Lys Cys Leu Arg Met Cys Ser Phe Pro Phe Val Lys Asn Gly His
 85 90 95
 Ser Glu Ser Ser Gly Leu Ile His Leu Glu Gly Asp Thr Val Gln Ile
 100 105 110
 Ile Cys Asn Thr Gly Tyr Ser Leu Gln Asn Asn Glu Lys Asn Ile Ser
 115 120 125
 Cys Val Glu Arg Gly Trp Ser Thr Pro Pro Ile Cys Ser Phe Thr Met
 130 135 140
 Lys Thr Cys Gly Tyr Ile Pro Glu Leu Glu Tyr Gly Tyr Val Gln Pro
 145 150 155 160
 Ser Val Pro Pro Tyr Gln His Gly Val Ser Val Glu Val Asn Cys Arg
 165 170 175
 Asn Glu Tyr Ala Met Ile Gly Asn Asn Met Ile Thr Cys Ile Asn Gly
 180 185 190
 Ile Trp Thr Glu Leu Pro Met Cys Val Glu Ser Thr Ala Tyr Cys Gly
 195 200 205
 Pro Pro Pro Ser Ile Asn Asn Gly Asp Thr Thr Ser Phe Pro Leu Ser
 210 215 220
 Val Tyr Pro Pro Gly Ser Thr Val Thr Tyr Arg Cys Gln Ser Phe Tyr
 225 230 235 240
 Lys Leu Gln Gly Ser Val Thr Val Thr Cys Arg Asn Lys Gln Trp Ser
 245 250 255
 Glu Pro Pro Arg Cys Leu Asp Pro Cys Val Val Ser Glu Glu Asn Met
 260 265 270
 Asn Lys Asn Asn Ile Gln Leu Lys Trp Arg Asn Asp Gly Lys Leu Tyr
 275 280 285

Ala Lys Thr Gly Asp Ala Val Glu Phe Gln Cys Lys Phe Pro His Lys
 290 295 300
 Ala Met Ile Ser Ser Pro Pro Phe Arg Ala Ile Cys Gln Glu Gly Lys
 305 310 315 320
 Phe Glu Tyr Pro Ile Cys Glu
 325

<210> 48
 <211> 154
 <212> PRT
 <213> homo sapiens

<400> 48
 Met Ala Pro Ala Arg Ala Gly Cys Cys Pro Leu Leu Leu Leu Leu
 1 5 10 15
 Gly Leu Trp Val Ala Glu Val Leu Val Arg Ala Lys Pro Lys Asp Met
 20 25 30
 Thr Ser Ser Gln Trp Phe Lys Thr Gln His Val Gln Pro Ser Pro Gln
 35 40 45
 Ala Cys Asn Ser Ala Met Ser Ile Ile Asn Lys Tyr Thr Glu Arg Cys
 50 55 60
 Lys Asp Leu Asn Thr Phe Leu His Glu Pro Phe Ser Ser Val Ala Ile
 65 70 75 80
 Thr Cys Gln Thr Pro Asn Ile Ala Cys Lys Asn Ser Cys Lys Asn Cys
 85 90 95
 His Gln Ser His Gly Pro Met Ser Leu Thr Met Gly Glu Leu Thr Ser
 100 105 110
 Gly Lys Tyr Pro Asn Cys Arg Tyr Lys Glu Lys His Leu Asn Thr Pro
 115 120 125
 Tyr Ile Val Ala Cys Asp Pro Pro Gln Gln Gly Asp Pro Gly Tyr Pro
 130 135 140
 Leu Val Pro Val His Leu Asp Lys Val Val
 145 150

<210> 49
 <211> 502
 <212> PRT
 <213> homo sapiens

<400> 49
 Met Arg Gln Leu Gly Gly Ser Leu Arg Pro Pro Arg Ala Ala His Gly
 1 5 10 15
 Ala Glu Pro Leu Pro Ser Ala Leu Gly Pro Cys Ala Gly Gly Asp Arg
 20 25 30
 Asp Leu Gly Arg Gly Thr Pro Gly Trp Glu Pro Arg Arg Ala Arg Val
 35 40 45
 Pro Ile His Glu Gln Val Asp Pro Pro Arg Glu Gly Pro His Leu Phe
 50 55 60
 Gln Asn Leu Leu Leu Phe Leu Trp Ala Leu Leu Asn Cys Gly Leu Gly
 65 70 75 80
 Val Ser Ala Gln Gly Pro Gly Glu Trp Thr Pro Trp Val Ser Trp Thr
 85 90 95
 Arg Cys Ser Ser Ser Cys Gly Arg Gly Val Ser Val Arg Ser Arg Arg
 100 105 110
 Cys Leu Arg Leu Pro Gly Glu Glu Pro Cys Trp Gly Asp Ser His Glu
 115 120 125
 Tyr Arg Leu Cys Gln Leu Pro Asp Cys Pro Pro Gly Ala Val Pro Phe

130	135	140
Arg Asp Leu Gln Cys Ala Leu Tyr Asn Gly Arg Pro Val Leu Gly Thr		
145	150	155
Gln Lys Thr Tyr Gln Trp Val Pro Phe His Gly Ala Pro Asn Gln Cys		160
165	170	175
Asp Leu Asn Cys Leu Ala Glu Gly His Ala Phe Tyr His Ser Phe Gly		
180	185	190
Arg Val Leu Asp Gly Thr Ala Cys Ser Pro Gly Ala Gln Gly Val Cys		
195	200	205
Val Ala Gly Arg Cys Leu Ser Ala Gly Cys Asp Gly Leu Leu Gly Ser		
210	215	220
Gly Ala Leu Glu Asp Arg Cys Gly Arg Cys Gly Gly Ala Asn Asp Ser		
225	230	235
Cys Leu Phe Val Gln Arg Val Phe Arg Asp Ala Gly Ala Phe Ala Gly		240
245	250	255
Tyr Trp Asn Val Thr Leu Ile Pro Glu Gly Ala Arg His Ile Arg Val		
260	265	270
Glu His Arg Ser Arg Asn His Leu Gly Ile Leu Gly Ser Leu Met Gly		
275	280	285
Gly Asp Gly Arg Tyr Val Leu Asn Gly His Trp Val Val Ser Pro Pro		
290	295	300
Gly Thr Tyr Glu Ala Ala Gly Thr His Val Val Tyr Thr Arg Asp Thr		
305	310	315
Gly Pro Gln Glu Thr Leu Gln Ala Ala Gly Pro Thr Ser His Asp Leu		320
325	330	335
Leu Leu Gln Val Leu Leu Gln Glu Pro Asn Pro Gly Ile Glu Phe Glu		
340	345	350
Phe Trp Leu Pro Arg Glu Arg Tyr Ser Pro Phe Gln Ala Arg Val Gln		
355	360	365
Ala Leu Gly Trp Pro Leu Arg Gln Pro Gln Pro Arg Gly Val Glu Pro		
370	375	380
Gln Pro Pro Ala Ala Pro Ala Val Thr Pro Ala Gln Thr Pro Thr Leu		
385	390	395
Ala Pro Val Phe Gln Ala Arg Val Leu Gly His His His Gln Ala Gln		400
405	410	415
Glu Thr Arg Tyr Glu Val Arg Ile Gln Leu Val Tyr Lys Asn Arg Ser		
420	425	430
Pro Leu Arg Ala Arg Glu Tyr Val Trp Ala Pro Gly His Cys Pro Cys		
435	440	445
Pro Met Leu Ala Pro His Arg Asp Tyr Leu Met Ala Val Gln Arg Leu		
450	455	460
Val Ser Pro Asp Gly Thr Gln Asp Gln Leu Leu Leu Pro His Ala Gly		
465	470	475
Tyr Ala Arg Pro Trp Ser Pro Ala Glu Asp Ser Arg Ile Arg Leu Thr		480
485	490	495
Ala Arg Arg Cys Pro Gly		
500		

<210> 50
 <211> 451
 <212> PRT
 <213> homo sapiens

<400> 50
 Met Asp Ser Ala Pro Leu Phe Pro Arg Pro His Leu Phe Gln Asn Leu
 1 5 10 15
 Leu Leu Phe Leu Trp Ala Leu Leu Asn Cys Gly Leu Gly Val Ser Ala
 20 25 30

Gln Gly Pro Gly Glu Trp Thr Pro Trp Val Ser Trp Thr Arg Cys Ser
 35 40 45
 Ser Ser Cys Gly Arg Gly Val Ser Val Arg Ser Arg Arg Cys Leu Arg
 50 55 60
 Leu Pro Gly Glu Pro Cys Trp Gly Asp Ser His Glu Tyr Arg Leu
 65 70 75 80
 Cys Gln Leu Pro Asp Cys Pro Pro Gly Ala Val Pro Phe Arg Asp Leu
 85 90 95
 Gln Cys Ala Leu Tyr Asn Gly Arg Pro Val Leu Gly Thr Gln Lys Thr
 100 105 110
 Tyr Gln Trp Val Pro Phe His Gly Ala Pro Asn Gln Cys Asp Leu Asn
 115 120 125
 Cys Leu Ala Glu Gly His Ala Phe Tyr His Ser Phe Gly Arg Val Leu
 130 135 140
 Asp Gly Thr Ala Cys Ser Pro Gly Ala Gln Gly Val Cys Val Ala Gly
 145 150 155 160
 Arg Cys Leu Ser Ala Gly Cys Asp Gly Leu Leu Gly Ser Gly Ala Leu
 165 170 175
 Glu Asp Arg Cys Gly Arg Cys Gly Gly Ala Asn Asp Ser Cys Leu Phe
 180 185 190
 Val Gln Arg Val Phe Arg Asp Ala Gly Ala Phe Ala Gly Tyr Trp Asn
 195 200 205
 Val Thr Leu Ile Pro Glu Gly Ala Arg His Ile Arg Val Glu His Arg
 210 215 220
 Ser Arg Asn His Leu Gly Ile Leu Gly Ser Leu Met Gly Gly Asp Gly
 225 230 235 240
 Arg Tyr Val Leu Asn Gly His Trp Val Val Ser Pro Pro Gly Thr Tyr
 245 250 255
 Glu Ala Ala Gly Thr His Val Val Tyr Thr Arg Asp Thr Gly Pro Gln
 260 265 270
 Glu Thr Leu Gln Ala Ala Gly Pro Thr Ser His Asp Leu Leu Leu Gln
 275 280 285
 Val Leu Leu Gln Glu Pro Asn Pro Gly Ile Glu Phe Glu Phe Trp Leu
 290 295 300
 Pro Arg Glu Arg Tyr Ser Pro Phe Gln Ala Arg Val Gln Ala Leu Gly
 305 310 315 320
 Trp Pro Leu Arg Gln Pro Gln Pro Arg Gly Val Glu Pro Gln Pro Pro
 325 330 335
 Ala Ala Pro Ala Val Thr Pro Ala Gln Thr Pro Thr Leu Ala Pro Val
 340 345 350
 Phe Gln Ala Arg Val Leu Gly His His His Gln Ala Gln Glu Thr Arg
 355 360 365
 Tyr Glu Val Arg Ile Gln Leu Val Tyr Lys Asn Arg Ser Pro Leu Arg
 370 375 380
 Ala Arg Glu Tyr Val Trp Ala Pro Gly His Cys Pro Cys Pro Met Leu
 385 390 395 400
 Ala Pro His Arg Asp Tyr Leu Met Ala Val Gln Arg Leu Val Ser Pro
 405 410 415
 Asp Gly Thr Gln Asp Gln Leu Leu Leu Pro His Ala Gly Tyr Ala Arg
 420 425 430
 Pro Trp Ser Pro Ala Glu Asp Ser Arg Ile Arg Leu Thr Ala Arg Arg
 435 440 445
 Cys Pro Gly
 450

<210> 51
 <211> 431
 <212> PRT

<213> homo sapiens

<400> 51

Met Ile Arg Thr Pro Leu Ser Ala Ser Ala His Arg Leu Leu Leu Pro
 1 5 10 15
 Gly Ser Arg Gly Arg Pro Pro Arg Asn Met Gln Pro Thr Gly Arg Glu
 20 25 30
 Gly Ser Arg Ala Leu Ser Arg Arg Tyr Leu Arg Arg Leu Leu Leu
 35 40 45
 Leu Leu Leu Leu Leu Arg Gln Pro Val Thr Arg Ala Glu Thr Thr
 50 55 60
 Pro Gly Ala Pro Arg Ala Leu Ser Thr Leu Gly Ser Pro Ser Leu Phe
 65 70 75 80
 Thr Thr Pro Gly Val Pro Ser Ala Leu Thr Thr Pro Gly Leu Thr Thr
 85 90 95
 Pro Gly Thr Pro Lys Thr Leu Asp Leu Arg Gly Arg Ala Gln Ala Leu
 100 105 110
 Met Arg Ser Phe Pro Leu Val Asp Gly Tyr Val Gly Leu Asn Ser Ser
 115 120 125
 Gln Lys Leu Ala Cys Leu Ile Gly Val Glu Gly Gly His Ser Leu Asp
 130 135 140
 Ser Ser Leu Ser Val Leu Arg Ser Phe Tyr Val Leu Gly Val Arg Tyr
 145 150 155 160
 Leu Thr Leu Thr Phe Thr Cys Ser Thr Pro Trp Ala Glu Ser Ser Thr
 165 170 175
 Lys Phe Arg His His Met Tyr Thr Asn Val Ser Gly Leu Thr Ser Phe
 180 185 190
 Gly Glu Lys Val Val Glu Glu Leu Asn Arg Leu Gly Met Met Ile Asp
 195 200 205
 Leu Ser Tyr Ala Ser Asp Thr Leu Ile Arg Arg Val Leu Glu Val Ser
 210 215 220
 Gln Ala Pro Val Ile Phe Ser His Ser Ala Ala Arg Ala Val Cys Asp
 225 230 235 240
 Asn Leu Leu Asn Val Pro Asp Asp Ile Leu Gln Leu Leu Lys Lys Asn
 245 250 255
 Gly Gly Ile Val Met Val Thr Leu Ser Met Gly Val Leu Gln Cys Asn
 260 265 270
 Leu Leu Ala Asn Val Ser Thr Val Ala Asp Asp Ser Asn Arg Cys Ser
 275 280 285
 Val Pro Val Ile Gly Ser Glu Phe Ile Gly Ile Gly Gly Asn Tyr Asp
 290 295 300
 Gly Thr Gly Arg Phe Pro Gln Gly Leu Glu Asp Val Ser Thr Tyr Pro
 305 310 315 320
 Val Leu Ile Glu Glu Leu Leu Ser Arg Ser Trp Ser Glu Glu Glu Leu
 325 330 335
 Gln Gly Val Leu Arg Gly Asn Leu Leu Arg Val Phe Arg Gln Val Glu
 340 345 350
 Lys Val Arg Glu Glu Ser Arg Ala Gln Ser Pro Val Glu Ala Glu Phe
 355 360 365
 Pro Tyr Gly Gln Leu Ser Thr Ser Cys His Ser His Leu Val Pro Gln
 370 375 380
 Asn Gly His Gln Ala Thr His Leu Glu Val Thr Lys Gln Pro Thr Asn
 385 390 395 400
 Arg Val Pro Trp Arg Ser Ser Asn Ala Ser Pro Tyr Leu Val Pro Gly
 405 410 415
 Leu Val Ala Ala Ala Thr Ile Pro Thr Phe Thr Gln Trp Leu Cys
 420 425 430

<210> 52
 <211> 480
 <212> PRT
 <213> homo sapiens

<400> 52
 Met Gln Pro Ser Gly Leu Glu Gly Pro Gly Thr Phe Gly Arg Trp Pro
 1 5 10 15
 Leu Leu Ser Leu Leu Leu Leu Leu Leu Gln Pro Val Thr Cys
 20 25 30
 Ala Tyr Thr Thr Pro Gly Pro Pro Arg Ala Leu Thr Thr Leu Gly Ala
 35 40 45
 Pro Arg Ala His Thr Met Pro Gly Thr Tyr Ala Pro Ser Thr Thr Leu
 50 55 60
 Ser Ser Pro Ser Thr Gln Gly Leu Gln Glu Gln Ala Arg Ala Leu Met
 65 70 75 80
 Arg Asp Phe Pro Leu Val Asp Gly His Asn Asp Leu Pro Leu Val Leu
 85 90 95
 Arg Gln Val Tyr Gln Lys Gly Leu Gln Asp Val Asn Leu Arg Asn Phe
 100 105 110
 Ser Tyr Gly Gln Thr Ser Leu Asp Arg Leu Arg Asp Gly Leu Val Gly
 115 120 125
 Ala Gln Phe Trp Ser Ala Tyr Val Pro Cys Gln Thr Gln Asp Arg Asp
 130 135 140
 Ala Leu Arg Leu Thr Leu Glu Gln Ile Asp Leu Ile Arg Arg Met Cys
 145 150 155 160
 Ala Ser Tyr Ser Glu Leu Glu Leu Val Thr Ser Ala Lys Gly Leu Asn
 165 170 175
 Ser Ser Gln Lys Leu Ala Cys Leu Ile Gly Val Glu Gly Gly His Ser
 180 185 190
 Leu Asp Ser Ser Leu Ser Val Leu Arg Ser Phe Tyr Val Leu Gly Val
 195 200 205
 Arg Tyr Leu Thr Leu Thr Phe Thr Cys Ser Thr Pro Trp Ala Glu Ser
 210 215 220
 Ser Thr Lys Phe Arg His His Met Tyr Thr Asn Val Ser Gly Leu Thr
 225 230 235 240
 Ser Phe Gly Glu Lys Val Val Glu Glu Leu Asn Arg Leu Gly Met Met
 245 250 255
 Ile Asp Leu Ser Tyr Ala Ser Asp Thr Leu Ile Arg Arg Val Leu Glu
 260 265 270
 Val Ser Gln Ala Pro Val Ile Phe Ser His Ser Ala Ala Arg Ala Val
 275 280 285
 Cys Asp Asn Leu Leu Asn Val Pro Asp Asp Ile Leu Gln Leu Leu Lys
 290 295 300
 Lys Asn Gly Gly Ile Val Met Val Thr Leu Ser Met Gly Val Leu Gln
 305 310 315 320
 Cys Asn Leu Leu Ala Asn Val Ser Thr Val Ala Asp His Phe Asp His
 325 330 335
 Ile Arg Ala Val Ile Gly Ser Glu Phe Ile Gly Ile Gly Asn Tyr
 340 345 350
 Asp Gly Thr Gly Arg Phe Pro Gln Gly Leu Glu Asp Val Ser Thr Tyr
 355 360 365
 Pro Val Leu Ile Glu Glu Leu Leu Ser Arg Ser Trp Ser Glu Glu Glu
 370 375 380
 Leu Gln Gly Val Leu Arg Gly Asn Leu Leu Arg Val Phe Arg Gln Val
 385 390 395 400
 Glu Lys Val Arg Glu Glu Ser Arg Ala Gln Ser Pro Val Glu Ala Glu
 405 410 415
 Phe Pro Tyr Gly Gln Leu Ser Thr Ser Cys His Ser His Leu Val Pro

420	425	430
Gln Asn Gly His Gln Ala Thr His	Leu Glu Val Thr Lys Gln Pro Thr	
435	440	445
Asn Arg Val Pro Trp Arg Ser Ser	Asn Ala Ser Pro Tyr Leu Val Pro	
450	455	460
Gly Leu Val Ala Ala Ala	Thr Ile Pro Thr Phe Thr Gln Trp Leu Cys	
465	470	475
		480
<210> 53		
<211> 371		
<212> PRT		
<213> homo sapiens		
<400> 53		
Met Asp Ala Ala Thr Ala Pro Lys Gln Ala Trp Pro Pro Trp Pro Pro		
1 5 10 15		
Leu Leu Phe Leu Leu Leu Pro Gly Gly Ser Gly Ser Cys Pro		
20 25 30		
Ala Val Cys Asp Cys Thr Ser Gln Pro Gln Ala Val Leu Cys Gly His		
35 40 45		
Arg Gln Leu Glu Ala Val Pro Gly Gly Leu Pro Leu Asp Thr Glu Leu		
50 55 60		
Leu Asp Leu Ser Gly Asn Arg Leu Pro Lys Ala Gln Pro Leu Val Arg		
65 70 75 80		
Leu Gln Glu Leu Arg Leu Ser Gly Ala Cys Leu Thr Ser Ile Ala Ala		
85 90 95		
His Ala Phe His Gly Leu Thr Ala Phe His Leu Leu Asp Val Ala Asp		
100 105 110		
Asn Ala Leu Gln Thr Leu Glu Glu Thr Ala Phe Pro Ser Pro Asp Lys		
115 120 125		
Leu Val Thr Leu Arg Leu Ser Gly Asn Pro Leu Thr Cys Asp Cys Arg		
130 135 140		
Leu Leu Trp Leu Leu Arg Leu Arg His Leu Asp Phe Gly Met Ser Pro		
145 150 155 160		
Pro Ala Cys Ala Gly Pro His His Val Gln Gly Lys Ser Leu Lys Glu		
165 170 175		
Phe Ser Asp Ile Leu Pro Pro Gly His Phe Thr Cys Lys Pro Ala Leu		
180 185 190		
Ile Arg Lys Ser Gly Pro Arg Trp Val Ile Ala Glu Glu Gly Gly His		
195 200 205		
Ala Val Phe Ser Cys Ser Gly Asp Gly Asp Pro Ala Pro Thr Val Ser		
210 215 220		
Trp Met Arg Pro His Gly Ala Trp Leu Gly Arg Ala Gly Arg Val Arg		
225 230 235 240		
Val Leu Glu Asp Gly Thr Leu Glu Ile Arg Ser Val Gln Leu Arg Asp		
245 250 255		
Arg Gly Ala Tyr Val Cys Val Val Ser Asn Val Ala Gly Asn Asp Ser		
260 265 270		
Leu Arg Thr Trp Leu Glu Val Ile Gln Val Glu Pro Pro Asn Gly Thr		
275 280 285		
Leu Ser Asp Pro Asn Ile Thr Val Pro Gly Ile Pro Gly Pro Phe Phe		
290 295 300		
Leu Asp Ser Arg Gly Val Ala Met Val Leu Ala Val Gly Phe Leu Pro		
305 310 315 320		
Phe Leu Thr Ser Val Thr Leu Cys Phe Gly Leu Ile Ala Leu Trp Ser		
325 330 335		
Lys Gly Lys Gly Arg Val Lys His His Met Thr Phe Asp Phe Val Ala		
340 345 350		

Pro Arg Pro Ser Gly Asp Lys Asn Ser Gly Gly Asn Arg Val Thr Ala
 355 360 365
 Lys Leu Phe
 370

<210> 54
 <211> 592
 <212> PRT
 <213> homo sapiens

<400> 54
 Met Asp Ala Ala Thr Ala Pro Lys Gln Ala Trp Pro Pro Trp Pro Pro
 1 5 10 15
 Leu Leu Phe Leu Leu Leu Pro Gly Gly Ser Gly Gly Ser Cys Pro
 20 25 30
 Ala Val Cys Asp Cys Thr Ser Gln Pro Gln Ala Val Leu Cys Gly His
 35 40 45
 Arg Gln Leu Glu Ala Val Pro Gly Gly Leu Pro Leu Asp Thr Glu Leu
 50 55 60
 Leu Asp Leu Ser Gly Asn Arg Leu Trp Gly Leu Gln Gln Gly Met Leu
 65 70 75 80
 Ser Arg Leu Ser Leu Leu Gln Glu Leu Asp Leu Ser Tyr Asn Gln Leu
 85 90 95
 Ser Thr Leu Glu Pro Gly Ala Phe His Gly Leu Gln Ser Leu Leu Thr
 100 105 110
 Leu Arg Leu Gln Gly Asn Arg Leu Arg Ile Met Gly Pro Gly Val Phe
 115 120 125
 Ser Gly Leu Ser Ala Leu Thr Leu Leu Asp Leu Arg Leu Asn Gln Ile
 130 135 140
 Val Leu Phe Leu Asp Gly Ala Phe Gly Glu Leu Gly Ser Leu Gln Lys
 145 150 155 160
 Leu Glu Val Gly Asp Asn His Leu Val Phe Val Ala Pro Gly Ala Phe
 165 170 175
 Ala Gly Leu Ala Lys Leu Ser Thr Leu Thr Leu Glu Arg Cys Asn Leu
 180 185 190
 Ser Thr Val Pro Gly Leu Ala Leu Ala Arg Leu Pro Ala Leu Val Ala
 195 200 205
 Leu Arg Leu Arg Glu Leu Asp Ile Gly Arg Leu Pro Ala Gly Ala Leu
 210 215 220
 Arg Gly Leu Gly Gln Leu Lys Glu Leu Glu Ile His Leu Trp Pro Ser
 225 230 235 240
 Leu Glu Ala Leu Asp Pro Gly Ser Leu Val Gly Leu Asn Leu Ser Ser
 245 250 255
 Leu Ala Ile Thr Arg Cys Asn Leu Ser Ser Val Pro Phe Gln Ala Leu
 260 265 270
 Tyr His Leu Ser Phe Leu Arg Val Leu Asp Leu Ser Gln Asn Pro Ile
 275 280 285
 Ser Ala Ile Pro Ala Arg Arg Leu Ser Pro Leu Val Arg Leu Gln Glu
 290 295 300
 Leu Arg Leu Ser Gly Ala Cys Leu Thr Ser Ile Ala Ala His Ala Phe
 305 310 315 320
 His Gly Leu Thr Ala Phe His Leu Leu Asp Val Ala Asp Asn Ala Leu
 325 330 335
 Gln Thr Leu Glu Glu Thr Ala Phe Pro Ser Pro Asp Lys Leu Val Thr
 340 345 350
 Leu Arg Leu Ser Gly Asn Pro Leu Thr Cys Asp Cys Arg Leu Leu Trp
 355 360 365
 Leu Leu Arg Leu Arg His Leu Asp Phe Gly Met Ser Pro Pro Ala Cys

370	375	380														
Ala	Gly	Pro	His	His	His	Val	Gln	Gly	Lys	Ser	Leu	Lys	Glu	Phe	Ser	Asp
385						390		395								400
Ile	Leu	Pro	Pro	Gly	His	Phe	Thr	Cys	Lys	Pro	Ala	Leu	Ile	Arg	Lys	
						405		410							415	
Ser	Gly	Pro	Arg	Trp	Val	Ile	Ala	Glu	Glu	Gly	Gly	His	Ala	Val	Phe	
						420		425							430	
Ser	Cys	Ser	Gly	Asp	Gly	Asp	Pro	Ala	Pro	Thr	Val	Ser	Trp	Met	Arg	
						435		440							445	
Pro	His	Gly	Ala	Trp	Leu	Gly	Arg	Ala	Gly	Arg	Val	Arg	Val	Leu	Glu	
						450		455							460	
Asp	Gly	Thr	Leu	Glu	Ile	Arg	Ser	Val	Gln	Leu	Arg	Asp	Arg	Gly	Ala	
						465		470							480	
Tyr	Val	Cys	Val	Val	Ser	Asn	Val	Ala	Gly	Asn	Asp	Ser	Leu	Arg	Thr	
						485		490							495	
Trp	Leu	Glu	Val	Ile	Gln	Val	Glu	Pro	Pro	Asn	Gly	Thr	Leu	Ser	Asp	
						500		505							510	
Pro	Asn	Ile	Thr	Val	Pro	Gly	Ile	Pro	Gly	Pro	Phe	Phe	Leu	Asp	Ser	
						515		520							525	
Arg	Gly	Val	Ala	Met	Val	Leu	Ala	Val	Gly	Phe	Leu	Pro	Phe	Leu	Thr	
						530		535							540	
Ser	Val	Thr	Leu	Cys	Phe	Gly	Leu	Ile	Ala	Leu	Trp	Ser	Lys	Gly	Lys	
						545		550							560	
Gly	Arg	Val	Lys	His	His	Met	Thr	Phe	Asp	Phe	Val	Ala	Pro	Arg	Pro	
						565		570							575	
Ser	Gly	Asp	Lys	Asn	Ser	Gly	Gly	Asn	Arg	Val	Thr	Ala	Lys	Leu	Phe	
						580		585							590	

<210> 55

<211> 142

<212> PRT

<213> homo sapiens

<400> 55

Met	Ala	Arg	Tyr	Met	Leu	Leu	Leu	Leu	Leu	Ala	Val	Trp	Val	Leu	Thr	
1				5					10					15		
Gly	Glu	Leu	Trp	Pro	Gly	Ala	Glu	Ala	Arg	Ala	Ala	Pro	Tyr	Gly	Val	
				20					25					30		
Arg	Leu	Cys	Gly	Arg	Glu	Phe	Ile	Arg	Ala	Val	Ile	Phe	Thr	Cys	Gly	
				35				40						45		
Gly	Ser	Arg	Trp	Arg	Arg	Ser	Asp	Ile	Leu	Ala	His	Glu	Ala	Met	Gly	
				50				55						60		
Asp	Thr	Phe	Pro	Asp	Ala	Asp	Ala	Asp	Glu	Asp	Ser	Leu	Ala	Gly	Glu	
				65				70						75		80
Leu	Asp	Glu	Ala	Met	Gly	Ser	Ser	Glu	Trp	Leu	Ala	Leu	Thr	Lys	Ser	
				85				90						95		
Pro	Gln	Ala	Phe	Tyr	Arg	Gly	Arg	Pro	Ser	Trp	Gln	Gly	Thr	Pro	Gly	
				100				105						110		
Val	Leu	Arg	Gly	Ser	Arg	Asp	Val	Leu	Ala	Gly	Leu	Ser	Ser	Ser	Cys	
				115				120						125		
Cys	Lys	Trp	Gly	Cys	Ser	Lys	Ser	Glu	Ile	Ser	Ser	Ser	Leu	Cys		
				130				135						140		

<210> 56

<211> 230

<212> PRT

<213> homo sapiens

<400> 56
 Met Ser Glu Glu Val Thr Tyr Ala Thr Leu Thr Phe Gln Asp Ser Ala
 1 5 10 15
 Gly Ala Arg Asn Asn Arg Asp Gly Asn Asn Leu Arg Lys Arg Gly His
 20 25 30
 Pro Ala Pro Ser Pro Ile Trp Arg His Ala Ala Leu Gly Leu Val Thr
 35 40 45
 Leu Cys Leu Met Leu Leu Ile Gly Leu Val Thr Leu Gly Met Met Phe
 50 55 60
 Leu Gln Ile Ser Asn Asp Ile Asn Ser Asp Ser Glu Lys Leu Ser Gln
 65 70 75 80
 Leu Gln Lys Thr Ile Gln Gln Gln Asp Asn Leu Ser Gln Gln Leu
 85 90 95
 Gly Asn Ser Asn Asn Leu Ser Met Glu Glu Glu Phe Leu Lys Ser Gln
 100 105 110
 Ile Ser Ser Leu Leu Lys Arg Gln Glu Gln Met Ala Ile Lys Leu Cys
 115 120 125
 Gln Glu Leu Ile Ile His Thr Ser Asp His Arg Cys Asn Pro Cys Pro
 130 135 140
 Lys Met Trp Gln Trp Tyr Gln Asn Ser Cys Tyr Tyr Phe Thr Thr Asn
 145 150 155 160
 Glu Glu Lys Thr Trp Ala Asn Ser Arg Lys Asp Cys Ile Asp Lys Asn
 165 170 175
 Ser Thr Leu Val Lys Ile Asp Ser Leu Glu Glu Lys Asp Phe Leu Met
 180 185 190
 Ser Gln Pro Leu Leu Met Phe Ser Phe Phe Trp Leu Gly Leu Ser Trp
 195 200 205
 Asp Ser Ser Gly Arg Ser Trp Phe Trp Glu Asp Gly Ser Val Pro Ser
 210 215 220
 Pro Ser Leu Tyr Val Ser
 225 230

<210> 57
 <211> 194
 <212> PRT
 <213> homo sapiens

<400> 57
 Met Trp Leu Ser Pro Ala Leu Leu Leu Ile Leu Pro Gly Tyr Ser
 1 5 10 15
 Ile Ala Ala Lys Ile Thr Gly Pro Thr Thr Val Asn Gly Ser Gln
 20 25 30
 Gly Ser Leu Thr Val Gln Cys Ala Tyr Gly Ser Gly Trp Glu Thr Tyr
 35 40 45
 Leu Lys Trp Arg Cys Gln Gly Ala Asp Trp Asn Tyr Cys Asn Ile Leu
 50 55 60
 Val Lys Thr Asn Gly Ser Glu Gln Glu Val Lys Lys Asn Arg Val Ser
 65 70 75 80
 Ile Arg Asp Asn Gln Lys Asn His Met Phe Thr Val Thr Met Glu Asn
 85 90 95
 Leu Lys Arg Asp Asp Ala Asp Ser Tyr Trp Cys Gly Thr Glu Arg Pro
 100 105 110
 Gly Ile Asp Leu Gly Val Lys Val Gln Val Thr Ile Asn Pro Gly Thr
 115 120 125
 Gln Thr Ala Val Ser Glu Trp Thr Thr Thr Ala Ser Leu Ala Phe
 130 135 140
 Thr Ala Ala Ala Thr Gln Lys Thr Ser Ser Pro Leu Thr Arg Ser Pro

145	150	155	160
Leu Lys Ser Thr His Phe Leu Phe Leu Phe Leu Leu Glu Leu Pro Leu			
165	170	175	
Leu Leu Ser Met Leu Gly Thr Val Leu Trp Val Asn Arg Pro Gln Arg			
180	185	190	
Arg Ser			

<210> 58
 <211> 333
 <212> PRT
 <213> homo sapiens

<400> 58			
Met Arg Ile Trp Trp Leu Leu Leu Ala Ile Glu Ile Cys Thr Gly Asn			
1	5	10	15
Ile Asn Ser Gln Asp Thr Cys Arg Gln Gly His Pro Gly Ile Pro Gly			
20	25	30	
Asn Pro Gly His Asn Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Ala			
35	40	45	
Lys Gly Asp Lys Gly Asp Ala Gly Glu Pro Gly Arg Pro Gly Ser Pro			
50	55	60	
Gly Lys Asp Gly Thr Ser Gly Glu Lys Gly Glu Arg Gly Ala Asp Gly			
65	70	75	80
Lys Val Glu Ala Lys Gly Ile Lys Gly Asp Gln Gly Ser Arg Gly Ser			
85	90	95	
Pro Gly Lys His Gly Pro Lys Gly Leu Ala Gly Pro Met Gly Glu Lys			
100	105	110	
Gly Leu Arg Gly Glu Thr Gly Pro Gln Gly Gln Lys Gly Asn Lys Gly			
115	120	125	
Asp Val Gly Pro Thr Gly Pro Glu Gly Pro Arg Gly Asn Ile Gly Pro			
130	135	140	
Leu Gly Pro Thr Gly Leu Pro Gly Pro Met Gly Pro Ile Gly Lys Pro			
145	150	155	160
Gly Pro Lys Gly Glu Ala Gly Pro Thr Gly Pro Gln Gly Glu Pro Gly			
165	170	175	
Val Arg Gly Ile Arg Gly Trp Lys Gly Asp Arg Gly Glu Lys Gly Lys			
180	185	190	
Ile Gly Glu Thr Leu Val Leu Pro Lys Ser Ala Phe Thr Val Gly Leu			
195	200	205	
Thr Val Leu Ser Lys Phe Pro Ser Ser Asp Met Pro Ile Lys Phe Asp			
210	215	220	
Lys Ile Leu Tyr Asn Glu Phe Asn His Tyr Asp Thr Ala Ala Gly Lys			
225	230	235	240
Phe Thr Cys His Ile Ala Gly Val Tyr Tyr Phe Thr Tyr His Ile Thr			
245	250	255	
Val Phe Ser Arg Asn Val Gln Val Ser Leu Val Lys Asn Gly Val Lys			
260	265	270	
Ile Leu His Thr Lys Asp Ala Tyr Met Ser Ser Glu Asp Gln Ala Ser			
275	280	285	
Gly Gly Ile Val Leu Gln Leu Lys Leu Gly Asp Glu Val Trp Leu Gln			
290	295	300	
Val Thr Gly Gly Glu Arg Phe Asn Gly Leu Phe Ala Asp Glu Asp Asp			
305	310	315	320
Asp Thr Thr Phe Thr Gly Phe Leu Leu Phe Ser Ser Pro			
325	330		

<210> 59
 <211> 225
 <212> PRT
 <213> homo sapiens

<400> 59
 Met Arg Ile Trp Trp Leu Leu Leu Ala Ile Glu Ile Cys Thr Gly Asn
 1 5 10 15
 Ile Asn Ser Gln Asp Thr Cys Arg Gln Gly His Pro Gly Ile Pro Gly
 20 25 30
 Asn Pro Gly His Asn Gly Leu Pro. Gly Arg Asp Gly Arg Asp Gly Ala
 35 40 45
 Lys Gly Asp Lys Gly Asp Ala Gly Glu Ala Gly Pro Thr Gly Pro Gln
 50 55 60
 Gly Glu Pro Gly Val Arg Gly Ile Arg Gly Trp Lys Gly Asp Arg Gly
 65 70 75 80
 Glu Lys Gly Lys Ile Gly Glu Thr Leu Val Leu Pro Lys Ser Ala Phe
 85 90 95
 Thr Val Gly Leu Thr Val Leu Ser Lys Phe Pro Ser Ser Asp Met Pro
 100 105 110
 Ile Lys Phe Asp Lys Ile Leu Tyr Asn Glu Phe Asn His Tyr Asp Thr
 115 120 125
 Ala Ala Gly Lys Phe Thr Cys His Ile Ala Gly Val Tyr Tyr Phe Thr
 130 135 140
 Tyr His Ile Thr Val Phe Ser Arg Asn Val Gln Val Ser Leu Val Lys
 145 150 155 160
 Asn Gly Val Lys Ile Leu His Thr Lys Asp Ala Tyr Met Ser Ser Glu
 165 170 175
 Asp Gln Ala Ser Gly Gly Ile Val Leu Gln Leu Lys Leu Gly Asp Glu
 180 185 190
 Val Trp Leu Gln Val Thr Gly Gly Glu Arg Phe Asn Gly Leu Phe Ala
 195 200 205
 Asp Glu Asp Asp Asp Thr Thr Phe Thr Gly Phe Leu Leu Phe Ser Ser
 210 215 220
 Pro
 225

<210> 60
 <211> 205
 <212> PRT
 <213> homo sapiens

<400> 60
 Met Met Arg Thr Leu Ile Thr Thr His Pro Leu Pro Leu Leu Leu
 1 5 10 15
 Pro Gln Gln Leu Leu Gln Leu Val Gln Phe Gln Glu Val Asp Thr Asp
 20 25 30
 Phe Asp Phe Pro Glu Glu Asp Lys Lys Glu Glu Phe Glu Glu Cys Leu
 35 40 45
 Glu Lys Phe Phe Ser Thr Gly Pro Ala Arg Pro Pro Thr Lys Glu Lys
 50 55 60
 Val Lys Arg Arg Val Leu Ile Glu Pro Gly Met Pro Leu Asn His Ile
 65 70 75 80
 Glu Tyr Cys Asn His Glu Ile Met Gly Lys Asn Val Tyr Tyr Lys His
 85 90 95
 Arg Trp Val Ala Glu His Tyr Phe Leu Leu Met Gln Tyr Asp Glu Leu
 100 105 110
 Gln Lys Ile Cys Tyr Asn Arg Phe Val Pro Cys Lys Asn Gly Ile Arg

115	120	125
Lys Cys Asn Arg Ser Lys Gly Leu Val Glu Gly Val Tyr Cys Asn Leu		
130	135	140
Thr Glu Ala Phe Glu Ile Pro Ala Cys Lys Tyr Glu Ser Leu Tyr Arg		
145	150	155
Lys Gly Tyr Val Leu Ile Thr Cys Ser Trp Gln Asn Glu Met Gln Lys		
165	170	175
Arg Ile Pro His Thr Ile Asn Asp Leu Val Glu Pro Pro Glu His Arg		
180	185	190
Ser Phe Leu Ser Glu Asp Gly Val Phe Val Ile Ser Pro		
195	200	205

<210> 61

<211> 95

<212> PRT

<213> homo sapiens

<400> 61

Met Glu Val Val Leu Ile Phe Leu Cys Ser Leu Leu Ala His Ile Val			
1	5	10	15
Leu Ala Asp Ala Val Glu Arg Glu Lys Gln Ile Asp Pro Phe His Tyr			
20	25	30	
Asp Tyr Gln Thr Leu Arg Ile Arg Gly Leu Val Cys Ala Val Val Leu			
35	40	45	
Phe Ser Ile Gly Ile Leu Leu Ile Leu Gly Cys Arg Cys Lys Cys Ser			
50	55	60	
Phe Asn Gln Lys Pro Arg Thr Pro Gly Glu Glu Ala Gln Val Glu			
65	70	75	80
Asn Leu Ile Thr Ala Asn Ala Thr Lys Leu Gln Lys Ala Glu Ser			
85	90	95	

<210> 62

<211> 595

<212> PRT

<213> homo sapiens

<400> 62

Met Glu Val Gly Met Gly Cys Trp Ala Arg Glu Val Leu Val Pro Glu			
1	5	10	15
Gly Pro Leu Tyr Arg Val Ala Gly Thr Ala Val Ser Ile Ser Cys Asn			
20	25	30	
Val Thr Gly Tyr Glu Gly Pro Ala Gln Gln Asn Phe Glu Trp Phe Leu			
35	40	45	
Tyr Arg Pro Glu Ala Pro Asp Thr Ala Leu Gly Ile Val Ser Thr Lys			
50	55	60	
Asp Thr Gln Phe Ser Tyr Ala Val Phe Lys Ser Arg Val Val Ala Gly			
65	70	75	80
Glu Val Gln Val Gln Arg Leu Gln Gly Asp Ala Val Val Leu Lys Ile			
85	90	95	
Ala Arg Leu Gln Ala Gln Asp Ala Gly Ile Tyr Glu Cys His Thr Pro			
100	105	110	
Ser Thr Asp Thr Arg Tyr Leu Gly Ser Tyr Ser Gly Lys Val Glu Leu			
115	120	125	
Arg Val Leu Pro Asp Val Leu Gln Val Ser Ala Ala Pro Pro Gly Pro			
130	135	140	
Arg Gly Arg Gln Ala Pro Thr Ser Pro Pro Arg Met Thr Val His Glu			
145	150	155	160

Gly Gln Glu Leu Ala Leu Gly Cys Leu Ala Arg Thr Ser Thr Gln Lys
 165 170 175
 His Thr His Leu Ala Val Ser Phe Gly Arg Ser Val Pro Glu Ala Pro
 180 185 190
 Val Gly Arg Ser Thr Leu Gln Glu Val Val Gly Ile Arg Ser Asp Leu
 195 200 205
 Ala Val Glu Ala Gly Ala Pro Tyr Ala Glu Arg Leu Ala Ala Gly Glu
 210 215 220
 Leu Arg Leu Gly Lys Glu Gly Thr Asp Arg Tyr Arg Met Val Val Gly
 225 230 235 240
 Gly Ala Gln Ala Gly Asp Ala Gly Thr Tyr His Cys Thr Ala Ala Glu
 245 250 255
 Trp Ile Gln Asp Pro Asp Gly Ser Trp Ala Gln Ile Ala Glu Lys Arg
 260 265 270
 Ala Val Leu Ala His Val Asp Val Gln Thr Leu Ser Ser Gln Leu Ala
 275 280 285
 Val Thr Val Gly Pro Gly Glu Arg Arg Ile Gly Pro Gly Glu Pro Leu
 290 295 300
 Glu Leu Leu Cys Asn Val Ser Gly Ala Leu Pro Pro Ala Gly Arg His
 305 310 315 320
 Ala Ala Tyr Ser Val Gly Trp Glu Met Ala Pro Ala Gly His Leu Gly
 325 330 335
 Pro Gly Arg Leu Val Ala Gln Leu Asp Thr Glu Gly Val Gly Ser Leu
 340 345 350
 Gly Pro Gly Tyr Glu Gly Arg His Ile Ala Met Glu Lys Val Ala Ser
 355 360 365
 Arg Thr Tyr Arg Leu Arg Leu Glu Ala Ala Arg Pro Gly Asp Ala Gly
 370 375 380
 Thr Tyr Arg Cys Leu Ala Lys Ala Tyr Val Arg Gly Ser Gly Thr Arg
 385 390 395 400
 Leu Arg Glu Ala Ala Ser Ala Arg Ser Arg Pro Leu Pro Val His Val
 405 410 415
 Arg Glu Glu Gly Val Val Leu Glu Ala Val Ala Trp Leu Ala Gly Gly
 420 425 430
 Thr Val Tyr Arg Gly Glu Thr Ala Ser Leu Leu Cys Asn Ile Ser Val
 435 440 445
 Arg Gly Gly Pro Pro Gly Leu Arg Leu Ala Ala Ser Trp Trp Val Glu
 450 455 460
 Arg Pro Glu Asp Gly Glu Leu Ser Ser Val Pro Ala Gln Leu Val Gly
 465 470 475 480
 Gly Val Gly Gln Asp Gly Val Ala Glu Leu Gly Val Arg Pro Gly Gly
 485 490 495
 Gly Pro Val Ser Val Glu Leu Val Gly Pro Arg Ser His Arg Leu Arg
 500 505 510
 Leu His Ser Leu Gly Pro Glu Asp Glu Gly Val Tyr His Cys Ala Pro
 515 520 525
 Ser Ala Trp Val Gln His Ala Asp Tyr Ser Trp Tyr Gln Ala Gly Ser
 530 535 540
 Ala Arg Ser Gly Pro Val Thr Val Tyr Pro Tyr Met His Ala Leu Asp
 545 550 555 560
 Thr Leu Phe Val Pro Leu Leu Val Gly Thr Gly Val Ala Leu Val Thr
 565 570 575
 Gly Ala Thr Val Leu Gly Thr Ile Thr Cys Cys Phe Met Lys Arg Leu
 580 585 590
 Arg Lys Arg
 595

<211> 613
 <212> PRT
 <213> homo sapiens

<400> 63

Met Gly Ala Leu Arg Pro Thr Leu Leu Pro Pro Ser Leu Pro Leu Leu
 1 5 10 15
 Leu Leu Leu Met Leu Gly Met Gly Cys Trp Ala Arg Glu Val Leu Val
 20 25 30 35
 Pro Glu Gly Pro Leu Tyr Arg Val Ala Gly Thr Ala Val Ser Ile Ser
 35 40 45
 Cys Asn Val Thr Gly Tyr Glu Gly Pro Ala Gln Gln Asn Phe Glu Trp
 50 55 60
 Phe Leu Tyr Arg Pro Glu Ala Pro Asp Thr Ala Leu Gly Ile Val Ser
 65 70 75 80
 Thr Lys Asp Thr Gln Phe Ser Tyr Ala Val Phe Lys Ser Arg Val Val
 85 90 95
 Ala Gly Glu Val Gln Val Gln Arg Leu Gln Gly Asp Ala Val Val Leu
 100 105 110
 Lys Ile Ala Arg Leu Gln Ala Gln Asp Ala Gly Ile Tyr Glu Cys His
 115 120 125
 Thr Pro Ser Thr Asp Thr Arg Tyr Leu Gly Ser Tyr Ser Gly Lys Val
 130 135 140
 Glu Leu Arg Val Leu Pro Asp Val Leu Gln Val Ser Ala Ala Pro Pro
 145 150 155 160
 Gly Pro Arg Gly Arg Gln Ala Pro Thr Ser Pro Pro Arg Met Thr Val
 165 170 175
 His Glu Gly Gln Glu Leu Ala Leu Gly Cys Leu Ala Arg Thr Ser Thr
 180 185 190
 Gln Lys His Thr His Leu Ala Val Ser Phe Gly Arg Ser Val Pro Glu
 195 200 205
 Ala Pro Val Gly Arg Ser Thr Leu Gln Glu Val Val Gly Ile Arg Ser
 210 215 220
 Asp Leu Ala Val Glu Ala Gly Ala Pro Tyr Ala Glu Arg Leu Ala Ala
 225 230 235 240
 Gly Glu Leu Arg Leu Gly Lys Glu Gly Thr Asp Arg Tyr Arg Met Val
 245 250 255
 Val Gly Gly Ala Gln Ala Gly Asp Ala Gly Thr Tyr His Cys Thr Ala
 260 265 270
 Ala Glu Trp Ile Gln Asp Pro Asp Gly Ser Trp Ala Gln Ile Ala Glu
 275 280 285
 Lys Arg Ala Val Leu Ala His Val Asp Val Gln Thr Leu Ser Ser Gln
 290 295 300
 Leu Ala Val Thr Val Gly Pro Gly Glu Arg Arg Ile Gly Pro Gly Glu
 305 310 315 320
 Pro Leu Glu Leu Leu Cys Asn Val Ser Gly Ala Leu Pro Pro Ala Gly
 325 330 335
 Arg His Ala Ala Tyr Ser Val Gly Trp Glu Met Ala Pro Ala Gly Ala
 340 345 350
 Pro Gly Pro Gly Arg Leu Val Ala Gln Leu Asp Thr Glu Gly Val Gly
 355 360 365
 Ser Leu Gly Pro Gly Tyr Glu Gly Arg His Ile Ala Met Glu Lys Val
 370 375 380
 Ala Ser Arg Thr Tyr Arg Leu Arg Leu Glu Ala Ala Arg Pro Gly Asp
 385 390 395 400
 Ala Gly Thr Tyr Arg Cys Leu Ala Lys Ala Tyr Val Arg Gly Ser Gly
 405 410 415
 Thr Arg Leu Arg Glu Ala Ala Ser Ala Arg Ser Arg Pro Leu Pro Val
 420 425 430

His Val Arg Glu Glu Gly Val Val Leu Glu Ala Val Ala Trp Leu Ala
 435 440 445
 Gly Gly Thr Val Tyr Arg Gly Glu Thr Ala Ser Leu Leu Cys Asn Ile
 450 455 460
 Ser Val Arg Gly Gly Pro Pro Gly Leu Arg Leu Ala Ala Ser Trp Trp
 465 470 475 480
 Val Glu Arg Pro Glu Asp Gly Glu Leu Ser Ser Val Pro Ala Gln Leu
 485 490 495
 Val Gly Gly Val Gly Gln Asp Gly Val Ala Glu Leu Gly Val Arg Pro
 500 505 510
 Gly Gly Pro Val Ser Val Glu Leu Val Gly Pro Arg Ser His Arg
 515 520 525
 Leu Arg Leu His Ser Leu Gly Pro Glu Asp Glu Gly Val Tyr His Cys
 530 535 540
 Ala Pro Ser Ala Trp Val Gln His Ala Asp Tyr Ser Trp Tyr Gln Ala
 545 550 555 560
 Gly Ser Ala Arg Ser Gly Pro Val Thr Val Tyr Pro Tyr Met His Ala
 565 570 575
 Leu Asp Thr Leu Phe Val Pro Leu Leu Val Gly Thr Gly Val Ala Leu
 580 585 590
 Val Thr Gly Ala Thr Val Leu Gly Thr Ile Thr Cys Cys Phe Met Lys
 595 600 605
 Arg Leu Arg Lys Arg
 610

<210> 64
 <211> 596
 <212> PRT
 <213> homo sapiens

<400> 64
 Met Ala Ala Asn Ser Thr Ser Asp Leu His Thr Pro Gly Thr Gln Leu
 1 5 10 15
 Ser Val Ala Asp Ile Ile Val Ile Thr Val Tyr Phe Ala Leu Asn Val
 20 25 30
 Ala Val Gly Ile Trp Ser Ser Cys Arg Ala Ser Arg Asn Thr Val Asn
 35 40 45
 Gly Tyr Phe Leu Ala Gly Arg Asp Met Thr Trp Trp Pro Ile Gly Ala
 50 55 60
 Ser Leu Phe Ala Ser Ser Glu Gly Ser Gly Leu Phe Ile Gly Leu Ala
 65 70 75 80
 Gly Ser Gly Ala Ala Gly Gly Leu Ala Val Ala Gly Phe Glu Trp Asn
 85 90 95
 Ala Thr Tyr Val Leu Leu Ala Leu Ala Trp Val Phe Val Pro Ile Tyr
 100 105 110
 Ile Ser Ser Glu Ile Val Thr Leu Pro Glu Tyr Ile Gln Lys Arg Tyr
 115 120 125
 Gly Gly Gln Arg Ile Arg Met Tyr Leu Ser Val Leu Ser Leu Leu
 130 135 140
 Ser Val Phe Thr Lys Ile Ser Leu Asp Leu Tyr Ala Gly Ala Leu Phe
 145 150 155 160
 Val His Ile Cys Leu Gly Trp Asn Phe Tyr Leu Ser Thr Ile Leu Thr
 165 170 175
 Leu Gly Ile Thr Ala Leu Tyr Thr Ile Ala Gly Gly Leu Ala Ala Val
 180 185 190
 Ile Tyr Thr Asp Ala Leu Gln Thr Leu Ile Met Val Val Gly Ala Val
 195 200 205
 Ile Leu Thr Ile Lys Ala Phe Asp Gln Ile Gly Gly Tyr Gly Gln Leu

210	215	220
Glu Ala Ala Tyr Ala Gln Ala Ile Pro Ser Arg Thr Ile Ala Asn Thr		
225	230	235
Thr Cys His Leu Pro Arg Thr Asp Ala Met His Met Phe Arg Asp Pro		240
245	250	255
His Thr Gly Asp Leu Pro Trp Thr Gly Met Thr Phe Gly Leu Thr Ile		
260	265	270
Met Ala Thr Trp Tyr Trp Cys Thr Asp Gln Val Ile Val Gln Arg Ser		
275	280	285
Leu Ser Ala Arg Asp Leu Asn His Ala Lys Ala Gly Ser Ile Leu Ala		
290	295	300
Ser Tyr Leu Lys Met Leu Pro Met Gly Leu Ile Ile Met Pro Gly Met		
305	310	315
Ile Ser Arg Ala Leu Phe Pro Asp Asp Val Gly Cys Val Val Pro Ser		320
325	330	335
Glu Cys Leu Arg Ala Cys Gly Ala Glu Val Gly Cys Ser Asn Ile Ala		
340	345	350
Tyr Pro Lys Leu Val Met Glu Leu Met Pro Ile Gly Leu Arg Gly Leu		
355	360	365
Met Ile Ala Val Met Leu Ala Ala Leu Met Ser Ser Leu Thr Ser Ile		
370	375	380
Phe Asn Ser Ser Ser Thr Leu Phe Thr Met Asp Ile Trp Arg Arg Leu		
385	390	395
Arg Pro Arg Ser Gly Glu Arg Glu Leu Leu Leu Val Gly Arg Leu Val		400
405	410	415
Ile Val Ala Leu Ile Gly Val Ser Val Ala Trp Ile Pro Val Leu Gln		
420	425	430
Asp Ser Asn Ser Gly Gln Leu Phe Ile Tyr Met Gln Ser Val Thr Ser		
435	440	445
Ser Leu Ala Pro Pro Val Thr Ala Val Phe Val Leu Gly Val Phe Trp		
450	455	460
Arg Arg Ala Asn Glu Gln Gly Ala Phe Trp Gly Leu Ile Ala Gly Leu		
465	470	475
Val Val Gly Ala Thr Arg Leu Val Leu Glu Phe Leu Asn Pro Ala Pro		480
485	490	495
Pro Cys Gly Glu Pro Asp Thr Arg Pro Ala Val Leu Gly Ser Ile His		
500	505	510
Tyr Leu His Phe Ala Val Ala Leu Phe Ala Leu Ser Gly Ala Val Val		
515	520	525
Val Ala Gly Ser Leu Leu Thr Pro Pro Pro Gln Ser Val Gln Ile Glu		
530	535	540
Asn Leu Thr Trp Trp Thr Leu Ala Gln Asp Val Pro Leu Gly Thr Lys		
545	550	555
Ala Gly Asp Gly Gln Thr Pro Gln Lys His Ala Phe Trp Ala Arg Val		560
565	570	575
Cys Gly Phe Asn Ala Ile Leu Leu Met Cys Val Asn Ile Phe Phe Tyr		
580	585	590
Ala Tyr Phe Ala		
595		

<210> 65
 <211> 393
 <212> PRT
 <213> homo sapiens

<400> 65
 Met Asp Ser Leu Lys Asn Glu Asn Tyr Asp Leu Val Phe Val Glu Ala
 1 5 10 15

Phe Asp Phe Cys Ser Phe Leu Ile Ala Glu Leu Val Lys Pro Phe
 20 25 30
 Val Ala Ile Leu Pro Thr Thr Phe Gly Ser Leu Asp Phe Gly Leu Pro
 35 40 45
 Ser Pro Leu Ser Tyr Val Pro Val Phe Pro Ser Leu Leu Thr Asp His
 50 55 60
 Met Asp Phe Trp Gly Arg Val Lys Asn Phe Leu Met Phe Phe Ser Phe
 65 70 75 80
 Ser Arg Ser Gln Trp Asp Met Gln Ser Thr Phe Asp Asn Thr Ile Lys
 85 90 95
 Glu His Phe Pro Glu Gly Ser Arg Pro Val Leu Ser His Leu Leu Leu
 100 105 110
 Lys Ala Glu Leu Trp Phe Val Asn Ser Asp Phe Ala Phe Asp Phe Ala
 115 120 125
 Arg Pro Leu Leu Pro Asn Thr Val Tyr Ile Gly Gly Leu Met Glu Lys
 130 135 140
 Pro Ile Lys Pro Val Pro Gln Asp Leu Asp Asn Phe Ile Ala Asn Phe
 145 150 155 160
 Gly Asp Ala Gly Phe Val Leu Val Ala Phe Gly Ser Met Leu Asn Thr
 165 170 175
 His Gln Ser Gln Glu Val Leu Lys Lys Met His Asn Ala Phe Ala His
 180 185 190
 Leu Pro Gln Gly Val Ile Trp Thr Cys Gln Ser Ser His Trp Pro Arg
 195 200 205
 Asp Val His Leu Ala Thr Asn Val Lys Ile Val Asp Trp Leu Pro Gln
 210 215 220
 Ser Asp Leu Leu Ala His Pro Ser Ile Arg Leu Phe Val Thr His Gly
 225 230 235 240
 Gly Gln Asn Ser Val Met Glu Ala Ile Arg His Gly Val Pro Met Val
 245 250 255
 Gly Leu Pro Val Asn Gly Asp Gln His Gly Asn Met Val Arg Val Val
 260 265 270
 Ala Lys Asn Tyr Gly Val Ser Ile Arg Leu Asn Gln Val Thr Ala Asp
 275 280 285
 Thr Leu Thr Leu Thr Met Lys Gln Val Ile Glu Asp Lys Arg Tyr Lys
 290 295 300
 Ser Ala Val Val Ala Ala Ser Val Ile Leu His Ser Gln Pro Leu Ser
 305 310 315 320
 Pro Ala Gln Arg Leu Val Gly Trp Ile Asp His Ile Leu Gln Thr Gly
 325 330 335
 Gly Ala Thr His Leu Lys Pro Tyr Ala Phe Gln Gln Pro Trp His Glu
 340 345 350
 Gln Tyr Leu Ile Asp Val Phe Val Phe Leu Leu Gly Leu Thr Leu Gly
 355 360 365
 Thr Met Trp Leu Cys Gly Lys Leu Leu Gly Val Val Ala Arg Trp Leu
 370 375 380
 Arg Gly Ala Arg Lys Val Lys Lys Thr
 385 390

<210> 66
 <211> 523
 <212> PRT
 <213> homo sapiens

<400> 66
 Met Val Gly Gln Arg Val Leu Leu Leu Val Ala Phe Leu Leu Ser Gly
 1 5 10 15
 Val Leu Leu Ser Glu Ala Ala Lys Ile Leu Thr Ile Ser Thr Leu Gly

20	25	30
Gly Ser His Tyr Leu Leu Leu Asp Arg Val Ser Gln Ile Leu Gln Glu		
35	40	45
His Gly His Asn Val Thr Met Leu His Gln Ser Gly Lys Phe Leu Ile		
50	55	60
Pro Asp Ile Lys Glu Glu Lys Ser Tyr Gln Val Ile Arg Trp Phe		
65	70	75
Ser Pro Glu Asp His Gln Lys Arg Ile Lys Lys His Phe Asp Ser Tyr		80
85	90	95
Ile Glu Thr Ala Leu Asp Gly Arg Lys Glu Ser Glu Ala Leu Val Lys		
100	105	110
Leu Met Glu Ile Phe Gly Thr Gln Cys Ser Tyr Leu Leu Ser Arg Lys		
115	120	125
Asp Ile Met Asp Ser Leu Lys Asn Glu Asn Tyr Asp Leu Val Phe Val		
130	135	140
Glu Ala Phe Asp Phe Cys Ser Phe Leu Ile Ala Glu Lys Leu Val Lys		
145	150	155
Pro Phe Val Ala Ile Leu Pro Thr Thr Phe Gly Ser Leu Asp Phe Gly		160
165	170	175
Leu Pro Ser Pro Leu Ser Tyr Val Pro Val Phe Pro Ser Leu Leu Thr		
180	185	190
Asp His Met Asp Phe Trp Gly Arg Val Lys Asn Phe Leu Met Phe Phe		
195	200	205
Ser Phe Ser Arg Ser Gln Trp Asp Met Gln Ser Thr Phe Asp Asn Thr		
210	215	220
Ile Lys Glu His Phe Pro Glu Gly Ser Arg Pro Val Leu Ser His Leu		
225	230	235
Leu Leu Lys Ala Glu Leu Trp Phe Val Asn Ser Asp Phe Ala Phe Asp		240
245	250	255
Phe Ala Arg Pro Leu Leu Pro Asn Thr Val Tyr Ile Gly Gly Leu Met		
260	265	270
Glu Lys Pro Ile Lys Pro Val Pro Gln Asp Leu Asp Asn Phe Ile Ala		
275	280	285
Asn Phe Gly Asp Ala Gly Phe Val Leu Val Ala Phe Gly Ser Met Leu		
290	295	300
Asn Thr His Gln Ser Gln Glu Val Leu Lys Lys Met His Asn Ala Phe		
305	310	315
Ala His Leu Pro Gln Gly Val Ile Trp Thr Cys Gln Ser Ser His Trp		320
325	330	335
Pro Arg Asp Val His Leu Ala Thr Asn Val Lys Ile Val Asp Trp Leu		
340	345	350
Pro Gln Ser Asp Leu Leu Ala His Pro Ser Ile Arg Leu Phe Val Thr		
355	360	365
His Gly Gly Gln Asn Ser Val Met Glu Ala Ile Arg His Gly Val Pro		
370	375	380
Met Val Gly Leu Pro Val Asn Gly Asp Gln His Gly Asn Met Val Arg		
385	390	395
Val Val Ala Lys Asn Tyr Gly Val Ser Ile Arg Leu Asn Gln Val Thr		400
405	410	415
Ala Asp Thr Leu Thr Leu Thr Met Lys Gln Val Ile Glu Asp Lys Arg		
420	425	430
Tyr Lys Ser Ala Val Val Ala Ala Ser Val Ile Leu His Ser Gln Pro		
435	440	445
Leu Ser Pro Ala Gln Arg Leu Val Gly Trp Ile Asp His Ile Leu Gln		
450	455	460
Thr Gly Gly Ala Thr His Leu Lys Pro Tyr Ala Phe Gln Gln Pro Trp		
465	470	475
His Glu Gln Tyr Leu Ile Asp Val Phe Val Phe Leu Leu Gly Leu Thr		480
485	490	495

Leu Gly Thr Met Trp Leu Cys Gly Lys Leu Leu Gly Val Val Ala Arg
 500 505 510
 Trp Leu Arg Gly Ala Arg Lys Val Lys Lys Thr
 515 520

<210> 67
 <211> 252
 <212> PRT
 <213> homo sapiens

<400> 67
 Met Ser Cys Val Leu Gly Gly Val Ile Pro Leu Gly Leu Leu Phe Leu
 1 5 10 15
 Val Cys Gly Ser Gln Gly Tyr Leu Leu Pro Asn Val Thr Leu Leu Glu
 20 25 30
 Glu Leu Leu Ser Lys Tyr Gln His Asn Glu Ser His Ser Arg Val Arg
 35 40 45
 Arg Ala Ile Pro Arg Glu Asp Lys Glu Glu Ile Leu Met Leu His Asn
 50 55 60
 Lys Leu Arg Gly Gln Val Gln Pro Gln Ala Ser Asn Met Glu Tyr Met
 65 70 75 80
 Thr Trp Asp Asp Glu Leu Glu Lys Ser Ala Ala Ala Trp Ala Ser Gln
 85 90 95
 Cys Ile Trp Glu His Gly Pro Thr Ser Leu Leu Val Ser Ile Gly Gln
 100 105 110
 Asn Leu Gly Ala His Trp Gly Arg Tyr Arg Ser Pro Gly Phe His Val
 115 120 125
 Gln Ser Trp Tyr Asp Glu Val Lys Asp Tyr Thr Tyr Pro Tyr Pro Ser
 130 135 140
 Glu Cys Asn Pro Trp Cys Pro Glu Arg Cys Ser Gly Pro Met Cys Thr
 145 150 155 160
 His Tyr Thr Gln Ile Val Trp Ala Thr Thr Asn Lys Ile Gly Cys Ala
 165 170 175
 Val Asn Thr Cys Arg Lys Met Thr Val Trp Gly Glu Val Trp Glu Asn
 180 185 190
 Ala Val Tyr Phe Val Cys Asn Tyr Ser Pro Lys Gly Asn Trp Ile Gly
 195 200 205
 Glu Ala Pro Tyr Lys Asn Gly Arg Pro Cys Ser Glu Cys Pro Pro Ser
 210 215 220
 Tyr Gly Gly Ser Cys Arg Asn Asn Leu Cys Tyr Arg Gly Arg Lys Phe
 225 230 235 240
 Thr Pro Asn Thr Phe Ala Met Asn Leu Pro Ser Val
 245 250

<210> 68
 <211> 497
 <212> PRT
 <213> homo sapiens

<400> 68
 Met Ser Cys Val Leu Gly Gly Val Ile Pro Leu Gly Leu Leu Phe Leu
 1 5 10 15
 Val Cys Gly Ser Gln Gly Tyr Leu Leu Pro Asn Val Thr Leu Leu Glu
 20 25 30
 Glu Leu Leu Ser Lys Tyr Gln His Asn Glu Ser His Ser Arg Val Arg
 35 40 45
 Arg Ala Ile Pro Arg Glu Asp Lys Glu Glu Ile Leu Met Leu His Asn

50	55	60													
Lys	Leu	Arg	Gly	Gln	Val	Gln	Pro	Gln	Ala	Ser	Asn	Met	Glu	Tyr	Met
65	70	75	80												
Thr	Trp	Asp	Asp	Glu	Leu	Glu	Lys	Ser	Ala	Ala	Ala	Trp	Ala	Ser	Gln
85	90	95													
Cys	Ile	Trp	Glu	His	Gly	Pro	Thr	Ser	Leu	Leu	Val	Ser	Ile	Gly	Gln
100	105	110													
Asn	Leu	Gly	Ala	His	Trp	Gly	Arg	Tyr	Arg	Ser	Pro	Gly	Phe	His	Val
115	120	125													
Gln	Ser	Trp	Tyr	Asp	Glu	Val	Lys	Asp	Tyr	Thr	Tyr	Pro	Tyr	Pro	Ser
130	135	140													
Glu	Cys	Asn	Pro	Trp	Cys	Pro	Glu	Arg	Cys	Ser	Gly	Pro	Met	Cys	Thr
145	150	155	160												
His	Tyr	Thr	Gln	Ile	Val	Trp	Ala	Thr	Thr	Asn	Lys	Ile	Gly	Cys	Ala
165	170	175													
Val	Asn	Thr	Cys	Arg	Lys	Met	Thr	Val	Trp	Gly	Glu	Val	Trp	Glu	Asn
180	185	190													
Ala	Val	Tyr	Phe	Val	Cys	Asn	Tyr	Ser	Pro	Lys	Gly	Asn	Trp	Ile	Gly
195	200	205													
Glu	Ala	Pro	Tyr	Lys	Asn	Gly	Arg	Pro	Cys	Ser	Glu	Cys	Pro	Pro	Ser
210	215	220													
Tyr	Gly	Gly	Ser	Cys	Arg	Asn	Asn	Leu	Cys	Tyr	Arg	Glu	Glu	Thr	Tyr
225	230	235	240												
Thr	Pro	Lys	Pro	Glu	Thr	Asp	Glu	Met	Asn	Glu	Val	Glu	Thr	Ala	Pro
245	250	255													
Ile	Pro	Glu	Glu	Asn	His	Val	Trp	Leu	Gln	Pro	Arg	Val	Met	Arg	Pro
260	265	270													
Thr	Lys	Pro	Lys	Lys	Thr	Ser	Ala	Val	Asn	Tyr	Met	Thr	Gln	Val	Val
275	280	285													
Arg	Cys	Asp	Thr	Lys	Met	Lys	Asp	Arg	Cys	Lys	Gly	Ser	Thr	Cys	Asn
290	295	300													
Arg	Tyr	Gln	Cys	Pro	Ala	Gly	Cys	Leu	Asn	His	Lys	Ala	Lys	Ile	Phe
305	310	315	320												
Gly	Thr	Leu	Phe	Tyr	Glu	Ser	Ser	Ser	Ile	Cys	Arg	Ala	Ala	Ile	
325	330	335													
His	Tyr	Gly	Ile	Leu	Asp	Asp	Lys	Gly	Gly	Leu	Val	Asp	Ile	Thr	Arg
340	345	350													
Asn	Gly	Lys	Val	Pro	Phe	Phe	Val	Lys	Ser	Glu	Arg	His	Gly	Val	Gln
355	360	365													
Ser	Leu	Ser	Lys	Tyr	Lys	Pro	Ser	Ser	Ser	Phe	Met	Val	Ser	Lys	Val
370	375	380													
Lys	Val	Gln	Asp	Leu	Asp	Cys	Tyr	Thr	Val	Ala	Gln	Leu	Cys	Pro	
385	390	395	400												
Phe	Glu	Lys	Pro	Ala	Thr	His	Cys	Pro	Arg	Ile	His	Cys	Pro	Ala	His
405	410	415													
Cys	Lys	Asp	Glu	Pro	Ser	Tyr	Trp	Ala	Pro	Val	Phe	Gly	Thr	Asn	Ile
420	425	430													
Tyr	Ala	Asp	Thr	Ser	Ser	Ile	Cys	Lys	Thr	Ala	Val	His	Ala	Gly	Val
435	440	445													
Ile	Ser	Asn	Glu	Ser	Gly	Gly	Asp	Val	Asp	Val	Met	Pro	Val	Asp	Lys
450	455	460													
Lys	Lys	Thr	Tyr	Val	Gly	Ser	Leu	Arg	Asn	Gly	Val	Gln	Ser	Glu	Ser
465	470	475	480												
Leu	Gly	Thr	Pro	Arg	Asp	Gly	Lys	Ala	Phe	Arg	Ile	Phe	Ala	Val	Arg
485	490	495													
Gln															

<210> 69
 <211> 438
 <212> PRT
 <213> homo sapiens

<400> 69
 Asx Met Leu His Asn Lys Leu Arg Gly Gln Val Gln Pro Gln Ala Ser
 1 5 10 15
 Asn Met Glu Tyr Met Thr Trp Asp Asp Glu Leu Glu Lys Ser Ala Ala
 20 25 30
 Ala Trp Ala Ser Gln Cys Ile Trp Glu His Gly Pro Thr Ser Leu Leu
 35 40 45
 Val Ser Ile Gly Gln Asn Leu Gly Ala His Trp Gly Arg Tyr Arg Ser
 50 55 60
 Pro Gly Phe His Val Gln Ser Trp Tyr Asp Glu Val Lys Asp Tyr Thr
 65 70 75 80
 Tyr Pro Tyr Pro Ser Glu Cys Asn Pro Trp Cys Pro Glu Arg Cys Ser
 85 90 95
 Gly Pro Met Cys Thr His Tyr Thr Gln Ile Val Trp Ala Thr Thr Asn
 100 105 110
 Lys Ile Gly Cys Ala Val Asn Thr Cys Arg Lys Met Thr Val Trp Gly
 115 120 125
 Glu Val Trp Glu Asn Ala Val Tyr Phe Val Cys Asn Tyr Ser Pro Lys
 130 135 140
 Gly Asn Trp Ile Gly Glu Ala Pro Tyr Lys Asn Gly Arg Pro Cys Ser
 145 150 155 160
 Glu Cys Pro Pro Ser Tyr Gly Gly Ser Cys Arg Asn Asn Leu Cys Tyr
 165 170 175
 Arg Glu Glu Thr Tyr Thr Pro Lys Pro Glu Thr Asp Glu Met Asn Glu
 180 185 190
 Val Glu Thr Ala Pro Ile Pro Glu Glu Asn His Val Trp Leu Gln Pro
 195 200 205
 Arg Val Met Arg Pro Thr Lys Pro Lys Lys Thr Ser Ala Val Asn Tyr
 210 215 220
 Met Thr Gln Val Val Arg Cys Asp Thr Lys Met Lys Asp Arg Cys Lys
 225 230 235 240
 Gly Ser Thr Cys Asn Arg Tyr Gln Cys Pro Ala Gly Cys Leu Asn His
 245 250 255
 Lys Ala Lys Ile Phe Gly Thr Leu Phe Tyr Glu Ser Ser Ser Ser Ile
 260 265 270
 Cys Arg Ala Ala Ile His Tyr Gly Ile Leu Asp Asp Lys Gly Gly Leu
 275 280 285
 Val Asp Ile Thr Arg Asn Gly Lys Val Pro Phe Phe Val Lys Ser Glu
 290 295 300
 Arg His Gly Val Gln Ser Leu Ser Lys Tyr Lys Pro Ser Ser Ser Phe
 305 310 315 320
 Met Val Ser Lys Val Lys Val Gln Asp Leu Asp Cys Tyr Thr Val
 325 330 335
 Ala Gln Leu Cys Pro Phe Glu Lys Pro Ala Thr His Cys Pro Arg Ile
 340 345 350
 His Cys Pro Ala His Cys Lys Asp Glu Pro Ser Tyr Trp Ala Pro Val
 355 360 365
 Phe Gly Thr Asn Ile Tyr Ala Asp Thr Ser Ser Ile Cys Lys Thr Ala
 370 375 380
 Val His Ala Gly Val Ile Ser Asn Glu Ser Gly Gly Asp Val Asp Val
 385 390 395 400
 Met Pro Val Asp Lys Lys Lys Thr Tyr Val Gly Ser Leu Arg Asn Gly
 405 410 415
 Val Gln Ser Glu Ser Leu Gly Thr Pro Arg Asp Gly Lys Ala Phe Arg

Ile Phe Ala Val Arg Gln	420 425	430
	435	

<210> 70
 <211> 308
 <212> PRT
 <213> homo sapiens

<400> 70
 Met Val Gly Gly Val Leu Ala Ser Leu Gly Phe Val Phe Ser Ala Phe
 1 5 10 15
 Ala Ser Asp Leu Leu His Leu Tyr Leu Gly Leu Gly Leu Leu Ala Gly
 20 25 30
 Phe Gly Trp Ala Leu Val Phe Ala Pro Ala Leu Gly Thr Leu Ser Arg
 35 40 45
 Tyr Phe Ser Arg Arg Arg Val Leu Ala Val Gly Leu Ala Leu Thr Gly
 50 55 60
 Asn Gly Ala Ser Ser Leu Leu Leu Ala Pro Ala Leu Gln Leu Leu Leu
 65 70 75 80
 Asp Thr Phe Gly Trp Arg Gly Ala Leu Leu Leu Gly Ala Ile Thr
 85 90 95
 Leu His Leu Thr Pro Cys Gly Ala Leu Leu Leu Pro Leu Val Leu Pro
 100 105 110
 Gly Asp Pro Pro Ala Pro Pro Arg Ser Pro Leu Ala Ala Leu Gly Leu
 115 120 125
 Ser Leu Phe Thr Arg Arg Ala Phe Ser Ile Phe Ala Leu Gly Thr Ala
 130 135 140
 Leu Val Gly Gly Tyr Phe Val Pro Tyr Val His Leu Ala Pro His
 145 150 155 160
 Ala Leu Asp Arg Gly Leu Gly Gly Tyr Gly Ala Ala Leu Val Val Ala
 165 170 175
 Val Ala Ala Met Gly Asp Ala Gly Ala Arg Leu Val Cys Gly Trp Leu
 180 185 190
 Ala Asp Gln Gly Trp Val Pro Leu Pro Arg Leu Leu Ala Val Phe Gly
 195 200 205
 Ala Leu Thr Gly Leu Gly Leu Trp Val Val Gly Leu Val Pro Val Val
 210 215 220
 Gly Gly Glu Glu Ser Trp Gly Gly Pro Leu Leu Ala Ala Ala Val Ala
 225 230 235 240
 Tyr Gly Leu Ser Ala Gly Ser Tyr Ala Pro Leu Val Phe Gly Val Leu
 245 250 255
 Pro Gly Leu Val Gly Val Gly Val Val Gln Ala Thr Gly Leu Val
 260 265 270
 Met Met Leu Met Ser Leu Gly Gly Leu Leu Gly Pro Pro Leu Ser Gly
 275 280 285
 Lys Asp Leu Ser Ser Gln Ile Cys Leu Gln Leu Ser Ser Ala Pro Gly
 290 295 300
 Val Arg Gly Phe
 305

<210> 71
 <211> 447
 <212> PRT
 <213> homo sapiens

<400> 71

Met Thr Pro Gln Pro Ala Gly Pro Pro Asp Gly Gly Trp Gly Trp Val
 1 5 10 15
 Val Ala Ala Ala Ala Phe Ala Ile Asn Gly Leu Ser Tyr Gly Leu Leu
 20 25 30
 Arg Ser Leu Gly Leu Ala Phe Pro Asp Leu Ala Glu His Phe Asp Arg
 35 40 45
 Ser Ala Gln Asp Thr Ala Trp Ile Ser Ala Leu Ala Leu Ala Val Gln
 50 55 60
 Gln Ala Ala Ser Pro Val Gly Ser Ala Leu Ser Thr Arg Trp Gly Ala
 65 70 75 80
 Arg Pro Val Val Met Val Gly Gly Val Leu Ala Ser Leu Gly Phe Val
 85 90 95
 Phe Ser Ala Phe Ala Ser Asp Leu Leu His Leu Tyr Leu Gly Leu Gly
 100 105 110
 Leu Leu Ala Gly Phe Gly Trp Ala Leu Val Phe Ala Pro Ala Leu Gly
 115 120 125
 Thr Leu Ser Arg Tyr Phe Ser Arg Arg Arg Val Leu Ala Val Gly Leu
 130 135 140
 Ala Leu Thr Gly Asn Gly Ala Ser Ser Leu Leu Ala Pro Ala Leu
 145 150 155 160
 Gln Leu Leu Leu Asp Thr Phe Gly Trp Arg Gly Ala Leu Leu Leu
 165 170 175
 Gly Ala Ile Thr Leu His Leu Thr Pro Cys Gly Ala Leu Leu Leu Pro
 180 185 190
 Leu Val Leu Pro Gly Asp Pro Pro Ala Pro Pro Arg Ser Pro Leu Ala
 195 200 205
 Ala Leu Gly Leu Ser Leu Phe Thr Arg Arg Ala Phe Ser Ile Phe Ala
 210 215 220
 Leu Gly Thr Ala Leu Val Gly Gly Tyr Phe Val Pro Tyr Val His
 225 230 235 240
 Leu Ala Pro His Ala Leu Asp Arg Gly Leu Gly Gly Tyr Gly Ala Ala
 245 250 255
 Leu Val Val Ala Val Ala Met Gly Asp Ala Gly Ala Arg Leu Val
 260 265 270
 Cys Gly Trp Leu Ala Asp Gln Gly Trp Val Pro Leu Pro Arg Leu Leu
 275 280 285
 Ala Val Phe Gly Ala Leu Thr Gly Leu Gly Leu Trp Val Val Gly Leu
 290 295 300
 Val Pro Val Val Gly Gly Glu Glu Ser Trp Gly Gly Pro Leu Leu Ala
 305 310 315 320
 Ala Ala Val Ala Tyr Gly Leu Ser Ala Gly Ser Tyr Ala Pro Leu Val
 325 330 335
 Phe Gly Val Leu Pro Gly Leu Val Gly Val Gly Gly Val Val Gln Ala
 340 345 350
 Thr Gly Leu Val Met Met Leu Met Ser Leu Gly Gly Leu Leu Gly Pro
 355 360 365
 Pro Leu Ser Gly Phe Leu Arg Asp Glu Thr Gly Asp Phe Thr Ala Ser
 370 375 380
 Phe Leu Leu Ser Gly Ser Leu Ile Leu Ser Gly Ser Phe Ile Tyr Ile
 385 390 395 400
 Gly Leu Pro Arg Ala Leu Pro Ser Cys Gly Pro Ala Ser Pro Pro Ala
 405 410 415
 Thr Pro Pro Pro Glu Thr Gly Glu Leu Leu Pro Ala Pro Gln Ala Val
 420 425 430
 Leu Leu Ser Pro Gly Gly Pro Gly Ser Thr Leu Asp Thr Thr Cys
 435 440 445

<211> 458
 <212> PRT
 <213> homo sapiens

 <400> 72
 Asx Met Ala Arg Arg Thr Glu Pro Pro Asp Gly Gly Trp Gly Trp Val
 1 5 10 15
 Val Val Leu Ser Ala Phe Phe Gln Ser Ala Leu Val Phe Gly Val Leu
 20 25 30
 Arg Ser Phe Gly Val Phe Phe Val Glu Phe Val Ala Ala Phe Glu Glu
 35 40 45
 Gln Ala Ala Arg Val Ser Trp Ile Ala Ser Ile Gly Ile Ala Val Gln
 50 55 60
 Gln Phe Gly Ser Pro Val Gly Ser Ala Leu Ser Thr Lys Phe Gly Pro
 65 70 75 80
 Arg Pro Val Val Met Thr Gly Gly Ile Leu Ala Ala Leu Gly Met Leu
 85 90 95
 Leu Ala Ser Phe Ala Thr Ser Leu Thr His Leu Tyr Leu Ser Ile Gly
 100 105 110
 Leu Leu Ser Gly Ser Gly Trp Ala Leu Thr Phe Ala Pro Thr Leu Ala
 115 120 125
 Cys Leu Ser Cys Tyr Phe Ser Arg Arg Arg Ser Leu Ala Thr Gly Leu
 130 135 140
 Ala Leu Thr Gly Val Gly Leu Ser Ser Phe Thr Phe Ala Pro Phe Phe
 145 150 155 160
 Gln Trp Leu Leu Ser His Tyr Ala Trp Arg Gly Ser Leu Leu Leu Val
 165 170 175
 Ser Ala Leu Ser Leu His Leu Val Ala Cys Gly Ala Leu Leu Arg Pro
 180 185 190
 Pro Ser Leu Ala Glu Asp Pro Ala Val Gly Gly Pro Arg Ala Gln Leu
 195 200 205
 Thr Ser Leu Leu His His Gly Pro Phe Leu Arg Tyr Thr Val Ala Leu
 210 215 220
 Thr Leu Ile Asn Thr Gly Tyr Phe Ile Pro Tyr Leu His Leu Val Ala
 225 230 235 240
 His Leu Gln Asp Leu Asp Trp Asp Pro Leu Pro Ala Ala Phe Leu Leu
 245 250 255
 Ser Val Val Ala Ile Ser Asp Leu Val Gly Arg Val Val Ser Gly Trp
 260 265 270
 Leu Gly Asp Ala Val Pro Gly Pro Val Thr Arg Leu Leu Met Leu Trp
 275 280 285
 Thr Thr Leu Thr Gly Val Ser Leu Ala Leu Phe Pro Val Ala Gln Ala
 290 295 300
 Pro Thr Ala Leu Val Ala Leu Ala Val Ala Tyr Gly Phe Thr Ser Gly
 305 310 315 320
 Ala Leu Ala Pro Leu Ala Phe Ser Val Leu Pro Glu Leu Ile Gly Thr
 325 330 335
 Arg Arg Ile Tyr Cys Gly Leu Gly Leu Leu Gln Met Ile Glu Ser Ile
 340 345 350
 Gly Gly Leu Leu Gly Pro Pro Leu Ser Gly Tyr Leu Arg Asp Val Ser
 355 360 365
 Gly Asn Tyr Thr Ala Ser Phe Val Val Ala Gly Ala Phe Leu Leu Ser
 370 375 380
 Gly Ser Gly Ile Leu Leu Thr Leu Pro His Phe Phe Cys Phe Ser Thr
 385 390 395 400
 Thr Thr Ser Gly Pro Gln Asp Leu Val Thr Glu Ala Leu Asp Thr Lys
 405 410 415
 Val Pro Leu Pro Lys Glu Gly Leu Glu Gly Gly Leu Asn Ser Thr Glu
 420 425 430

Ser Gly Pro Glu Ser Gln Ser Leu Thr Ala Pro Gly Leu Leu Leu Pro
 435 440 445
 Arg Leu Gly Leu His Arg Thr Thr Val Pro
 450 455

<210> 73
 <211> 169
 <212> PRT
 <213> homo sapiens

<400> 73
 Met Thr Met Lys Thr Ser Gly Ala Thr Cys Asp Ala Asn Ser Val Met
 1 5 10 15
 Asn Cys Gly Ile Arg Gly Ser Glu Met Phe Ala Glu Met Asp Leu Arg
 20 25 30
 Ala Ile Lys Pro Tyr Gln Thr Leu Ile Lys Lys Val Gly Gln Arg His
 35 40 45
 Cys Val Asp Pro Ala Val Ile Ala Ala Ile Ile Ser Arg Glu Ser His
 50 55 60
 Gly Gly Ser Val Leu Gln Asp Gly Trp Asp His Arg Gly Leu Lys Phe
 65 70 75 80
 Gly Leu Met Gln Leu Asp Lys Gln Thr Tyr His Pro Val Gly Ala Trp
 85 90 95
 Asp Ser Lys Glu His Leu Ser Gln Ala Thr Gly Ile Leu Thr Glu Arg
 100 105 110
 Ile Lys Ala Ile Gln Lys Lys Phe Pro Thr Trp Ser Val Ala Gln His
 115 120 125
 Leu Lys Gly Leu Ser Ala Phe Lys Ser Gly Ile Glu Ala Ile Ala
 130 135 140
 Thr Pro Ser Asp Ile Asp Asn Asp Phe Val Asn Asp Ile Ile Ala Arg
 145 150 155 160
 Ala Lys Phe Tyr Lys Arg Gln Ser Phe
 165

<210> 74
 <211> 186
 <212> PRT
 <213> homo sapiens

<400> 74
 Met Lys Pro His Leu His Pro Arg Leu Tyr His Gly Cys Tyr Gly Asp
 1 5 10 15
 Ile Met Thr Met Lys Thr Ser Gly Ala Thr Cys Asp Ala Asn Ser Val
 20 25 30
 Met Asn Cys Gly Ile Arg Gly Ser Glu Met Phe Ala Glu Met Asp Leu
 35 40 45
 Arg Ala Ile Lys Pro Tyr Gln Thr Leu Ile Lys Lys Val Gly Gln Arg
 50 55 60
 His Cys Val Asp Pro Ala Val Ile Ala Ala Ile Ile Ser Arg Glu Ser
 65 70 75 80
 His Gly Gly Ser Val Leu Gln Asp Gly Trp Asp His Arg Gly Leu Lys
 85 90 95
 Phe Gly Leu Met Gln Leu Asp Lys Gln Thr Tyr His Pro Val Gly Ala
 100 105 110
 Trp Asp Ser Lys Glu His Leu Ser Gln Ala Thr Gly Ile Leu Thr Glu
 115 120 125
 Arg Ile Lys Ala Ile Gln Lys Lys Phe Pro Thr Trp Ser Val Ala Gln

130	135	140
His Leu Lys Gly Gly Leu Ser Ala Phe Lys Ser Gly Ile Glu Ala Ile		
145	150	155
Ala Thr Pro Ser Asp Ile Asp Asn Asp Phe Val Asn Asp Ile Ile Ala		160
165	170	175
Arg Ala Lys Phe Tyr Lys Arg Gln Ser Phe		
180	185	

<210> 75
 <211> 675
 <212> PRT
 <213> homo sapiens

<400> 75		
Met Glu Ser Gly Thr Ser Ser Pro Gln Pro Pro Gln Leu Asp Pro Leu		
1	5	10
Asp Ala Phe Pro Gln Lys Gly Leu Glu Pro Gly Asp Ile Ala Val Leu		15
20	25	30
Val Leu Tyr Phe Leu Phe Val Leu Ala Val Gly Leu Trp Ser Thr Val		
35	40	45
Lys Thr Lys Arg Asp Thr Val Lys Gly Tyr Phe Leu Ala Gly Gly Asp		
50	55	60
Met Val Trp Trp Pro Val Gly Ala Ser Leu Phe Ala Ser Asn Val Gly		
65	70	75
Ser Gly His Phe Ile Gly Leu Ala Gly Ser Gly Ala Ala Thr Gly Ile		80
85	90	95
Ser Val Ser Ala Tyr Glu Leu Asn Gly Leu Phe Ser Val Leu Met Leu		
100	105	110
Ala Trp Ile Phe Leu Pro Ile Tyr Ile Ala Gly Gln Val Thr Thr Met		
115	120	125
Pro Glu Tyr Leu Arg Lys Arg Phe Gly Gly Ile Arg Ile Pro Ile Ile		
130	135	140
Leu Ala Val Leu Tyr Leu Phe Ile Tyr Ile Phe Thr Lys Ile Ser Val		
145	150	155
Asp Met Tyr Ala Gly Ala Ile Phe Ile Gln Gln Ser Leu His Leu Asp		160
165	170	175
Leu Tyr Leu Ala Ile Val Gly Leu Leu Ala Ile Thr Ala Val Tyr Thr		
180	185	190
Val Ala Gly Gly Leu Ala Ala Val Ile Tyr Thr Asp Ala Leu Gln Thr		
195	200	205
Leu Ile Met Leu Ile Gly Ala Leu Thr Leu Met Gly Tyr Ser Phe Ala		
210	215	220
Ala Val Gly Gly Met Glu Gly Leu Lys Glu Lys Tyr Phe Leu Ala Leu		
225	230	235
Ala Ser Asn Arg Ser Glu Asn Ser Ser Cys Gly Leu Pro Arg Glu Asp		240
245	250	255
Ala Phe His Ile Phe Arg Asp Pro Leu Thr Ser Asp Leu Pro Trp Pro		
260	265	270
Gly Val Leu Phe Gly Met Ser Ile Pro Ser Leu Trp Tyr Trp Cys Thr		
275	280	285
Asp Gln Val Ile Val Gln Arg Thr Leu Ala Ala Lys Asn Leu Ser His		
290	295	300
Ala Lys Gly Gly Ala Leu Met Ala Ala Tyr Leu Lys Val Leu Pro Leu		
305	310	315
Phe Ile Met Val Phe Pro Gly Met Val Ser Arg Ile Leu Phe Pro Asp		320
325	330	335
Gln Val Ala Cys Ala Asp Pro Glu Ile Cys Gln Lys Ile Cys Ser Asn		
340	345	350

Pro Ser Gly Cys Ser Asp Ile Ala Tyr Pro Lys Leu Val Leu Glu Leu
 355 360 365
 Leu Pro Thr Gly Leu Arg Gly Leu Met Met Ala Val Met Val Ala Ala
 370 375 380
 Leu Met Ser Ser Leu Thr Ser Ile Phe Asn Ser Ala Ser Thr Ile Phe
 385 390 395 400
 Thr Met Asp Leu Trp Asn His Leu Arg Pro Arg Ala Ser Glu Lys Glu
 405 410 415
 Leu Met Ile Val Gly Arg Val Phe Val Leu Leu Val Leu Val Ser
 420 425 430
 Ile Leu Trp Ile Pro Val Val Gln Ala Ser Gln Gly Gly Gln Leu Phe
 435 440 445
 Ile Tyr Ile Gln Ser Ile Ser Ser Tyr Leu Gln Pro Pro Val Ala Val
 450 455 460
 Val Phe Ile Met Gly Cys Phe Trp Lys Arg Thr Asn Glu Lys Gly Ala
 465 470 475 480
 Phe Trp Gly Leu Ile Ser Gly Leu Leu Gly Leu Val Arg Leu Val
 485 490 495
 Leu Asp Phe Ile Tyr Val Gln Pro Arg Cys Asp Gln Pro Asp Glu Arg
 500 505 510
 Pro Val Leu Val Lys Ser Ile His Tyr Leu Tyr Phe Ser Met Ile Leu
 515 520 525
 Ser Thr Val Thr Leu Ile Thr Val Ser Thr Val Ser Trp Phe Thr Glu
 530 535 540
 Pro Pro Ser Lys Glu Met Val Ser His Leu Thr Trp Phe Thr Arg His
 545 550 555 560
 Asp Pro Val Val Gln Lys Glu Gln Ala Pro Pro Ala Ala Pro Leu Ser
 565 570 575
 Leu Thr Leu Ser Gln Asn Gly Met Pro Glu Ala Ser Ser Ser Ser
 580 585 590
 Val Gln Phe Glu Met Val Gln Glu Asn Thr Ser Lys Thr His Ser Cys
 595 600 605
 Asp Met Thr Pro Lys Gln Ser Lys Val Val Lys Ala Ile Leu Trp Leu
 610 615 620
 Cys Gly Ile Gln Glu Lys Gly Lys Glu Glu Leu Pro Ala Arg Ala Glu
 625 630 635 640
 Ala Ile Ile Val Ser Leu Glu Glu Asn Pro Leu Val Lys Thr Leu Leu
 645 650 655
 Asp Val Asn Leu Ile Phe Cys Val Ser Cys Ala Ile Phe Ile Trp Gly
 660 665 670
 Tyr Phe Ala
 675

<210> 76
 <211> 485
 <212> PRT
 <213> homo sapiens

<400> 76
 Met Glu Pro Cys Trp Gly Glu Gly Leu Phe His Leu Ala Pro Pro Arg
 1 5 10 15
 His His Pro Gln Lys Ala Asp Trp His Phe Cys Pro Gln His Ile Gln
 20 25 30
 Glu Phe Thr Asn Glu Thr Trp Gln Ala Arg Thr Gly Glu Pro Leu Pro
 35 40 45
 Asp His Leu Val Leu Leu Met Trp Ser Leu Ile Val Ser Leu Tyr Pro
 50 55 60
 Leu Gly Gly Leu Phe Gly Ala Leu Leu Ala Gly Pro Leu Ala Ile Thr

65	70	75	80
Leu	Gly	Arg	Lys
Lys	Ser	Leu	Leu
Leu	Val	Asn	Asn
Asn	Ile	Phe	Val
Ile	Phe	Gly	Val
85	85	90	95
Ala	Ala	Ile	Leu
Phe	Gly	Phe	Ser
Ser	Arg	Lys	Ala
Ala	Gly	Ser	Phe
Gly	95	100	105
100	105	110	115
Ile	Met	Leu	Gly
Gly	Arg	Leu	Leu
Leu	Val	Gly	Val
Val	Asn	Ala	Gly
Ala	Gly	Val	Ser
Gly	115	120	125
115	120	125	130
Asn	Ile	Gln	Pro
Pro	Met	Tyr	Leu
Tyr	Gly	Glu	Ser
Ser	Ala	Pro	Lys
Ala	Gly	Glu	Leu
Gly	130	135	140
130	135	140	145
Gly	Ala	Val	Ala
Ala	Met	Ser	Ser
Ser	Ala	Ile	Phe
Ile	Phe	Thr	Ala
Ala	Gly	Ile	Val
145	150	155	160
Met	Gly	Gln	Val
Val	Gly	Leu	Arg
Arg	Glu	Leu	Leu
Leu	Gly	Gly	Pro
Gly	165	170	175
165	170	175	180
Trp	Pro	Leu	Leu
Leu	Ala	Ser	Cys
Cys	Leu	Val	Pro
Pro	Gly	Ala	Gly
Gly	180	185	190
180	185	190	195
Ala	Ser	Leu	Pro
Pro	Leu	Leu	Pro
Pro	Gly	Ser	Pro
Ser	Pro	Arg	Tyr
Tyr	Leu	Leu	Ile
Ile	Asp	195	200
195	200	205	210
Cys	Gly	Asp	Thr
Thr	Glu	Ala	Cys
Ala	Leu	Ala	Leu
Leu	Arg	Arg	Gly
Gly	210	215	220
Ser	Gly	Asp	Leu
Leu	Ala	Gly	Gly
Gly	225	230	235
225	230	235	240
Ala	Cys	Gln	Gly
Gly	Cys	Arg	Ala
Ala	Arg	Arg	Arg
Arg	245	250	255
245	250	255	260
Arg	Ala	Leu	Arg
Arg	Arg	Gln	Val
Val	Thr	Ser	Leu
Leu	Val	Val	Leu
Leu	Gly	Ser	Ala
Met	Glu	Leu	Cys
Cys	Gly	Asn	Asp
Asp	Ser	Val	Tyr
Tyr	Ala	Tyr	Ala
Ala	Ser	Ser	Val
275	280	285	290
Phe	Arg	Lys	Ala
Ala	Gly	Val	Pro
Pro	Glu	Ala	Lys
Lys	Ile	Gly	Ile
Ile	Tyr	Ala	Ile
290	295	300	305
Gly	Thr	Gly	Ser
Ser	Cys	Glu	Leu
Leu	Leu	Thr	Ala
310	315	320	325
Ile	Glu	Arg	Val
Val	Gly	Arg	Arg
Arg	Val	Leu	Leu
Leu	Ile	Gly	Gly
Ile	Tyr	Tyr	Ser
Ser	Leu	325	330
Met	Thr	Cys	Trp
Trp	Gly	Ser	Ile
Ile	Phe	Thr	Val
Val	Ala	Leu	Cys
Cys	Leu	Gln	Ser
340	345	350	355
Ser	Phe	Pro	Trp
Pro	Trp	Thr	Leu
Thr	Tyr	Leu	Ala
Ala	Met	Ala	Cys
Cys	Ile	Phe	Ala
Ala	355	360	365
Ile	Leu	Ser	Phe
Phe	Ile	Gly	Ile
Ile	Gly	Pro	Ala
Ala	370	375	380
Thr	Glu	Leu	Phe
Phe	Asp	Gln	Met
Met	Ala	Arg	Pro
Ala	385	390	395
Gly	Ala	Leu	Met
Met	Trp	Ile	Met
Ile	Leu	Ile	Leu
Leu	Val	Gly	Leu
Leu	Gly	Phe	Pro
405	410	415	420
Phe	Ile	Met	Glu
Glu	Ala	Leu	Ser
Ser	His	Phe	Leu
Leu	Tyr	Tyr	Val
Val	420	425	430
Cys	Val	Cys	Gly
Gly	Ala	Ile	Tyr
Ile	Tyr	Thr	Gly
Gly	435	440	445
Lys	Gly	Lys	Thr
Thr	Phe	Gln	Glu
Glu	Ile	Ser	Lys
Lys	Leu	Leu	Leu
Leu	His	Arg	Leu
Arg	450	455	460
Phe	Pro	Arg	Arg
Arg	Ala	Gln	Gly
Gly	465	470	475
Pro	Thr	Trp	Arg
Trp	Arg	Ser	Ser
Ser	Leu	Glu	Val
Leu	Gly	Val	Ile
Ile	480	485	485

<210> 77
 <211> 496
 <212> PRT
 <213> homo sapiens

<400> 77
 Met Arg Ala Leu Arg Arg Leu Ile Gln Gly Arg Ile Leu Leu Leu Thr
 1 5 10 15
 Ile Cys Ala Ala Gly Ile Gly Gly Thr Phe Gln Phe Gly Tyr Asn Leu
 20 25 30
 Ser Ile Ile Asn Ala Pro Thr Leu His Ile Gln Glu Phe Thr Asn Glu
 35 40 45
 Thr Trp Gln Ala Arg Thr Gly Glu Pro Leu Pro Asp His Leu Val Leu
 50 55 60
 Leu Met Trp Ser Leu Ile Val Ser Leu Tyr Pro Leu Gly Gly Leu Phe
 65 70 75 80
 Gly Ala Leu Leu Ala Gly Pro Leu Ala Ile Thr Leu Gly Arg Lys Lys
 85 90 95
 Ser Leu Leu Val Asn Asn Ile Phe Val Val Ser Ala Ala Ile Leu Phe
 100 105 110
 Gly Phe Ser Arg Lys Ala Gly Ser Phe Glu Met Ile Met Leu Gly Arg
 115 120 125
 Leu Leu Val Gly Val Asn Ala Gly Val Ser Met Asn Ile Gln Pro Met
 130 135 140
 Tyr Leu Gly Glu Ser Ala Pro Lys Glu Leu Arg Gly Ala Val Ala Met
 145 150 155 160
 Ser Ser Ala Ile Phe Thr Ala Leu Gly Ile Val Met Gly Gln Val Val
 165 170 175
 Gly Leu Arg Glu Leu Leu Gly Gly Pro Gln Ala Trp Pro Leu Leu Leu
 180 185 190
 Ala Ser Cys Leu Val Pro Gly Ala Leu Glu Leu Ala Ser Leu Pro Leu
 195 200 205
 Leu Pro Glu Ser Pro Arg Tyr Leu Leu Ile Asp Cys Gly Asp Thr Glu
 210 215 220
 Ala Cys Leu Ala Ala Leu Arg Arg Leu Arg Gly Ser Gly Asp Leu Ala
 225 230 235 240
 Gly Glu Leu Glu Leu Glu Glu Glu Arg Ala Ala Cys Gln Gly Cys
 245 250 255
 Arg Ala Arg Arg Pro Trp Glu Leu Phe Gln His Arg Ala Leu Arg Arg
 260 265 270
 Gln Val Thr Ser Leu Val Val Leu Gly Ser Ala Met Glu Leu Cys Gly
 275 280 285
 Asn Asp Ser Val Tyr Ala Tyr Ala Ser Ser Val Phe Arg Lys Ala Gly
 290 295 300
 Val Pro Glu Ala Lys Ile Gln Tyr Ala Ile Ile Gly Thr Gly Ser Cys
 305 310 315 320
 Glu Leu Leu Thr Ala Val Val Ser Cys Val Val Ile Glu Arg Val Gly
 325 330 335
 Arg Arg Val Leu Leu Ile Gly Gly Tyr Ser Leu Met Thr Cys Trp Gly
 340 345 350
 Ser Ile Phe Thr Val Ala Leu Cys Leu Gln Ser Ser Phe Pro Trp Thr
 355 360 365
 Leu Tyr Leu Ala Met Ala Cys Ile Phe Ala Phe Ile Leu Ser Phe Gly
 370 375 380
 Ile Gly Pro Ala Gly Val Thr Gly Ile Leu Ala Thr Glu Leu Phe Asp
 385 390 395 400
 Gln Met Ala Arg Pro Ala Ala Cys Met Val Cys Gly Ala Leu Met Trp
 405 410 415
 Ile Met Leu Ile Leu Val Gly Leu Gly Phe Pro Phe Ile Met Glu Ala
 420 425 430
 Leu Ser His Phe Leu Tyr Val Pro Phe Leu Gly Val Cys Val Cys Gly
 435 440 445
 Ala Ile Tyr Thr Gly Leu Phe Leu Pro Glu Thr Lys Gly Lys Thr Phe

450	455	460
Gln Glu Ile Ser Lys	Glu Leu His Arg Leu Asn Phe Pro Arg Arg Ala	
465	470	475
Gln Gly Pro Thr Trp Arg Ser Leu Glu Val Ile Gln Ser Thr Glu Leu		480
485		490
		495
<210> 78		
<211> 500		
<212> PRT		
<213> homo sapiens		
<400> 78		
Asx Met Leu His Ala Leu Leu Arg Ser Arg Met Ile Gln Gly Arg Ile		
1	5	10
Leu Leu Leu Thr Ile Cys Ala Ala Gly Ile Gly Gly Thr Phe Gln Phe		15
20	25	30
Gly Tyr Asn Leu Ser Ile Ile Asn Ala Pro Thr Leu His Ile Gln Glu		35
35	40	45
Phe Thr Asn Glu Thr Trp Gln Ala Arg Thr Gly Glu Pro Leu Pro Asp		50
50	55	60
His Leu Val Leu Leu Met Trp Ser Leu Ile Val Ser Leu Tyr Pro Leu		65
65	70	75
Gly Gly Leu Phe Gly Ala Leu Leu Ala Gly Pro Leu Ala Ile Thr Leu		80
85	90	95
Gly Arg Lys Lys Ser Leu Leu Val Asn Asn Ile Phe Val Val Ser Ala		100
100	105	110
Ala Ile Leu Phe Gly Phe Ser Arg Lys Ala Gly Ser Phe Glu Met Ile		115
115	120	125
Met Leu Gly Arg Leu Leu Val Gly Val Asn Ala Gly Val Ser Met Asn		130
130	135	140
Ile Gln Pro Met Tyr Leu Gly Glu Ser Ala Pro Lys Glu Leu Arg Gly		145
145	150	155
Ala Val Ala Met Ser Ser Ala Ile Phe Thr Ala Leu Gly Ile Val Met		160
165	170	175
Gly Gln Val Val Gly Leu Arg Glu Leu Leu Gly Gly Pro Gln Ala Trp		180
180	185	190
Pro Leu Leu Leu Ala Ser Cys Leu Val Pro Gly Ala Leu Gln Leu Ala		195
195	200	205
Ser Leu Pro Leu Leu Pro Glu Ser Pro Arg Tyr Leu Leu Ile Asp Cys		210
210	215	220
Gly Asp Thr Glu Ala Cys Leu Ala Ala Leu Arg Arg Leu Arg Gly Ser		225
225	230	235
Gly Asp Leu Ala Gly Glu Leu Glu Leu Glu Glu Glu Arg Ala Ala		240
245	250	255
Cys Gln Gly Cys Arg Ala Arg Arg Pro Trp Glu Leu Phe Gln His Arg		260
260	265	270
Ala Leu Arg Arg Gln Val Thr Ser Leu Val Val Leu Gly Ser Ala Met		275
275	280	285
Glu Leu Cys Gly Asn Asp Ser Val Tyr Ala Tyr Ala Ser Ser Val Phe		290
290	295	300
Arg Lys Ala Gly Val Pro Glu Ala Lys Ile Gln Tyr Ala Ile Ile Gly		305
305	310	315
Thr Gly Ser Cys Glu Leu Leu Thr Ala Val Val Ser Cys Val Val Ile		320
325	330	335
Glu Arg Val Gly Arg Arg Val Leu Leu Ile Gly Gly Tyr Ser Leu Met		340
340	345	350
Thr Cys Trp Gly Ser Ile Phe Thr Val Ala Leu Cys Leu Gln Ser Ser		355
360		365

Phe Pro Trp Thr Leu Tyr Leu Ala Met Ala Cys Ile Phe Ala Phe Ile
 370 375 380
 Leu Ser Phe Gly Ile Gly Pro Ala Gly Val Thr Gly Ile Leu Ala Thr
 385 390 395 400
 Glu Leu Phe Asp Gln Met Ala Arg Pro Ala Ala Cys Met Val Cys Gly
 405 410 415
 Ala Leu Met Trp Ile Met Leu Ile Leu Val Gly Leu Gly Phe Pro Phe
 420 425 430
 Ile Met Glu Ala Leu Ser His Phe Leu Tyr Val Pro Phe Leu Gly Val
 435 440 445
 Cys Val Cys Gly Ala Ile Tyr Thr Gly Leu Phe Leu Pro Glu Thr Lys
 450 455 460
 Gly Lys Thr Phe Gln Glu Ile Ser Lys Glu Leu His Arg Leu Asn Phe
 465 470 475 480
 Pro Arg Arg Ala Gln Gly Pro Thr Trp Arg Ser Leu Glu Val Ile Gln
 485 490 495
 Ser Thr Glu Leu
 500

<210> 79
 <211> 1358
 <212> PRT
 <213> homo sapiens

<400> 79
 Met Val Val Val Lys Pro Met Asn Thr Met Ala Pro Val Val Thr Arg
 1 5 10 15
 Asn Thr Gly Leu Ile Leu Tyr Glu Gly Gln Ser Arg Pro Leu Thr Gly
 20 25 30
 Pro Ala Gly Ser Gly Pro Gln Asn Leu Val Ile Ser Asp Glu Asp Asp
 35 40 45
 Leu Glu Ala Val Arg Leu Glu Val Val Ala Gly Leu Arg His Gly His
 50 55 60
 Leu Val Ile Leu Gly Ala Ser Ser Gly Ser Ser Ala Pro Lys Ser Phe
 65 70 75 80
 Thr Val Ala Glu Leu Ala Ala Gly Gln Val Val Tyr Gln His Asp Asp
 85 90 95
 Arg Asp Gly Ser Leu Ser Asp Asn Leu Val Leu Arg Met Val Asp Gly
 100 105 110
 Gly Gly Arg His Gln Val Gln Phe Leu Phe Pro Ile Thr Leu Val Pro
 115 120 125
 Val Asp Asp Gln Pro Pro Val Leu Asn Ala Asn Thr Gly Leu Thr Leu
 130 135 140
 Ala Glu Gly Glu Thr Val Pro Ile Leu Pro Leu Ser Leu Ser Ala Thr
 145 150 155 160
 Asp Met Asp Ser Asp Asp Ser Leu Leu Leu Phe Val Leu Glu Ser Pro
 165 170 175
 Phe Leu Thr Thr Gly His Leu Leu Leu Arg Gln Thr His Pro Pro His
 180 185 190
 Glu Lys Gln Glu Leu Leu Arg Gly Leu Trp Arg Lys Glu Gly Ala Phe
 195 200 205
 Tyr Glu Arg Thr Val Thr Glu Trp Gln Gln Asp Ile Thr Glu Gly
 210 215 220
 Arg Leu Phe Tyr Arg His Ser Gly Pro His Ser Pro Gly Pro Val Thr
 225 230 235 240
 Asp Gln Phe Thr Phe Arg Val Gln Asp Asn His Asp Pro Pro Asn Gln
 245 250 255
 Ser Gly Leu Gln Arg Phe Val Ile Arg Ile His Pro Val Asp Arg Leu

260	265	270
Pro Pro Glu Leu Gly Ser Gly Cys	Pro Leu Arg Met Val Val Gln Glu	
275	280	285
Ser Gln Leu Thr Pro Leu Arg Lys Lys Trp Leu Arg Tyr Thr Asp Leu		
290	295	300
Asp Thr Asp Asp Arg Glu Leu Arg Tyr Thr Val Thr Gln Ser Pro Thr		
305	310	315
Asp Thr Asp Glu Asn His Leu Pro Ala Pro Leu Gly Thr Leu Val Leu		320
325	330	335
Thr Asp Asn Pro Ser Val Val Val Thr His Phe Thr Gln Ala Gln Ile		
340	345	350
Asn His His Lys Ile Ala Tyr Arg Pro Pro Gly Gln Glu Leu Gly Val		
355	360	365
Ala Thr Arg Val Ala Gln Phe Gln Phe Gln Val Glu Asp Arg Ala Gly		
370	375	380
Asn Val Ala Pro Gly Thr Phe Thr Leu Tyr Leu His Pro Val Asp Asn		
385	390	395
Gln Pro Pro Glu Ile Leu Asn Thr Gly Phe Thr Ile Gln Glu Lys Gly		400
405	410	415
His His Ile Leu Ser Glu Thr Glu Leu His Val Asn Asp Val Asp Thr		
420	425	430
Asp Val Ala His Ile Ser Phe Thr Leu Thr Gln Ala Pro Lys His Gly		
435	440	445
His Met Arg Val Ser Gly Gln Ile Leu His Val Gly Leu Phe His		
450	455	460
Leu Glu Asp Ile Lys Gln Gly Arg Val Ser Tyr Ala His Asn Gly Asp		
465	470	475
Lys Ser Leu Thr Asp Ser Cys Ser Leu Glu Val Ser Asp Arg His His		480
485	490	495
Val Val Pro Ile Thr Leu Arg Val Asn Val Arg Pro Val Asp Asp Glu		
500	505	510
Val Pro Ile Leu Ser His Pro Thr Gly Thr Leu Glu Ser Tyr Leu Asp		
515	520	525
Val Leu Glu Asn Gly Ala Thr Glu Ile Thr Ala Asn Val Ile Lys Gly		
530	535	540
Thr Asn Glu Glu Thr Asp Asp Leu Met Leu Thr Phe Leu Leu Glu Asp		
545	550	555
Pro Pro Leu Tyr Gly Glu Ile Leu Val Asn Gly Ile Pro Ala Glu Gln		560
565	570	575
Phe Thr Gln Arg Asp Ile Leu Glu Gly Ser Val Val Tyr Thr His Thr		
580	585	590
Ser Gly Glu Ile Gly Leu Leu Pro Lys Ala Asp Ser Phe Asn Leu Ser		
595	600	605
Leu Ser Asp Met Ser Gln Glu Trp Arg Ile Gly Gly Asn Thr Ile Gln		
610	615	620
Gly Val Thr Ile Trp Val Thr Ile Leu Pro Val Asp Ser Gln Ala Pro		
625	630	635
Glu Ile Phe Val Gly Glu Gln Leu Ile Val Met Glu Gly Asp Lys Ser		640
645	650	655
Val Ile Thr Ser Val His Ile Ser Ala Glu Asp Val Asp Ser Leu Asn		
660	665	670
Asp Asp Ile Leu Cys Thr Ile Val Ile Gln Pro Thr Ser Gly Tyr Val		
675	680	685
Glu Asn Ile Ser Pro Ala Pro Gly Ser Glu Lys Ser Arg Ala Gly Ile		
690	695	700
Ala Ile Ser Ala Phe Asn Leu Lys Asp Leu Arg Gln Gly His Ile Asn		
705	710	715
Tyr Val Gln Ser Val His Lys Gly Val Glu Pro Val Glu Asp Arg Phe		720
725	730	735

Val Phe Arg Cys Ser Asp Gly Ile Asn Phe Ser Glu Arg Gln Phe Phe
 740 745 750
 Pro Ile Val Ile Ile Pro Thr Asn Asp Glu Gln Pro Glu Met Phe Met
 755 760 765
 Arg Glu Phe Met Val Met Glu Gly Met Ser Leu Val Ile Asp Thr Pro
 770 775 780
 Ile Leu Asn Ala Ala Asp Ala Asp Val Pro Leu Asp Asp Leu Thr Phe
 785 790 795 800
 Thr Ile Thr Gln Phe Pro Thr His Gly His Ile Met Asn Gln Leu Ile
 805 810 815
 Asn Gly Thr Val Leu Val Glu Ser Phe Thr Leu Asp Gln Ile Ile Glu
 820 825 830
 Ser Ser Ser Ile Ile Tyr Glu His Asp Asp Ser Glu Thr Gln Glu Asp
 835 840 845
 Ser Phe Val Ile Lys Leu Thr Asp Gly Lys His Ser Val Glu Lys Thr
 850 855 860
 Val Leu Ile Ile Val Ile Pro Val Asp Asp Glu Thr Pro Arg Met Thr
 865 870 875 880
 Ile Asn Asn Gly Leu Glu Ile Glu Ile Gly Asp Thr Lys Ile Ile Asn
 885 890 895
 Asn Lys Ile Leu Met Ala Thr Asp Leu Asp Ser Glu Asp Lys Ser Leu
 900 905 910
 Val Tyr Ile Ile Arg Tyr Gly Pro Gly His Gly Leu Leu Gln Arg Arg
 915 920 925
 Lys Pro Thr Gly Ala Phe Glu Asn Ile Thr Leu Gly Met Asn Phe Thr
 930 935 940
 Gln Asp Glu Val Asp Arg Asn Leu Ile Gln Tyr Val His Leu Gly Gln
 945 950 955 960
 Glu Gly Ile Arg Asp Leu Ile Lys Phe Asp Val Thr Asp Gly Ile Asn
 965 970 975
 Pro Leu Ile Asp Arg Tyr Phe Tyr Val Ser Ile Gly Ser Ile Asp Ile
 980 985 990
 Val Phe Pro Asp Val Ile Ser Lys Gly Val Ser Leu Lys Glu Gly Gly
 995 1000 1005
 Lys Val Thr Leu Thr Thr Asp Leu Leu Ser Thr Ser Asp Leu Asn Ser
 1010 1015 1020
 Pro Asp Glu Asn Leu Val Phe Thr Ile Thr Arg Ala Pro Met Arg Gly
 1025 1030 1035 1040
 His Leu Glu Cys Thr Asp Gln Pro Gly Val Ser Ile Thr Ser Phe Thr
 1045 1050 1055
 Gln Leu Gln Leu Ala Gly Asn Lys Ile Tyr Tyr Ile His Thr Ala Asp
 1060 1065 1070
 Asp Glu Val Lys Met Asp Ser Phe Glu Phe Gln Val Thr Asp Gly Arg
 1075 1080 1085
 Asn Pro Val Phe Arg Thr Phe Arg Ile Ser Ile Ser Asp Val Asp Asn
 1090 1095 1100
 Lys Lys Pro Val Val Thr Ile His Lys Leu Val Val Ser Glu Ser Glu
 1105 1110 1115 1120
 Asn Lys Leu Ile Thr Pro Phe Glu Leu Thr Val Glu Asp Arg Asp Thr
 1125 1130 1135
 Pro Asp Lys Leu Leu Lys Phe Thr Ile Thr Gln Val Pro Ile His Gly
 1140 1145 1150
 His Leu Leu Phe Asn Asn Thr Arg Pro Val Met Val Phe Thr Lys Gln
 1155 1160 1165
 Asp Leu Asn Glu Asn Leu Ile Ser Tyr Lys His Asp Gly Thr Glu Ser
 1170 1175 1180
 Ser Glu Asp Ser Phe Ser Phe Thr Val Thr Asp Gly Thr His Thr Asp
 1185 1190 1195 1200
 Phe Tyr Val Phe Pro Asp Thr Val Phe Glu Thr Arg Arg Pro Gln Val

1205	1210	1215
Met Lys Ile Gln Val Leu Ala Val Asp Asn Ser Val Pro Gln Ile Ala		
1220	1225	1230
Val Asn Lys Gly Ala Ser Thr Leu Arg Thr Leu Ala Thr Gly His Leu		
1235	1240	1245
Gly Phe Met Ile Thr Ser Lys Ile Leu Lys Val Glu Asp Arg Asp Ser		
1250	1255	1260
Leu His Ile Ser Leu Arg Phe Ile Val Thr Glu Ala Pro Gln His Gly		
1265	1270	1275
Tyr Leu Leu Asn Leu Asp Lys Gly Asn His Ser Ile Thr Gln Phe Thr		1280
1285	1290	1295
Gln Ala Asp Ile Asp Asp Met Lys Ile Cys Tyr Val Leu Arg Glu Gly		
1300	1305	1310
Ala Asn Ala Thr Ser Asp Met Phe Tyr Phe Ala Val Glu Asp Gly Gly		
1315	1320	1325
Lys Tyr Ser Pro Leu Leu Val Val Thr Ala Arg Arg Asp Ala Phe Leu		
1330	1335	1340
Gly Cys Ser Leu Met Thr Leu Leu Gln Glu Val Phe Ile Lys		
1345	1350	1355

<210> 80
<211> 3105
<212> PRT
<213> homo sapiens

<400> 80		
Met Ala Arg Ser Trp Leu Thr Ala Thr Ser Thr Ser Arg Pro Ala Ala		
1	5	10
Phe Gly Arg Ala Leu Leu Ser Pro Gly Leu Ala Gly Ala Ala Gly Val		15
20	25	30
Pro Ala Glu Glu Ala Ile Val Leu Ala Asn Arg Gly Leu Arg Val Pro		
35	40	45
Phe Gly Arg Glu Val Trp Leu Asp Pro Leu His Asp Leu Val Leu Gln		
50	55	60
Val Gln Pro Gly Asp Arg Cys Ala Val Ser Val Leu Asp Asn Asp Ala		
65	70	75
Leu Ala Gln Arg Pro Gly Arg Leu Ser Pro Lys Arg Phe Pro Cys Asp		80
85	90	95
Phe Gly Pro Gly Glu Val Arg Tyr Ser His Leu Gly Ala Arg Ser Pro		
100	105	110
Ser Arg Asp Arg Val Arg Leu Gln Leu Arg Tyr Asp Ala Pro Gly Gly		
115	120	125
Ala Val Val Leu Pro Leu Val Leu Glu Val Glu Val Val Phe Thr Gln		
130	135	140
Leu Glu Val Val Thr Arg Asn Leu Pro Leu Val Val Glu Glu Leu Leu		
145	150	155
Gly Thr Ser Asn Ala Leu Asp Ala Arg Ser Leu Glu Phe Ala Phe Gln		160
165	170	175
Pro Glu Thr Glu Glu Cys Arg Val Gly Ile Leu Ser Gly Leu Gly Ala		
180	185	190
Leu Pro Arg Tyr Gly Glu Leu Leu His Tyr Pro Gln Val Pro Gly Gly		
195	200	205
Ala Arg Glu Gly Ala Pro Glu Thr Leu Leu Met Asp Cys Lys Ala		
210	215	220
Phe Gln Glu Leu Gly Val Arg Tyr Arg His Thr Ala Ala Ser Arg Ser		
225	230	235
Pro Asn Arg Asp Trp Ile Pro Met Val Val Glu Leu Arg Ser Arg Gly		240
245	250	255

Ala Pro Val Gly Ser Pro Ala Leu Lys Arg Glu His Phe Gln Val Leu
 260 265 270
 Val Arg Ile Arg Gly Gly Ala Glu Asn Thr Ala Pro Lys Pro Ser Phe
 275 280 285
 Val Ala Met Met Met Glu Val Asp Gln Phe Val Leu Thr Ala Leu
 290 295 300
 Thr Pro Asp Met Leu Ala Ala Glu Asp Ala Glu Ser Pro Ser Asp Leu
 305 310 315 320
 Leu Ile Phe Asn Leu Thr Ser Pro Phe Gln Pro Gly Gln Gly Tyr Leu
 325 330 335
 Val Ser Thr Asp Asp Arg Ser Leu Pro Leu Ser Ser Phe Thr Gln Arg
 340 345 350
 Asp Leu Arg Leu Leu Lys Ile Ala Tyr Gln Pro Pro Ser Glu Asp Ser
 355 360 365
 Asp Gln Glu Arg Leu Phe Glu Leu Glu Leu Glu Val Val Asp Leu Glu
 370 375 380
 Gly Ala Ala Ser Asp Pro Phe Ala Phe Met Val Val Val Lys Pro Met
 385 390 395 400
 Asn Thr Met Ala Pro Val Val Thr Arg Asn Thr Gly Leu Ile Leu Tyr
 405 410 415
 Glu Gly Gln Ser Arg Pro Leu Thr Gly Pro Ala Gly Ser Gly Pro Gln
 420 425 430
 Asn Leu Val Ile Ser Asp Glu Asp Asp Leu Glu Ala Val Arg Leu Glu
 435 440 445
 Val Val Ala Gly Leu Arg His Gly His Leu Val Ile Leu Gly Ala Ser
 450 455 460
 Ser Gly Ser Ser Ala Pro Lys Ser Phe Thr Val Ala Glu Leu Ala Ala
 465 470 475 480
 Gly Gln Val Val Tyr Gln His Asp Asp Arg Asp Gly Ser Leu Ser Asp
 485 490 495
 Asn Leu Val Leu Arg Met Val Asp Gly Gly Arg His Gln Val Gln
 500 505 510
 Phe Leu Phe Pro Ile Thr Leu Val Pro Val Asp Asp Gln Pro Pro Val
 515 520 525
 Leu Asn Ala Asn Thr Gly Leu Thr Leu Ala Glu Gly Glu Thr Val Pro
 530 535 540
 Ile Leu Pro Leu Ser Leu Ser Ala Thr Asp Met Asp Ser Asp Asp Ser
 545 550 555 560
 Leu Leu Leu Phe Val Leu Glu Ser Pro Phe Leu Thr Thr Gly His Leu
 565 570 575
 Leu Leu Arg Gln Thr His Pro Pro His Glu Lys Gln Glu Leu Leu Arg
 580 585 590
 Gly Leu Trp Arg Lys Glu Gly Ala Phe Tyr Glu Arg Thr Val Thr Glu
 595 600 605
 Trp Gln Gln Gln Asp Ile Thr Glu Gly Arg Leu Phe Tyr Arg His Ser
 610 615 620
 Gly Pro His Ser Pro Gly Pro Val Thr Asp Gln Phe Thr Phe Arg Val
 625 630 635 640
 Gln Asp Asn His Asp Pro Pro Asn Gln Ser Gly Leu Gln Arg Phe Val
 645 650 655
 Ile Arg Ile His Pro Val Asp Arg Leu Pro Pro Glu Leu Gly Ser Gly
 660 665 670
 Cys Pro Leu Arg Met Val Val Gln Glu Ser Gln Leu Thr Pro Leu Arg
 675 680 685
 Lys Lys Trp Leu Arg Tyr Thr Asp Leu Asp Thr Asp Asp Arg Glu Leu
 690 695 700
 Arg Tyr Thr Val Thr Gln Pro Pro Thr Asp Thr Asp Glu Asn His Leu
 705 710 715 720
 Pro Ala Pro Leu Gly Thr Leu Val Leu Thr Asp Asn Pro Ser Val Val

725	730	735
Val Thr His Phe Thr Gln Ala Gln Ile Asn His His Lys Ile Ala Tyr		
740	745	750
Arg Pro Pro Gly Gln Glu Leu Gly Val Ala Thr Arg Val Ala Gln Phe		
755	760	765
Gln Phe Gln Val Glu Asp Arg Ala Gly Asn Val Ala Pro Gly Thr Phe		
770	775	780
Thr Leu Tyr Leu His Pro Val Asp Asn Gln Pro Pro Glu Ile Leu Asn		
785	790	795
Thr Gly Phe Thr Ile Gln Glu Lys Gly His His Ile Leu Ser Glu Thr		800
805	810	815
Glu Leu His Val Asn Asp Val Asp Thr Asp Val Ala His Ile Ser Phe		
820	825	830
Thr Leu Thr Gln Ala Pro Lys His Gly His Met Arg Val Ser Gly Gln		
835	840	845
Ile Leu His Val Gly Gly Leu Phe His Leu Glu Asp Ile Lys Gln Gly		
850	855	860
Arg Val Ser Tyr Ala His Asn Gly Asp Lys Ser Leu Thr Asp Ser Cys		
865	870	875
Ser Leu Glu Val Ser Asp Arg His His Val Val Pro Ile Thr Leu Arg		880
885	890	895
Val Asn Val Arg Pro Val Asp Asp Glu Val Pro Ile Leu Ser His Pro		
900	905	910
Thr Gly Thr Leu Glu Ser Tyr Leu Asp Val Leu Glu Asn Gly Ala Thr		
915	920	925
Glu Ile Thr Ala Asn Val Ile Lys Gly Thr Asn Glu Glu Thr Asp Asp		
930	935	940
Leu Met Leu Thr Phe Leu Leu Glu Asp Pro Pro Leu Tyr Gly Glu Ile		
945	950	955
Leu Val Asn Gly Ile Pro Ala Glu Gln Phe Thr Gln Arg Asp Ile Leu		960
965	970	975
Glu Gly Ser Val Val Tyr Thr His Thr Ser Gly Glu Ile Gly Leu Leu		
980	985	990
Pro Lys Ala Asp Ser Phe Asn Leu Ser Leu Ser Asp Lys Ser Gln Glu		
995	1000	1005
Trp Arg Ile Gly Gly Asn Thr Ile Gln Gly Val Thr Ile Trp Val Thr		
1010	1015	1020
Ile Leu Pro Val Asp Ser Gln Ala Pro Glu Ile Ser Val Gly Glu Gln		
1025	1030	1035
Leu Ile Val Met Glu Gly Asp Lys Ser Val Ile Thr Ser Val His Ile		1040
1045	1050	1055
Ser Ala Glu Asp Val Asp Ser Leu Asn Asp Asp Ile Leu Cys Thr Ile		
1060	1065	1070
Val Ile Gln Pro Thr Ser Gly Tyr Val Glu Asn Ile Ser Pro Ala Pro		
1075	1080	1085
Gly Ser Glu Lys Ser Arg Ala Gly Ile Ala Ile Ser Ala Phe Asn Leu		
1090	1095	1100
Lys Asp Leu Arg Gln Gly His Ile Asn Tyr Val Gln Ser Val His Lys		
1105	1110	1115
Gly Val Glu Pro Val Glu Asp Arg Phe Val Phe Arg Cys Ser Asp Gly		1120
1125	1130	1135
Ile Asn Phe Ser Glu Arg Gln Phe Phe Pro Ile Val Ile Ile Pro Thr		
1140	1145	1150
Asn Asp Glu Gln Pro Glu Met Phe Met Arg Glu Phe Met Val Met Glu		
1155	1160	1165
Gly Met Ser Leu Val Ile Asp Thr Pro Ile Leu Asn Ala Ala Asp Ala		
1170	1175	1180
Asp Val Pro Leu Asp Asp Leu Thr Phe Thr Ile Thr Gln Phe Pro Thr		
1185	1190	1195
		1200

His Gly His Ile Met Asn Gln Leu Ile Asn Gly Thr Val Leu Val Glu
 1205 1210 1215
 Ser Phe Thr Leu Asp Gln Ile Ile Glu Ser Ser Ser Ile Ile Tyr Glu
 1220 1225 1230
 His Asp Asp Ser Glu Thr Gln Glu Asp Ser Phe Val Ile Lys Leu Thr
 1235 1240 1245
 Asp Gly Lys His Ser Val Glu Lys Thr Val Leu Ile Ile Val Ile Pro
 1250 1255 1260
 Val Asp Asp Glu Thr Pro Arg Met Thr Ile Asn Asn Gly Leu Glu Ile
 1265 1270 1275 1280
 Glu Ile Gly Asp Thr Lys Ile Ile Asn Asn Lys Ile Leu Met Ala Thr
 1285 1290 1295
 Asp Leu Asp Ser Glu Asp Lys Ser Leu Val Tyr Ile Ile Arg Tyr Gly
 1300 1305 1310
 Pro Gly His Gly Leu Leu Gln Arg Arg Lys Pro Thr Gly Ala Phe Glu
 1315 1320 1325
 Asn Ile Thr Leu Gly Met Asn Phe Thr Gln Asp Glu Val Asp Arg Asn
 1330 1335 1340
 Leu Ile Gln Tyr Val His Leu Gly Gln Glu Gly Ile Arg Asp Leu Ile
 1345 1350 1355 1360
 Lys Phe Asp Val Thr Asp Gly Ile Asn Pro Leu Ile Asp Arg Tyr Phe
 1365 1370 1375
 Tyr Val Ser Ile Gly Ser Ile Asp Ile Val Phe Pro Asp Val Ile Ser
 1380 1385 1390
 Lys Gly Val Ser Leu Lys Glu Gly Lys Val Thr Leu Thr Thr Asp
 1395 1400 1405
 Leu Leu Ser Thr Ser Asp Leu Asn Ser Pro Asp Glu Asn Leu Val Phe
 1410 1415 1420
 Thr Ile Thr Arg Ala Pro Met Arg Gly His Leu Glu Cys Thr Asp Gln
 1425 1430 1435 1440
 Pro Gly Val Ser Ile Thr Ser Phe Thr Gln Leu Gln Leu Ala Gly Asn
 1445 1450 1455
 Lys Ile Tyr Tyr Ile His Thr Ala Asp Asp Glu Val Lys Met Asp Ser
 1460 1465 1470
 Phe Glu Phe Gln Val Thr Asp Gly Arg Asn Pro Val Phe Arg Thr Phe
 1475 1480 1485
 Arg Ile Ser Ile Ser Asp Val Asn Lys Pro Val Val Thr Ile
 1490 1495 1500
 His Lys Leu Val Val Ser Glu Ser Glu Asn Lys Leu Ile Thr Pro Phe
 1505 1510 1515 1520
 Glu Leu Thr Val Glu Asp Arg Asp Thr Pro Asp Lys Leu Leu Lys Phe
 1525 1530 1535
 Thr Ile Thr Gln Val Pro Ile His Gly His Leu Leu Phe Asn Asn Thr
 1540 1545 1550
 Arg Pro Val Met Val Phe Thr Lys Gln Asp Leu Asn Glu Asn Leu Ile
 1555 1560 1565
 Ser Tyr Lys His Asp Gly Thr Glu Ser Ser Glu Asp Ser Phe Ser Phe
 1570 1575 1580
 Thr Val Thr Asp Gly Thr His Thr Asp Phe Tyr Val Phe Pro Asp Thr
 1585 1590 1595 1600
 Val Phe Glu Thr Arg Arg Pro Gln Val Met Lys Ile Gln Val Leu Ala
 1605 1610 1615
 Val Asp Asn Ser Val Pro Gln Ile Ala Val Asn Lys Gly Ala Ser Thr
 1620 1625 1630
 Leu Arg Thr Leu Ala Thr Gly His Leu Gly Phe Met Ile Thr Ser Lys
 1635 1640 1645
 Ile Leu Lys Val Glu Asp Arg Asp Ser Leu His Ile Ser Leu Arg Phe
 1650 1655 1660
 Ile Val Thr Glu Ala Pro Gln His Gly Tyr Leu Leu Asn Leu Asp Lys

1665	1670	1675	1680
Gly Asn His Ser Ile Thr Gln Phe Thr Gln Ala Asp Ile Asp Asp Met			
1685	1690	1695	
Lys Ile Cys Tyr Val Leu Arg Glu Gly Ala Asn Ala Thr Ser Asp Met			
1700	1705	1710	
Phe Tyr Phe Ala Val Glu Asp Gly Gly Asn Lys Leu Thr Tyr Gln			
1715	1720	1725	
Asn Phe Arg Leu Asn Trp Ala Trp Ile Ser Phe Glu Lys Glu Tyr Tyr			
1730	1735	1740	
Leu Val Asn Glu Asp Ser Lys Phe Leu Asp Val Val Leu Lys Arg Arg			
1745	1750	1755	1760
Gly Tyr Leu Gly Glu Thr Ser Phe Ile Ser Ile Gly Thr Arg Asp Arg			
1765	1770	1775	
Thr Ala Glu Lys Asp Lys Asp Phe Lys Gly Lys Ala Gln Lys Gln Val			
1780	1785	1790	
Gln Phe Asn Pro Gly Gln Thr Arg Ala Thr Trp Arg Val Arg Ile Leu			
1795	1800	1805	
Ser Asp Gly Glu His Glu Gln Ser Glu Thr Phe Gln Val Val Leu Ser			
1810	1815	1820	
Glu Pro Val Leu Ala Ala Leu Glu Phe Pro Thr Val Ala Thr Val Glu			
1825	1830	1835	1840
Ile Val Asp Pro Gly Asp Glu Pro Thr Val Phe Ile Pro Gln Ser Lys			
1845	1850	1855	
Tyr Ser Val Glu Glu Asp Val Gly Glu Leu Phe Ile Pro Ile Arg Arg			
1860	1865	1870	
Ser Gly Asp Val Ser Gln Glu Leu Met Val Val Cys Tyr Thr Gln Gln			
1875	1880	1885	
Gly Thr Ala Thr Gly Thr Val Pro Thr Ser Val Leu Ser Tyr Ser Asp			
1890	1895	1900	
Tyr Ile Ser Arg Pro Glu Asp His Thr Ser Val Val Arg Phe Asp Lys			
1905	1910	1915	1920
Asp Glu Arg Glu Lys Leu Cys Arg Ile Val Ile Ile Asp Asp Ser Leu			
1925	1930	1935	
Tyr Glu Glu Glu Thr Phe His Val Leu Leu Ser Met Pro Met Gly			
1940	1945	1950	
Gly Arg Ile Gly Ser Glu Phe Pro Gly Ala Gln Val Thr Ile Val Pro			
1955	1960	1965	
Asp Lys Asp Asp Gly Pro Ser Asp Ser Lys Phe Asn Val Ala Glu Asn			
1970	1975	1980	
Tyr Ser Leu Leu Pro Phe Thr Cys Phe Gln Gly Ser Ile Ala Thr Ala			
1985	1990	1995	2000
Glu Ala Ala Thr Gln Gly Gly Arg Ser Thr Arg Gln Val Ala Ala			
2005	2010	2015	
Val Lys Lys Asp Lys Asp Phe Lys Gly Lys Ala Gln Lys Gln Val Gln			
2020	2025	2030	
Phe Asn Pro Gly Gln Thr Arg Ala Thr Trp Arg Val Arg Ile Leu Ser			
2035	2040	2045	
Asp Gly Glu His Glu Gln Ser Glu Thr Phe Gln Val Val Leu Ser Glu			
2050	2055	2060	
Pro Val Leu Ala Ala Leu Glu Phe Pro Thr Val Ala Thr Val Glu Ile			
2065	2070	2075	2080
Val Asp Pro Gly Asp Ala Cys Pro Trp Gly Glu Glu Ser Asp Gln Ser			
2085	2090	2095	
Ser Gln Gly Leu Lys Leu Gln Ser Phe Leu Thr Lys Met Met Val Ser			
2100	2105	2110	
Thr Asn Leu Leu Glu Asn Ser Phe Ser Arg Glu Asp Gln His Gln Glu			
2115	2120	2125	
Gln Leu Ser Arg Gln Lys Lys Trp Glu Ser Lys Thr Met Ile Ile Tyr			
2130	2135	2140	

Thr Phe Ile Leu Cys Glu Thr Glu Lys Pro Cys Ile Leu Glu Leu Met
 2145 2150 2155 2160
 Asp Asp Val Leu Tyr Glu Glu Val Glu Glu Leu Arg Leu Val Leu Gly
 2165 2170 2175
 Thr Pro Gln Ser Asn Ser Pro Phe Gly Ala Ala Val Gly Gln Asn
 2180 2185 2190
 Glu Thr Leu Ile Arg Ile Arg Asp Asp Ala Asp Lys Thr Val Ile Lys
 2195 2200 2205
 Phe Gly Glu Thr Lys Phe Ser Val Thr Glu Pro Lys Glu Pro Gly Glu
 2210 2215 2220
 Ser Val Val Ile Arg Ile Pro Val Ile Arg Gln Gly Asp Thr Ser Lys
 2225 2230 2235 2240
 Val Ser Ile Val Arg Val His Thr Lys Asp Gly Ser Ala Thr Ser Gly
 2245 2250 2255
 Glu Asp Tyr His Pro Val Ser Glu Glu Ile Glu Phe Lys Glu Gly Glu
 2260 2265 2270
 Thr Gln His Val Val Glu Ile Glu Val Thr Phe Asp Gly Val Arg Glu
 2275 2280 2285
 Met Arg Glu Ala Phe Thr Val His Leu Lys Pro Asp Glu Asn Met Ile
 2290 2295 2300
 Ala Glu Met Gln Leu Ser Asn Phe Glu Leu Thr Leu Ser Pro Asp Gly
 2305 2310 2315 2320
 Thr Arg Val Gly Asn His Lys Cys Ser Asn Leu Leu Asp Tyr Thr Glu
 2325 2330 2335
 Val Lys Thr His Tyr Gly Phe Leu Thr Asp Ala Thr Lys Asn Pro Glu
 2340 2345 2350
 Ile Ile Gly Glu Thr Tyr Pro Tyr Gln Tyr Ser Leu Ser Ile Arg Gly
 2355 2360 2365
 Ser Thr Thr Leu Arg Phe Tyr Arg Asn Leu Asn Leu Glu Ala Cys Leu
 2370 2375 2380
 Trp Glu Phe Val Ser Tyr Tyr Asp Met Ser Glu Leu Leu Ala Asp Cys
 2385 2390 2395 2400
 Arg Ser Val Leu Asn Ala Ser Ile Phe His Glu Met Ala Pro Glu Gly
 2405 2410 2415
 Lys Gln Ser Lys Cys Leu Val Asn Ser Thr Leu Tyr Ser Ile Leu Glu
 2420 2425 2430
 Cys His Glu Ser Leu Pro Asn Phe Cys Ile Ser Ala Leu Arg Met Gly
 2435 2440 2445
 Lys Trp Arg Lys Ile Lys Ser Lys Pro Ser Ala Gln Thr Pro Cys Ala
 2450 2455 2460
 Gln Arg Leu Arg Gly Phe Ile Asp His Pro Arg Lys Gln Pro Leu Gln
 2465 2470 2475 2480
 Gln Ala Ser Ala Asp Pro Gly Met Leu Pro Val Ile Ser Thr Arg Glu
 2485 2490 2495
 Leu Ser Asn Phe Glu Leu Thr Leu Ser Pro Asp Gly Thr Arg Val Gly
 2500 2505 2510
 Asn His Lys Cys Ser Asn Leu Leu Asp Tyr Thr Glu Val Lys Thr His
 2515 2520 2525
 Tyr Gly Phe Leu Thr Asp Ala Thr Lys Asn Pro Glu Ile Ile Gly Glu
 2530 2535 2540
 Thr Tyr Pro Tyr Gln Tyr Ser Leu Ser Ile Arg Gly Ser Thr Thr Leu
 2545 2550 2555 2560
 Arg Phe Tyr Arg Asn Leu Asn Leu Glu Ala Cys Leu Trp Glu Phe Val
 2565 2570 2575
 Ser Tyr Tyr Asp Met Ser Glu Leu Leu Ala Asp Cys Gly Gly Thr Ile
 2580 2585 2590
 Gly Thr Asp Gly Gln Val Leu Asn Leu Val Gln Ser Tyr Val Thr Leu
 2595 2600 2605
 Arg Val Pro Leu Tyr Val Ser Tyr Val Phe His Ser Pro Val Gly Val

2610	2615	2620
Gly Gly Trp Gln His Phe Asp Leu Lys Ser Glu Leu Arg Leu Thr Phe		
2625	2630	2635
Val Tyr Asp Thr Ala Ile Leu Trp Asn Asp Gly Ile Gly Ser Pro Pro		2640
2645	2650	2655
Glu Ala Glu Leu Gln Gly Ser Leu Tyr Pro Thr Ser Met Arg Ile Gly		
2660	2665	2670
Asp Glu Gly Arg Leu Ala Val His Phe Lys Thr Glu Ala Gln Phe His		
2675	2680	2685
Gly Leu Phe Val Leu Ser His Pro Ala Ser Phe Thr Ser Ser Val Ile		
2690	2695	2700
Met Ser Ala Asp His Pro Gly Leu Thr Phe Ser Leu Arg Leu Ile Arg		
2705	2710	2715
Ser Glu Pro Thr Tyr Asn Gln Pro Val Gln Gln Trp Ser Phe Val Ser		2720
2725	2730	2735
Asp Phe Ala Val Arg Asp Tyr Ser Gly Thr Tyr Thr Val Lys Leu Val		
2740	2745	2750
Pro Cys Thr Ala Pro Ser His Gln Glu Tyr Arg Leu Pro Val Thr Cys		
2755	2760	2765
Asn Pro Arg Glu Pro Val Thr Phe Asp Leu Asp Ile Arg Phe Gln Gln		
2770	2775	2780
Val Ser Asp Pro Val Ala Ala Glu Phe Ser Leu Asn Thr Gln Met Tyr		
2785	2790	2795
Leu Leu Ser Lys Lys Ser Leu Trp Leu Ser Asp Gly Ser Met Gly Phe		2800
2805	2810	2815
Gly Gln Glu Ser Asp Val Ala Phe Ala Glu Gly Asp Ile Ile Tyr Gly		
2820	2825	2830
Arg Val Met Val Asp Pro Val Gln Asn Leu Gly Asp Ser Phe Tyr Cys		
2835	2840	2845
Ser Ile Glu Lys Val Phe Leu Cys Thr Gly Ala Asp Gly Tyr Val Pro		
2850	2855	2860
Lys Tyr Ser Pro Met Asn Ala Glu Tyr Gly Cys Leu Ala Asp Ser Pro		
2865	2870	2875
Ser Leu Leu Tyr Arg Phe Lys Ile Val Asp Lys Ala Gln Pro Glu Thr		2880
2885	2890	2895
Gln Ala Thr Ser Phe Gly Asn Val Leu Phe Asn Ala Lys Leu Ala Val		
2900	2905	2910
Asp Asp Pro Glu Ala Ile Leu Leu Val Asn Gln Pro Gly Ser Asp Gly		
2915	2920	2925
Phe Lys Val Asp Ser Thr Pro Leu Phe Gln Val Ala Leu Gly Arg Glu		
2930	2935	2940
Trp Tyr Ile His Thr Ile Tyr Thr Val Arg Ser Lys Asp Asn Ala Asn		
2945	2950	2955
Arg Gly Ile Gly Lys Arg Ser Val Glu Tyr His Ser Leu Val Ser Gln		2960
2965	2970	2975
Gly Lys Pro Gln Ser Thr Thr Lys Ser Arg Lys Lys Arg Glu Ile Arg		
2980	2985	2990
Ser Thr Pro Ser Leu Ala Trp Glu Ile Gly Ala Glu Asn Ser Arg Gly		
2995	3000	3005
Thr Asn Ile Gln His Ile Ala Leu Asp Arg Thr Lys Arg Gln Ile Pro		
3010	3015	3020
His Gly Arg Ala Pro Pro Asp Gly Ile Leu Pro Trp Glu Leu Asn Ser		
3025	3030	3035
Pro Ser Ser Ala Val Ser Leu Val Thr Val Val Gly Gly Thr Thr Val		3040
3045	3050	3055
Gly Leu Leu Thr Ile Cys Leu Thr Val Ile Ala Val Leu Met Cys Arg		
3060	3065	3070
Gly Lys Glu Ser Phe Arg Gly Lys Asp Ala Pro Lys Gly Ser Ser Ser		
3075	3080	3085

Ser Glu Pro Met Val Pro Pro Gln Ser His His Asn Asp Ser Ser Glu
 3090 3095 3100
 Val
 3105

<210> 81
 <211> 457
 <212> PRT
 <213> homo sapiens

<400> 81
 Met Gly Cys Ser Gly Ala Trp Gly Leu Ser Cys Pro Cys Pro Gln Thr
 1 5 10 15
 Pro Ser Trp Ala Trp Arg Lys Met Arg Thr Pro Ser Met Arg Asn Arg
 20 25 30
 Ser Gly Ala Val Trp Ser Arg Ala Ser Val Pro Phe Ser Ala Trp Glu
 35 40 45
 Val Glu Val Gln Met Arg Val Thr Gly Leu Gly Arg Arg Gly Ala Gln
 50 55 60
 Gly Met Ala Val Trp Tyr Thr Arg Gly Arg Gly His Val Gly Ser Val
 65 70 75 80
 Leu Gly Gly Leu Ala Ser Trp Asp Gly Ile Gly Ile Phe Phe Asp Ser
 85 90 95
 Pro Ala Glu Asp Thr Gln Asp Ser Pro Ala Ile Arg Val Leu Ala Ser
 100 105 110
 Asp Gly His Ile Pro Ser Glu Gln Pro Gly Asp Gly Ala Ser Gln Gly
 115 120 125
 Leu Gly Ser Cys His Trp Asp Phe Arg Asn Arg Pro His Pro Phe Arg
 130 135 140
 Ala Arg Ile Thr Tyr Trp Gly Gln Arg Leu Arg Met Ser Leu Asn Ser
 145 150 155 160
 Gly Leu Thr Pro Ser Asp Pro Gly Glu Phe Cys Val Asp Val Gly Pro
 165 170 175
 Leu Leu Leu Val Pro Gly Gly Phe Phe Gly Val Ser Ala Ala Thr Gly
 180 185 190
 Thr Leu Ala Asp Asp His Asp Val Leu Ser Phe Leu Thr Phe Ser Leu
 195 200 205
 Ser Glu Pro Ser Pro Glu Val Pro Pro Gln Pro Phe Leu Glu Met Gln
 210 215 220
 His Val Arg Leu Ala Arg Gln Leu Glu Gly Leu Trp Ala Arg Leu Gly
 225 230 235 240
 Leu Gly Thr Arg Glu Asp Val Thr Pro Lys Ser Asp Ser Glu Ala Gln
 245 250 255
 Gly Glu Gly Glu Arg Leu Phe Asp Leu Glu Glu Thr Leu Gly Arg His
 260 265 270
 Arg Arg Ile Leu Gln Ala Leu Arg Gly Leu Ser Lys Gln Leu Ala Gln
 275 280 285
 Ala Glu Arg Gln Trp Lys Lys Gln Leu Gly Pro Gln Ala Lys Pro Gly
 290 295 300
 Leu Thr Glu Ala Gly Asp Ala Ala Val Arg Met Ala Ala Glu Ala Gln
 305 310 315 320
 Val Ser Tyr Leu Pro Val Gly Ile Glu His His Phe Leu Glu Leu Asp
 325 330 335
 His Ile Leu Gly Leu Leu Gln Glu Glu Leu Arg Gly Pro Ala Lys Ala
 340 345 350
 Ala Ala Lys Ala Pro Arg Pro Pro Gly Gln Pro Pro Arg Ala Ser Ser
 355 360 365
 Cys Leu Gln Pro Gly Ile Phe Leu Phe Tyr Leu Leu Ile Gln Thr Val

370	375	380
Gly Phe Phe Gly Tyr Val His Phe Arg Arg Pro Val Pro Arg Pro Ala		
385	390	395
Lys Thr Met Ala Phe Met Val Lys Thr Met Val Gly Gly Gln Leu Lys		400
405		410
Asn Leu Thr Gly Ser Leu Gly Gly Glu Asp Lys Gly Asp Gly Asp		415
420	425	430
Lys Ser Ala Ala Glu Ala Gln Gly Met Ser Arg Glu Glu Tyr Glu Glu		
435	440	445
Tyr Gln Lys Gln Leu Val Glu Glu Lys		
450	455	

<210> 82
 <211> 526
 <212> PRT
 <213> homo sapiens

<400> 82		
Met Pro Ala Val Ser Gly Pro Gly Pro Leu Phe Cys Leu Leu Leu Leu		
1 5 10 15		
Leu Leu Asp Pro His Ser Pro Glu Thr Gly Cys Pro Pro Leu Arg Arg		
20 25 30		
Phe Glu Tyr Lys Leu Ser Phe Lys Gly Pro Arg Leu Ala Leu Pro Gly		
35 40 45		
Ala Gly Ile Pro Phe Trp Ser His His Gly Asp Ala Ile Leu Gly Leu		
50 55 60		
Glu Glu Val Arg Leu Thr Pro Ser Met Arg Asn Arg Ser Gly Ala Val		
65 70 75 80		
Trp Ser Arg Ala Ser Val Pro Phe Ser Ala Trp Glu Val Glu Val Gln		
85 90 95		
Met Arg Val Thr Gly Leu Gly Arg Arg Gly Ala Gln Gly Met Ala Val		
100 105 110		
Trp Tyr Thr Arg Gly Arg Gly His Val Gly Ser Val Leu Gly Gly Leu		
115 120 125		
Ala Ser Trp Asp Gly Ile Gly Ile Phe Phe Asp Ser Pro Ala Glu Asp		
130 135 140		
Thr Gln Asp Ser Pro Ala Ile Arg Val Leu Ala Ser Asp Gly His Ile		
145 150 155 160		
Pro Ser Glu Gln Pro Gly Asp Gly Ala Ser Gln Gly Leu Gly Ser Cys		
165 170 175		
His Trp Asp Phe Arg Asn Arg Pro His Pro Phe Arg Ala Arg Ile Thr		
180 185 190		
Tyr Trp Gly Gln Arg Leu Arg Met Ser Leu Asn Ser Gly Leu Thr Pro		
195 200 205		
Ser Asp Pro Gly Glu Phe Cys Val Asp Val Gly Pro Leu Leu Leu Val		
210 215 220		
Pro Gly Gly Phe Phe Gly Val Ser Ala Ala Thr Gly Thr Leu Ala Asp		
225 230 235 240		
Asp His Asp Val Leu Ser Phe Leu Thr Phe Ser Leu Ser Glu Pro Ser		
245 250 255		
Pro Glu Val Pro Pro Gln Pro Phe Leu Glu Met Gln His Val Arg Leu		
260 265 270		
Ala Arg Gln Leu Glu Gly Leu Trp Ala Arg Leu Gly Leu Gly Thr Arg		
275 280 285		
Glu Asp Val Thr Pro Lys Ser Asp Ser Glu Ala Gln Gly Glu Gly Glu		
290 295 300		
Arg Leu Phe Asp Leu Glu Glu Thr Leu Gly Arg His Arg Arg Ile Leu		
305 310 315 320		

Gln Ala Leu Arg Gly Leu Ser Lys Gln Leu Ala Gln Ala Glu Arg Gln
 325 330 335
 Trp Lys Lys Gln Leu Gly Pro Pro Gly Gln Ala Arg Pro Asp Gly Gly
 340 345 350
 Trp Ala Leu Asp Ala Ser Cys Gln Ile Pro Ser Thr Pro Gly Arg Gly
 355 360 365
 Gly His Leu Ser Met Ser Leu Asn Lys Asp Ser Ala Lys Val Gly Ala
 370 375 380
 Leu Leu His Gly Gln Trp Thr Leu Leu Gln Ala Leu Gln Glu Met Arg
 385 390 395 400
 Asp Ala Ala Val Arg Met Ala Ala Glu Ala Gln Val Ser Tyr Leu Pro
 405 410 415
 Val Gly Ile Glu His His Phe Leu Glu Leu Asp His Ile Leu Gly Leu
 420 425 430
 Leu Gln Glu Glu Leu Arg Gly Pro Ala Lys Ala Ala Lys Ala Pro
 435 440 445
 Arg Pro Pro Gly Gln Pro Pro Arg Ala Ser Ser Cys Leu Gln Pro Gly
 450 455 460
 Ile Phe Leu Phe Tyr Leu Leu Ile Gln Thr Val Gly Phe Phe Gly Tyr
 465 470 475 480
 Val His Phe Arg Gln Glu Leu Asn Lys Ser Leu Gln Glu Cys Leu Ser
 485 490 495
 Thr Gly Ser Leu Pro Leu Gly Pro Ala Pro His Thr Pro Arg Ala Leu
 500 505 510
 Gly Ile Leu Arg Arg Gln Pro Leu Pro Ala Ser Met Pro Ala
 515 520 525

<210> 83
 <211> 904
 <212> PRT
 <213> homo sapiens

<400> 83
 Met Leu Leu Ala Leu Cys Ser Ser Leu Ala Leu Ile Phe Ala Ala Pro
 1 5 10 15
 Val Ser Gly Gln Leu Glu His Ser Gly Asn Tyr Tyr Cys Thr Ala Asp
 20 25 30
 Asn Gly Phe Gly Pro Gln His Ser Glu Val Val Ser Leu Ser Val Thr
 35 40 45
 Val Pro Val Ser His Pro Val Leu Thr Leu Ser Ser Ala Glu Ala Leu
 50 55 60
 Thr Phe Glu Gly Ala Thr Val Thr Leu His Ser Ser Leu Ile Leu Gln
 65 70 75 80
 Ala Pro Leu Ser Val Phe Glu Gly Asp Phe Val Val Leu Arg Cys Arg
 85 90 95
 Ala Lys Ala Glu Val Thr Leu Asn Thr Met Tyr Lys Asn Gly Asn Val
 100 105 110
 Leu Thr Phe Leu Asn Lys Ser Ser Asp Phe His Ile His His Ala Ser
 115 120 125
 Leu Lys Asp Asn Gly Ala Tyr His Phe Thr Gly Phe Asn Gly Ser Asn
 130 135 140
 Phe Ser Val Ser Ser Asn Ile Val Lys Ile Gln Val Gln Glu His Leu
 145 150 155 160
 Leu Pro Gln Trp Phe Leu Lys Ala Pro Asp Pro Thr Val Ala Leu Ser
 165 170 175
 Glu Ile Phe Ser Val Asn Arg Gly Pro Leu Leu Thr Gly Thr Gly Ser
 180 185 190
 Arg Val Met Thr Pro Trp Ile Tyr Phe Pro Thr Glu Asp Trp Asn Phe

195	200	205
Thr Leu Ile Pro Ile Thr Val Asp Asp Ala Cys Lys Arg Pro Cys Ala		
210	215	220
Pro Arg Ala Pro Trp Glu Val Gly Ser Leu Thr Pro Gly Lys Ser Phe		
225	230	235
Gln Gln Lys Gly Asn Pro Asp Leu Leu Met Gly Pro Phe Asp Val Leu		
245	250	255
His Leu Ser Leu Ile Thr Leu Phe Cys Asn Met Ala Gly Ser Leu Phe		
260	265	270
Tyr Tyr Met Glu Leu Gly Glu Lys Lys Asp Ala Leu Phe Val Thr Gly		
275	280	285
Asn Glu Ser Arg Ser Tyr His Trp Phe Gln Lys Phe Ser Leu Ala Gly		
290	295	300
Gly Gln Glu Ala Asp Gln Lys Leu Trp Phe Pro Pro Gly Leu Met Ser		
305	310	315
Gln Asp Ile Phe Ile Tyr Ile Arg Gln Gly Glu Ser Cys Leu Val Ile		
325	330	335
Glu Met Phe His Gln Val Tyr Arg Arg Pro Ala Gly Gly Val Pro Val		
340	345	350
Glu His Met Ser Val Trp Ala Leu Arg Val Asn Ser Ser Gly Leu Phe		
355	360	365
Ala Tyr Ala Asp Gly Trp Leu Phe Thr Leu Phe Gln Leu Gln Ser Val		
370	375	380
Asp Asn Leu Ser Pro Ser Thr Gln Ser Gln Thr His Glu Gly His Glu		
385	390	395
Lys Leu Cys Pro Phe Leu Ala Ile Gly Pro Pro Ala His Ser Arg Gly		
405	410	415
Ser Phe Leu Arg Ala Lys Lys Ser Leu Val Ala Tyr Ile Lys Gly Asn		
420	425	430
Gln Leu Ser Phe Pro Pro Val Glu Asp Leu Leu Pro Lys Ser Gln Trp		
435	440	445
Pro Cys Ile Gln Val Leu Pro Arg Asn Ile Ala Ala Ala Ala His Lys		
450	455	460
Pro Val Ile Ser Val His Pro Pro Trp Thr Thr Phe Phe Lys Gly Glu		
465	470	475
Arg Val Thr Leu Thr Cys Asn Gly Phe Gln Phe Tyr Ala Thr Glu Lys		
485	490	495
Thr Thr Trp Tyr His Arg His Tyr Trp Gly Glu Lys Leu Thr Leu Thr		
500	505	510
Pro Gly Asn Thr Leu Glu Val Arg Glu Ser Gly Leu Tyr Arg Cys Gln		
515	520	525
Ala Arg Gly Ser Pro Arg Ser Asn Pro Val Arg Leu Leu Phe Ser Ser		
530	535	540
Gly Glu Lys Glu Asp Cys Val Ser Asp Lys Asn Pro Ala Thr Asn His		
545	550	555
Thr Pro Met Ser Arg Lys Arg Ser Ser Cys Ser Ser Leu Ser Ala Thr		
565	570	575
Ser Phe Ile Ala Pro Ala Leu Arg Leu Asp Ser Leu Ile Leu Gln Ala		
580	585	590
Pro Tyr Ser Val Phe Glu Gly Asp Thr Leu Val Leu Arg Cys His Arg		
595	600	605
Arg Arg Lys Glu Lys Leu Thr Ala Val Lys Tyr Thr Trp Asn Gly Asn		
610	615	620
Ile Leu Ser Ile Ser Asn Lys Ser Trp Asp Leu Leu Ile Pro Gln Ala		
625	630	635
Ser Ser Asn Asn Asn Gly Asn Tyr Arg Cys Ile Gly Tyr Gly Asp Glu		
645	650	655
Asn Asp Val Phe Arg Ser Asn Phe Lys Ile Ile Lys Ile Gln Gly Ile		
660	665	670

Pro Val Ser Gly Val Leu Leu Glu Thr Gln Pro Ser Gly Gly Gln Ala
 675 680 685
 Val Glu Gly Glu Met Leu Val Leu Val Cys Ser Val Ala Glu Gly Thr
 690 695 700
 Gly Asp Thr Thr Phe Ser Trp His Arg Glu Asp Met Gln Glu Ser Leu
 705 710 715 720
 Gly Arg Lys Thr Gln Arg Ser Leu Arg Ala Glu Leu Glu Leu Pro Ala
 725 730 735
 Ile Arg Gln Ser His Ala Gly Gly Tyr Tyr Cys Thr Ala Asp Asn Ser
 740 745 750
 Tyr Gly Pro Val Gln Ser Met Val Leu Asn Val Thr Val Arg Glu Thr
 755 760 765
 Pro Gly Asn Arg Asp Gly Leu Val Ala Ala Gly Ala Thr Gly Gly Leu
 770 775 780
 Leu Ser Ala Leu Leu Ala Val Ala Leu Leu Phe His Cys Trp Arg
 785 790 795 800
 Arg Arg Lys Ser Val His Pro Lys Lys Gly Asp Leu Val Tyr Ser Glu
 805 810 815
 Ile Gln Thr Thr Gln Leu Gly Glu Glu Glu Gly Asn His Gly Asn
 820 825 830
 Lys Asn Gln Glu Leu Glu Leu Val Asn Val Gly Glu Ser Phe Ser His
 835 840 845
 Arg Ala Cys Ile Trp Ser Thr Leu Met Gly Thr Cys Gln Thr Ile Gly
 850 855 860
 Gly Ala Asn Thr Ser Arg Thr Leu Leu Glu Asp Lys Asp Val Ser Val
 865 870 875 880
 Val Tyr Ser Glu Val Lys Thr Gln His Pro Asp Asn Ser Ala Gly Lys
 885 890 895
 Ile Ser Ser Lys Asp Glu Glu Ser
 900

<210> 84
 <211> 515
 <212> PRT
 <213> homo sapiens

<400> 84
 Met Leu Leu Trp Ala Ser Leu Leu Ala Phe Ala Pro Val Cys Gly Gln
 1 5 10 15
 Ser Ala Ala Ala His Lys Pro Val Ile Ser Val His Pro Pro Trp Thr
 20 25 30
 Thr Phe Phe Lys Gly Glu Arg Val Thr Leu Thr Cys Asn Gly Phe Gln
 35 40 45
 Phe Tyr Ala Thr Glu Lys Thr Thr Trp Tyr His Arg His Tyr Trp Gly
 50 55 60
 Glu Lys Leu Thr Leu Thr Pro Gly Asn Thr Leu Glu Val Arg Glu Ser
 65 70 75 80
 Gly Leu Tyr Arg Cys Gln Ala Arg Gly Ser Pro Arg Ser Asn Pro Val
 85 90 95
 Arg Leu Leu Phe Ser Ser Asp Ser Leu Ile Leu Gln Ala Pro Tyr Ser
 100 105 110
 Val Phe Glu Gly Asp Thr Leu Val Leu Arg Cys His Arg Arg Arg Lys
 115 120 125
 Glu Lys Leu Thr Ala Val Lys Tyr Thr Trp Asn Gly Asn Ile Leu Ser
 130 135 140
 Ile Ser Asn Lys Ser Trp Asp Leu Leu Ile Pro Gln Ala Ser Ser Asn
 145 150 155 160
 Asn Asn Gly Asn Tyr Arg Cys Ile Gly Tyr Gly Asp Glu Asn Asp Val

165	170	175	
Phe Arg Ser Asn Phe Lys Ile Ile Lys	Ile Gln Glu Leu Phe Pro His		
180	185	190	
Pro Glu Leu Lys Ala Thr Asp Ser Gln Pro Thr Glu Gly Asn Ser Val			
195	200	205	
Asn Leu Ser Cys Glu Thr Gln Leu Pro Pro Glu Arg Ser Asp Thr Pro			
210	215	220	
Leu His Phe Asn Phe Phe Arg Asp Gly Glu Val Ile Leu Ser Asp Trp			
225	230	235	
Ser Thr Tyr Pro Glu Leu Gln Leu Pro Thr Val Trp Arg Glu Asn Ser		240	
245	250	255	
Gly Ser Tyr Trp Cys Gly Ala Glu Thr Val Arg Gly Asn Ile His Lys			
260.	265	270	
His Ser Pro Ser Leu Gln Ile His Val Gln Arg Ile Pro Val Ser Gly			
275	280	285	
Val Leu Leu Glu Thr Gln Pro Ser Gly Gly Gln Ala Val Glu Gly Glu			
290	295	300	
Met Leu Val Leu Val Cys Ser Val Ala Glu Gly Thr Gly Asp Thr Thr			
305	310	315	320
Phe Ser Trp His Arg Glu Asp Met Gln Glu Ser Leu Gly Arg Lys Thr			
325	330	335	
Gln Arg Ser Leu Arg Ala Glu Leu Glu Leu Pro Ala Ile Arg Gln Ser			
340	345	350	
His Ala Gly Gly Tyr Tyr Cys Thr Ala Asp Asn Ser Tyr Gly Pro Val			
355	360	365	
Gln Ser Met Val Leu Asn Val Thr Val Arg Glu Thr Pro Gly Asn Arg			
370	375	380	
Asp Gly Leu Val Ala Ala Gly Ala Thr Gly Gly Leu Leu Ser Ala Leu			
385	390	395	400
Leu Leu Ala Val Ala Leu Leu Phe His Cys Trp Arg Arg Arg Lys Ser			
405	410	415	
Gly Val Gly Phe Leu Gly Asp Glu Thr Arg Leu Pro Pro Ala Pro Gly			
420	425	430	
Pro Gly Glu Ser Ser His Ser Ile Cys Pro Ala Gln Val Glu Leu Gln			
435	440	445	
Ser Leu Tyr Val Asp Val His Pro Lys Lys Gly Asp Leu Val Tyr Ser			
450	455	460	
Glu Ile Gln Thr Thr Gln Leu Gly Glu Glu Glu Ala Asn Thr Ser			
465	470	475	480
Arg Thr Leu Leu Glu Asp Lys Asp Val Ser Val Val Tyr Ser Glu Val			
485	490	495	
Lys Thr Gln His Pro Asp Asn Ser Ala Gly Lys Ile Ser Ser Lys Asp			
500	505	510	
Glu Glu Ser			
515			

<210> 85
 <211> 831
 <212> PRT
 <213> homo sapiens

<400> 85
 Asx Met Ala Val Gly Gly His Lys Gly Val Arg Cys Pro Pro Ser
 1 5 10 15
 Ala Arg Ser Ser Gln Val Pro Thr Cys Cys Ala Gly Trp Arg Gln Gln
 20 25 30
 Gly Asp Glu Cys Gly Ile Ala Val Cys Glu Gly Asn Ser Thr Cys Ser
 35 40 45

Glu Asn Glu Val Cys Val Arg Pro Gly Glu Cys Arg Cys Arg His Gly
 50 55 60
 Tyr Phe Gly Ala Asn Cys Asp Thr Lys Cys Pro Arg Gln Phe Trp Gly
 65 70 75 80
 Pro Asp Cys Lys Glu Leu Cys Ser Cys His Pro His Gly Gln Cys Glu
 85 90 95
 Asp Val Thr Gly Gln Cys Thr Cys His Ala Arg Arg Trp Gly Ala Arg
 100 105 110
 Cys Glu His Ala Cys Gln Cys Gln His Gly Thr Cys His Pro Arg Ser
 115 120 125
 Gly Ala Cys Arg Cys Glu Ser Gly Trp Trp Gly Ala Gln Cys Ala Ser
 130 135 140
 Ala Cys Tyr Cys Ser Ala Thr Ser Arg Cys Asp Pro Gln Thr Gly Ala
 145 150 155 160
 Cys Leu Cys His Ala Gly Trp Trp Gly Arg Ser Cys Asn Asn Gln Cys
 165 170 175
 Ala Cys Asn Ser Ser Pro Cys Glu Gln Gln Ser Gly Arg Cys Gln Cys
 180 185 190
 Arg Glu Arg Thr Phe Gly Ala Arg Cys Asp Arg Tyr Cys Gln Cys Phe
 195 200 205
 Arg Gly Arg Cys His Pro Val Asp Gly Thr Cys Ala Cys Glu Pro Gly
 210 215 220
 Tyr Arg Gly Lys Tyr Cys Arg Glu Pro Cys Pro Ala Gly Phe Tyr Gly
 225 230 235 240
 Leu Gly Cys Arg Arg Cys Gly Gln Cys Lys Gly Gln Gln Pro Cys
 245 250 255
 Thr Val Ala Glu Gly Arg Cys Leu Thr Cys Glu Pro Gly Trp Asn Gly
 260 265 270
 Thr Lys Cys Asp Gln Pro Cys Ala Thr Gly Phe Tyr Gly Glu Gly Cys
 275 280 285
 Ser His Arg Cys Pro Pro Cys Arg Asp Gly His Ala Cys Asn His Val
 290 295 300
 Thr Gly Lys Cys Thr Arg Cys Asn Ala Gly Trp Ile Gly Asp Arg Cys
 305 310 315 320
 Glu Thr Lys Cys Ser Asn Gly Thr Tyr Gly Glu Asp Cys Ala Phe Val
 325 330 335
 Cys Ala Asp Cys Gly Ser Gly His Cys Asp Phe Gln Ser Gly Arg Cys
 340 345 350
 Leu Cys Ser Pro Gly Val His Gly Pro His Cys Asn Val Thr Cys Pro
 355 360 365
 Pro Gly Leu His Gly Ala Asp Cys Ala Gln Ala Cys Ser Cys His Glu
 370 375 380
 Asp Thr Cys Asp Pro Val Thr Gly Ala Cys His Leu Glu Thr Asn Gln
 385 390 395 400
 Arg Lys Gly Val Met Gly Ala Gly Ala Leu Leu Val Leu Val Cys
 405 410 415
 Leu Leu Leu Ser Leu Leu Gly Cys Cys Ala Cys Arg Gly Lys Asp
 420 425 430
 Pro Thr Arg Arg Pro Arg Pro Arg Arg Glu Leu Ser Leu Gly Arg Lys
 435 440 445
 Lys Ala Pro His Arg Leu Cys Gly Arg Phe Ser Arg Ile Ser Met Lys
 450 455 460
 Leu Pro Arg Ile Pro Leu Arg Arg Gln Lys Leu Pro Lys Val Val Val
 465 470 475 480
 Ala His His Asp Leu Asp Asn Thr Leu Asn Cys Ser Phe Leu Glu Pro
 485 490 495
 Pro Ser Gly Leu Glu Gln Pro Ser Pro Ser Trp Ser Ser Arg Ala Ser
 500 505 510
 Phe Ser Ser Phe Asp Thr Thr Asp Glu Gly Pro Val Tyr Cys Val Pro

515	520	525
His Glu Glu Ala Pro Ala Glu	Ser Arg Asp Pro	Glu Val Pro Thr Val
530	535	540
Pro Ala Glu Ala Pro Ala Pro	Ser Pro Val Pro	Leu Thr Thr Pro Ala
545	550	555
Ser Ala Glu Glu Ala Ile Pro	Leu Pro Ala Ser Ser Asp	Ser Glu Arg
565	570	575
Ser Ala Ser Ser Val Glu Gly	Pro Gly Gly Ala	Leu Tyr Ala Arg Val
580	585	590
Ala Arg Arg Glu Ala Arg Pro	Ala Arg Ala Arg	Gly Glu Ile Gly Gly
595	600	605
Leu Ser Leu Ser Pro Ser Pro	Glu Arg Arg Lys	Pro Pro Pro Asp
610	615	620
Pro Ala Thr Lys Pro Lys Val	Ser Trp Ile His	Gly Lys His Ser Ala
625	630	635
Ala Ala Ala Gly Arg Ala Pro	Ser Pro Pro Pro	Gly Ser Glu Ala
645	650	655
Ala Pro Ser Pro Ser Lys Arg	Lys Arg Thr Pro Ser Asp	Lys Ser Ala
660	665	670
His Thr Val Glu His Gly Ser	Pro Arg Thr Arg Asp	Pro Thr Pro Arg
675	680	685
Pro Pro Gly Leu Pro Glu Glu	Ala Thr Ala Leu Ala	Ala Pro Ser Pro
690	695	700
Pro Arg Ala Arg Ala Arg Ala	Pro Arg Pro Leu Gly	Ala His Gly
705	710	715
Arg Arg Arg Ser Pro Ala Lys	Arg Ala Glu Ala	Ala Ser Met Leu Ala
725	730	735
Ala Asp Val Arg Gly Lys	Thr Arg Ser Leu Gly	Arg Ala Glu Val Ala
740	745	750
Leu Gly Ala Gln Gly Pro Arg	Glu Lys Pro Ala Pro	Pro Gln Lys Ala
755	760	765
Lys Arg Ser Val Pro Pro Ala	Ser Pro Ala Arg	Ala Pro Pro Ala Thr
770	775	780
Glu Thr Pro Gly Pro Glu Lys	Ala Ala Thr Asp	Leu Pro Ala Pro Glu
785	790	795
Thr Pro Arg Lys Lys	Thr Pro Ile Gln Lys	Pro Pro Arg Lys Lys Ser
805	810	815
Arg Glu Ala Ala Gly Glu Leu	Gly Arg Ala Gly	Ala Pro Thr Leu
820	825	830

<210> 86

<211> 871

<212> PRT

<213> homo sapiens

<400> 86

Asx Met Glu Gly Ala Gly Pro Arg Gly	Ala Gly Pro Ala Arg Arg Arg		
1	5	10	15
Gly Ala Gly Gly Pro Pro Ser Pro	Leu Leu Pro Ser Leu Leu Leu		
20	25	30	
Leu Leu Leu Trp Met Leu Pro Asp	Thr Val Ala Pro Gln Glu Leu Asn		
35	40	45	
Pro Arg Gly Arg Asn Val Cys	Arg Ala Pro Gly Ser Gln Val Pro Thr		
50	55	60	
Cys Cys Ala Gly Trp Arg Gln Gln	Gly Asp Glu Cys Gly Ile Ala Val		
65	70	75	80
Cys Glu Gly Asn Ser Thr Cys Ser	Glu Asn Glu Val Cys Val Arg Pro		
85	90	95	

Gly Glu Cys Arg Cys Arg His Gly Tyr Phe Gly Ala Asn Cys Asp Thr
 100 105 110
 Lys Cys Pro Arg Gln Phe Trp Gly Pro Asp Cys Lys Glu Leu Cys Ser
 115 120 125
 Cys His Pro His Gly Gln Cys Glu Asp Val Thr Gly Gln Cys Thr Cys
 130 135 140
 His Ala Arg Arg Trp Gly Ala Arg Cys Glu His Ala Cys Gln Cys Gln
 145 150 155 160
 His Gly Thr Cys His Pro Arg Ser Gly Ala Cys Arg Cys Glu Ser Gly
 165 170 175
 Trp Trp Gly Ala Gln Cys Ala Ser Ala Cys Tyr Cys Ser Ala Thr Ser
 180 185 190
 Arg Cys Asp Pro Gln Thr Gly Ala Cys Leu Cys His Ala Gly Trp Trp
 195 200 205
 Gly Arg Ser Cys Asn Asn Gln Cys Ala Cys Asn Ser Ser Pro Cys Glu
 210 215 220
 Gln Gln Ser Gly Arg Cys Gln Cys Arg Glu Arg Thr Phe Gly Ala Arg
 225 230 235 240
 Cys Asp Arg Tyr Cys Gln Cys Phe Arg Gly Arg Cys His Pro Val Asp
 245 250 255
 Gly Thr Cys Ala Cys Glu Pro Gly Tyr Arg Gly Lys Tyr Cys Arg Glu
 260 265 270
 Pro Cys Pro Ala Gly Phe Tyr Gly Leu Gly Cys Arg Arg Cys Gly
 275 280 285
 Gln Cys Lys Gly Gln Gln Pro Cys Thr Val Ala Glu Gly Arg Cys Leu
 290 295 300
 Thr Cys Glu Pro Gly Trp Asn Gly Thr Lys Cys Asp Gln Pro Cys Ala
 305 310 315 320
 Thr Gly Phe Tyr Gly Glu Gly Cys Ser His Arg Cys Pro Pro Cys Arg
 325 330 335
 Asp Gly His Ala Cys Asn His Val Thr Gly Lys Cys Thr Arg Cys Asn
 340 345 350
 Ala Gly Trp Ile Gly Asp Arg Cys Glu Thr Lys Cys Ser Asn Gly Thr
 355 360 365
 Tyr Gly Glu Asp Cys Ala Phe Val Cys Ala Asp Cys Gly Ser Gly His
 370 375 380
 Cys Asp Phe Gln Ser Gly Arg Cys Leu Cys Ser Pro Gly Val His Gly
 385 390 395 400
 Pro His Cys Asn Val Thr Cys Pro Pro Gly Leu His Gly Ala Asp Cys
 405 410 415
 Ala Gln Ala Cys Ser Cys His Glu Asp Thr Cys Asp Pro Val Thr Gly
 420 425 430
 Ala Cys His Leu Glu Thr Asn Gln Arg Lys Gly Val Met Gly Ala Gly
 435 440 445
 Ala Leu Leu Val Leu Val Cys Leu Leu Ser Leu Leu Gly Cys
 450 455 460
 Cys Cys Ala Cys Arg Gly Lys Asp Pro Thr Arg Arg Pro Arg Pro Arg
 465 470 475 480
 Arg Glu Leu Ser Leu Gly Arg Lys Lys Ala Pro His Arg Leu Cys Gly
 485 490 495
 Arg Phe Ser Arg Ile Ser Met Lys Leu Pro Arg Ile Pro Leu Arg Arg
 500 505 510
 Gln Lys Leu Pro Lys Val Val Val Ala His His Asp Leu Asp Asn Thr
 515 520 525
 Leu Asn Cys Ser Phe Leu Glu Pro Pro Ser Gly Leu Glu Gln Pro Ser
 530 535 540
 Pro Ser Trp Ser Ser Arg Ala Ser Phe Ser Ser Phe Asp Thr Thr Asp
 545 550 555 560
 Glu Gly Pro Val Tyr Cys Val Pro His Glu Glu Ala Pro Ala Glu Ser

565	570	575
Arg Asp Pro Glu Val Pro Thr Val Pro Ala Glu Ala Pro Ala Pro Ser		
580	585	590
Pro Val Pro Leu Thr Thr Pro Ala Ser Ala Glu Glu Ala Ile Pro Leu		
595	600	605
Pro Ala Ser Ser Asp Ser Glu Arg Ser Ala Ser Ser Val Glu Gly Pro		
610	615	620
Gly Gly Ala Leu Tyr Ala Arg Val Ala Arg Arg Glu Ala Arg Pro Ala		
625	630	635
Arg Ala Arg Gly Glu Ile Gly Gly Leu Ser Leu Ser Pro Ser Pro Glu		
645	650	655
Arg Arg Lys Pro Pro Pro Asp Pro Ala Thr Lys Pro Lys Val Ser		
660	665	670
Trp Ile His Gly Lys His Ser Ala Ala Ala Ala Gly Arg Ala Pro Ser		
675	680	685
Pro Pro Pro Pro Gly Ser Glu Ala Ala Pro Ser Pro Ser Lys Arg Lys		
690	695	700
Arg Thr Pro Ser Asp Lys Ser Ala His Thr Val Glu His Gly Ser Pro		
705	710	715
Arg Thr Arg Asp Pro Thr Pro Arg Pro Pro Gly Leu Pro Glu Glu Ala		
725	730	735
Thr Ala Leu Ala Ala Pro Ser Pro Pro Arg Ala Arg Ala Arg Ala Ala		
740	745	750
Pro Arg Pro Leu Gly Ala His Gly Arg Arg Arg Ser Pro Ala Lys Arg		
755	760	765
Ala Glu Ala Ala Ser Met Leu Ala Ala Asp Val Arg Gly Lys Thr Arg		
770	775	780
Ser Leu Gly Arg Ala Glu Val Ala Leu Gly Ala Gln Gly Pro Arg Glu		
785	790	795
Lys Pro Ala Pro Pro Gln Lys Ala Lys Arg Ser Val Pro Pro Ala Ser		
805	810	815
Pro Ala Arg Ala Pro Pro Ala Thr Glu Thr Pro Gly Pro Glu Lys Ala		
820	825	830
Ala Thr Asp Leu Pro Ala Pro Glu Thr Pro Arg Lys Lys Thr Pro Ile		
835	840	845
Gln Lys Pro Pro Arg Lys Lys Ser Arg Glu Ala Ala Gly Glu Leu Gly		
850	855	860
Arg Ala Gly Ala Pro Thr Leu		
865	870	

<210> 87
 <211> 134
 <212> PRT
 <213> homo sapiens

<400> 87
 Ile Asp Cys Arg Ala Glu Gln Gly Arg Thr Pro Leu Met Val Ala Val
 1 5 10 15
 Gly Leu Pro Asp Pro Ala Leu Arg Ala Arg Phe Val Arg Leu Leu
 20 25 30
 Glu Gln Gly Ala Ala Val Asn Leu Arg Asp Glu Arg Gly Arg Thr Ala
 35 40 45
 Leu Ser Leu Ala Cys Glu Arg Gly His Leu Asp Ala Val Gln Leu Leu
 50 55 60
 Val Gln Phe Ser Gly Asp Pro Glu Ala Ala Asp Ser Ala Gly Asn Ser
 65 70 75 80
 Pro Val Met Trp Ala Ala Ala Cys Gly His Gly Ala Val Leu Glu Phe
 85 90 95

Leu Val Arg Ser Phe Arg Arg Leu Gly Leu Arg Leu Asp Arg Thr Asn
 100 105 110
 Arg Ala Gly Leu Thr Ala Leu Gln Leu Ala Ala Ala Arg Gly His Gly
 115 120 125
 Thr Cys Val Gln Ala Leu
 130

<210> 88
 <211> 324
 <212> PRT
 <213> homo sapiens

<400> 88
 Met Leu Lys Pro Lys Asp Leu Cys Pro Arg Ala Gly Thr Arg Thr Phe
 1 5 10 15
 Leu Glu Ala Met Gln Ala Gly Lys Val His Leu Ala Arg Phe Val Leu
 20 25 30
 Asp Ala Leu Asp Arg Ser Ile Ile Asp Cys Arg Ala Glu Gln Gly Arg
 35 40 45
 Thr Pro Leu Met Val Ala Val Gly Leu Pro Asp Pro Ala Leu Arg Ala
 50 55 60
 Arg Phe Val Arg Leu Leu Glu Gln Gly Ala Ala Val Asn Leu Arg
 65 70 75 80
 Asp Glu Arg Gly Arg Thr Ala Leu Ser Leu Ala Cys Glu Arg Gly His
 85 90 95
 Leu Asp Ala Val Gln Leu Leu Val Gln Phe Ser Gly Asp Pro Glu Ala
 100 105 110
 Ala Asp Ser Ala Gly Asn Ser Pro Val Met Trp Ala Ala Ala Cys Gly
 115 120 125
 His Gly Ala Val Leu Glu Phe Leu Val Arg Ser Phe Arg Arg Leu Gly
 130 135 140
 Leu Arg Leu Asp Arg Thr Asn Arg Ala Gly Leu Thr Ala Leu Gln Leu
 145 150 155 160
 Ala Ala Ala Arg Gly His Gly Thr Ser Ala Gly Gly His Gly Gly Glu
 165 170 175
 Ala Gly Ser Ala Gly Lys Asn Ser Gly Arg His Arg Ala Gln Gly Ser
 180 185 190
 Glu Arg Pro Glu Leu Gly Arg Ser Met Ser Leu Ala Leu Gly Ala Val
 195 200 205
 Thr Glu Glu Ala Ala Arg Leu Arg Ala Gly Ala Leu Met Ala Leu
 210 215 220
 Pro Asn Ser Pro Gln Ser Ser Gly Thr Gly Arg Trp Arg Ser Gln Glu
 225 230 235 240
 Val Leu Glu Gly Ala Pro Pro Thr Leu Ala Gln Ala Pro Ile Gly Leu
 245 250 255
 Ser Pro His Pro Glu Gly Gly Pro Gly Ser Gly Arg Leu Gly Leu Arg
 260 265 270
 Arg Arg Ser Thr Ala Pro Asp Ile Pro Ser Leu Val Gly Glu Ala Pro
 275 280 285
 Gly Pro Glu Ser Gly Pro Glu Leu Glu Ala Asn Ala Leu Ser Val Ser
 290 295 300
 Val Pro Gly Pro Asn Pro Trp Gln Ala Gly Thr Glu Ala Val Val Leu
 305 310 315 320
 Arg Ala Gln Arg

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/28462

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 15/00, 12; C07K 14/435
US CL : 435/69.1, 320.1, 325; 530/350; 536/23.1, 23.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 320.1, 325; 530/350; 536/23.1, 23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	Genbank Accession No. AC007395, 30 September 2000 (30.09.00), see in particular nucleotides 123581 through 122421.	1-7

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

30 October 2001 (30.10.2001)

Date of mailing of the international search report

15 JAN 2002

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Marianne P. Allen

Telephone No. 703-308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/28462

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-7 with respect to SEQ ID NOS: 1 and 45

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/28462

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Claims 1-7 reference SEQ ID NOS. listed in Table 1 on page 24 of the description. Each nucleotide and corresponding amino acid sequence pair in Table 1 forms an inventive concept. Thus, with respect to claims 1-7, SEQ ID NOS: 1 and 45 form the first inventive concept, SEQ ID NOS: 2 and 46 form the second inventive concept, and so forth. There are a total of 44 inventions encompassed by the claims. The different sequence pairs have no obvious special technical feature in common as they appear to be structurally unrelated sequences.

As such, claims 1-7 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features.